A STUDY OF THE MOLECULAR GENETICS OF RENAL CELL CARCINOMA IN MAN by Ollerenshaw, Martin
A STUDY OF THE MOLECULAR GENEifJrCS OF,RENAL CELL 
CARCINOMA IN MAN 
by 
Martin Ollcrenshaw 
A thesis submitted to the University ofPlymouth in partial fulfilment for the 
degree of 
DOCTOR OF PHILOSOPHY (PhD) 
Molecular Medicine Research Group 
University of Plyl'nouth 
2003 
A study of the molecular genetics of renal cell carcinoma in man 
Martin Ollerenshaw 
Abstract 
The aim was to measure the expression levels of hypoxia inducible factor 1-a (HJF-la), glucose 
transporter one (GLUT -I), and vascular endothelial growth factor (VEGF) isoforms 165 and 189 
m RNA in patients with renal cell carcinoma (RCC). Patients with RCC underwent radical 
nephrectomy at Derriford Hospital, Plymouth. Tumour as well as matched normal tissue from 
the kidney was harvested, snap frozen and stored in liquid nitrogen, and used to quantitate 
VEGF 165, VEGF 189, GLUT-I and HJF-1 a mRNA expression using ribonuclease protection 
assays, and quantified using a Phosphor-imager system. 
The VEGF 165 isofonn was increased in the tumour tissue in comparison with the adjacent 
normal tissue (3.05 vs. 1.56 P=0.00002) as was the VEGF 189 isoform (2.41 vs. 1.43 P=0.0002). 
Forty four patients were analysed for the expression ofHIF-la and GLUT-I with statically 
significant differences seen between the tumour tissues with respect to the nonnal tissue for both 
HIF-la (1.34 vs. 1.10 P=O.Ol) and GLUT-I (1.99 vs. 1.63 P=0.003). 
Hypoxia inducible factor I (HIF-1) is a key regulator of genes involved in the hypoxic response. 
HIF consists of alpha and beta subunits, with the alpha subunit being degraded under normoxic 
conditions and stabilised under hypoxia. Polymorph isms in exon 12 of the HIF gene have been 
recently been identified consisting of nucleotide changes (C+ 1772T and G+ 1790A) resulting in 
an amino acid substitution from Proline 582 to Serine, and Alanine 588 to Threonine 
respectively. These polymorphisms are found within the oxygen-dependent degradation domain 
(ODD) of the ffiF-la protein when transcribed which is important in the oxygen regulation of 
the protein via hydroxylation of the proline residue at position 564 (P564) by HIF-a prolyl-
hydroxylase (ffiF-PH). The regulation ofHIF-Ia by this method is a novel way of regulating 
the levels of the protein, and polymorphisms in the ODD ofHIF-la may affect the ability of 
VHL to direct the alpha subunit for destruction. 
We have genotyped 146 patients and 288 controls for the G+ 1790A, and 160 patients and 162 
controls for the C+ 1772T polymorphisms respectively. We found an increase in both the GA and 
CC (P<O.OOOOI and P= 0.00002) genotypes in our patients with renal cell carcinoma, and a 
decrease in GG and CT (P<O.OOOOI and P=0.00002) genotypes respectively. Haplotype analysis 
revealed there to be an increase in the T-A and C-A haplotypes (P=0.00008, and P=0.02) and a 
decrease in the T-G haplotype P=O.Ol. No statistical difference was found for the other 
haplotypes. We have shown that these 1-IIF-la polymorphisms are present in RCC with 
increased frequency and may play an important role in the disease process, leading to increased 
angiogenesis in the tumour. 
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Vascular endothelial growth factor (VEGF) is a highly specific mitogen that is able to stimulate 
the proliferation of endothelial cells. There have been a number of findings linking the 
expression of VEGF with RCC, with it also being used to assess the prognosis of the disease. 
Polymorphisms in the VEGF gene have been recently identified. A possible link between 
promoter polymorphisms and expression of m RN A isofonns has been found in a variety of 
cytokines. Certain polymorphisms in renal cell carcinoma patients can lead to an up regulation of 
the expression of the mRNA, and may be a factor in the highly vascularized nature of the 
tumours studied. The aim was to investigate the frequency of polymorphisms within the VEGF 
gene (C-2578A) in 173 patients with RCC and 142 nonnal controls. No differences were seen 
between the patients and control populations, and the polymorphism did not correlate with 
Robson stage, Fuhnnan grade or age and gender. Although a trend was seen between the C-
2578A polymorphism and expression ofVEGF mRNA species in RCC patients. 
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Chapter 1: INTRODUCTION 
1.1 Cancer 
Cancer is the most common human genetic disease. A disease that is caused by changes in 
DNA resulting in continued and uncontrolled growth of the cell. One in three individuals 
in Europe and North American will develop one of the approximately 200 different types 
of cancer, and it is the cause of death for one in five. 
Tumour progression is a multi-step process, proceeded by multiple alterations from a 
normal cell to a localized tumour, and then finally to a tumour that acquires the ability to 
invade and metastasise. Tumours are characterised by many mutations in the form of base 
substitutions, deletions, chromosomal translocations, and gene amplifications. For many 
cancers a number of factors have been identified which are of prognostic importance. 
These include patient performance status, tumour grade and stage, and response to 
cytotoxic therapy. Even among patients with a similar tumour there is huge heterogeneity 
in tumour response, suggesting that the biological properties of the tumour cells 
themselves may be of prognostic importance. These properties include the expression of 
drug or radiation resistance genes, specific and non-specific chromosomal abnonnalities, 
and alteration in the expression of a range of oncogenes. 
1.1.1 Multistage nature of cancer development 
Beginning in 1949, Bereblum and Shublit stated from their experiments that the 
recognition that carcinogenesis is at least a two stage process should be invariably borne in 
mind [Bereblum & Shublit 1949]. Armitage and Doll published age/incidence curves for 
17 common types of cancer and concluded that carcinogenesis was at least a six or seven 
stage process [ Annitage & Doll 1957]. Being able to define each of these steps to 
malignancy has been the goal ever since. This step wise progression in which tumours 
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acquire more aggressive characteristics was determined by the activation, mutation or loss 
of specific genes [Foulds 1957]. 
The majority of cancers arise from a single cell that has acquired some heritable form of 
growth advantage [Nowell 1976]. This initiation step is believed to be caused by some 
form of genotoxic agent such as radiation or a chemical carcinogen. Cells at this stage, 
although altered at the DNA level, are still phenotypically normal. It requires further 
mutational events involving genes responsible for control of cell growth. Supply of blood 
vessels is of paramount importance to the rapidly growing cells and without recruitment of 
a new vascular supply they will be unable to survive. The ability to increase expression of 
angiogenic or decrease the expression of anti-angiogenic peptides will confer a more 
aggressive phenotype to the tumour mass. The ability of cells to breakaway from the initial 
clone of cells and travel through the body initiating a new site of malignancy is the final 
step in conferring a malignant phenotype, by providing the cell a mechanism to escape the 
basement membrane and circulate through the body. 
Each of these sequential changes may result from a variety of different mechanisms. One 
such mechanism is a mutation in a normal cellular gene controlling cell growth and 
proliferation, which confers on the cell some potential for malignant transformation 
24 
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1.1.2 Oncogenes 
Oncogenes are mutated forms of proto-oncogenes, whose functions are to promote the 
normal growth and division of cells. When the gene is either mutated or expressed at 
abnormally high levels it contributes to converting a normal cell into a cancer cell. 
Expressed oncogenes are generally considered to be 'dominantly acting' within a cell 
because the presence of the mutation, even a single copy, appear to be sufficient to drive 
the cell towards malignancy. The various types of oncogene can be seen in table I. l. 
Cells are capable of producing and responding to their own growth factors. One group of 
proto-oncogenes are those, which encode growth factors. The SIS oncogene encodes a 
protein homologous to PDGF 8 chain. Another group encode either the growth factor 
receptors themselves or their functional homologs. Thus the product of the ERBB gene 
[Sergeant et a/1982] is homologous to the epidermal growth factor receptor (EGFR) 
[Akiyama et a/1984] and the FMS product is homologous to the receptor for colony-
stimulating factor-] (CSF I R). A third group are the signal transducers. The signals for 
stimulation of growth from growth factors and their receptors must ultimately act, via a 
number of second messengers, at the level of gene expression. Second messengers are 
essentially signal transducers and transmitters that function by activating a protein cascade. 
This is controlled at the level of protein phosphorylation by protein kinases. Products of 
several of the membrane associated proto-oncogenes such as SRC and ABL have tyrosine 
kinase activity, as do several of those which act in the cytoplasm, such as products of 
RAFl and MOS. Several transmembrane growth factor receptors have protein kinase 
activity associated with the cytoplasmic domain. The final group of proto-oncogenes are 
those associated with the control of gene expression by their action on DNA itself This is 
the final site of action for messages sent from growth factors and is the level at which 
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control of growth and proliferation ultimately operates. Several proto-oncogene proteins 
(MYC, FOS, and JUN) have been shown to bind to and control the transcription of genes. 
Role Oncogene Viral/ Homolog 
Growth factors SIS PDGF 
Receptor tyrosine kinases ERBB/FMS EGFR/CSFIR 
Membrane associated SRC v-src 
non-receptor kinases 
G-protein coupled M as v-mas 
receptor 
Membrane associated G- Ras v-ras 
proteins 
Serine I Threonine Raf v-raf 
kinases 
Nuclear DNA-binding Myc v-myc 
transcription factors 
Tablet. I Role of proto-oncogenes in the cell 
Proto-oncogenes can be categorized into growth factors, receptor tyrosine kinases, G-
protein coupled receptors, serine I threonine kinases or nuclear factors. 
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Oncogene Implicated pro-angiogenic activity Ref 
KRAS, HRAS VEGF upregulation, TSPI downregulation Rak et a/ 1995, 
Grugel et a/ 1995 
SRC VEGF upregulation, TSP 1 downregulation Rak et a/ 2000a 
c-MYB TSP2 downregulation Bein et a/ 1998 
n-MYC Angiogenic properties in neuroblastoma Meitar et a/ 1995 
c-MYC Angiogenic properties in epidermis . Pelengaris et a/1999 
ERBB2 VEGF upregulation Petit et a/ 1997 
EGFR VEGF, bFGF, IL-8 upregulation Perrotte et a/ 1999 
PyMT TPI upregulation Sheibani & Frazier 
1996 
FOS VEGF expression Saez et a/ 1995 
TrkB VEGF downregulation McGregor et a/ 1999 
HPV-16 Secretion ofVEGF and IFN-a Le Buanec et a/ 
1999 
v-p3k VEGF production and angiogenesis Jiang et a/2000 
ODC Novel angiogenic factor Auvinen et a/1997 
PTTGI VEGF and bFGF upregulation Heaney et a/1999 
E2a-Pbxl Induction of mouse angiogenin-3 Fu et a/1999 
BCL2 VEGF upregulation Fernandez et a/2001 
Table 1.2 Pro-angiogenic oncogenes 
This table shows a variety of pro-angiogenic oncogenes. 
bFGF, basic fibroblast growth factor; EGFR, epidermal growth factor receptor; IFN-a, 
interferon-a; IL-8, interleukin-8; TSP, thrombospondin; VEGF, vascular endothelial 
growth factor. Adapted from Kerbal & Folkman 2002. 
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1.1.3 Tumour suppressor genes 
A second group of genes, which play a crucial role in tumorigenesis, are the tumour 
suppressor genes. The normal function of tumour suppressor genes is to inhibit cell growth 
and the cell cycle. Mutations in tumour suppressor genes cause cells to ignore one or more 
of the components of the network of inhibitory signals, removing the brakes from the cell 
cycle and resulting in a higher rate of uncontrolled growth. Tumour suppressor genes are 
defined by the impact of their absence and thus tend to be recessive, both normal alleles 
must mutate before cancerous growth begins. The loss or inactivation of a nonnal tumour 
suppressor gene may be acquired somatically in a single clone of cells or be 
constitutionally present throughout the body, including the germ line. Therefore it was 
hypothesised that it required two separate mutational events. One of these events may 
occur in the germline and be inherited, the second then occurs somatically. Alternatively, 
the two mutational events may occur only in the somatic cell of an individual. The 'two 
hit' model of mutation was proposed by Knudson in 1971 after studying cases of 
retinoblastoma [Knudson 1971]. 
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Tumour suppressor gene Description Cancer type 
APC Adenomatous polyposis Involved with familial 
of the colon gene adenomatous polyposis 
of the colon 
BRCA1 Familial breast/ovarian Hereditary 
cancer gene 1 breasUovarian cancer 
RBI Retinoblastoma Familial RB, bone, 
bladder, small cell lung 
P53 Tumour suppressor p53 Wide variety of tumours 
gene 
TSCl Tuberous sclerosis type Tuberous sclerosis, some 
1 gene hamartomas and RCC 
VHL von Hippei-Lindau VHL syndrome, RCC, 
syndrome gene haemangiomas and 
pheochromocytomas 
Table 1.3 Tumour suppressor genes 
This table shows the wide variety of tumour suppressor genes. 
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1.2 The History of Renal Cell Carcinoma 
Renal cell carcinoma (RCC) makes up 2% to 3% of all cancers, and 2% of all cancer 
deaths. The worldwide mortality was expected to exceed 100,000 in 2000 [Pisani et a/, 
1985]. There is a wide variation in incidence between countries, with Scandinavians and 
North Americans having the highest rates [Parkin et a/, 1993]. RCC is twice as common in 
males as in females although this is beginning to narrow [Landis et al, 1998] occurring 
most commonly in the 51h to ih decades of life. 
1 .2. 1 Classification of RCC 
Since the first misclassification ofRCC by Grawitz as a hypernephroma which was though 
to originate in the adrenal gland in 1883 [Grawitz, 1883) there have been various attempts 
to reclassify these tumours according to morphological and genetic patterns. Over the last 
10 years there have been advances in the understanding of genetic changes in RCC. The 
Union Intemationale Control le Cancer (UICC) and the American Joint Committee on 
Cancer (AJCC) classification ( 1997) identifies five groups of RCC, namely clear cell, 
papillary, chromophobe, collecting duct and unclassified carcinomas [Storkel et a/, 1997) 
see table 1.4. RCC can be graded according to the appearance of the nuclei as described in 
the Fuhrman grading system (see table 1.5, fig 1.1 ). The spread of the tumour can also be 
staged and takes into account the size and any metastasis that has taken place (see table 
1.6). 
Renal cell carcinomas originate within the renal cortex and are believed to arise from cells 
of the proximal tubule, and account for 80% to 85% of all primary renal neoplasms [Land is 
et a/1998]. The next most common is transitional carcinomas, which originate in the renal 
pelvis and account for 7% to 8% of primary neoplasms. The other tumours include, 
collecting duct tumours, oncocytomas, chromophobic, and chromophillic (previously 
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classified as papillary). The 5-year survival rate of patients diagnosed with kidney cancer 
has improved from 52% to 60% for those diagnosed between 1974 and 1976, and those 
diagnosed between 1986 and 1993 [Landis et a/, 1998]. 
1.2.3 Clinical and environmental factors in the etiology of RCC 
A number of clinical and environmental factors have been implicated in the etiology of 
RCC. These include use of tobacco, asbestos, and exposure to cadmium, urbanization, and 
exposure to petroleum by-products [McLaughlin et a/1985, La Vecchia et a/1990, Wolk 
et a/1996, Mandel et a/1996]. Cigarette smoking has been shown to double the 
likelihood of RCC and may contribute to as many as one third of cases [McLaughlin et a/ 
1984, Yu et a/ 1986, La Vecchia et a/ 1990]. Obesity is also a risk factor, with a I inear 
relationship between increasing body weight and risk of developing RCC, particularly in 
women [Y u et a/ 1986]. Clinical factors associated with the development of RCC include, 
hypertension [Yu et a/1986], unopposed estrogen therapy [Lindblad et al 1995], analgesic 
abuse [McCredie et a/1995], and acquired polycystic disease of the kidney (with a 30 
times increased risk than the general population) [Brennan et a/1991]. 
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Carcinoma Type Growth Cell of Origin Cytogenetic characteristics Incidence 
Pattern (%) 
Acinar or Proximal tubule Major Minor 75-85 
Clear-cell sarcomatoid 3p- +5,+7,+12,-
6q,-8p,-9,-
14q, -Y 
Chromophillic Papillary or Proximal tubule +7, +17, -Y 12+, +16, 12-14 
sarcoma to id +20,-14 
Chromophobic Solid, tubular, Intercalated cell of Hypodiploidy 4-6 
or cortical collecting duct 
sarcomatoid 
Oncocytic Typified by Intercalated cell of Undetermined 2-4 
tumour nests cortical collecting duct 
Collecting-duct Papillary or Medullary collecting Undetermined 
sarcomatoid duct 
Table 1.4 Classification of renal cell carcinomas 
Pathological classification of renal cell carcinomas. Adapted from Storkel & van den Berg 
1995 
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1.2.4 Genetics of RCC 
RCC can occur in inherited and sporadic forms. The former is usually found in patients 
suffering from von Hippel-Lindau (VHL) disease, which is associated with a mutation of 
the VHL gene. This classical tumour suppresser gene is situated on the short ann of 
chromosome 3 (3p.25). The sporadic form ofRCC is associated with somatic mutations in 
the VHL gene in at least 80% of cases [Foster et a/ 1994b ]. Mutation of the VHL gene 
occurs early in the disease, and as it progresses changes in other chromosomes occur 
including 3p 14, 3p21, 5q, 6q, and I Oq [Morita et a/1991 a, Thrash-Bingham et a/ 1995, 
Morita et a/ 1991 b, Foster et a/ 1994, Kenck et a/ 1997]. 
RCC is characteristically associated with an abundant neovasculature. This feature makes 
RCC an ideal cancer to study in relation to tumour-associated angiogenesis and cellular 
responses to hypoxic stress [Brown et a/1993, Sato et a/1994, Krieg et a/2000, 
Hemmerlein et a/2001, Le Jan et a/2003]. 
Both forms (sporadic & hereditary) ofRCC are associated with a translocation on the short 
arm of chromosome 3 [Seizinger et a/ 1988]. Southern blot analysis of this region in 
sporadic cases demonstrated loss of DNA on chromosome 3 in a high percentage of 
tumours examined [Presti et a/ 1991]. It appears that defects distal on the short arm of 
chromosome 3 are fundamental to the development of RCC. There is a high frequency of 
chromosomal breakage at 3pl3-14 and 3p21.3 [Yamakawa et a/1991]. Other less common 
abnormalities include trisomy for the region 5q22-qter and the deletion of 14q22-qter 
[Kovacs & Frisch 1989, Nagao et a/ 2002). More recently advances in analysis of the 
breakpoints and translocations, has lead to a more in-depth picture of complex structural 
rearrangements. Using spectral karyotyping it has been possible to detect these 
rearrangements which conventional banding analysis was unable to detect [Pavlovich et a/ 
2003]. 
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Grade Criteria 
Round uniform nuclei approximately 
Grade 1 I OJ.lm in diameter with minute or absent 
nucleoli 
Slightly irregular nuclear contours and 
Grade 2 diameters of approximately l5J.lm with 
nucleoli visible at 400X 
Moderately to markedly irregular nuclear 
Grade 3 contours and diameters of approximately 
20J.lm with large nucleoli visible at IOOX 
Nuclei similar to those of grade 3 but also 
Grade4 multi-lobular or multiple nuclei or bizarre 
nuclei and heavy clumps of chromatin 
Table 1.5 Fuhrman system of nuclear grading for renal cell carcinoma 
This table shows the Fuhrman grading system for renal cell carcinomas, based on a method 
of scoring the nucleus of the cells to determine the aggressiveness of the cancer [Fuhrman 
et a/ 1982]. 
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A 
B 
c 
Fig 1.1 Renal cell carcinoma Fuhrman grades 1, 2 and 3 
A, RCC Fuhm1an grade 1. Grade I tumours have round, uniform nuclei with 
inconspicuous or absent nucleoli. B, Fuhrrnan grade 2, nuclear contours are more irregular 
than Grade I; nuclei are about 15 microns in diameter. Nucleoli may be visible at high 
magnification. C, Fuhrman grade 3, nuclear contours are even more irregular. Nuclear 
diameters can approach 20 microns. Nucleoli are readily seen. Figures adapted from 
Webpathology.com 
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Familial renal cancers are characterised by their early age of onset compared to sporadic 
cases, frequent bilaterality and multicentricity. The mean age of diagnosis in familial cases 
is about 45 years compared with 60 years for sporadic cases [Cheville et a/2003]. 
1.2.5 Treatment for RCC 
There are few treatments for RCC due to the fact that it is highly resistant to traditional 
therapies like chemotherapy, radiotherapy, hormonal therapy, and immunotherapy [Motzer 
et a/2000]. The currently used strategies to treat RCC are described below. 
1.2.5.1 Surgery 
Depending on the stage of the tumour the 5-year survival ranges from 30 to 60%. The 
standard procedure for treatment of localised renal carcinoma is radical nephrectomy. 
Radical nephrectomy includes complete removal of Gerota 's fascia and its contents, 
including the kidney and the adrenal gland, and provides a better surgical margin than 
simple removal of the kidney [Robson 1963). Current opinion on the removal of the 
adrenal gland is that it only needs to be removed if it is involved in the tumour or contains 
metastasis, or the tumour is in the upper pole of the kidney [Autorino et a/2003]. Nephron 
sparing surgery (NSS) is emerging as a successful treatment for patients with localised 
RCC when the need exists to preserve functioning renal parenchyma [Moll et a/ 1993]. 
NSS has recently been shown to have similar long-tenn survival statistics in comparison 
with radical nephrectomy for low stage patients with RCC [Lundstam et a/2003]. 
Partial resection is indicated in cases of a single kidney, bilateral tumours and possibly for 
tumours smaller than 4 cm in diameter. Analysis of the cause of death in patients with 
RCC shows that the tumour is not always responsible. A 40-year-old man's lifetime risk of 
renal carcinoma is 1.27%, and the risk of death (from RCC) is 0.51% [Motzer et a/ 1996]. 
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Kidney tumours are detected more frequently by the newer radiological techniques, and at 
lower stages, when they can be resected for a cure. Using computed tomography (CT) scan 
and ultrasound, an increasing number of incidental RCCs have been identified. The 
Robson stage can be described as an amalgamation of the T, N, M, system to provide a 
readily usable system (see table 1.6). 
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Sta e 
Stage I TJ NO MO 
Stage 11 T2 NO MO 
Stage Ill Tl NI MO 
T2 NI MO 
T3a NO MO 
T3a N1 MO 
T3b NO MO 
T3b N1 MO 
T3c NO MO 
T3c N1 MO 
Stage IV T4 NO MO 
T4 N1 MO 
AnyT N2 MO 
AnyT AnyN M1 
Table 1.6 Tumour, Node, Metastasis, (TNM) staging system for renal cell carcinoma 
This table shows the Robson classification with regard to the T, N, M staging of the 
tumour. 
Primary tumour (T) 
Tx Primary tumour cannot be assessed 
TO No evidence of primary tumour 
T 1 Tumour 7cm or less in greatest dimension limited to kidney 
T2 Tumour more than 7cm in greatest dimension limited to kidney 
T3 Tumour extends into major veins or invades the adrenal gland or perinephric 
tissues, but not beyond Gerota's fascia 
T3a Tumour invades the adrenal gland or perinephric tissues, but not beyond Gerota's 
fascia 
T3b Tumour grossly extends into the renal vein or vena cava below the diaphragm 
T3c Tumour grossly extends into the renal vein or vena cava above the diaphragm 
T4 Twnour invades beyond Gerota's fascia 
Regional lymph nodes (N) 
Nx Regional lymph nodes cannot be assessed 
NO No regional lymph node metastasis 
N 1 Metastasis to single regional lymph node 
N2 Metastasis to more than one regional lymph node 
Distant metastasis 
Mx Distant metastasis cannot be assessed 
MO No distant metastasis 
M 1 Distant metastasis 
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1.2.5.2 Immunotherapy 
Although no curative treatment other then surgery is available, new treatment modalities, 
including immunotherapy (IL-2, Rosenberg et a/1985) and anti-angiogenesis therapies are 
currently being investigated. Anti-angiogenesis therapies include anti-VEGF antibodies 
[ Asano et a! 1995], and anti-VEGF receptor antibodies that block the VEGF receptors and 
their signal transduction functions [Zhu et a/2003], and thalidomide [D' Amato et a/ 1994, 
Li et a/2003]. 
The two principle cytokines available as agents for RCC therapy are interferon-a (IFN-a) 
and interleukin-2 (IL-2). Dosage is measured as millions of units (miU). IFN-a is usually 
administered via subcutaneous injection, while IL-2 is administered either by the 
subcutaneous route or intravenously, usually in the in-patient setting with the higher doses. 
Prominent cytokine side effects can interfere with delivery of planned drug doses and 
necessitate hospitalisation and ICU admission for supportive care. 
The food and drug administration (FDA) has approved IL-2 for the treatment of metastatic 
RCC at a dose of 600,000 IU/Kg (approximately 40 to 50 miU) per dose, administered in a 
slow intravenous infusion every 8 hours as tolerated to a maximum of 14 doses per cycle 
(see www.proleukin.com/index.html and for the FDA approval 
www .fda.gov/cber/products/aldechiO I 0998.htm). 
IFN-a has been approved for use in Europe for the treatment ofRCC [Pyrhonen et a/!999, 
Kankuri et a/200 I], for review see Fossa 2000. Side effects are also dose limiting, the 
broad range oftoxicities can overlap those ofiL-2 or other partner drugs. These associated 
side effects include a flu like syndrome (fatigue, fever, chills, anorexia, myalgia, 
headache), dry skin and mucus membranes, mental status changes and depression. 
Although the exact mechanism of action of cytokines is complex and unknown m an 
immunotherapy model, the effect of the drugs on the cancer cells is indirect. The cytokines 
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bind to their specific receptors and initiate intracellular and intercellular signalling 
cascades. IL-2 is a potent stimulator ofT cell proliferation, and if anti-tumour T cells are 
present, they could be stimulated. The consequence of this action is that tumour specific 
cytotoxic T-Iymphocytes (CTLs), natural killer (NK) cells and tumour-infiltrating 
lymphocytes (TILs), are activated and these lymphocytes then kill the cancer cells. 
Pegylated ( 40Kd) interferon-a2a is a modified form of recombinant human IFN-a2a with 
sustained absorption and prolonged half-life after subcutaneous injection. Pegylated 
interferon (PEG-intron) has been used in phase I and 11 trials in-patients with advanced 
RCC to assess the efficacy and toxicity advantages over conventional IFN-a therapy. The 
efficacy and tolerability profile was qualitatively similar to standard IFN-a, and the 
adverse effects were mostly mild to moderate in nature [Motzer et a/ 2001, Motzer et al 
2002]. PEG modified IL-2 has also been tested in a phase I trial in-patients with RCC 
(combined with standard IL-2) [Yang et a/ 1995], and a liposomal IL-2 has also been 
developed [Kedar et a/2000]. 
Other cytokines are known to be involved in immune signalling. Several have been 
manufactured in clinical quantities and tested in RCC, including IFN-y and IL-6. In vitro, 
IL-2 and IFN-y act synergistically to generate lymphokine-activated killer cells. Phase 11 
evaluation for RCC therapy in TL-2 combination had I 0% to 11% objective response rates 
[Schimidinger et a/ 2000, Schimidinger et a/ 200 I]. A phase I trial using IL-6 and GM-
CSF were safe, but further development for RCC application was not recommended [Tate 
et a/2001]. 
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1.2.5.3 Vaccines to modulate immunity 
While cytokine therapy activates the immune system, vaccine therapy seeks to direct the 
immune system specifically to the tumour cell targets. The first step in the clinical 
development of a vaccine is demonstrating the acquisition or amplification of CTLs with 
anti-tumour specificity. The process of antigen presentation to lymphocytes is a key step in 
development of lymphocytes with specificity for a particular tumour antigen. The next 
crucial step is to get the CTLs to act on the tumour. The presence of the tumour at a 
particular point in time is evidence that homeostasis has broken down. This may reflect a 
general immune suppression, or may be a tumour-directed, pathologic, immune-tolerant, 
anergic state of tumour-specific CTL clones. 
At present there are no licensed vaccines available for the treatment of RCC. Several 
approaches to this problem are currently in the trials phase of development. Vaccination 
with the peptide corresponding to a particular VHL mutation is one. Individuals whose 
tumour has a VHL mutation are immunized with the particular mutation {which is an 
antigen unique to the tumour), with a keyhole limpet hemocyanin (KLH) adjuvant (see 
www .cancer.gov/search/clinical trialsQ. The single peptide vaccination approach is in 
contrast to the whole protein or cell approaches. The antigenic peptides of cells are 
associated with the heat shock protein HSPP96. The Oncophage product (Antigenesis Inc) 
uses this autologous tumour-specific set of peptides and is being tested in two placebo-
controlled, randomised phase Ill trials, one for stage Ill and one for stage IV disease 
[Caudill & Li 2001] see also www.antigenic.com/trials/. 
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Transfonning growth factors (TGFs) a and ~are two tumour produced regulatory growth 
factors that may be related to the development of RCC. Using northern blotting it has been 
shown that enhanced expression of TGF-a and TGF-~1 mRNA in solid tumour may be 
related to the development of RCC [Gomella et al 1989, Uhlman et a/ 1995, Hise et a/ 
1996, Gunaratnam et a/2003]. 
Epidennal growth factor receptor (EGFR) is a transmembrane glycoprotein, which binds 
the mitogenic polypeptide hormone epidermal growth factor (EGF) as well as the EGF 
related TGF-a. Increases in the EGFR gene expression and protein production have been 
implicated in the phenotype of various cancers [Sargent et a/ 1989, Bolufer et a/ 1990, 
Laderoute et a/ 1992, Di Lorenzo et a/ 2002, Tsutsui et a/ 2003]. The EGFR gene was 
shown to be constitutively expressed in 90% of normal kidney samples. Tumours 
expressed an increased amount of EGFR mRNA coupled with the corresponding normal 
tissue, suggesting that over expression of EGFR mRNA may be associated with malignant 
transformation in RCC [Sargent et a/ 1989]. Since TGF-a is known to bind to the EGFR, 
the finding of an increased expression of both TGF-a and EGFR mRNA in kidney tumour 
tissue suggests that interaction between TGF-a and EGFR may play a role in promoting 
transformation or production of kidney neoplasm [Mydlo et a/ 1989]. Using two RCC cell 
lines (UOK-39 and SKRC-7) Gomella et a/ [1989] showed that TGF-~ inhibits the 
proliferation of RCC in vitro and this may be mediated by binding of exogenous TGF-~ to 
functional TGF-~ receptors on the cell surface. 
By using immunohistochemistry there was no significant correlation between TGF-a 
staining intensity and tumour size, stage or grade. When the tumour expressed either 
EGFR or TGF-a, average patient survival was 38 months, whilst the average survival of 
patients whose tumour expressed both EGFR and TGF-a was 61 months. EGFR and TGF-
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a are likely to play a role in the progression of RCC, and their eo-expression may have 
favourable prognostic implications [Lager et a/1994]. RCC cell lines SKRC-4 and SKRC-
29 were growth stimulated by greater than 35% when cultured in the presence ofTGF-a or 
EGF, and inhibited by 29-46% if cultured with anti-EGF monoclonal antibody 255. This 
suggests that proliferation of human RCC may be regulated by endogenously produced 
TGF-a and this pathway can be interrupted using an antibody to its receptor [Atlas et a/ 
1992]. Papillary tumours were shown to express relatively lower levels of EGFR in 
comparison with non-papillary tumours [Uhlman et a/1995]. 
Increased levels of latent TGF-~ I are common in the plasma of RCC patients. The TGF-~ l 
plasma level in RCC was found to be significantly higher than in cases of inflammation, 
thus the TGF-~ I is a possible tumour prognostic marker in RCC [Wunderlich et al 1998]. 
Elevated latent TGF-P I is common in RCC, and is at least partially produced by the 
tumour and might be a cause for local immunosuppressive effects within the tumour 
[Junker et a/ 1996]. Loss of expression of TGF-~R could result in escape from the growth 
inhibitory effect of TGF-~ in TGF-~ secreting cancer. Loss of TGF-~-R-II was associated 
with clinical stage suggesting that loss ofTGF-~-R-II expression in the primary tumour is 
a significant prognostic factor in patients with RCC [Miyajima et a/ 2003]. Using 
immunohistochemistry VEGF and TGF-~1 can be a useful prognostic factor in RCC 
[Yagasaki et a/2003].ln contrast, it has recently been shown by ELISA that TGF-~ l is not 
a suitable marker for the diagnosis of localized RCC, but may be useful in early detection 
ofRCC recurrence or to control the success ofimmunochemo-therapy [Hegele et a/2002]. 
TGF-a and FGF are functionally involved in the progression of clear cell RCC, directly 
stimulating proliferation by autocrine and/or paracrine actions. In contrast TGF-a and FGF 
did not directly stimulate the proliferation of papillary RCCs, thereby suggesting functional 
defects or a blockade in the corresponding signalling cascades. This differential 
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functionality might contribute to the more aggressive behaviour of clear cell RCCs [Ramp 
eta/2000]. 
TGF-a has been shown to support RCC cell growth through an autocrine loop. VHL has 
been shown to substantially decrease TGF-a mRNA and protein by shortening TGF-a 
mRNA half-life. Jn contrast VHL has no effect on the TGF-a receptor, EGFR, either at the 
m RNA or protein level [Knebelmann et a/ J 998]. 
1.3 History of Angiogenesis 
Dating back to 1787 surgeon Dr John Hunter first used the term angiogenesis to describe 
blood vessels growing in the reindeer antler [Hunter 1787]. The tenn angiogenesis means 
new blood vessel growth and has become an important process to study in relation to 
disease over the last 200 years since it was coined. Development of the vascular 
endothelium, and endothelial cell signal transduction mechanisms involved in angiogenesis 
are a fundamental requirement for organ development and differentiation in multicellular 
organisms [Hamilton et al 1962]. The relationship between angiogenesis and disease has 
become a highly studied process over the last few years. Increased knowledge of 
angiogenesis, coupled with a greater understanding of the diseases that may either have a 
pro or anti-angiogenic stand point has lead to strategies to inhibit or stimulate 
angiogenesis. Currently there are over 200 drugs related to angiogenesis in clinical trials 
and many more that are being developed in laboratories around the world [for review see 
Kerbal & Folkman 2002 and www.angio.org/ for angiogenesis inhibitors and drugs under 
current investigation]. The application ofpharmacogenomics to drug design will increase 
our capacity to fight RCC. 
The paper that began the current interest in angiogenesis and subsequent therapy to prevent 
angiogenesis was by surgeon Dr Judah Folkman, published in the New England Journal of 
Medicine [Folkman, 1971], hypothesizing that tumour growth is dependent on 
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angiogenesis. This theory was regarded as heresy by leading physicians and scientists at 
the time. A few years later the first angiogenesis inhibitor was discovered by Henry Brem 
and Judah Folkman in cartilage and called angiostatin [Brem & Folkman 1975]. 
Tumour growth depends on angiogenesis, without it the rapidly growing tumour will be 
unable to survive [Hanahan & Weinberg 2000, Folkman 2001]. Cancer cells have to 
promote angiogenesis early in the formation ofthe tumour. This 'angiogenic switch' is 
characterized by oncogene-driven tumour expression of pro-angiogenic proteins [Rak et a/ 
2000b], including bFGF, IL-8, PLGF, VEGF, TGF-j3, and PD-EGF [Relf et a/1997]. The 
angiogenic switch also involves the down regulation of angiogenesis suppressor proteins, 
such as Thrombospondin [Dameron et a/1994]. 
1.3.1 Angiogenesis inhibitors 
Angiogenesis inhibitors are a new class of drugs, which do not necessarily follow the 
general rules of conventional therapies such as chemotherapy and radiotherapy. It is 
possible to target the genetically stable cells that support tumour growth, and therefore less 
likely to accumulate mutations that allow them to develop drug resistance. They fall into 
one of two classes of inhibitor; direct or indirect [see fig 1.2 and tables 1.7 and 1.8]. Direct 
angiogenesis inhibitors target vascular endothelial cells and prevent them from 
proliferating, migrating, and avoiding cell death in response to a pro-angiogenic response 
by proteins including VEGF, bFGF, IL-8, PDGF, PD-EGF (see direct angiogenesis 
inhibitor table I. 7). It is thought that these direct angiogenesis inhibitors are the least likely 
to induce acquired drug resistance, as they target genetically stable endothelial cells and 
not unstable mutating tumour cells [Kerbel 1991]. In comparison indirect angiogenesis 
inhibitors prevent or block the expression of tumour proteins that activate angiogenesis 
(see fig 1.2 and table 1.8). 
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The first use of anti-angiogenic therapy in a human being was in 1988 using a daily low 
dose ofiFN-a (3 million unit/m2) to treat pulmonary haemangiomatosis in a 12-year-old 
boy [White et a/1989, Folkman 1989]. Tumour angiogenesis was mediated mainly by 
bFGF in this tumour, and IFN-a has been shown to down-regulate bFGF expression in 
human cancer cells [Singh et a/1995]. 
Transtuzumab which is an antibody that blocks ERBB2 receptor tyrosine kinase signalling, 
suppresses cancer-cell production of angiogenic factor such as TGF-~, angiopoietin-1, and 
plasminogen activated inhibitor-! [Tzumi et a/ 2002] and may also possibly suppress 
VEGF [Petit et a/1997]. 
In comparison with the traditional methods of testing cytotoxic chemotherapeutic drugs in 
cancer patients, it has been revealed that many angiogenesis inhibitors are most effective 
when the dose and schedule maintains a constant concentration of the inhibitor in the 
circulation, instead of a once daily bolus dose [Kisker et a/200 I]. 
Use of anti-cancer drug TNP-470 in RCC patients caused regression of the tumour volume 
[Stadler et a/ 1999]. TNP-470 is a synthetic analogy of Fumagillin [Jngber et a/1990], and 
inhibits methionine aminopeptidase-2, blocks the activity of cyclin-dependent kinase 2 
(CDK2), and inhibits phosphorylation of the RB protein [Griffith et a/1997, Sin et a/ 
1997]. 
As well as differences in dosing schedules, the clinical end points applied to anti-
angiogenesis therapy are also different. When a cytotoxic drug stabilizes the disease it 
might be considered a failure because the tumour will eventually become resistant to the 
drug and begin growing again. Stabilization of disease using an angiogenesis inhibitor on 
the other hand may arrest the tumour growth for long periods of time because of the 
genetically stable cells that are targeted. 
46 
Inhibitor 
rumoureD&~ 
Indirect 
Inhibits synthesis 
by tumour cells 
of angiogenic 
protein 
Endothelial ceUs 
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Direct 
Inhibits endothelial 
cells from 
responding to 
multiple angiogenic 
proteins 
Direct angiogenesis inhibitors target the vascular endothelial cells, which are recmited to 
the tumour bed and prevent them from responding to multiple angiogenic proteins. Indirect 
angiogenesis inhibitors target proteins or receptors on the endothelium that are expressed 
by tumour cells. Adapted from Kerbal & Folkman 2002. 
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Drug Cell Target Clinical trail Authors 
staee 
Angiostatin Binds to A TP synthase, Phase I O'Reilly et a/ 
angiomotin, and annexin li 1994; Moser et a/ 
on endothelial cells. Inhibits 1999; 
endothelial cell proliferation Troyanovsky et a/ 
and migration 2001 
Bevacizumab Humanized recombinant Phase ll and Ill 
(Avastin) monoclonal antibody 
against VEGF 
Arrest in Binds to integrin-a1P1 to No Colorado et a! 
inhibit endothelial cell 2000 
proliferation, migration, 
tube formation, and 
neovascularization 
Canstatin Binds to integtin-a.1 P 1 to Phase I Kamphaus et a/ 
inhibit endothelial cell 2000 
proliferation, migration, 
tube formation 
Combretastatin Microtubules: lnduces Completed phase Kanthou and 
reorganization of the of the I Tozer 2002 
actin cytoskeleton and early 
membrane blebbing in 
human endothelial cells 
Endostatin Targets integrin-a1P1 to Phase I and II Dixelius et al 
inhibit endothelial ceJI 2000; O'Reilly et 
proliferation and migration, al 1997 
and induce apoptosis 
NM-3 An isocoumarin small- Phase I Reimer et a/2002 
molecule inhibitor ofVEGF 
Thrombospondin Blocks endothelial cell No Dameron et al 
migration and 1994 
neovascularization in the 
cornea 
Tumstatin Binds to integrin-a1 P1 on No Maeshima et al 
endothelial cells, inhibits 200 I; Maeshima 
endothelial cell proliferation et a/ 2002 
and neovascularization 
2-methoxyestradiol Inhibits microtubule Phase l and 11 D'Amato et a/ 
function in proliferating 1994 
endothelial cells, resulting 
in endothelial cell apoptosis 
Vi tax in A humanized monoclonal Phase I and II Gutheil et a/ 2002 
antibody against integrin-
avP3 
Table 1.7 Direct angiogenesis inhibitors. 
This table shows the cell target of various direct angiogenesis inhibitors. Adapted from 
Kerbal and Folkman 2002. 
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Cancer-cell target Pro-angiogenic Drug Reference 
proteins 
EGF receptor VEGF, bFGF, TGF- ZD 1839 (lressa); Giardiello et a! 
tyrosine kinase a ZD6474; OS 1774 2001 
(Tarceva); Cl 1 033; 
PKI1666; IMC225 
(Erbitux) 
VEGF receptor VEGF receptor on PTK787; SU11248 Tille et a/ 2001 ; 
endothelium Hoekman 200 I 
PDGF receptor PDGF receptor PTK787 Tille et a/200 1 
ERBB-2 (HER- VEGF, Herceptin Kerbal et al 1998; 
2/neu receptor angiopoietin-1, Izumi et a! 2002 
tyrosine kinase) TGF-p, PAil, 
upregulates 
thrombospondin-1 
Interferon (IFN)-a Inhibits expression IFN-a Singh et a/ 1995 
receptor of bFGF by cancer 
cells 
Table 1.8 Indirect angiogenesis inhibitors. 
This table shows the cancer cell target of indirect angiogenesis inhibitors. Adapted from 
Kerbal and Folkman 2002. 
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1.4 von Hippel-Lindau gene 
Eugene von Hippel ( 1867 -1939) is credited with providing the first full description of a 
retinal vascular abnormality [ von Hippel 1904], although cases dating back to the 1800s 
have been identified [Collins 1894]. A Swedish pathologist called Arvind Lindau described 
patients who were at high risk of developing blood vessel tumour of the brain and spinal 
cord [Lindau 1927]. 
von Hippel-Lindau disease is a familial cancer syndrome that is dominantly inherited and 
predisposes affected individuals to a wide variety of highly vascularized tumours [Maher 
& Kaelin 1997]. The most frequent tumours are haemangioblastomas of the central 
nervous system and retina, renal cell carcinoma (RCC), and pheochromocytoma [Maher & 
Kaelin 1997]. 
VHL disease affects I in 36,000 of the population. Renal carcinomas and central nervous 
system (CNS) haemangioblastomas remain the major causes of morbidity and mortality in 
VHL patients [Crossey et a/ 1994, Clifford et a/ 200 I]. At the molecular level, VHL 
disease is autosomal recessive as tumours arise only after the remaining wild-type VHL 
allele is somatically mutated or silenced [Maher & Kaelin, 1997]. VHL disease can be 
categorised into four types, termed type I, 2A, 28, and 2C (see table 1.9 for descriptions). 
1.4.1 Variety of neoplasms 
V on Hippel-Lindau disease is a familial multiple cancer syndrome (see table 1.9) in which 
there is a predisposition to a variety of neoplasm's, including RCC (with clear cell 
histology), renal cysts, retinal haemangiomas, haemangioblastomas of the cerebellum, 
spinal cord, pheochromocytomas, pancreatic carcinomas and cysts. RCC develops in 
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nearly 40% of patients w ith VHL disease and is a major cause of death among these 
patients. 
Type of VHL disease VHL mutation type Molecular defect Clinical manifestation 
Upregulation of Haemangioblastomas 
Type 1 Loss of VHL or a mutation that HlF-a and HIF Diminished risk of 
effects protein folding target genes pheochromocytoma 
Renal cell carcinoma 
Upregulation of Haemangioblastomas 
Type 2A VHL missense mutation HIF-a and HIF Pheochromocytoma 
target genes Low risk ofRCC 
Upregulation of Haemangioblastomas 
Type 2B VHL missense mutation HIF-a and HIF Pheochromocytoma 
target genes High risk ofRCC 
PVHL retains Pheochromocytoma only 
Type 2C VHL missense mutation ability to degrade 
HIF-a; decreased 
binding to 
fibronectin, 
fibronectin matrix 
assembly defect 
Table 1.9 Characteristics of VHL disease. 
This table shows the four types of VHL disease according to the mutations and functiona l 
differences that occur. Adapted from Kaelin 2002. 
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1.4.2 Identification of the V HL gene 
Seizinger et a/ mapped the VHL tumour suppressor gene locus to the short arm of 
chromosome 3 in 1988. The gene was located in 1993 by Latif et al using positional 
cloning, with the promoter being identified by Kuzmin et al in 1995. This method 
identified the gene using cDNA libraries that were scanned using a cosmid (cos11) that 
mapped to a commonly deleted region. Two apparently unrelated clones were identified 
and denoted g6 and g7. It was concluded that g7 proved to be a strong candidate for the 
VHL gene. The expression pattern of g7 was first studied using northern blotting, and a 
transcript was observed in all human tissues tested, including brain and kidney, tissues 
which are frequently affected in VHL disease [Latif et al, 1993). The positional cloning 
strategies delineated the VHL gene to the region on the human chromosome 3p25-p26. 
The expression of the VHL transcript is not restricted to organs affected by VHL disease 
[Ohh & Kaelin, 1999]. The VHL coding sequence is contained within 3 exons, which can 
be alternatively spliced to produce two mRNAs that reflect the presence (isoform l) or 
absence (isoform 11) of ex on two. 
The VHL gene encodes a 4.7 Kb mRNA that is widely expressed in both foetal and adult 
tissues [lliopoulos et a/, 1995, Latif et a/, 1993]. The VHL mRNA encodes two protein 
products (pVHL) with molecular weights of -30 and -19 kDa [lliopoulos et a/ 1995], the 
former being 213 amino acids long and the latter containing 160 amino acids as the result 
of internal translation from the second methionine residue at codon 54 within the VHL 
open reading frame [IIiopoulos et al, 1998]. The smaller form of the protein appears to 
predominate in many tissues. It is not currently known why cells make two forms of 
pVHL, and the two isoforms behave similarly in biochemical and functional assay 
performed on them. 
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1.4.3 Mutational analysis of the VHL gene 
A comprehensive database of mutations in the VHL gene called the Universal VHL-
mutation database can be found at www.umd.necker.fr:2005/ and includes 747 mutations 
of the gene from 62 references. Identification of the VHL gene has allowed the detection of 
germline mutation in approximately 75% of VHL families. A number of mutations have 
been identified in the VHL gene of patients with RCC, spanning across the whole gene 
[Gnarra et al, 1994]. 
A mutational hot spot was identified at a CpG island in codon 167 where 12% of the 
mutations were found. The codon 167 mutation was associated with a phenotype 
characterised by minimal or absence of renal carcinoma and frequent pheochromocytomas 
[Maher et al 1996]. 
Reintroduction of the VHL gene into renal carcinoma cell lines lacking normal expression 
of the gene restored the expression of the protein and led to a dramatic suppression of 
growth [Chen et al, 1995]. Inactivation of the VHL gene is the most frequent genetic 
mutation in RCC [Whaley et al, 1994, Kaelin & Maher, 1998]. When Zbar and associates 
used RFLP analysis to study studied tumour tissue from 18 patients with sporadic 
nonhereditary renal carcinoma, loss of heterozygosity of chromosome 3p was detected in 
all the tumour tissues [Zbar et a/ 1996]. The VHL gene has been shown to be silenced by 
CpG islands being methylated in RCC [Herrnan, 1994]. It has also been shown that 
reintroduction of either 30-kDa (pVHL30) or 19-kDa (pVHL19) pVHL into VHL·'· renal 
carcinoma cells suppresses their ability to form tumours in nude mice [Schoenfield et a/, 
1998, lliopoulos et al, 1995, Gnarra et al, 1996]. This observation might account for the 
fact that VHL mutations invariably map C-terminal to residue 54. Mutations that affect the 
first 54 amino acids would in principle allow the production of the wild-type pVHL19• 
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1.4.4 Localization of p VHL 
Localisation of the pVHL has shown that pVHL30 is predominantly cytoplasmic, although 
a significant amount has been found in the nucleus and in association with the endoplasmic 
reticulum [Schraml et a/ 2003]. This means that the pVHL can shuttle back and forth 
between the nucleus and cytoplasm in response to certain signals [Iliopoulos et a/ 1995, 
Lee et a/, 1996]. VHL was shown to contain a nuclear export domain. Nuclear export of 
VHL is dependent on at least four independent factors; an A TP hydrolysis step, the 
presence of GTP, synthesis of polyadenylated ATP and the small GTPase Ran [Groulx et 
a/ 2000]. Several cancer-causing substitutions found in sporadic RCC do not affect the 
ability of VHL to assemble with elongin B/C and Cul-2 and appear to inactivate a yet 
undescribed tumour suppression function [Stebins et a/ 1999]. These inactivating 
substitutions may prevent the nuclear export of VHL. Reasons for this ability to shuttle 
between the nucleus and the cytoplasm have yet to be discovered, but may be related to its 
role as an E3 ligase. This nuclear cytoplasmic shuttling has recently been shown to 
correlate with HIF-Ia. levels, linking the previously described ability of VHL to shuttle 
between nuclear and cytoplasmic compartments with the ubiquitination and degradation of 
HIF-1 a [Groulx & Lee 2002]. 
While its interaction with some proteins has been understood VHL has been shown to 
inhibit vascular endothelial growth factor in RCC by blocking protein kinase C pathways 
[Pal et a/, 1997]. 
Combined nuclear and cytoplasmic pVHL expression was associated with low histological 
grade, early tumour stage and better prognosis in RCC patients. Implying that subcellular 
trafficking is of potential relevance for the aetiology of RCC [Schraml et a/2003]. 
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1.4.5 VHL associated proteins 
The pVHL tumour suppressor has been shown to associate with a number of other 
proteins, giving it a wide variety of functions that are only now being categorised and 
understood, and are summarised below (see fig 1.3). 
1.4.5.1 Elongins 8 and C. 
Elongins B and C were first identified by virtue of their ability to stimulate the 
transcriptional elongation activity of elongin A [Garrett et a/1994]. This trimeric ( elongin-
SIII) complex enhances the rate of elongation by RNA polymerase Il, suppressing the 
basal transcription machinery from pausing or stalling on the DNA template [Aso et a/, 
1995]. These two transcriptional elongation factors were subsequently shown to bind in 
vitro and in vivo to a short eo-linear region of the VHL protein (pVHL) [Kibel, et a/, 1995, 
Duan et a/ 1995]. Binding of pVHL to the elongin B/C complex occurs between the C-
terminal residues 157-172 termed the a binding site. The a site is the only region of p VHL 
that is similar to elongin A. The homologous region of elongin A likewise interacts with 
the B/C complex, establishing this set of amino acid residues as an elongin B/C binding 
motif [Kibel et a/, 1995], which stabilises the structure of elongin C [Botuyan et a/, 1999]. 
The elongin B/C binding domain on p VHL is a frequent site of mutations, suggesting that 
elongin binding contributes to tumour suppression by pVHL. Polymorphism's or mutations 
in this region may affect the binding between the pVHL and B/C complex and predispose 
individuals to an increased risk of tumour formation 
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1.4.5.2 Cullin-2. 
pVHL binds to cullin-2 (Cul-2), a member of the cullin family. Immunofluorescence 
studies showed Cul-2 to be a cytosolic protein that can be translocated to the nucleus by 
pVHL [Pause et a/, 1997]. It was shown that pVHL mutants that were unable to bind to 
complexes containing elongin C and Cul-2 were likewise unable to inhibit the 
accumulation of hypoxia-inducible mRNAs [Lonergan et a/1998]. 
Cullins were first identified in Caenorhabditis elegans during a screen for mutants that 
displayed excess post-embryonic cell divisions. Cul-l and Cul-2 bear a striking similarity 
to yeast Cdc53, which plays a role in ubiquitination, and hence degradation of certain 
proteins. There is significant homology between the Skpl-Cui-2-F-box protein (SCF) 
complex and the pVHL-elongin-Cul-2 (VEC) complex suggests that both complexes may 
possess a number of similar functions. Recent elucidation of the crystal structure of the 
VHL-Elongin C-Elongin 8 has increased the knowledge of the similarities of the SCF 
complex and the VEC complex [Stebbins et a/, 1999]. 
The Rbx1 and Cul-2 proteins were identified as part of the VCB multi-component complex 
mediating ubiquitination of target proteins [Kamura et a/ 1999]. 
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Fig 1.3 The von Hippel-Lindau protein (pVHL) and accessory proteins. 
This fig shows the p VHL and the various proteins that are in complex with it. These 
include the elongins Band C, cullin-2 and Rbx, E2. This complex of proteins forms the 
YCB complex which is an E3 ubiquitin ligase. Also shown is the HIF-la. subunit which 
binds to the p site of the VHL protein. 
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1.4.6 Downstream targets of pVHL. 
pVHL is able to regulate, at least indirectly, the abundance of a variety of mRNAs. These 
include the mRNAs encoding VEGF, PDGF-B, glucose transporter I (GLUT-I), TGF-a, 
and carbonic anhydrases (CA) 9 and 12 [Maher & Kaelin, 1997]. It has been demonstrated 
that VHL·'· tumour cells produce high levels of hypoxia-inducible mRNAs, such as the 
VEGF and GLUT-I mRNAs, under hypoxic and normoxic conditions. Reintroduction of 
wild-type pVHL into these cells inhibited the production of hypoxia-inducible mRNAs 
under normoxic conditions [Maher & Kaelin, 1997]. The hypervascular nature of VHL 
associated tumours may therefore be linked to the expression and overproduction of 
hypoxia-inducible mRNAs. 
The role ofpVHL on VEGF has not been fully elucidated, with conflicting data describing 
the effect as being either transcriptional or post-transcriptional [Gnarra et a/, 1996). 
Figure 1.3 shows the hypothesised relationship between hypoxia inducible factor one alpha 
HIF-la) and the VEC complex. lt appears that pVHL binds to the HIF-la subunit and 
directs it to the proteosome for ubiquitin-mediated proteolysis (see fig 1.4) [Maxwell et a/, 
1999]. Currently it is not known which other proteins are targeted for ubiquitin mediated 
proteolysis in this manner, and may be important in elucidating any other functions of 
pVHL. The number of proteins associated with pVHL is increasing all the time and 
includes Rbxl (RING box proteinl) [Kamura et a/, 1999), and E2 protein [Lisztwan et a/, 
1999]. 
Apart from binding to HIF-a subunits, pVHL has been shown to bind protein kinase C 
(PKC) and may serve as an E3 ubiquitin ligase for PKC-A. [Pal et a/1997, Pal et a/1998]. 
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Fig 1.4 Regulation of HIF-la by pVHL under normoxic and hypoxic conditions. 
Under hypoxic conditions, transcriptional activators p300 and cAMP-response-binding 
protein (CREB)-binding protein (CBP) bind to the carboxy-tenninal transactivation 
domain (CT AD) of hypoxia-inducible factor-a activating transcription of HIF regulated 
genes. Under nonnoxic conditions an asparagine in the CTAD is hydroxylated by factor 
inhibiting HIF-1 (FIH I), preventing the binding of p300/CBP. Proline residues in the 
oxygen-dependent degradation domain, which is found within the amino-tenninal 
transactivation domain (NT AD), are hydroxylated by EGLN proteins. This aids the 
binding of the pVHL-elongin-cullin 2 complex, that polyubiquitylates HIF-a, and targets it 
for destruction by the proteosome. 
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pVHL can also bind to the transcription factor Sp I suppressing its activity [Cohen e/ a/ 
1999, Mukhopadhyay et a/ 1997). In addition to this pVHL interacts with a cytosolic 
protein-folding complex called CCT [Feldman et a/ 1999, Hanen e/ a/2002). 
pVHL may also associate with the endoplasmic reticulum (ER), although there IS no 
evidence that the protein is secreted into the ER lumen [Ohh et a/ 1998, Schoenfeld et a/ 
2001]. Fibronectin molecules that are malfolded or malprocessed may undergo retrograde 
transport to the cytosolic surface of the ER membrane, which makes them available to 
interact with pVHL. Cells lacking pVHL secrete fibronectin, but are defective with respect 
to fibronectin-matrix assembly [Ohh et a/ 1998). VHL .f. renal carcinoma cells were not 
able to assemble exogenous fibronectin into a matrix, linking this to abnormalities of 
integrin assembly on their cell surface [Schoenfeld et a/ 2001). Tissue inhibitors of 
metalloproteinases (TIMPs) and matrix metalloproteinases (MMP) are regulated by pVHL, 
possibly via HlF and are implicated in extracellular-matrix turnover [Koochelpour et a/ 
1999]. 
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1.5 Vascular Endothelial Growth Factor 
In 1983 investigators at Beth Israel Hospital in Boston, reported the identification and 
partial purification (from conditioned medium of a guinea-pig tumour cell line) of a protein 
that induced vascular leakage [Senger et a/1983]. It was proposed that it could mediate the 
hyperpermeability of tumour blood vessels and was termed tumour vascular permeability 
factor (VPF). 
1.5.1 Isolation and purification of VEGF 
Complete purification of Vascular endothelial growth factor (VEGF) was by Plouet et a/ 
(1989) from the mouse pituitary cell line AtT20 and named 'vasculotropin', and Ferrara 
and Henzel ( 1989) who isolated the protein from bovine pituitary follicular cells, showing 
that it is a basic, heparin-binding homodimeric protein of 46-kDa that disassociates into 
two identical23 kDa subunits. Vasculotropin proved to be the mouse ortholog ofVEGF. 
The human VEGF gene is located on chromosome 6 at 6p21.3 [Vinceti et a/1996]. 
1.5.2 Alternative splicing of the VEGF gene 
cON A sequence analysis of a variety of human VEGF clones indicated that VEGF may 
exist as one of at least six different molecular species, having 121, 145, 148, 165, 189, and 
206 amino acids respectively (see fig 1.5) [Leung et a/1989, Keck et a/1989, Tisher et a/ 
1991, Houck et al1991, Poltorak et al1997, Whittle et a/1999]. Analysis ofthese clones 
showed that they contain a classical signal sequence, supporting the hypothesis that VEGF 
is a secreted protein. A novel spliced variant of 183 amino acids has been identified in 
human mUller cells with an IS-nucleotide deletion, equating to the loss of 6 amino acids 
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[Jingjing et a!, 1999]. Identification of a species with 148 amino acids has been reported to 
have an inhibitory effect, by binding to another of the isoforms but not activating the 
receptor [Whittle et a/, 1999]. Each of these isoforms display different characteristics 
biochemically and physiologically. Addition of the 44 amino acid-long peptide encoded by 
exon 7 of the VEGF gene distinguishes VEGF165 from VEGF121 [Park et a/1993, Cohen et 
a/1995]. VEGF 145 is distinguished by the presence of the 21 amino acid peptide encoded 
by exon 6 [Poltorak et a/ 1997]. The shortest form VEGF 121 was found to be freely 
diffusible and does not bind to heparin or extracellular matrix [Park et a/1993]. Whilst 
VEGF165 is secreted, some of the protein is sequestered in the extracellular matrix, and 
VEGF 189 is almost completely sequestered by the extracellular matrix [Houck et a/1991, 
Park et a/ 1993]. The VEGF 189 isoform can be released from the extracellular matrix by 
plasmin following cleavage at the carboxyl terminus [Park et al 1993]. This combination of 
exon splicing and ability to be sequestered by the extracellular matrix provides VEGF with 
two different mechanisms of availability. 
1.5.3 Differential Isoform expression 
VEGF 165 is the predominant isoform secreted by a variety of normal and transformed cells. 
Wizigmann-Voos et a/ (1995) found that VEGF 121 and VEGF165 are predominately 
expressed in capillary hemangioblastoma. In RCC, Tomisawa et a/ ( 1999) found that 
patients with pathological stage pT3-4 showed expression ofVEGF 121 + 165 + 189 at a 
significantly higher incidence than those with pT0-2. Their observations suggest that the 
VEGF 189 isofonn is closely associated with angiogenesis in RCC. 
The central role of VEGF in angiogenesis and neovascularization is analogous to the role 
of erythropoietin (EPO) in erthropoiesis. Induction of VEGF expression in hypoxic cells 
was similar to that of EPO [Go1dberg & Schneider, 1994]. Transcription of the VEGF gene 
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and stability ofVEGF RNA were both increased in hypoxic cells [Goldberg & Schneider, 
1994, Liu et a/ 1995]. 
Exons: 1-5 8 VEGF12t 
Exons: l -5 8 VEGFt4s 
Exons: 1-5 n 7 8 VEGFt6s 
/'-... 
Exons: 1-5 6 I I 7 8 VEGFts9 
Exons: 1-5 7 8 VEGF2o6 
11 5 44 6 Amino-acids 
Figure 1.5 Human VEGF gene structure. 
Showing the locations of exons 1 to 8 and the various forms ofVEGF that arise by 
alternative splicing. Exon 6, is marked in blue. Exon 6b is red; the orange/pink shading 
indicates exon7, present in VEGF 189 and VEGF 165. 
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1.5.4 Role of VEGF in the regulation of blood vessel growth 
The development of a vascular supply is a fundamental requirement for organ development 
and differentiation in multicellular organisms. Blood vessel fonnation is also necessary for 
tissue repair and reproductive functions in the adult. Substantial experimental evidence 
also indicates that neovascularization (angiogenesis) plays an important role in the 
pathogenesis of a variety of disorders [Folkman, 1991]. VEGF mRNA is known to be 
correlated with blood vessel growth in the developing mouse embryo, supporting the idea 
that VEGF is an in vivo angiogenic factor [Brei er et at 1992]. Binding sites of VEGF are 
largely restricted to the vascular endothelium of large or small vessels [Jakeman et al 
1992). VEGF mRNA expression in glioblastoma multifonne correlates with the most 
ischemic areas of the tumour, indicating that VEGF might be induced by hypoxia [Shweiki 
et al 1992, Plate et al 1992]. This was confirmed by culturing cells under hypoxic 
conditions [Plate et al 1992]. 
1.5.5 Biological activities ofVEGF 
Whilst VEGF is a potent mitogen for vascular endothelial cells but it is apparently devoid 
of any appreciable mitogenic activity in other cell types [Ferrara & Henzel, 1989). 
Consequently, VEGF has been regarded as an endothelial cell-specific mitogen [Ferrara, 
1993]. VEGF is able to induce a marked angiogenic response in a variety of in vivo models 
including the chick chorioallantoic membrane, the rabbit cornea, and the primate iris 
[Leung et al, 1989]. VEGF has been shown to promote angiogenesis in a tri-dimensional in 
vitro model; inducing confluent microvascular endothelial cells to invade a collagen gel 
and fonn tube like structures [Pepper et al, 1992]. 
64 
Chapter 1: INTRODUCTION 
VEGF induces expression of the serine protease's urokinase-type (uP A) and tissue type 
(tPA) plasminogen activators and also PA inhibitor l (PAl) in cultured bovine 
microvascular endothelial cells [Pepper et a/, 1991]. It also induces the expression of 
metalloproteinase interstitial collagenase in human umbilical vein endothelial cells but not 
in dermal fibroblasts [Unemori et al, 1992]. VEGF also induces expression of urokinase 
receptors in vascular endothelial cells [Mandriota et a/, 1995]. 
VEGF has been independently purified and cloned as a vascular permeability factor (VPF) 
based on its ability to induce vascular leakage in guinea-pig skin [Keck et a!, 1989]. An 
increase in microvascular permeability may be a crucial step in angiogenesis associated 
with tumours and wounds, by inducing plasma protein leakage. This would result in the 
formation of an extravascular fibrin gel, a substrate for endothelial and tumour cell growth 
[Dvorak, 1986]. 
An additional effect ofVEGF on the vascular endothelium is the stimulation of hexose 
transport. Exposure of bovine aortic endothelial cells to VEGF or TNF-a resulted in a 
significant increase in the rate of hexose transport [Pekala et a/, 1990]. 
VEGF also induces tissue factor expression in cultured endothelial cells. The induction of 
such a procoagulant protein may contribute to the abnonnal coagulant properties of tumour 
vessels in response to TNF-a [Nawroth & Stem, 1988]. 
VEGF can also induce vasodilatation in vitro in a dose dependent fashion, which translates 
into a transient hypotension in vivo [Y ang et a/, 1996]. 
1.5.6 Regulation of VEGF 
Several mechanisms have been shown to involve the regulation ofVEGF gene expression. 
Oxygen tension appears to play a major regulatory part, both in vitro and in vivo 
[Minchenko et a/, 1994]. VEGF mRNA expression is rapidly and reversibly induced by 
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exposure to low oxygen partial pressure (P02) in a variety of cultured cells including 
retinal pigmented epithelial cells, myoblasts, cardiomyocytes, and tumour cells [Shweiki et 
a/, 1992]. In sections of glioblastoma multi forme, VEGF mRNA is highly expressed in 
ischaemic tumour cells that are juxtaposed to areas of necrosis [Shweiki et a/, 1992, Plate 
et a/, 1992]. 
1.5.7 Other VEGF family members. 
Currently the main focus on VEGF has been on VEGF-A, with less emphasis on the other 
family members. With the isolation and characterisation of VEGF-B [Olofsson et a/, 
1996], VEGF-C [Joukov et a/, 1996], VEGF-0 [Yamada et a/1991] and VEGF-E [Ogawa 
et a/ 1998] as well as a newly identified factor related to the VEGF family termed, 
endocrine derived vascular endothelial growth factor (ED-VEGF) [LeCouter et a/, 2001]. 
Expression of VEGF-B and C has recently been measured in RCCs [Gunningham et a/ 
2001] showing significant up regulation of VEGF-B but not C in neoplastic compared to 
normal kidney. 
1.5.7.1 VEGF-8 
VEGF-B is a novel growth factor for endothelial cells, identified as a non-glycosylated 
highly basic heparin-binding growth factor with structural similarities to VEGF and PIGF. 
It is widely distributed but mostly abundant in heart, skeletal muscle, and the pancreas. 
VEGF-B forms disulfide-linked dimers that are secreted but remain bound to cells or the 
ECM and can be cleaved by heparin [Olofsson et a/ 1996a]. The VEGF-B gene was 
localized to chromosome 11 q 13, proximal to the cyclin D l gene [Paavonen et a/ 1996]. 
VEGF-B consists of two isoforms obtained by alternative splicing of mRNA from the 
VEGF-B gene, which spans about 4KB of DNA [Oiofsson et a/1996b]. The gene consists 
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of seven exons, and has a similar exon-intron organization to VEGF and PIGF [Grimmond 
et a/ 1996, Olofsson et a/ 1996b]. The mature proteins are 167 (VEGF-B 167) and 186 
(VEGF-B 186) amino acid residues respectively. VEGF-8 186 is generated by an alternative 
splice acceptor site in exon 6, resulting in an insertion of I 0 I bp between 410 and 411 in 
the coding sequence ofVEGF-8167. This insertion introduces a frameshift and a stop codon 
at the position corresponding to nucleotides 521-523 of the coding region of VEGF-B167 
cDNA. The two VEGF-B isoforms have an identical NH2-terminal domain of liS amino 
acid residues and different COOH-terminal domains [Grimmond et a/ 1996, Olofsson et a/ 
1996). The secreted VEGF-8161 and VEGF-B1s6 polypeptides are 21 kDa and 32 kDa 
respectively. 
The ability ofVEGF-B to heterodimerize with VEGF-A is consistent with the conservation 
of eight cysteine residues involved in inter- and intramolecular disulfide bonding, and eo-
expression of VEGF-B and VEGF-A in many tissues suggests that VEGF-B-VEGF 
heterodimers occur naturally. The formation of VEGF-B-VEGF heterodimers suggests 
there is at least a partial overlap between the cellular signalling receptors (See fig 1.7 
showing VEGF family receptors and ligands). VEGF-B specifically binds to VEGFR-1 
and endothelial cells respond to VEGF-8 by inducing the expression and activity of uP A 
and PAI-l. It might therefore be involved in endothelial ECM degradation and adhesion 
[Oiofsson et a/ 1998). 
VEGF-B was shown to be strongly expressed in the heart and that both isofonns (VEGF-B 
167 and VEGF-B 186) bind to neuropillin-1 (NRP-1), suggesting involvement ofVEGF-B 
in NRP-l mediated signalling [Makinen et a/1999]. 
VEGF-B knockout mice (Vegfb (-/-)) are healthy and fertile unlike VEGF-A knockout 
mice which die during embryogenesis. The hearts from the VEGF-B knockout mice are 
reduced in size and show impaired recovery from experimentally induced myocardial 
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ischemia, suggesting a role for VEGF-8 m the development of coronary vasculature 
[Bellomo et a/2000]. 
VEGF-B 167 accounts for more then 80% of the total transcripts in most tissues. VEGF-8 
186 was expressed at lower levels. The VEGF-8 186 is up-regulated in mouse and human 
tumour cell lines and primary tumours compared to their nonnal matched tissue [Li et a/ 
2001]. 
It has recently been shown that VEGF-8, through its receptor VEGFR-1, promotes 
angiogenesis in association with activation of Akt and eNOS-pathways [Silvestre et a/ 
2003]. 
1.5.7.2 VEGF-C 
While VEGF-C is homologous to other members of the VEGF I PDGF family, it's C 
terminal half contains extra cysteine-rich motifs. The VEGF-C precursor is more than 
twice as large as the mature polypeptide [Joukov et a/1996]. Proteolytic processing of 
VEGF-C increases its affinity and activating properties toward VEGFR-3 and it also 
acquires the ability to bind to VEGFR-2. Synthesis ofVEGF-C as a precursor prevents 
unnecessary angiogenic effects, via VEGFR-2, and allows preferential signalling via 
VEGFR-3, which is restricted to the venous endothelia during early stages of development 
and to the lymphatic endothelium during later stages [Joukov et a/1997]. VEGF-C binds 
VEGFR-3 and induces autophosphorylation ofVEGFR-3 and VEGFR-2. The critical 
region for receptor binding and activation by VEGF-C is contained within the first 180 or 
so amino acid residues [Joukov et a/1996]. The VEGF -C dimer consists of polypeptides of 
29-31 kDa that are generated by proteolytic cleavage of the precursor peptide between 
residues 227 and 228 [Joukov et a/1997]. Unlike the VEGF gene, the VEGF-C gene 
promoter does not contain putative binding sites for hypoxia-regulated factors. VEGF-C 
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was shown to induce specific lymphatic endothelium proliferation and hyperplasia of the 
lymphatic vasculature in vivo [Jeltsch et al 1997). 
VEGF-C expression has been correlated with lymph node status, lymphatic invasion, 
venous invasion, and tumour infiltrating patterns in gastric cancer, with patients who had a 
high expression ofVEGF-C protein having a poorer prognosis than those in the low 
expression group [Yonemura et a/1999]. It was also seen that VEGF-C expression in 
human prostate carcinoma cells was correlated with the presence of lymph node metastasis 
[Tsurusaki et a/ 1999). 
1.5.7.3 VEGF-D/ FIGF 
c-fos-induced growth factor (FIGF) or VEGF-D encodes a 358 amino acid residue long 
secreted protein. The amino acid sequence indicates that VEGF-D is strongly related to the 
PDGFNEGF family of growth factors. VEGF-D contains a central region of eight cysteine 
residues that are important for dimerization [Orlandini et a/1996]. VEGF-D is the only 
member of the VEGF family that is not induced by hypoxia, but via cell-to-cell contact 
mediated by the cell surface molecule cadherin-11 [Orlandini et a/ 1996, Orlandini & 
Oliviero 200 I). It has recently been demonstrated that P-catenin inversely regulates VEGF-
D mRNA stability [Orlandini et a/ 2003). 
1.5.7.4 Placenta growth factor 
A human cDNA coding for a protein related to VEGF was isolated from a term placenta 
cDNA library and named placenta growth factor [Maglione et a/ 1991). PIGF, VEGF, and 
VEGF-B are able to form heterodimers and share a number of biochemical and functional 
features [Cao et a/1996, Olofsson et a/ 1996b, Di Salvo et a/ 1995]. PIGF is active as a 
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dimeric glycosylated protein, and the formation of an active dimer involves intra and 
intermolecular disulfide bonds among eight cysteine residues to produce a cysteine knot. 
Unlike VEGF, which is able to bind VEGFR-1 and VEGFR-2, homodimeric PIGF is able 
to only recognise the VEGF decoy receptor VEGFR-1 [Park et a/1994]. Within the PIGF 
family, at least three PIGF isoforms (PIGF-1, PIGF-2, and PIGF-3) have been identified, 
which are all generated by alternative splicing of the same gene [Maglione et a/1991, 
1993, Cao et a/1997]. The two fonns named PIGF-1 and 2 (PIGF 13 1 and PIGF 15z) differ by 
the insertion of a highly basic 21 amino acid stretch at the carboxyl end of the protein, 
conferring the ability of PIGF-2 to bind heparin [Maglione et a! 1993]. The three-
dimensional structure ofPIGF at 2.0 A resolution has been elucidated and shows a high 
similarity to VEGF even though there is only 42% amino acid homology between the two 
proteins. PIGF-2 possesses heparin binding ability and can also bind to the neuropilin-1 
receptor [Migdal et a/1998]. PIGF-1 is less active than PlGF-2 at stimulating endothelial 
cell growth angiogenesis [Ziche et a/1998]. These properties of PlGF-2 could be mediated 
by the neuropilin-1 receptor, and activation of the receptor increases angiogenic responses 
mediated by VEGF RTKs support this finding [Soker et a/1998]. It is therefore possible 
that PIGF-1, but not PIGF-2 is a natural antagonist for VEGF when produced as a 
heterodimer with VEGF. 
It has been shown that in tumours expressing high levels of both PIGF and VEGF, 
functionally inactive heterodimers are formed thus decreasing the activity of VEGF 
[Eriksson et a/2002]. PIGF may play a dual role in the regulation ofVEGF-induced 
angiogenesis and tumour growth as seen in fig 1.6. 
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? Angiogenesis t ? Angiogenesis J. 
The. importance of VEGF in RCC can le attributed to its role in angiogenesis [Folkman l 
1971]. Without a supply of new blood vessels the rapidly expending tumour architecture 
will not be able to survive. HlMm\IPM fR"'l'ffih without additional vasculature t~HUfu~S"ftlting or 
and metastasis dormant tumour 
only able to grow to a size of approximately I mm3 before they require additional vessels to 
supply 0 2 and nutrients and remove waste products [Folkman & Hochberg 1973]. 
The role of VEGF in RCC has been shown to be important in the progression of the 
disease. One of the phenotypic features of RCC is the highly vascularized nature of the 
tumour [Brown et a! 1993, Sato et a! 1994, Takahashi et a! 1994]. 
7 1 
Chapter 1: INTRODUCTION 
Increased expression ofVEGF has been demonstrated because destruction of genes related 
to the hypoxia sensitive sensing nature of the cell [IIiopoulos et a/1996]. VHL mutation 
and hypennethylation, or loss of function in the ability of pVHL to direct HI F-a subunits 
to the 28S proteosome can directly contribute to the increase in angiogenesis within this 
system [Krieg et a/2000]. RCC contains a large number of mutations within the VHL gene 
and inactivation of the protein may therefore lead to increases in hypoxia-inducible 
proteins [ Kovacs et a/ 1991, Yao et a/ 1993, Gnarra et a/ 1994 ]. 
A number of isoforms of VEGF have been identified with the role of each of them 
becoming more apparent. The most common isoform is VEGF 165 and has been shown to 
be increased in RCC by various groups by methods including, reverse transcriptase 
polymerase chain reaction (RT-PCR), ribonucleic acid protection assay (RPA) and enzyme 
linked immunosorbent assay (ELISA) [Nicol et a/1997, Tomisawa et a/1999, Thelen et 
a/1999, Gunningham et a/2001 b, Ljungberd et a/2003]. Given the wide variety of 
different sources and methods used to determine the levels ofVEGF protein and mRNA 
expression, it is firmly established that VEGF has an important role to play in RCC. 
Association between VEGF and tumour progression has indicated that certain RCCs may 
be potential targets for anti-angiogenic therapy, after measuring the levels ofVEGF 
mRNA [Ljungberg et a/2003]. Association between VEGF and RCC progression has also 
been found for protein levels [Yang et a/2003b], with their results demonstrating that 
expression ofVEGF is proportional to the formation and progression ofRCC. It has also 
been demonstrated by immunohistochemistry that there is a link between VEGF 
expression and stage, nuclear grade, and microvessel density (MVD) [Zhang et a/2002, 
Jacobsen et a/2004]. Mutations in the VHL gene have been correlated with increased 
expression ofVEGF and may in turn be linked to a more aggressive phenotype ofRCC 
[Na et a/2003]. VEGF overexpression was shown to correlate with monoallelic and 
biallelic VHL activation [Igarashi et a/2002]. Treatment of Caki-1 cells with anti sense-
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oligos to VEGF led to a reduction in expressed VEGF levels sufficient enough to impair 
the proliferation and migration of eo-cultured endothelial cells [Shi & Siemann 2002]. 
Urinary VEGF levels were increased in-patients with RCC (27 patients) [Chang et a/ 
2001). 
Recent identification of a new form of VEGF tenned VEGF 165 b has opened a whole new 
area ofVEGF biology and function into focus. VEGF 165b was identified as an inhibitory 
sliced variant which contains 6 alternative amino acids (SL TRKD instead ofCDKPRR) at 
the C-terminal end of the protein [Bates et a/2002]. The dimerization [Potgens et a/1994] 
and receptor binding [Keyt et a/1996] domains are unaffected by these changes (being in 
exons 3 and 4 respectively). This spliced variant is unable to activate its cognate receptor 
(VEGF-R2), and initiate autophosphorylation of the receptor and activate signal 
transduction molecules down stream. Amounts of this spliced variant have been 
demonstrated (by RT-PCR) to be reduced in the tumour tissue from patients with RCC in 
comparison with the normal matched tissue, which had elevated levels of this species 
[Bates et a/2002]. Two mechanisms for the action of this isoform have been postulated; 
the first being that VEGF 165b binds to the receptor but is unable to activate the 
autophosphorylation of the TK domain. Second, it may heterodimerize with VEGF 165 
and prevents stimulation ofthe receptor. IfVEGF 165 has an isoform such as VEGF 165b 
then it would be biologically probable that the other VEGF isoforms also have an 
inhibitory partner. It has been demonstrated that some of these inhibitory partners do exist 
and are currently undergoing further investigation (personal communication Prof. Peter 
Mathieson). If these inhibitory isofonns are identified and measured, much of the VEGF 
literature may need to be revised. This may be due to the fact that various assays to 
measure VEGF stimulatory isofonns may also be inadvertently be measuring the 
endogenously expressed isoforms. With the ever-increasing number of anti-angiogenic 
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molecules currently undergoing trial (see www.angio.org) the ability to express these 
natural inhibitors to the angiogenic process may provide a new method to tackle disease. 
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1.5.9 VEGF polymorphisms 
The VEGF gene is highly polymorphic, with different polymorphisms distributed across 
the entire gene, including the 5' and 3' UTR and promoter regions (see table 1.10). Some 
of these polymorphisms have shown the ability to produce altered levels of the protein 
[Brogan et a/1999, Watson et a/2000]. 
Promoter region polymorphisms have been shown to affect the expression level of various 
cytokines [Watson et a/2000]. Associations have been found with polymorphisms in the 5' 
UTR of VEGF and diabetic retinopathy in type 2 diabetes [Awata et a/2002], as well as 
acute allograft rejection [Shahbazi et a/2002] and preeclampsia [Brenchley et a/2002]. A 
common C/T (at nucleotide position 936) mutation may be an important determinant of 
VEGF plasma levels [Renner et a/2000]. 
There are ethnic differences between Japanese and Caucasian populations for the G 16l2A 
and G702T genotypes. The C705T, C936T, and G 1612A polymorphisms in the 3 '-UTR 
are not associated with the risk ofRCC [Abe et a/2002]. The 3'-UTR ofVEGF also 
increases the stability of the mRNA and is associated with hypoxic induction of the gene 
[A wata et a/ 2002]. 
Links between promoter polymorphisms, expression of the protein and promoter activity 
have been reported by a number of groups [Watson et a/2000, Yang et a/2003]. The CC 
genotype of an 18 nucleotide deletion/insertion polymorphism at -2549 is in complete 
linkage with a SNP (C-2578A) and been shown to be increased inpatients with diabetic 
nephropathy in comparison with uncomplicated patients and normal controls. The C allele 
is also increased in the diabetic nephropaths in comparison with the uncomplicated patients 
and normal control groups. The C or A allele and the 18 nucleotide insert in the promoter 
region was cloned into a luciferase reporter plasmid to analyse changes in transcriptional 
activity. The construct containing the C allele bad an activity of 1.95 fold compared to the 
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A allele. This suggests that the C allele in the promoter region (minus the 18 nucleotide 
insert) will lead to enhanced expression of the gene [Yang et a/2003]. 
Recent haplotype analysis of the VEGF promoter has shown that the -460/+405 
polymorphism increased the mean induction by phorbol ester from 5-fold to 8.5-fold 
[Stevens et a/2003]. 
The gene designated as the Hu family binds to the AU rich elements of the 3'-UTR of 
several genes including VEGF mRNA [Nabors et a/2001, Goldberg-Cohen et a/2002], 
with the suggestion that Hu is able to prevent attack by RNAses by conformational 
changes in m RNA. Any single nucleotide changes in the 3 '-UTR may alter the ability of 
these Hu proteins to stabilize the mRNA and create differences in gene expression. 
The CC genotype of the C936T in the 3'-UTR is associated with higher plasma levels in 
comparison with the CT and TT genotypes [Renner et a/2000]. The C toT polymorphism 
leads to the loss of a potential binding site for AP-4 (a helix-loop-helix transcription factor) 
although the relevance of this has yet to be elucidated [Renner et a/2000]. Although the 
numbers in this study were small it may be of importance in the understanding of the 
stabilization of the mRNA. 
The G-1154A polymorphism in the 5 '-UTR of the gene is associated with higher VEGF 
production in patients with acute renal rejection or with the risk of prostate cancer 
[Shahbazi et a/2002, McCarron et a/2002]. 
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Polymorphism Description I Association Reference 
G - 2578 A Includes 18-nucleotide insert for the A allele, Brogan et a/1999, Yang et 
diabetic nep_hropathy a/2003 
G - 1455 A No current associations Brogan et a! 1999 
G - 1190 A No current associations 
G - 1154 C Risk factor for prostate cancer Brogan et a/ 1999, 
McCarron et a/2002 
G - 1001 C No current associations Brogan et a! 1999 
C-634 G No current associations 
C-460 T Not associated with childhood steroid- Holt et a/ 2003, 
sensitive nephrotic syndrome (SSNS), Lin et a! 2003 
calcium oxalate stone disease 
-460 I +405 Enhanced production ofVEGF in vitro Stevens et a/2003 
A - 141 C Not associated with SSNS Holt et a/2003, 
C - 7T No cunent associations Brogan et al 1999 
G +405 C Not associated with SSNS, Significant Holt et a/2003 , 
correlation between LPS stimulated PBMCs 
and VEGF protein production 
C +702 T Not associated with Japanese RCC Abe et a/ 2002 
population, no association with plasma levels 
C +936 T Associated with plasma levels, not associated Renner et a/ 2000, Abe et 
with Japanese RCC, T alle le may decrease a/2002 
susceptibility to sarcoidosis Morohasbi et al 2003 
G +1612 A Not associated with Ja2_anese RCC population Abe et a/ 2002 
Table 1.10 Polymorphisms located in the VEGF gene and associations with disease 
T his table shows polymorph isms of the VEGF gene and any associations with disease or 
expression levels of the protein. Included are polymorphisms that have yet to be associated 
with any disease. 
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1.5.10 VEGF receptors 
Three VEGF receptors have been identified to date. These are designated VEGFR-1, 
VEGFR-2, and VEGFR-3, and were previously called fit-/ (fins-like tyrosine kinase), KDR 
(kinase insert domain-containing receptor)/jlk-/ (fetal liver kinase- I), and FLT4 
respectively [Shibuya et a/ 1990, Shibuya et a/ 1999, Neufeld et a/ 1999, Aprelikova et a/ 
1992] (see fig 1.7). Structurally they all consist of seven Ig homology domains in their 
extracellular part and a tyrosine kinase signalling domain, which is split by a kinase insert. 
The VEGFR-1 and VEGFR-2 are expressed mainly in the blood vascular endothelium, and 
VEGFR-3 is found mainly in the lymphatic endothelium. VEGF binds to both YEGFR-1 
and VEGFR-2 using symmetrical binding sites at each pole of the dimer for receptor 
binding [Wiesmann et a/1997, Muller et a/ 1997] (see fig I. 7). The second Ig homology 
domain was found to be essential for ligand binding [Wiesmann et a/ 1997], although to 
reconstitute full activity the first three domains were required [Davis-Smyth et a/ 1996, 
Barleon et a/1991, Davis-Smyth et a/, 1998]. 
VEGFR-1 is a M, 180,000 transmembrane glycoprotein, although the mRNA can be 
spliced to produce a shorter soluble form consisting of the first six extracellular lg 
homology domains [Shibuya et a/1990, De Yries et a/1992, Pajusola et a/1993]. 
VEGFR-2 is a M, 195,000 protein with no spliced variants reported for the receptor 
[Pajusola et a/1993]. VEGFR-3 is a M. 195,000 which is proteolytically cleaved in the 
fifth Ig homology domain, resulting in Mr 120,000 and 75,000 chains linked by a 
disulphide bond [Lee et a/1996, Pajusola et a/1994]. 
The promoter for YEGFR-1 contains sequences matching the HIF-1 a consensus binding 
sites, and H1F-2u may stimulate VEGFR-2 promoter activity [Gerber et a/1997, Ikeda et 
a/ 1996, Kappel et a/ 1999]. 
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Fig 1.7 The various VEGFs and their receptors. 
This fig shows the VEGF receptors I , 2, 3, and the soluble VEGFR-1. YEGFR-1 and 
VEGFR-2 have seven immunoglobulin homology domains, in VEGFR-3 the fifth 
immunoglobulin domain is cleaved on receptor processing into disulphide-linked subunits. 
TI1e accessory proteins for each receptor are also shown, consisting of neuropil! in- I (NRP-
1) with RI, aVf33 integrin with R2, and vascular endothelial-cadherin (VEC) with R3. 
These co-receptors are required for correct activation of the receptor. 
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1.5.10.1 VEGFR signalling 
As a class ofreceptor tyrosine kinases (RTK), the VEGFR are believed to dimerize and 
undergo trans-autophosphorylation on ligand binding [Joukov et a/1996, Waltenberger et 
a/1994]. VEGFR-1 and VEGFR-2 activate the MAPK pathway in response to VEGF in 
many types of endothelial cells [Seetharam et a/ 1995, Landgren et al 1998, D' Angelo et al 
1995, Kroll & Waltenberger 1997, Abed & Zachary 1997, Rousseau et a/1997, 
Mukhopadhyay et a/ 1998, Takahashi et a/1999] (see fig 1.8). 
The role of Ras in the VEGFR-MAPK pathway remains to be elucidated. In VEGFR-2 
transfected fibroblasts PKC has been implicated in VEGF-induced MAPK activation 
[Takahashi & Shibuya 1997]. Phosphorylation of the Ras GTPase-activating protein in 
endothelial cells after VEGF stimulation has been reported by various groups 
[Waltenberger et a/!994, Seetharam et a/!995, Guo et a/!995]. In addition to MAPK, the 
p38 pathway has been shown to be activated by VEGF [Rousseau et a/1997]. 
The PLC-y-PKC pathway has been implicated in the mitogenic action ofVEGF. VEGFR-1 
interacts with the PLC-y-SH domain in the yeast two-hybrid system [Igarashi et a/1998]. 
VEGF induces the phosphorylation and activation ofPLC-y, leading to the hydrolysis of 
phosphatidylinositol 4,5-biphosphate to diacylglycerol and inositol I ,4,5-triphosphate 
[D' Angelo et a/ 1995, Xia et a/ 1996]. Inositol 1 ,4,5-triphophate is likely to be responsible 
for the increase in intracellular Ca2+ after VEGF stimulation and diacylglycerol activated 
certain PKC isoforms expressed in target cells [De Vries et a/1992]. 
ST A TS are latent cytoplasmic transcription factors. All three receptors were shown to be 
strong activators ofSTAT3 and STAT5, while STATI was not activated by any ofthe 
VEGFRs [Korpelainen et a/1999]. 
VEGFR-3 isoforms bind to and phosphorylated adapter protein Sch, while phosphorylation 
is stronger in cells expressing the longer isoform [Borg et a/!995, Foumier et a/ 1995]. 
80 
Chapter I: INTRODUCTION 
The She PTB domain is required for ligand-induced Sch tyrosine phosphorylation by 
VEGFR-3 [Foumier et a/1999]. Both VEGFR-3 isoforrns bind to Grb2 via it Sl-12 domain 
in an inducible manner [Pajusola et a/ 1994, Foumier et a/ 1995]. 
The VEGF receptors have been shown to associate with cell surface adhesive proteins (see 
fig I. 7). It has been shown that activated VEGFR-2 was found in complex with integrin 
av~3 , which is an adhesion molecule expressed on angiogenic endothelium [Soldi et a/ 
1999]. av~J binds to pericellular matrix proteins containing an arginine-glycine-aspartic 
acid (RDG) peptide motif, and has been shown to be involved in the cell cycle and survival 
of endothelial cells [Brooks et a/1994, Scatena et a/1998]. 
Another endothelium-specific cell-cell adhesion protein that has been implicated in the 
molecular interactions with the VEGF receptors is VE-cadherin. In normal endothelial 
cells VEGFR-2 eo-localized with VE-cadherin [Carrneliet et a/1999], similarly VEGFR-3, 
but not VEGFR-1 is co-immunoprecipitated with VE-cadherin. 
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Fig 1.8 Signal transduction pathway for the VEGF receptor 
This fig shows the signal transduction pathway for the VEGF receptor via the MAPK and 
Akt pathways. Phosphorylation occurs via the MAPK or Akt pathways and leads to s ignal 
transduction in the cell nucleus. 
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Newly formed tumour vessels are often 'leaky', VEGF has been shown to be one of the 
most potent inducers of vascular penneabil ity [Dvorak et a/ 1995]. VEGF -C induces 
vascular penneability which is not transduced via its receptor VEGFR-3 [Joukov et al 
1998]. PIGF is unable to induce penneability via its receptor (VEGFR-1) [Park et al 1994]. 
This implies that either VEGFR-2 or an unidentified receptor mediates the permeability 
response. To test this, the third variable domain in the VEGF polypeptide was substituted 
with the analogous region ofPIGF, creating a chimeric molecule with reduced binding to 
VEGFR-2. This mutant still induced vascular permeability with an activity similar to that 
of wild type VEGF [Stacker et a/1999]. Most of the signal transduction studies have been 
carried out using endothelial cells that express more than one type of VEGFR. 
Disruption of any of the three VEGFRs leads to embryonic death. The various VEGFRs 
are expressed in the mouse embryonic mesoderm between embryonic day (E) 7.5 and E9.5 
[Dumont et al 1995]. No blood vessels are fonned with embryos that have targeted null 
mutations ofVEGFR-2 [Shalaby et a/1995]. When VEGFR-1 was homozygous for a 
targeted mutation an excess of cells in both embryonic and extra-embryonic locations were 
seen, but the endothelial cells fail to organize into normal vascular channels [Fong et a! 
1995]. When only the tyrosine kinase domain ofVEGFR-1 was deleted, the mice 
developed normal vessel and survived [Hiratsuka et a! 1998]. During embryogenesis 
VEGFR-1 acts as a VEGF sink, regulating the amount of free VEGF available for vascular 
development. Loss or disruption ofVEGFR-3 led to cardiovascular failure after E9.5 
[Dumont et a! 1998], suggesting that VEGFR-3 is required for maturation of the primary 
vascular plexus into a hierarchy of large and small vessels. VEGFR-3 has a general blood 
vascular function during early development and only later becomes restricted to the 
lymphatic endothelium. 
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1.6 Hypoxia Inducible Factor (HIF) 
Molecular oxygen (02) is required by mammals for essential metabolic processes, 
including oxidative phosphorylation, which 0 2 serves as an electron acceptor during ATP 
formation. Low levels of 0 2 is tenned hypoxia and there are a number of adaptive 
responses to this including, erythropoiesis [Jelkman et a/1992], neovascularization [White 
et a/1992] and glycolysis in cells cultured at reduced 0 2 tension [Wolfle et a/1993]. 
These adaptive responses either increase 0 2 delivery or activate alternative metabolic 
pathways which do not require 0 2• 
Erythropoietin (EPO) was the first gene investigated which mediated a response to 
hypoxia. Cis-acting DNA sequences were identified in the 3' flanking region [Semenza 
1994]. 
HIF is a heterodimeric transcription factor, which consists of, a and p subunits, it was 
discovered in studies of hypoxia-inducible expression ofthe haematopoietic growth factor 
erythropoietin [Semenza & Wang 1992] (see fig 1.9). The HIF-1 p subunit is constitutively 
expressed, while the expression and transcriptional activity of HIF-1 a subunits is precisely 
regulated by the cellular 0 2 concentration [Wang et a/ 1995]. The HIF system is key to the 
response of a variety of cell types to hypoxia [Semenza 2000]. The HIF-1 a sub-unit is a 
novel polypeptide of826 amino acids [Wang & Semenza 1995]. HIF-Ia contains a basic 
helix-loop-helix (bHLH) domain, PAS domain, ID domain, oxygen dependent-degradation 
domain (ODD), N terminal transactivation domain (NTAD), and C terminal transactivation 
domain (CTAD). These different domains serve as the regulatory domains for HIF-la 
activation. The bHLH and PAS domains aid dimerization with HIF-1 p and DNA binding 
[Salceda et a/ 1997, Huang et a/1998, Maxwell et a/ 1999, Berra et a/2001]. 
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Figure 1.9 Structure of the IDF-1. 
Amino terminal transaetivation domain 
• Carboxy terminal transactivation domain 
Helix-loop-helix domain 
The figure shows the oxygen-regulated a subunit and the constitutively expressed p 
subunit, proline and asparagine hydroxylation sites, the amino-terminal transactivation 
domain and carboxy-terminal transactivation domain along with the basic-helix-loop-helix 
and Per-Arnt-Sim domains. 
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1.6.1 Hypoxic response of HlF 
Local hypoxia is often due to a vascular aetiology and is a component of ischaemic 
processes whereby cellular 0 2 delivery, energy substrate delivery and metabolite removal 
are all affected. Hypoxia plays a significant role in the pathophysiology of many diseases 
including renal disease. It is also a major pathogenic factor in other vascular related disease 
processes, including retinal and tumour neovascularization. 
Regardless of aetiology, hypoxia ultimately has its effects at the cellular level by depriving 
cells of adequate 0 2 to meet their metabolic demands [Semenza, 1998]. Individual cells 
sense hypoxia and respond by altering the expression of specific genes, that are involved in 
the maintenance of02 homeostasis under normoxic conditions. Homeostatic responses to 
hypoxia can be classified as systemic, local or cellular in nature. Cellular responses include 
the transition from oxidative phosphorylation to glycolysis as the pathway for ATP 
generation. HIF-1 a is a transcriptional activator of genes encoding proteins that play major 
roles in cellular, local and systemic homeostatic responses to hypoxia [Ratcliffe et a/, 
1998]. Hypoxia can be systemic or local in its aetiology [Semenza, 1996]. A number of 
causes of systemic hypoxia include decreased ambient 0 2 concentration (high altitude), 
decreased 0 2 exchange, decreased blood 0 2 carrying capacity, decreased cardiac output 
(cardiomyopathy), right-to-left shunt, and decreased 0 2 unloading in peripheral tissues 
[Semenza 1996]. 
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1.6.2 Transcriptional activation of HIF 
HIF-1 a recognizes the hypoxia response element (HRE) (5' (G/C/T)-ACGTGC-(Gff) 3 ') 
which is present in the enhancers of several genes and leads to their expression [Semenza 
et a/1996). Erythropoietin (EPO), VEGF, and various glycolytic enzymes have HRE 
sequences in their promoters/enhancers. The transcriptional activation ofHIF is linked to 
its ability to recruit various coactivator proteins including, p300, CREB-binding protein 
(CBP), steroid receptor coactivator-1, and translation initiation factor 2 [ Arany et a/1996, 
Ema et a/ 1999, Carrero et a/2000]. The amino acid composition of the helix-loop-helix 
(HLl-1) and basic domain determines the transcription factors specificity toward a particular 
DNA sequence [Semenza et a/ 1996). NMR and X-ray crystallographic structures have 
shown that the HLJ-1 domain dimerizes to form a parallel four-bundle left handed helix, 
with the contacts occurring within a hydrophobic core region [Michel et a/2000]. 
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G enes 
Growth factor related 
Endocrine gland-derived YEGF 
Erythropoietin 
IGF-11 
TGFB3 
VEGF 
Receptors 
FLT-1 
a 1 B-adrenergic receptor 
Transferrin receptor 
Glucose metabolism 
Aldolase A 
Aldolase C 
Enolase 
Glucose transporter I 
Glucose transporter 3 
Hexokinase L 
Phosphoglycerate kinase 1 
Lactate dehydrogenase A 
Genes related to vascular growth and development 
Adenylate kinase 3 
Endothelin- L 
Heme oxygenase- I 
LDL receptor-related protein 
Plasminogen activator inhibitor 1 (PAI-l) 
Prolyl-4-hydroxylase a l 
Transferrin 
Table 1.11 Genes regulated by HIF-1 
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Reference 
LeCouter et a/ 200 1 
Jiang et a! 1996a 
Feldser et a! 1999 
Canniggia et a/ 2000 
Carmeliet et a! 1998; Jyer et a/ 1998a 
Gerber et a/ 1997 
Eckhart et a/ 1997 
Tacchini et a/ 1999 
Iyer et a/1 998a; Ryan et a/ 1998 
Iyer et a/ 1998a; Ryan et a/ L 998 
Iyer et a /1 998a 
Ryan et a! 1998; Wood et a/ 1998 
Iyer et a! 1998a 
Iyer et a/ J 998a 
Cann el iet et a/ 1998; Iyer et a/ 1998a 
Iyer et a! 1998a; Ryan et a/ 1998 
Wood et a/ 1998 
Hu et a /1 998 
Lee et a! 1997 
Wykoff et a12000b 
Kietzmann et a/ 1999 
Takahashi et a/ 2000 
Rolfs et a/ 1997 
This table shows a number of the different types of genes that under the regulatory control 
of the HTF- 1 gene. Adapted from Choi et a/ 2003. 
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lmmunoblot analysis of HIF-1 a and HIF-1 p protein expression in Hep38 cells revealed 
low levels ofHIF-1 proteins in cells at 20% 0 2 and a marked increase in cells at I% 0 2 
with peak levels at 4-8h of continuous hypoxia [Wang et a/1995]. The major intracellular 
process that consumes 0 2 is oxidative phosphorylation, which is the primary metabolic 
pathway for A TP generation in most cell types. When 0 2 is limited, expression of genes 
encoding components ofthe electron transport chain is down regulated, whereas 
transcription of genes encoding glucose transporter I and enzymes of the glycolytic 
pathway are activated [Stein et a/1995, Webster et a/1990]. This metabolic adaptation 
allows cells to continue to synthesise ATP by an 0 2 independent pathway. HIF-1 appears 
to play a major role in the co-ordinate transcriptional activation of genes encoding 
glycolytic enzymes [Semenza et a/!994, Minchenko et a/2002]. The induction of multiple 
glycolytic enzymes in response to hypoxia appears inconsistent with long-held theories of 
rate limiting enzymatics [Kashiwaya et a/1994]. 
A growing body of experimental evidence supports the hypothesis that HIF-1 co-ordinates 
systemic, local, and cellular homeostatic responses to hypoxia through the transcriptional 
activation of specific genes, many of which remain to be identified. To date at least I 00-
300 genes have been found with hypoxia response elements (HREs) in their promoter 
regions, ranging from genes involved in glucose metabolism [Iyer et a/ 1998a] to 
angiogenic molecules [Carmeliet et a/ 1998] and genes involved in vascular development 
[Kietzmann et a/ 1999] see table 1.11. 
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1.6.3 Prolyl hydroxylation ofHIF-Ja and subsequent breakdown 
The regulation of HIF-1 a activity has come under increasing scrutiny over the last few 
years (see fig 1.1 0). Two proline residues (P402 and P564) in HIF-1 a are constitutively 
hydroxylated under normoxic conditions [I van et a/200 I, Jaakkola et a/2001]. 
Hydroxylation of these proline residues allows binding and subsequent degradation by 
pVHL [Maxwell et a/1999,]. Other residues have also been found to be critical for pVHL-
mediated degradation (tyrosine 564 and lie 565 in mice) [Pereira et a/2003]. This site-
specific hydroxylation of proline residues under normoxic conditions takes place by a 
family of enzymes called prolyl hydroxylases (PHD I, PHD2, and PHD3), which catalyse 
proline hydroxylation by using Fe2+ and ascorbate as co factors [Epstein et a/200 I, Bruick 
& McKnight 200 I]. Prolyl hydroxylases use molecular oxygen and 2-oxoglutarate as 
substrates in addition to the hydroxyl acceptor proline residue. This occurs at specific 
prolines within a conserved motifofLXXLAP. [Kivirikko & Pihlajaniemi 1998]. 
Treatment of cardiac myocytes, smooth muscle cells and endothelial cells with hypoxia or 
a hypoxia mimetic (i.e. CoCh) results in a significant time dependent increase in PHD3, 
but not PHD I or 2 m RN A levels, which correlated with an increase in HIF -I a protein 
expression [Cioffi et a/2003]. The PHD-pathway may play a key role in phenotypic 
changes that are observed in a hypoxic myocyte, and may suggest a strategy to 
pharmacologically induce protection in the heart [Wright et a/2003]. Localisation of the 
three PHD enzymes by confocal fluorescence microscopy showed that PHDI was 
exclusively present in the nucleus, PHD2 and FIH-1 mainly were mainly located in the 
cytoplasm, and PHD3 was distributed in the cytoplasm and nucleus [Metzer et a/2003]. 
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Normoxia Hypoxia 
I 
p 
M l 
Ubiquitin molecule (s) 
\ 
Proteosome Nucleus 
Figure 1.10 oxygen-dependent regulation of the HIF-la transcription factor 
This fig shows the addition of an OH moiety to the proline 564 that aids binding to the 
VHL protein and leads to the subsequent degradation of the HIF-la subunit, via addition 
of ubiquitin molecules. 
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1.6.4 Factor inhibiting HIF-1 (FIH-1) 
Fe2+ -dependent enzymes that use molecular oxygen to oxidize both 2-oxoglutarate and 
either polypeptide or metabolic substrates are found throughout nature. Several members 
of this family have been identified, revealing a conserved double stranded J3-helix 
composing the enzyme core [Roach et a/1995, Clifton et a/2001]. A critical His-X-
Asp/Giu dyad and C-terminal His residue lies within this fold and is responsible for 
binding the iron atom [Hegg & Que 1997]. 
HIF transcriptional activity is suppressed under normoxic conditions by hydroxylation of 
an asparagine residue within its C-terminal transactivation domain, blocking association 
with p300/CBP [Mahon et a/2001] (see fig 1.11). 
The protein factor inhibiting HIF-1 (FIH-1 ), which has previously been shown to interact 
with HIF, is an asparaginyl hydroxylase, and like other hydroxylase enzymes FIH-1 is a 
Fe2+ -dependent enzyme that uses molecular oxygen to modify its substrate [Dann et a/ 
2002). 
An inhibitory protein that interacted with residues 757-826 at the C-terminus ofHIF-1 a, 
encompassing part of the inhibitory domain and C-T AD [Mahon et a/200 I]. Homodimer 
formation is required for substrate recognition [Dann et a/2002] 
Asparagine-803 in the C-T AD is hydroxylated by FIH-1 under normoxic conditions 
causing abrogation of the HIF -I a/p300 interaction [McNeil et a/ 2002]. 
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0 Oxygen dependant degradation domain 
T Hydroxyproline N-TAD 
i Hydroxyasparagine • 
C-TAD 
• PAS domain bHLH 
Factor inhibiting HIF-la. 
Fig 1.11 Hypothetical model of the complex formation by the FIH-1 dimer, VHL and 
HIF-la.. 
This model represents the FIH-1 dimer acting as a bridge for the association between VHL 
and HfF-1 a. under normoxic conditions. 
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To achieve full induction of the hypoxic response pathway after exposure to low 0 2 levels 
requires both stabilisation of the HIF-a transcription factor and activation of the 
N-T AD [Lando et a/2002]. Each of these events depends on the abrogation of a 
hydroxylase enzyme that negatively regulates HIF under norrnoxic conditions. Although 
the two modes of regulation can be uncoupled via construction of chimeras containing 
either the ODD or C-T AD, the machinery regulating both appears to be linked [Mahon et 
a/200 I). Under nomoxic conditions HIF-a C-T AD association with the CH I domain of 
the co activator p300 is blocked by hydroxylation of a conserved asparagine residue 
[Lando et a/2002]. Aparagine-803 in the C-TAD ofHIF-la is hydroxylated under 
nonnoxic conditions causing abrogation of the HIF-1 a I p300 association [McNeil et a/ 
2002]. Hydroxylases that catalyse the post-translational modification of aspartic acid I 
asparagine residues have been previously described [Stenflo et a/ 1989, Lavaisiere et a/ 
1996]. 
The crystal structure of FIH-1 at 2.8 A resolution shows that it is composed of a central ~­
barrel surrounded by eight a-helices. The prominent feature in the FlH-1 structure is a 
distinctive groove that extends from the active site towards the interconnecting loop 
between domains I and 11. The FIH-1 structure suggests a mechanism for the physiological 
regulation of HIF-1 activity by revealing three-dimensional locations of regions in FIH-1 
that are implicated in the interactions with HIF -1 a C-T AD and VHL. The distinctive 
binding sites for HIF-1 aC-T AD, and VHL on the surface of FIH-1 support the possibility 
that the ternary complex and cooperation of the three proteins may be required in the 
hydroxylation of HI F-a by FIH-1 [Lee et a/2003]. 
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1.6.5 HIF-2a 
Isolation and characterization of a cDNA for a novel Per-Arntl Ahr-Sim basic-helix-loop-
helix (bl-ILH-PAS) factor that interacts with the Aryl-receptor nuclear translocator (Arnt), 
and its predicted amino acid sequence was shown to exhibit significant similarity to the 
hypoxia-inducible factor-la. This HTF-Ia like factor (HLF) encoded by the isolated cDNA 
bound the hypoxia-response element (HRE) found in enhancers of genes for 
erythropoietin, VEGF, and various glycolytic enzymes, and activated the transcription of a 
reporter gene the HRE. Although the transcription-activating properties of HLF were 
similar to those reported for HIF-1 a their expression patterns were quite different. HLF 
m RNA was most abundantly expressed in the lung, followed by the heart, liver and various 
organs under nonnoxic conditions, whereas HIF-1a mRNA was ubiquitously expressed at 
much lower levels. HLF mRNA was closely correlated with that ofVEGF mRNA [Ema et 
a/1997]. Cloning and chromosomal localization for HIF-2a led to chromosome 11 p 15 
[Wolting & McGiade 1998]. HIF-2a was shown to be strongly expressed, and strongly 
induced by hypoxia at the level of protein but not mRNA. Although differences between 
the abundance ofHIF-2a and HIF-Ia were seen in different cell types, the differences in 
the inducible response was more subtle with HIF-2a protein being slightly more evident in 
nonnoxic and mildly hypoxic cells [Wiesener et a/1998]. A comparison of the oxygen-
regulated and transactivating domains in HIF-Ia and HIF-2a produced two domains in 
HIF-2a similar to HTF-1a, a C-tenninal domain (amino acids 828-870) and a larger 
internal domain (amino acids 517-682) demonstrating a similar organization for both 
proteins. HIF-2a sequences were less inducible than those of HlF-1 a, and was strikingly 
reduced as their expression level increased [O'Rourke et a/1999]. HTF-2a may play an 
important role in vascular remodelling, as mutant embryos that were derived from HlF-2a-
,_ embryonic stem cells developed severe vascular defects both in the yolk sac and embryo 
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proper and died between embryonic day (E) 9.5. and E 12.5. Normal blood vessels were 
found by vasculogenesis but they either fused improperly or failed to assemble into larger 
vessels later during development [Peng et a/2000]. Using immunohistochemistry the 
expression and distribution ofHIF-1a and HIF-2a was seen in the nucleus of a number of 
solid tumours including, bladder, brain, breast, colon, ovarian, pancreatic, prostate, and 
renal carcinoma [Xia et a/2001, Leek et a/2002, Onita et a/2002, Khatua et a/2003]. 
HIF-2a was also strongly expressed by subsets of tumour-associated macrophages, 
sometimes in the absence of any expression in tumour cells [Talks et a/2000]. 
In the presence of functional VHL protein, HIF-1 a mRNA levels are elevated, where as 
HIF-2a mRNA expression is increased only in VHL deficient RCC cell lines lacking a 
functional VHL gene product. On a protein level, in VHL deficient cell lines both HIF-1 a 
and HIF-2a subunits are constitutively expressed, whereas re-introduction of a functional 
VHL gene restores the instability ofHIF-Ia and HIF-2a proteins under normoxic 
conditions to direct the HIF-a subunits for destruction in the proteosome [Krieg et a/ 
2000]. Using human breast cancer cell lines it has been shown that there was an inverse 
correlation between HIF-Ia and H1F-2a induction under hypoxia. Cell line with reduced 
induction ofHIF-1a or HIF-2a showed high basal levels ofVEGF and improved survival 
under hypoxia. Despite the fact that HIF proteins are necessary for optimal tumour growth 
and angiogenesis in vivo, over expression of these molecules seem detrimental to tumour 
growth [Blancher et a/2000]. 
Complete cDNA ofHIF-2a was cloned and tranfected to cells from the 293 Tet-Offfetal 
kidney cell line and expression pattern ofVEGF and transferrin receptor (TfR), target 
genes ofHIF-Ia examined by reverse transcriptase polymerase chain reaction (RT-PCR). 
Endogenous VEGF was increased by the introduction of HIF-2a cDNA at both the mRNA 
and protein level. This suggests that endogenous VEGF can be upregulated by HIF-2a that 
may be involved in the angiogenesis ofRCC [Xia et a/2001]. 
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Increased expression ofHIF-la and HIF-2a mRNA has also been shown in primary 
human bladder tumours compared with normal bladder specimens [Jones et a/200 I]. 
Tumour associated macrophages (TAMs) preferentially migrate to hypoxic areas within 
tumours and strongly express HIF-2a. By correlating HIF-2a with microvessel density 
(M VD) as a marker of angiogenesis it suggested that T AM HIF-2a signalling may be a 
useful target for future anti-angiogenic strategies [Leek et a/ 2002). 
Under hypoxic conditions heart, lung, brain, kidney, liver, pancreas, and intestine of rats 
showed marked induction of HIF-2a. Immunohistochemistry revealed nuclear 
accumulation indicating the HJF-2a plays an important role in the transcriptional response 
to hypoxia in vivo [Wiesener et a/2003]. 
1.6.6 HI F -3a 
The HIF-3a transcription factor is a 662 amino acid protein with a predicted molecular 
weight of73kDa, and was expressed in adult thymus, lung, brain, heart, and kidney. The 
N-tenninal bl-ILI-1-PAS domain of this protein shares amino acid sequence identity with 
that ofHlF-la and HIF-2a (57% and 53% identity respectively, see fig l.l2). It was 
shown that HIF-3a dimerizes with ARNT, and this resultant heterodimer recognized the 
HRE core sequence, TACGTG. Transient transfection experiments showed that the HIF-
3a-ARNT dimer can occur in vivo, and that the activity ofH1F-3a is up regulated in 
response to cobalt chloride and low oxygen tension [Gu et a/1998]. Sequence analysis 
revealed that, like mouse HIF-3a, human HIF-3a has high similarity with HIF-la and 
HIF-2a in the bHLH and PAS domains, but lack structures for transactivation found in the 
C-tenninus of HIF-1 a and 2a. Reporter gene analysis showed that HTF-3a suppresses 
hypoxia-inducible HIF-mediated gene expression, and HIF-3a might be a negative 
regulator of hypoxia-inducible gene expression in the human kidney [Hara et a/200 I]. 
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The inhibitory PAS (Per/ Arnt/Sim) domain protein, I PAS, functions as a dominant 
negative regulator of hypoxia-inducible factors by forming complexes with those proteins 
that fail to bind to hypoxia response elements of target genes. Sequencing of the mouse 
I PAS genomic structure revealed that !PAS is a spliced variant of the HIF-3a.locus. In 
addition to three unique exons ( 1 a, 4a, and 6) IP AS shares three exons (2, 4, and 5) with 
HIF-3a. as well as alternatively spliced variants of exons 3 and 6. Using mice exposed to 
nonnoxia or hypoxia (6% 02 for 6 hrs) the alternatively spliced HIF-3a. transcript was 
observed in the heart and lung. The alternatively spliced transcript was only observed 
under hypoxic conditions, this mechanism may establish negative feedback loop regulation 
of adapted responses to hypoxia/ischemia in tissues [Makino et a/2002]. 
Recently multiple splice variants of the HIF-3a. locus have been reported, HIF-3a. 1-6 
(with the HIF-3a. 2 also known as !PAS domain protein). The common oxygen-dependent 
degradation domain of HIF-3a. 1-3 splice variants is targeted for ubiquitination by pVHL 
complex in vitro and in vivo. This activity is enhanced in the presence ofprolyl 
hydroxylase and is dependent on a proline residue at position 490. It was also shown that 
ubiquitin conjugation occurs on lysine residues at position 465 and 568 within the ODD, 
demonstrating additional targets of the pVHL complex and suggests a growing complexity 
in the regulation of hypoxia-inducible genes by the HIF family of transcription factors 
[Maynard et a/2003]. In contrast to HIF-1 a., 113, and 2a. levels of HIF-3a. mRNA 
increased after 2 hours ofhypoxia, suggesting that induction of HIF-3a. at the 
transcriptional level may represent a rapidly reacting component of the HIF system to 
protect against hypoxic damage [Heidbreder et a/2003]. 
98 
lF-la 
?-3a 
F-2a 
Chapter 1: INTRODUCTION 
blll..H I PAS NTAD CTAD 
I I I I 
I I I I 
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:74%: 53% \ 52% \ \ \ 
I I \ \ 
I I \ \ 
I I \ \ 
I I \ \ \ \ 
Fig 1.12 Structural similarities between the three ffiF-a species 
There is structural similarity between the various domains of the HIF-a subunit, with 
homology between the PAS, bHLH, NTAD and CTAD domains ofthe protein. 
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1.6.7 Antisense HIF 
A novel species has been identified, tenned antisense hypoxia inducible factor (aHIF) 
which is a natural anti sense transcript from the HIF-1 a gene sequences encoding the 3' 
UTR of HIF-1 a mRNA [Trash-Bingham & Tartof, 1999]. It is thought to bind to the HIF 
mRNA and provide a link between HIF and VHL [Neckers, 1999]. aHIF is widely 
expressed in normal foetal and adult tissues as in tumour tissues. Foetal aHIF expression is 
higher than adult expression and high enough to effect the HIF-1 a mRNA/aHIF transcript 
ratio. It is thought that aHIF could expose AU rich elements present in the 3' UTR of HIF-
1 a and increase the degradation speed ofHIF-1 a mRNA. It has also been shown that the 
aHIF promoter contains several putative HREs, which may explain the overexpression of 
aHIF under hypoxic conditions, creating a loop ofregulation for HIF -1 a expression 
[Rossignol et a/2002]. 
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1. 7 Hypothesis 
The highly vascularized nature of renal cell carcinoma makes it an ideal disease to study 
genes that are involved in the angiogenesis of tumours. There are a number of genes 
involved in the regulation of renal cell carcinoma, and the angiogenesis of the tumour. 
Polymorphic variants of hypoxia-inducible factor-1 alpha (HIF-1 a) that change the coding 
region of the gene have been shown to alter transactivation activity, which in conjunction 
with polymorphisms in the glucose transporter-! (GLUT -1) promoter may effect the 
progression of renal cell carcinoma (RCC). We have shown, for the first time, that these 
polymorphisms are associated with RCC [OIIerenshaw et a/2004]. 
The expression of genes related to tissue hypoxia (HIF-la, GLUT-I, and VEGF) will be 
analysed using a ribonuclease protection assay (RPA). RPA analysis was chosen as a 
method to measure the levels of mRNA in the samples because of the advantages over 
other assay methods. The assay is performed in a liquid interface within a single tube 
reducing user error, it is able to detect partially degraded mRNA and was a technique 
which had been optimised in our laboratory. 
I. Samples for the study will be obtained from a variety of sources; tumour samples will 
be taken prospectively from all nephrectomy patients. DNA will also be obtained 
retrospectively from paraffin embedded sections to elucidate any role polymorphisms 
in either the VEGF or HIF-Ia genes play in the progression or severity ofRCC. 
2. The expression of the different isoforms of VEGF has been poorly studied to date in 
RCC, and may provide important clues as to the severity of the disease. Are the levels 
of mRNA elevated in the tumour verses normal tissue of patients with RCC? 
Expression of the VEGF 165 and 189 isofonns of the VEGF gene will be 
quantitatively analysed using a ribonuclease protection assay {RPA). Particular 
isoforms have been associated with cancer including VEGF189, and VEGF165 (the 
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predominately expressed isoform secreted by normal and transformed cells). Will the 
levels of these isoforms relate to the tumour stage? 
3. Recent identification of the polymorphic nature of the VEGF gene has lead to a number 
of studies of diseases in relation to these polymorphisms. Polymorphisms have been 
described in the promoter region of the VEGF gene, which I intend to analyse in 
conjunction with the expression of the mRNA to look for any correlations. DNA from 
paraffin embedded RCC tissue will be used for subsequent PCR analysis of VEGF 
promoter polymorphisms. The C-2578A (containing an 18 nucleotide insertion at -
2550 which is in complete linkage with the A allele) will be evaluated for any possible 
role in RCC. Will it be possible to attribute in part these polymorph isms to the outcome 
or severity of RCC or the expression levels of the VEGF mRNA in the tumour and 
non-neoplastic tissue in patients with RCC? Using the Robson stage and Fuhrman 
grade will it be possible to determine any links between these polymorphisms and a 
particular stage or grade 
4. Recently identified polymorphisms in the HIF-Ia gene (CI772T and GI790A) have 
been linked to the transactivation of the protein. These polymorph isms in the HIF-1 a 
gene will be studied to identify any differences between the control and patient 
populations. Will any of the alleles be linked to patients with RCC, and will there be a 
segregation of the alleles according to the severity of disease? 
These experiments will hopefully lead to an increased knowledge of the role of hypoxia 
inducible genes in RCC, and angiogenesis of the tumour. Can polymorphisms in the VEGF 
gene lead to differences in the expression levels of mRNA produced by the gene? If there 
are differences in expression levels ofmRNA can they be linked to severity of disease? 
Initially using the whole population ofRCC patients and then using the CC RCC subgroup 
to see if there are any correlations within this group and the polymorphisms studied. 
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Subgroups of RCC will be measured for all the assays, and then divided into just CC RCC 
to see if any significant differences can be found. 
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2.0 Materials 
2.1 General reagents and stock solutions 
2.1.1 Water 
Double distilled tap water was used to make up all stock, general purpose and specialist 
solutions. Sterile water (Parkfields Pharmaceuticals Ltd, UK) was used to make 
oligonucleotide probe and primer solutions and used for PCR. 
2.1.2 Diethyl pyrocarbonate (DECP) treated water 
I ml of diethyl pyrocarbonate (DEPC)(Sigma, UK) was added to I L of double distilled tap 
water, and allowed to dissolve overnight, and was subsequently used for all RNA work. 
2.2 Proprietary solutions, and reagents 
All reagents used were analytical grade or equivalent. 
2.2.1 Stock solutions 
I. 
11. 
Ill. 
IV. 
V. 
Tris/borate electrophoresis buffer {TBE) 
I OX solution: 0.89mM Tris base, 0.89M Boric acid, 2mM EDT A (pH8) 
Ethidium bromide 
lOmg ml" 1 in H20 
OrangeG 
Sodium Chloride 
Tris 
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2.3 Autoclaving 
All solutions, glassware and plastic ware used in the techniques of DNNRNA analysis 
were autoclaved at a temperature of 121°C and a pressure of 15 p.s.i for 30 minutes in a 
steam autoclave (Prior Clave, UK). 
2.4 Patients 
Patients for this study were selected from those undergoing surgery for radical 
nephrectomy for suspected RCC. Histological analysis of the tumour was carried out in the 
histopathology department at Derriford hospital, Plymouth by a consultant 
histopathologist. Tumours were graded using the Fuhrman grade and staged by Robson 
stage, which is based on the Tumour Node Metastasis (TNM) staging of the tumour. An 
experienced consultant pathologist in Derriford hospital removed tumour and normal tissue 
from the RCC sample, taking care to remove sections of tumour from non-necrotic looking 
areas of the tumour mass (approximate size ofthese sections was I x I x 2-cm). Patient 
notes were reviewed to obtain the TNM staging and any other information regarding the 
patient was extracted from the notes. 
2.5 Ethics 
Ethics for the project were obtained for the removal and analysis of patients DNA, RNA, 
and protein from the tumour and normal tissue. This was carried out in accordance to the 
local regional ethics committee (LREC) approved protocol. The project and any relevant 
background information was explained to each patient, by an SHO or registrar in urology 
before informed consent could be given. 
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2.6 Control population 
Controls for the genetic polymorphism study were obtained from sequential cord bloods 
taken from deliveries at the Obstetrics and Gynaecology department, Derriford hospital, 
Plymouth. DNA was then prepared using standard salt extraction protocols, with only the 
sex of the sample being known. 
lntro to Methods 
Methodological approached used include polymerase chain reaction, ribonuclease 
protection assay, DNA extraction, RNA extraction. 
These methods were uses to quantify the levels ofmRNA and frequency ofpolymorphisms 
in the genes studied. RPA was chosen as a method to study the expression of mRNA 
because of: ease of use, experience in this method in our laboratory, ability to detect 
partially degraded mRNA, and it is a single tube experiment eliminating user error through 
transfer of the material. 
2.7 Polymerase chain reaction (PCR). 
Polymerase chain reaction or PCR has become a highly used assay in the tool box of all 
molecular biologists. PCR is a very powerful tool that can be used in a wide variety of 
assays. Primarily for the purposes of this thesis it was used to amplify stretches of subject 
DNA. The principles behind PCR are as follows: Short complementary oligonucleotides 
are used to bind to the DNA that serves as a binding site for a thermostable DNA 
polymerase. Amplification of genomic DNA using oligonucleotides that bind to 
complementary regions of the DNA in the 5' to 3' direction thus allowing elongation of the 
DNA by thermostable DNA dependant DNA polymerases, i.e Taq polymerase from the 
bacterium Thermus Aquaticus. 
The DNA is denatured at 94-95°C for 30 seconds, the oligonucleotide primers annealed at 
temperatures ranging from 50-65°C for 1.30 to 2 minutes, and then the DNA extended at 
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72°C for I to 2 minutes. This cycle of denaturation, annealing, and extension is then 
repeated for 30-35 cycles. Conditions for each PCR are optimised according to the primers 
T m and MgCh concentration required. Primers can either be designed by hand/eye or a 
computer package such as "DNA Star". A schematic representation ofPCR can be seen in 
fig 2.1. A wide variety of thermostable DNA dependent DNA polymersases have become 
available, Taq polymerase (originating from the bacterium Thermus Aquaticus) has been 
used in the PCR assays here. 
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Cool to 56~C 
5' 11 3' 5' E I 3' 3' a 5' Heat m vtc ? ' L, 5' \) 
s· 8' 
I 3' • I 6' 
Elongation occurs in 
the 3' -.. 6' direction 
Fig 2.1 Polymerase chain reaction 
This fig shows a cycle o f the polymerase chain reaction, consisting of a denaturation step 
followed by annealing of the primers and finally extension of the DNA 
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2.7.1 PCR for the polymorphisms in the VEGF gene 
2.7.1.1 PCR for the C to A @-2578 in the VEGF gene promoter 
Primers were designed to produce a fragment which would be 212 bp long for the C allele, 
and 230 bp long for the A allele (which contains the 18 nucleotide insertion). 
The conditions for the PCR reaction were: Denaturation at 95°C for 4 m ins, followed by 30 
cycles of denaturation at 95°C, anneal at 60°C for 2 m ins, and extension at 72°C for 2 mins, 
followed by a final extension of 72°C for 4 mins. 
VEGF sense primer for C to A @ -2578 
5'- TIC CCT CTTTAG CCA GAG CCG GGG-3' 
VEGF antisense primer for C to A @ -2578 
5' CTG AGA GCC GTT CCC TCT TTG CTA -3' 
The PCR products were separated by agarose gel electrophoresis (ISO V) using a 3-4% 
agarose gel 
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2.7.2 Polymorphisms in the hypoxia-inducible factor-la 
2.7.2.1 PCR for the C toT@ nucleotide 1772 in codon 582 in the hypoxia inducible 
factor la exon 12. 
The C( 1772)T nucleotide substitution creates a change from a proline to serine at codon 
582. Primers were designed to produce a fragment which would be 346 bp long for the T 
allele, and 229, and 118 bp long for the C allele. The substitution from a C to a T 
abolishes a 1-lph I cut site. 
The conditions for the PCR reaction were: Denaturation at 95°C for 4 m ins, followed by 30 
cycles of denaturation at 95°C for 30 secs, anneal at 57°C for 2 m ins, and extension at 72°C 
for 2 mins, followed by a final extension of 72°C for I 0 m ins. Samples were digested 
overnight using 2U of I-I ph I at 3 7°C. 
The forward primer is 5'- AAG GTG TGG CCA TTGTAA AAACTC- 3' 
The reverse primer is 5 '- GCA CT A GT A GTT TCT TT A TGT ATG - 3' 
2.7.2.2 PCR for the G to A@ nucleotide 1790 in codon 588 in the hypoxia inducible 
factor la exon 12. 
The G( 1790)A nucleotide substitution creates a change from a alanine to threonine at 
codon 588. 
The conditions for the PCR reaction were: Denaturation at 95°C for 4 m ins, followed by 30 
cycles of denaturation at 95°C for 30 secs, anneal at 57°C for 2 m ins, and extension at 72°C 
for 2 mins, followed by a final extension of 72°C for I 0 m ins. Samples were digested 
overnight using 2U of Aci I at 37°C. 
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The forward primer is 5'- AAG GTG TGG CCA TTGTAA AAA CTC- 3' 
The reverse primer is 5'- TGA CTC AAA GCC ACA GAT AAC ACG- 3' 
This produces a fragment of 475 base pairs in length. 
Digestion of the PCR product with the restriction enzyme Aci I (New England Biolabs) 
produces a single cut site to give two bands of331 and 144 base pairs respectively for the 
G allele. The change to an A allele abolishes the cut site and the fragment produced is 475 
base pairs. 
2.8 Extraction of high molecular weight DNA from whole blood using standard kits 
DNA was extracted using a Nucleon BACC kit following standard procedure. 3-10ml of 
blood was placed in a 50ml Falcon tube (Becton Dickinson, UK) and 4x volume of 
Nucleon A added and shaken for 4 minutes. The solution was centrifuged for 4 mins at 
1300g. The supematant was discarded and 2ml ofNucleon B was added to pellet vortexed 
and incubated at 37°C for 10-15 minutes. 500fll of 5M Na Perchlorate was added and 
inverted 10-15 times, centrifuged at l300g for 3 minutes. 200fll of Silica suspension 
layered onto the red layer without disturbing the phases. Centrifuged at 1300g for 3 
minutes the upper aqueous phase was transferred to a fresh 15ml Falcon. 2x volume of 
ethanol was added (-20°C) and inverted a few times. The DNA was hooked out with a 
glass rod, washed in 70% ethanol and dissolved in 500fll of sterile water or TE buffer. 
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aaggtgtggccattgtaaaaactcatgtatttgctgttttaaagg 
acacagatttagacttggagatgttagctccctat 
atcccaat atgatgacctccagttacgttccttcgatcagttg 
tc tagaaagcagttcc c agccctgaaag 
cgcaagtcctcaaagcacagttacagtattccagcagactcaa 
atacaagaacctactgctaatgccaccactaccactg 
ccaccactgatgaattaaaaacagtgacaaaagaccgtatgg 
aagacattaaaatattgattgcatctccatctcctacc 
c acatcatcaccatatag 
agatactcaaagtcggacagcctcaccaaacagagc 
aggaaaaggagtcatagaacagacagaaaaatctcatccaa 
gaagccctaacgtgttatctgtcgctttgagtca 
Fi ure 2.2 Hypoxia-inducible factor la. exon 12 PCR amplimers and polymorphisms. 
cc to c =Proline to Serine (Hph I), C allele= 229, 118 bp bands (wild type), T allele= 
346 bp bands. c to c =Alanine to Threonine (Aci I), G allele= 331 bp & 144bp (wild 
type), A allele= 475 bp. 
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2.8.1 Extraction of high molecular weight DNA from kidney tumour samples using 
standard kits 
Tumour and nonnal tissue were subjected to a homogenisation procedure before DNA 
extraction. Tissue was ground in a pestle with a mortar, in the presence of liquid nitrogen. 
DNA was extracted using a Nucleon BACC kit following standard procedure. 
2.8.2 Extraction of high molecular weight DNA from paraffin embedded sections of 
kidney from patients with renal cell carcinoma (Using the Nucleospin C & T kit, 
Macherey-Nagel) 
I 011m sections of tumour and nonnal tissue from RCC patients was taken and placed in a 
sterile 1.5ml eppendorf. The sections were trimmed of any excess paraffm before being 
placed in Iml of xylene for 30 minutes (vortex every 5 mins) to remove the remaining 
paraffin. 
180111 of BUFFER TI (tissue lysis mix), and 25!11 of proteinase k (20mg/ml) (which is 
stored at -20°C) was added to the eppendorf containing the paraffin section and placed in a 
shaking incubator at 55°C. Remove samples and vortex after 30 minutes and return to the 
incubator overnight. 
Preheat BUFFER B2 to 70°C for 5 m ins. Add I volume of 82 to 4 volumes B I, and pipette 
to mix (this is BUFFER B3). 
Pre-heat ELUTION BUFFER BE to 70°C. 
For each sample, place a Nucleospin column into a 2ml collection tube. Add 200111 
BUFFER B3 to the lysed paraffin sample, vortex IMMEDIATELY for 15 seconds to mix, 
incubate at 70°C for I 0 m ins. Add 210111 ethanol to the sample mix, vortex 
IMMEDIATELY and QUICKLEY transfer sample to Nucleospin column, centrifuge at 
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8200 rpm for I min. Discard eluate and replace column in collection tube. If some liquid or 
solidified paraffin remains in the spin column, transfer the column to a fresh I.Sml tube 
and incubate at 70°C for I min. Transfer the column back to the ml collection tube 
QUlCKLEY and centrifuge at 8200 rpm for I min. 
Add 500!11 of BUFFER 85 to the column, and centrifuge at 8200 rpm for I min. Discard 
the eluate and replace column in collection tube. Repeat by adding 500J1l BUFFER 85 to 
the column and centrifuge at 8200 rpm for 3 mins. Discard the collection tube. 
Place the Nucleospin column into a fresh 1.5ml tube, add 50J1I ELUTION BUFFER BE 
(70°C) and incubate at 70°C for I min. Centrifuge at 8200 rpm for I min, discard the 
column and close 1.5ml tube. 
2.8.3 Extraction of high molecular weight DNA from fresh frozen tumour and normal 
kidney tissue from patients with renal cell carcinoma 
After snap freezing of the tumour and normal kidney tissue and storage at -196°C in liquid 
nitrogen, samples were removed and a small section sliced off the end of the tissue block. 
This section was minced using a scalpel until a paste like consistency was made. 
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2.9 Isolation and Culturing of Peripheral Blood Mononuclear cells (PBMCs) from 
whole blood 
20mls of peripheral blood was collected into 5% EDTA Vacutainers (Becton-Dickinson). 
The blood was diluted I: I in phosphate buffered saline and the PBMCs harvested 
following standard density gradient centrifugation. The PBMCs were washed twice and re-
suspended at a concentration of 0.5xi06/ml in RPMI 1640 (llmM D-glucose) 
supplemented with I% penicillin/streptomycin (Gibco GRL, UK), I 0% fetal calf serum 
(Gibco GRL, UK) and separated into 2 flasks. 
2.10 Extraction of total and messenger RNA 
Using a guanidine phenol extraction kit (RNA-Stat 60™). 
At the end of the incubation period the cells were pelleted by centrifugation the supematant 
removed and the cells re-suspended and lysed in RNA Stat 60™. The solution was then 
transferred to an RNase-free eppendorf, 200J1l of chloroform was added (Sigma 
Chemicals, UK), vortexed and centrifuged at 13000g for 15 minutes at 4°C. The upper 
aqueous phase was transferred to a clean eppendorf, mixed with 500J1l of isopropanol and 
centrifuged. The supematant was discarded and the pellet was washed in 75% ethanol and 
re-suspended in 50-I OOJ.l.l DEPC treated water by vortexing. The approximate amount of 
total RNA extracted was determined using a Cecil 5500 spectrophotometer scanning 240-
280nm (Cecil Instruments Ltd, UK). 
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2.11 Preparation of first strand cDNA. 
RNA and primers were mixed and heated to 70°C for I 0 m ins, and then placed on ice for I 
minute (all reaction were undertaken using a thennal cycler to obtain correct 
temperatures). IOmM dNTP mix (lOmM each dATP, dCTP, dCTP, dTTP) was added 
along with MgCh (25mM), PCR buffer, and DRR (0.1 M) and incubated at 42°C for 5 
mins. IJ.ll of SUPERSCRlPT II RT was added to the mix and incubated at 42°C for 50 
mins. The reaction was tenninated at 70°C for IS mins and then chilled on ice. IJ.ll of 
RNase H was added and incubated at 37°C for 20 mins. The products were then stored at 
-20°C or used for PCR amplification of RPA probes (see fig 2.3). 
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AAAA(A)n 3' 
poly (A) tail 
Ol igo (dT)12-1s 
3' V\/\/\/"\ 5' 
AAAA(A)n 3' 
MMLV RT 
Reverse Moloney murine 
transcriptase leukaemia virus 
3' V\/\/\/"\ 5' 
AAAA(A)n 3' 
5' 
cDNA : mRNA hybrid 
5' 
'-------------------------------------------- AAAA{A)n 3' 
Removal of RNA 
Fig 2.3 Preparation of first strand cDNA. 
This fig shows a schematic representation of the preparation of first strand cON A using a 
reverse transcriptase 
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2.12 Ribonuclease protection assay (RPA) 
In the case of PCR for RP A the primers were designed so that the fragment would equate 
to the size of RNA probe that would be subsequently transcribed, using an antisense primer 
that has had a T7 promoter inserted at the 5' end. 
2.12.1 Preparation of antisense RNA probes 
High molecular weight DNA was prepared from I Oml of peripheral blood using Nucleon 
extraction kits (Scotlab, Paisley, Scotland). An aliquot of this DNA was amplified using 
the polymerase chain reaction (PCR). 3 primers were designed to amplify exons of the 
gene to be analysed. The first round amplification reaction was performed in 30!11 
volumes, containing the amplimers for the gene of interest. 
lOmM dNTPs (Amersham Pharmacia Biotech, Bucks, UK), IOX buffer solution, IOmM 
MgCh, I U Taq polymerase {HT Biotech UK). The samples were subjected to an initial 
cycle of denaturation for 4 mins at 94°C. This was followed by 30 cycles of amplification 
that consisted of denaturation for 30 sec's at 94°C, annealing for 2 min at 57°C, and 
extension for 2 min at 72°C, with a final extension for 2 mins at 72°C in a icycler (BioRad, 
UK). A second round of amplification was then employed using the antisense amplimer 
with a RNA polymerase T7 adapter and stuffer nucleotides, IOmM dNTPs, IOX buffer 
solution, IOmM MgCh, I U Taq polymerase. The samples were then subjected to DNA 
amplification as described above. 2.5!-lg of the product was used to generate the radioactive 
RNA probes by incorporating a 32P UTP (Amersham Pharmacia Biotech, Bucks, UK) 
using the MAXIscript System (Ambion, Texas, USA). 
An equal volume of gel loading buffer (Ambion, Texas, USA) was added to the reaction 
and heated to 85-95°C for 3-5 mins and then loaded onto a 5% acrylamide/8M urea gel and 
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run at approx. 100-200 volts for 40mins- I hour. The gel was wrapped in SaranWrap and 
exposed to Kodak X-Omat film for 10- 30 sec's. The radioactive band was marked and the 
gel re-aligned to enable the radioactive probe to be excised and immersed in 350f.ll of 
elution buffer (Ambion, Texas, USA) and then incubated overnight at 37°C to get 95% 
recovery. 
2.12.2 Hybridisation of RPA probe to RNA sample: 
The RNA sample and the RPA antisense probe were mixed together and precipitated with 
ethanol and ammonium acetate 1/10 volume of 5M NH40AC (Ambion, Texas, USA) and 
2.5 X volumes of ethanol (Rathburn, Scotland) were added. The sample was mixed 
thoroughly and then placed in -20°C for 15 mins. The RNA was pelleted by centrifugation 
at a max of 4°C for 15 mins. The supernatant was drawn off and the pellet was dissolved in 
20f.ll of hybridisation buffer (Ambion, Texas, USA) vortexed for 5-l 0 seconds and then 
centrifuged to collect at the bottom of the tube. The sample was then incubated at 92°C for 
3-4 mins, vortexed, centrifuged and then incubated overnight at 42°C to allow 
hybridisation. 
RNase Digestion: 
The sample was spun briefly after hybridisation and 200f.1l of diluted RNase mix (Ambion, 
Texas, USA) was added and spun briefly. The reaction was incubated for 30 mins at 37°C, 
after which 300f.ll of RNase inactivation/precipitation solution (Ambion, Texas, USA) was 
added, vortexed and centrifuged. The reaction was then transferred to -20°C for at least 15 
mms. 
Separation and detection of protected fragments: 
A 5% denaturing polyacrylamide gel was prepared as before. The sample was centrifuged 
for 15 mins at 4°C and the supernatant was removed. The pellet was re-suspended in gel 
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loading buffer and vortexed for I min. The sample then was heated for 3-4 mins at 94 C, 
vortexed and spun briefly. The gel was run for approx. 40mins- I hour at 100- 200 volts. 
The gel was then transferred to filter paper (Amersham Phannacia Biotech, USA), covered 
with saran (Dow) and exposed to Kodak X-Omat film (Kodak) at -20°C to -80°C 
overnight. The bands were analysed using a phosphor-imager (BioRad, UK). 
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~ Total RN~ A lAss;.tisense Probe 
Combine and eo-precipitate if Denature and 7ybridise (2-24 hrs) 
Digest with RNase 
Precipitate RNA and [nactivate RNase 
1-----1 Denaturing PAGE Analysis ~ 
Quantitation by Phospbor-[mager 
Figure 2.4 Schematic representation of the ribonuclease protection assay (RP A) 
Total RNA and antiscnse probe are combined in a single tube, hybridized and after 
digestion with an appropriate RNase nm on a PAGE gel and quantitated using a Phosphor-
tmager. 
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VEGF RPA Primers 
Sense Anti-sense T7 Tag + Anti-sense 
5' -GGG CAG AA T CAT 5' -ACG CTC CAG GAC 5' -TAA TAC GAC TCA 
CAC GAA GTG GTG- TTA TAC CGG- 3' CTA TAG GGA GGC 
3' TTT ACG CTC CAG 
GAC TTA TAC CGG- 3' 
HIF-la. RPA Primers 
Sense Anti-sense T7 Tag + Anti-sense 
5'- GTG CCA CAT 5' - GCT GCA TGA 5' - TAA TAC GAC 
CAT CAC CAT ATA TCG TCT GGC TGC- TCA CTA TAG GGA 
GAG- 3' 3' GGC TTT GCT GCA 
TGA TCG TCT GGC 
TGC- 3' 
GLUT-1 RPA Primers 
Sense Anti-sense T7 Tag + Anti-sense 
5' - GGG TCG CCT 5' - CCC CCA ACA 5' - TAA TAC GAC 
CAT GCT GGC TGT GAA AAG A TG GCC - TCA CTA TAG GGA 
GGG- 3' 3' GGC TTT CCC CCA 
ACA GAA AAG ATG 
GCC - 3' 
18SrRNA RP A Primers 
Sense Anti-sense T7 Tag + Anti-sense 
5' - CGG CTA CCA 5' - CGC CGA GAG 5'- TAA TAC GAC 
CAT CCA AGG AGG GGC AAG GGG GGG- TCA CTA TAG GGA 
GCA - 3' 3' GGC TTT CGC CGA 
GAG GGC AAG GGG 
GGG- 3' 
Table 2.1 RPA primers for various RNA species 
This table shows the RP A primers used for VEGF, HIF- 1 a., GLUT -1 and 18SrRNA 
122 
Chapter 2: MATERIALS AND METHODS 
Probe Size lsoform detection 
VEGF 395, and 323 189, 165 spliced variants 
HIF- l a 280 
---
GLUT-I 201 
18SrRNA 305 
Table 2.2 RP A probe sizes and isoform detection 
This table shows the sizes of the RP A probes protected fragments and isoform detected. 
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Probe MgCh Concentration Annealing Temperaure 
(rnMol) (oC) 
VEGF 6 57 
GLUT-I 6 63 
HIF-la 9 52 
18SrRNA 6 66 
Table 2.3 PCR conditions for the RP A probes. 
This table shows the MgCh concentration and annealing temperature of the PCR reactions 
for the RP A probes 
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2.13 Statistical Analysis 
Expression of mRNA in the RPA assay was analysed by using a Phospho-Imager (BioRad) 
to measure the levels ofmRNA. This data was then normalized the by dividing by the 
18SrRNA value of that sample. These values were analysed using a non-parametric test, 
Mann-Whitney (Wilcoxon W) test, to assess any differences between the tumour and 
normal tissue expression values. All statistical analysis was performed using' Excel' 
(Microsoft) and 'Statgraphics' (Statistical Graphics Corp) statistical packages. 
Genotypes and alleles for the VEGF and HIF-Ia polymorphisms were analysed using 2X2 
contingency tables and a P value of <0.05 was taken to be significant. Bonferroni 
corrections were used to correct for the number of observations made in the analysis of 
multiple groups. 
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3.0 RESULTS 
3.1 Patients for ribonuclease protection assay (RP A) 
Patients undergoing radical nephrectomy were recruited into the study, after diagnosis of a 
probable renal cell carcinoma being the cause of the tumour mass in the kidney. Tumour 
and normal tissue from 44 patients was used to measure HIF-Ia and GLUT-I mRNA, 
while tumour and nonnal tissue from 34 patients was used to measure the levels of VEGF 
isoforrns 165 and 189. 
3.1.1 RPA for VEGF isoforms 165 and 189, HIF-la and GLUT-1 
Expression ofVEGF isoforrns 165 and 189 in the tumour and normal tissue can be seen in 
fig. 3.1. The two VEGF RNA species are labelled as well as the internal control 18SrRNA. 
For the differences in m RNA expression to be described as real differences and not just 
errors in loading it is important to include an internal control. For the internal control to be 
valid it needs to be a species of RNA that is expressed constitutively in the cell under 
hypothesis. For the purposes of these experiments we chose 18SrRNA as the internal 
control. 
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Patient 
2 3 
T N T N T N 
VEGF 189 
VEGF 165 
18S rRNA 
Figure 3.1. Expression ofVEGF 189 and 165 in tumour (T), and normal (N) tissue of 
renal cell carcinoma patients. 
This fig shows the expression of VEGF 165 and VEGF 189 along with 18S rRNA which 
was used as a control and is shown in the lower band. 
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Fig 3.2 RPA assay for VEGF 165 and VEGF 189 
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Figs A and B show a number of patients measured for VEGF 165 and 189 mRNA 
transcripts. The boxes demonstrate the size used to measure the intensity of the bands, 
which are then moved from band to band. Five patients are shown in both A and B. 
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Fig 3.3 RPA assay for VEGF 165 and VEGF 189 
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Figs A and B show a number of patients measured for VEGF 165 and 189 mRNA 
transcripts. Two patients are shown in A and five patients in B. 
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Variable HIF-la & GLUT-1 RPA VEGF isoforms RPA 
%(n=44) %(n=34) 
Mean Age (years) 64 63 
Range 33-87 33-82 
Gender 
Male 72.7 (32) 70.6 (24) 
Female 27.3 (12) 29.4 (10) 
Robson Stage 
I 34.1 (15) 32.3 (11) 
11 27.3 (12) 26.5 (9) 
Ill 20.4 (9) 14.7 (5) 
IV 18.2 (8) 26.5 (9) 
Histology 
Clear cell 86.4 (38) 82.3 (28) 
PapilJary 6.8 (3) 11.8(4) 
Chromophobe 4.5 (2) 5.9 (2) 
Leiomyosarcoma 2.3 (1) 0.0 (0) 
Fuhrman grade * 
Gl 0.0 (0) 0.0 (0) 
G2 33.3 (12) 31.0 (9) 
G3 66.7 (24) 62.1 (18) 
G4 0.0 (0) 6.9 (2) 
Table 3.1.1 Characteristics of the patients recruited for ribonuclease protection 
assays. 
This table shows the frequency of gender, Robson stage, histology and Fuhnnan grade for 
the RP A assay for both HIF-1 a/GLUT -1 and VEGF 165 and VEGF 189. The value n 
represents the number of patients in each group, and the number in parenthesis represents 
the number of patient s in each subgroup. 
·Fuhnnan grades unobtainable for 8 and 5 patients for the HIF-la/GLUT- 1 and VEGF 
isoforrns respectively 
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Table 3.1.1 shows that of the patients analysed for m RNA expression the average age for 
the HlF-Ia and GLUT-I RPA was 64 (range 33-87) and the average age for the VEGF 
isofonns was 63 (range 33-82). The distribution between sex was similar for both HIF-
Ia/GLUT-1 and VEGF isofonns (72.7% male 27.3% female for HIF-1a/GLUT-I and 70.6 
male and 29.4% female for VEGF isofonns respectively). The most common Robson 
tumour stage for patients analysed for HIF-1 a and GLUT -I were stage I, followed by II, 
III, and IV. Whilst for the VEGF isofonns it was Robson stage I, followed by stage 11, IV, 
and Ill. 
The clear cell histology was the most prevalent with a frequency of 86.4% for the HIF-1 a I 
GLUT -I and 82.3% for the VEGF isofonns, with the other subtypes making up only 
13.6% and 17.7% for the HlF-Ia I GLUT-I and VEGF isoforms respectively. No Fuhnnan 
grade I patients were found for either cohort, with the majority being grade 3 followed by 
grade 2 ( 66.7% for HIF -I a I GLUT -I and 62.1% for VEGF isofonns ), showing a similar 
distribution for Fuhnnan grade for both the HIF-1a/GLUT-1 and VEGF isofonns. For 
technical reasons it was not possible to analyse all the patients for each assay. 
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VEGF 165 (34) 
VEGF 189 (34) 
HJF-1 a. ( 44) 
GLUT- I (44) 
Tumour Tissue 
3 3.05 ± 0.40 
b2.4 1 ± 0.32 
c 1.34 + 0.11 
d 1.99 ± 0.2 1 
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RCC patients 
Normal Tissue 
1.56 ± 0.22 
1.43 ± 0.22 
1.10 ± 0.08 
1.63 ± 0.20 
Table 3.1.2 Expression of VEGF isoforms, HIF-la., and GLUT-1 in patients with 
renal cell carcinoma 
This table shows the expression levels for VEGF 165, VEGF 189, HIF - I a, and GLUT - I in 
both the tumour and nonnal tissue of patients with RCC. Comparisons between the tumour 
and normal tissue were made for each group using the Mann-Whitney W test for non-
parametric data and a value of <0.05 was considered as significant. The number of patients 
is shown in parenthesis. The data is expressed as a mean of the target mRNA/18SrRNA ± 
SE. 3P-==VEGF165 tumour vs. nonnal, P-==0.00002, bP=VEGF189 tumour vs. nonnal, 
?=0.0002, cP-==HIF-la tumour vs. nonnal, P-==0.01 , dP=GLUT-1 tumour vs. normal, 
P-==0.003. 
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A highly significant increase in mRNA expression was seen for YEGF 165 with 
expression in tumour tissue being 3.05 in comparison with the normal tissue which was 
1.56 (sample RNA/18SrRNA internal control) P=0.00002 {Table 3.1.2). A significant 
difference was also found between VEGF 189 expression in the tumour and nonnal tissue 
(2.4 1 vs. 1.43 expression between tumour and normal tissue) ? =0.0002. There was no 
preferential expression of VEGF 165 to YEGF 189 in the tumour or normal tissue. 
There was a significant difference in the expression of HIF-1 a and GLUT -1 in the tumour 
compared to matched normal tissue (P=O.O I and P=0.003 respectively) as shown in table 
3.1.2 with the increases in HIF-1 a being from 1.10 in the nonnal to 1.34 in the tumour 
tissue and for GLUT -1 1.63 in the nonnal to 1.99 in the tumour. 
Regression analysis of the expression levels of both HJF-1 a and GLUT - I showed that 
there was a significant correlation between the increasing levels ofHIF-1a and GLUT- I. 
There was no significant difference in the expression of 18SrRNA between the tumour 
tissue and the nonnal tissue, showing that comparable quantities of RN A had been used 
between samples. 
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VEGF isoform 
VEGF 165 VEGF 189 
cHistology (n=34) Tumour Normal Tumour Normal 
cc (28) 3 3.2 + 0.46 1.6 ± 0.26 b2.5 + 0.38 1.4 + 0.26 
CH (2) 3.9 + 1.24 1.8 ± 0.75 2.0 + 0.28 1.8 + 0.38 
p (4) 1.9 ± 0.7 1 1.4 + 0.51 1.9 ± 0.76 1.5 + 0.61 
Table 3.1.3 VEGF expression vs. histology in RCC patients. 
This table shows the expression levels ofVEGF165 and VEGF 189 according to histology. 
The number in parenthesis represents the actual number of patients in each group. The data 
is expressed as a mean of the VEGF isoform/18SrRNA control value± SE. 3P =VEGF165 
Tumour vs. Normal CC, P=O.OOl , bP=VEGF 189 T vs. N CC, P=0.02. cP= Histology CC 
vs. CH vs. P for VEGF165 tumour and normal and VEGF189 tumour and nonnal. P= N/S 
CC clear cell, P papi11ary, CH chromophobe. 
The RCC patients which were measured for expression of VEGF 165 and VEGF 189 fell 
into three histological subtypes; clear cell, papillary, and chromophobe with 28, 2, and 4 
patients respectively (see table 3. 1.3) 
Levels of VEGF 165 were significantly increased in the tumour vs. normal tissue of 
patients with clear cell RCC (3 .2 vs. 1.6) P=O.OO l . This significant increase was also seen 
in the tumour vs. normal tissue for VEGF 189 of patients with clear cell RCC (2.5 vs. 1.4) 
P=0.02. Between patients with papillary and chromophobe RCC there was no difference 
between tumour vs. normal tissue for VEGF 165 or VEGF 189. There was no significant 
difference between the levels ofVEGF 165 or VEGF 189 in any ofthe histological 
subtypes (CC vs. CH vs. P) P=N/S. 
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VEGF isoform 
VEGF 165 VEGF 189 
cFuhrman grade Tumour Normal Tumour Normal 
(n=29) 
2 (9) a4.84 ± 1.11 2.44 ± 0.56 3.70 ± 0.80 2.11 ± 0.59 
3 (18) b 2.53 ± 0.37 1.25 ± 0.25 1.87 ± 0.38 1.11 ± 0.25 
4 (2) 2.25 ± 0.22 0.89 ± 0.18 2.92 ± 0.76 1.17 ± 0.43 
Table 3.1.4 VEGF expression vs. Fuhrman grade in RCC patients. 
This table shows the expression levels ofVEGF165 and VEGF189 according to Fuhrrnan 
grade. The number of patients in each group is in parenthesis. The data is expressed as a 
mean ofthe VEGF isofonn/18SrRNA control value+ SE. aP=VEGF165 T vs. N Fuhrrnan 
grade 2, ?=0.04, bP=VEGF165 T vs. N Fuhrman grade 3, P=O.O I , cP= Fuhrman grade 2 
vs. 3 vs. 4 for VEGF 165 tumour and normal and VEGF 189 tumour and normal, P=N/S. 
Significant differences were seen for the expression levels ofVEGF 165 tumour vs. nonnal 
in Fuhrman grade 2 (4.84 vs. 2.44) P=0.04, but not VEGF 189 (3.70 vs. 2. 11) P=N/S. 
Fuhnnan grade 3 also showed significant differences for VEGF 165 tumour vs. normal 
(2.53 vs. 1.25) P=O.Ol , but not VEGF 189 tumour vs. normal (1.87 vs. 1.11) P=N/S. 
Increases were seen in Fuhnnan grade 4 for both YEGF 165 (2.25 vs. 0.89) and VEGF 189 
(2.92 vs. 1.17) although it was not statistically significant P=N/S (see table 3.1.4) 
No patients studied had Fuhrrnan grade 1 tumours. Fuhrman grade 2 had the highest 
expression levels of both isofonns 4.84 and 3.70 (expressed as VEGF isoform mRNA I 
l 8SrRNA) for 165 and 189 isoforrns. The expression levels of VEGF 165 decreased as the 
stage increased with grade 3 being 2.53 and stage 4 being 2.25. In comparison VEGF 189 
decreased from stage 2 to 3 (1.87) but increased in patients with Fuhnnan grade 4 to 2.92 
135 
Chapter 3: RESULTS 
VEGF isoform 
VEGF 165 VEGF 189 
cRobson stage Tumour Normal Tumour Normal 
(n=34) 
1 (11) a3.67 ± 1.04 1.84 ± 0.41 2.80 ± 0.79 1.64 ± 0.40 
2 (9) 2.47 ± 0.65 1.34 ± 0.49 1.61 ± 0.57 1.16 ±0.51 
3 (5) 2.53 ± 0.43 1.32 ± 0.57 2. 15 ± 0.63 1.33 ± 0.59 
4 (9) b3.18 ± 0.47 1.56 ± 0.40 2.87 ± 0.39 1.50 ± 0.39 
Table 3.1.5 VEGF expression vs. Robson stage in RCC patients. 
This table shows the expression ofVEGF165 and VEGF189 in relation to Robson stage. 
The data is expressed as a mean of the VEGF isofonn/ 18SrRN A control value ± SE. The 
numbers of patients are shown in parenthesis. a P=VEGF 165 Tumour vs. Normal Robson 
stage I, P=0.05,bP=VEGF I65 T vs. N Robson stage 4, P=0.03, cP= Robson stage 1 vs. 2 
vs. 3 vs. 4 for VEGF 165 tumour and nonnal and VEGF 189 tumour and normal, P=N/S. 
VEGF 165 was significantly increased in Robson stage l for tumour vs. normal (3.67 vs. 
1.84) ?=0.05. While it was increased in tumour vs. nmma1 for VEGF 189 it was not 
significant. Robson grade 2 tumours showed increases of both VEGF 165 and VEGF 189 
compared to tumour tissue (2.47 vs. 1.34 and 1.61 vs. 1.16) but neither were significant. 
Increases were seen for VEGF 165 and VEGF 189 in Robson stage 3 although those were 
not statistically significant. Robson stage 4 showed significant increases for VEGF 165 
(3.18 vs. 1.56) P=0.03, although VEGF 189 was increased (2.87 vs. 1.50) it was not 
significant. Robson stage 1 vs. 2 vs. 3 vs. 4 showed no significant difference for VEGF 165 
or VEGF 189 tumour or normal (table 3.1.5) 
There was no correlation between the expression of VEGF and the pathological stage of 
the tumour in relation to Robson stage for either VEGF 165 or VEGF 189 expression 
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(table 3 .1.6). The highest levels of expression for VEGF 165 were in Robson stage 1 
followed by 4, 3, and 2, with no significant differences between the stages. 
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VEGF lsoform 
VEGF 165 VEGF 189 
cGender Tumour Normal Tumour Normal 
(n=34) 
Male (24) 32.98 ± 0.53 1.39 ± 0.25 02.31 ± 0.4 1 1.31 ± 0.24 
Female (10) 3.23 ± 0.50 1.96 ± 0.44 2.65 ± 0.54 1.72 ± 0.49 
Table 3.1.6 Expression of VEGF isoforms 165 and 189 vs. Gender. 
This table shows the expression levels of VEGF 165 and VEGF 189 according to gender. 
The data is expressed as a mean of the VEGF isoform/ l8SrRNA control value ± SE. The 
numbers of patients are shown in parenthesis. 3P =VEGF I65 Tumour vs. Nonnal for males, 
?=0.002, bP=VEGFl89 T vs. N for males, P=0.04, cP=Male vs. female for both VEGF 
isofonns and tumour and nonnal tissues, P=N/S. 
Significant increases for VEGF 165 and VEGF 189 were seen in tumour vs. normal for 
males (2.98 vs. 1.39, and 2.3 1 vs. 1.31) ? =0.002 and P=0.04. VEGF 165 and VEGF 189 
tumour vs. normal for females was increased (3.23 vs. 1.96 and 2.65 vs. 1.72) but was not 
statistically significant P=N/S. VEGF 165 and VEGF 189 were increased in females vs. 
males for tumour and normal tissue although none of these increases were significant (see 
table 3.1.6). 
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Gender 
aRobson Stage (34) bMale %(n=24) rFemale %(n=10) 
1 (11) 37.5 (9) 20.0 (2) 
2 (9) 25.0 (6) 30.0 (3) 
3 (5) 12.5 (3) 20.0 (2) 
4 (9) 25.0 (6) 30.0 (3) 
Table 3.1.7 Distribution of Robson stage with Gender for RCC patients 
This table shows the distribution of Robson stage with respect to gender for VEGF 
isoforrns. Values are expressed as frequencies with the number of patients in parenthesis. 
3P= Male vs. female for all Robson stages, P=NIS. bP=Robson stage l vs. 2 vs. 3 vs. 4 for 
males, P=NIS. cP=Robson stage l vs. 2 vs. 3 vs. 4 for females, P=N/S. 
Robson stage I was the most common stage in males, followed by 2 and 4 equally and then 
3. There were no statistically significant differences between the distribution ofRobson 
stage vs. males P=N/S. Robson stages 3 and 4 were the most common in females followed 
by stages l and 3. No sign ificant differences were found between male and female for any 
of the Robson stages l to 4 (see table 3. 1.7). 
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Gender 
aFuhrman grade (29) bMale %(n=20) cFemale %(n=9) 
2 (9) 20.0 (4) 55.6 (5) 
3 (18) 70.0 (14) 44.4 (4) 
4 (2) 10.0 (2) 0.0 (0) 
Table 3.1.8 Distribution of Fuhrman grade with Gender for RCC patients 
This table shows the distribution of Fuhnnan grade with respect to gender for VEGF 
isoforms. Values are expressed as frequencies with the number of patients in parenthesis. 
aP= Male vs. female for all Fuhnnan grades, P=NIS. bP=Fuhnnan grade 2 vs. 3 vs. 4 for 
males, P=0.00009. cP=Fuhnnan grade 2 vs. 3 for females, P=N/S. 
No Fuhm1an grade I was found for either male of fema le in the population. Fuhnnan grade 
3 was the most common in the male population (70.0) followed by Fuhnnan grades 2 and 3 
(20.0 and I 0.0 respectively). Fuhrman grade 2 vs. 3 vs. 4 for the male population was 
statistically significant P=0.00009. Fuhrman grade 2 was the most common in the female 
population (55.6) fo llowed by Fuhtman grade 3 (44.4). Fuhrman grade 2 vs. 3 for the 
female population was not significant. Comparing Fuhnnan grade vs. gender produced no 
significant differences (table 3.1.8). 
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VEG F Isoforms 
VEGF 165 VEGF 189 
cAge (34) Tumour Normal Tumour Normal 
<50 (6) 3 1.86 ± 0.30 0.71 ± 0.16 1.51±0.51 0.79 ± 0.24 
51-70 (16) b3.76 ± 0.74 1.83 ± 0.36 2.89 ± 0.58 1.68 ± 0.36 
71> (12) 2.71 ± 0.44 1.62 ± 0.36 2.21 ± 0.42 1.42 ± 0.38 
Table 3.1.9 Expression ofVEGF isoforms with age distribution 
This table shows the expression ofVEGFl 65 and VEGF 189 with respect to age. The data 
is expressed as a mean of the VEGF isoform/18SrRNA control value ± SE. The numbers 
of patients are shown in parenthesis. 3P=VEGF165 Tumour vs. Normal <50, P=O.O I , 
bP=VEGF165 T vs. N 51-70, P=0.02, cP= Age <50 vs. 51-70 vs. 71 > for VEGF165 
tumour and nonnal and VEGF189 tumour and normal, P=N/S. 
VEGF 165 tumour vs. normal was increased for patients in age groups, <50 ( 1.86 vs. 0.71) 
P=O.O I , and 51-70 (3.76 vs. 1.83) P=0.02. VEGF 189 twuour vs. normal was increased for 
all age groups <50 ( 1.51 vs. 0.79), 51-70 (2.89 vs. 1.68), and 71 > (2.21 vs. 1.42) but was 
not significantly increased. There was no significant for <50 vs. 5 1-70 vs. 71 > for VEGF 
165 and VEGF 189 tumour or normal tissue (see table 3.1.9). 
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VEGF 165 and VEGF 189 
Age 
3 Robson stage (34) b<50 (6) c51-70 (16) d71> (12) 
1 (11) 33.3 (2) 25.0 (4) 41.7 (5) 
2 (9) 33.3 (2) 37.5 (6) 8.3 (1) 
3 (5) 33.3 (2) 12.5 (2) 8.3 (1) 
4 (9) 0.0 (0) 25.0 (4) 41.7 (5) 
Table 3.1.1 0 Distribution of Rob son stage with age for RCC patients 
This table shows the distribution of Robson stage with respect to age for VEGF 165 and 
VEGF 189 in patients with RC C. The number of patients are shown in parenthesis. 
3P=Age <50 vs. 51-70 vs. 71 > for all Robson stages, P=N/S. bP=Age <50 Robson 1 vs. 2 
vs. 3 vs. 4, P=N/S. cP =Age 51-70 Robson 1 vs. 2 vs. 3 vs. 4, P=N/S. cP=Age 71> Robson 
1 vs. 2 vs. 3 vs. 4, P=N/S. 
There were equal numbers of patients in Robson stages 1, 2, and 3 for the <50 years old 
group. Robson stage 2 had the most patients for the 51-70 age group followed by groups 1 
and 4 equally and then Robson stage 3. The 71 > age group had the most patients in Robson 
stages 1 and 4 followed by 2 and 3 equally. There were no significant differences between 
Robson stages and any of the groups (see table 3.1.1 0). 
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HIF-la GLUT-I 
cHistology (44) Tumour Normal Tumour Normal 
cc (38) 3 1.33 + 0.12 1.12 ± 0.09 tJ2.06 ± 0.23 1.67 ± 0.23 
p (3) 1.16 ± 0.06 1.08 ± 0.17 1.46 ± 0.27 1.56 ± 0.36 
CH (2) 1.63 ± 0.82 0.62 ± 0.06 0.97 ± 0.01 1.07 + 0.40 
L (1) 1.52 1.29 2.60 1.71 
Table 3.1.11 HJF-la and GLUT-I expression vs. histology in RCC patients. 
This table shows the expression of HIF -I a and GLUT -1 according to histology. The data 
is expressed as a mean of the HIF-la and GLUT-I mRNA/18SrRNA control value± SE. 
The numbers of patients are shown in parenthesis. 3P=HIF-Ia Tumour vs. Nonnal for CC, 
?=0.03, bP=GLUT-1 T vs. N for CC, ? =0.003 , cP= Histology CC vs. P vs. CH for HIF-1a 
and GLUT-I tumour and nonnal, P=N/S. 
CC clear cell, P papillary, CH chromophobe, L leiomyosarcoma. 
HIF-1 a was significantly increased in the tumour vs. nonnal tissue for clear cell RCC 
patients (1 .33 vs. 1.12) P=0.03, whilst it was increased in the papillary, chromophobe and 
leiomyosarcoma patients it was not significant. GLUT -1 was significantly increased in the 
tumour vs. normal tissue for the clear cell patients (2.06 vs. 1.67) ?=0.003. There were no 
other significant differences for any of the other sub types (see table 3 .1 .18). 
The chromophobe patients had the highest expression levels ofHIF-1a (1.63) followed by 
a patient with leiomyosarcoma (1.52), and clear cell (1 .33) with the papillary patients 
having the lowest expression ofHIF-1 a. ( 1.16). 
The patient with leiomyosarcoma had the highest expression ofGLUT-1 (2.60), followed 
by the clear cells (2.06), and papillary (I .46) with the chromophobe being the lowest at 
0.97 (table 3.1.11 ). 
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HJF-la. GLUT-1 
bFuhrman grade Tumour Normal cTumour Normal 
(n=36) 
2 (12) 1.63 ± 0.20 1.27 ± 0.22 2.85 ± 0.55 2.28 ± 0.57 
3 (24) 1.27 ± 0.16 1.05 ± 0.10 3 l.71±0.2l 1.34 ± 0.19 
Table 3.1.12 HIF-la. and GLUT-1 expression vs. Fuhrman grade in RCC patients. 
This table shows the expression ofHIF-la and GLUT-I according to Fuhrman grade. The 
data is expressed as a mean of the HIF-la and GLUT-I mRNA/18SrRNA control value± 
SE. The numbers of patients are shown in parenthesis. 3P= GLUT-I Tumour vs. Normal 
for Fuhrman grade 3, P=0.03, bp= Fuhnnan grade 2 vs. 3 for HIF-la. tumour and normal 
and GLUT-I normal tissue, P=NIS, cP= Fuhrman grade 2 vs. 3 for GLUT-I tumour, 
P=0.05 . 
HIF-1 a was increased in both Fuhrman grades 2 and 3 (1.63 vs. 1.27 and 1.27 vs. 1.05) 
although these were not significant, P=N/S. GLUT - 1 was increased in the tumour vs. 
normal but was not significant for Fuhrman grade 2. Fuhrman grade 3 for GLUT - 1 was 
significantly increased in the tumour vs. nomml (1.71 vs. 1.34) P=0.03. Fuhrman grade 2 
vs. grade 3 for HlF- 1 a. tumour and normal and GLUT-I normal was not significant P=N/S, 
but Fuhrman grade 2 vs. grade 3 for GLUT-I tumour was significant (2.85 vs. 1.71) 
P=0.05 (see table 3.1.12). 
No Fuhrman grades 1 or 4 were seen for the patients studied, with only grades 2 and 3 
found. The expression levels ofboth HIF- la and GLUT-I decreased from grade 2 to 3. A 
decrease from 1.63 to 1.27 was seen for the HIF-1 a tumour mRNA, and a decrease from 
2.85 to 1.71 seen forGLUT-1 tumourmRNA. 
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HIF-Ia. GLUT-I 
bRobson stage Tumour Normal Tumour Normal 
(n=44) 
I (15) 1.47 ± 0.27 1.11 ± 0.18 2.04 ± 0.45 1.64 ± 0.39 
2 (12) 1.16±0.14 1.12±0.13 1.51 + 0.28 1.23 + 0.26 
3 (9) 3 1.27±0.10 1.02 ± 0.08 2.00 ± 0.25 1.69 ± 0.28 
4 (8) 1.42 ± 0.21 1.14 ± 0.24 2.57 ± 0.54 2.15±0.70 
Table 3.I.13 HIF-Ia. and GLUT-I expression vs. Robson stage in RCC patients. 
This table shows the expression of HIF -1 a. and GLUT -I according to Robson stage. The 
data is expressed as a mean of the HIF-Ia and GLUT-I mRNA/18SrRNA control value± 
SE. The numbers ofpatients are shown in parenthesis. 3P= HIF-la. Tumour vs. Normal for 
Robson stage 3, P=0.001, bP= Robson stage 1 vs. 2 vs. 3 vs. 4 for HIF-la and GLUT-1 
tumour and normal tissue, P=N/S. 
The highest levels of expression for HIF -1 a. were seen in Robson stage 1 ( 1.4 7), preceded 
by Robson 4, 3, and 2 (1.42, 1.27, and 1.16 respectively). 
The highest levels for GLUT -1 were seen in Robson stage 4 (2.57) followed by Robson 1, 
3 and 2. There were no significant differences between the levels of expression and 
Robson stage. 
HIF -1 a tumour vs. normal tissue was increased in all Robson stages although only Robson 
stage 3 was significant (1 .27 vs. 1.02) P=O.OO 1. Although GLUT -1 was increased in the 
h1mour vs. normal tissue for all Robson stages this was not significant. There were no 
significant differences between Robson stage 1 vs. 2 vs. 3 vs. 4 for HIF-Ia or GLUT-1 
tumour or normal tissue (see table 3.1.13). 
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3 HIF-1a. bGLUT-1 
cGender Tumour Normal Tumour Normal 
(n=44) 
Male (32) 1.34±0.14 1.09 ± 0.09 1.90 + 0.24 1.65 ± 0.2 1 
Female (12) 1.34 ± 0. 11 1.13±0.20 2. 19±0.38 1.59 ± 0.49 
Table 3.1.14 Expression of HIF-la. and GLUT-1 vs. Gender. 
This table shows the expression levels of HIF-1 a. and GLUT - I according to gender. 
Values are expressed as a mean oftbe HIF-la and GLUT-1 mRNA I 18SrRNA value± 
SE. The numbers of patients are shown in parenthesis. 3P= HIF- 1a Tumour vs. Normal for 
male and females, P=N/S, bP= GLUT-1 T vs. N for male and females, P=N/S, cP= Male 
vs. Female for HIF- Ia and GLUT- I tumour and normal tissue, P=N/S. 
Increases for HIF-1 a. in tumour vs. nonnal for males and females was seen ( 1.34 vs. 1.09 
and 1.34 vs. 1.13) although these were not s ignificant increases P=N/S. GLUT-1 was 
increased in tumour vs. normal tissue for males and females ( 1.90 vs. 1.65 and 2.19 vs. 
1.59) though not significant P=N/S. The levels of HIF- 1 a. mR.NA were exactly the same in 
both male and fema le ( 1.34). There was a slightly higher level ofGLUT-1 expression seen 
in the females in comparison to the males of2. I 9 vs. 1.91, although th is was not a 
significant increase (see table 3.1 .14). 
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HIF-1a. GLUT-1 
bAge Tumour Normal Tumour Normal 
(n=44) 
<50 (4) 0.93 ± 0.22 0.68 ± 0.20 0.93 ± 0.38 0.77 ± 0.51 
51-70 (22) 1.40 ± 0.14 1.20 ± 0.12 2.3 1 ± 0.35 2.04 + 0.34 
71> (18) 1.35 ± 0.19 1.08 ± 0.12 3 1.83 ± 0.2I 1.32 ± 0.18 
Table 3.1.15 Expression of HIF-la. and GLUT-1 with age distribution 
This table shows the expression levels of HIF -1 a. and GLUT -1 according to age. Values 
are expressed as a mean of the HlF-1a. and GLUT-I mRNA I I8SrRNA value± SE. The 
numbers of patients are shown in parenthesis. 3P= GLUT-I Tumour vs. Normal for 71 >, 
P=O.Ol , bp = Age <50 vs. 51-70 vs. 71> for HIF-1a. and GLUT-I tumour and normal 
tissue, P=N/S. 
Although HIF-1 a. expression in the tumour vs. normal was increased for all age groups it 
was not significant. Similarly GLUT - 1 expression in tumour vs. normal tissue was 
increased for all age groups, only the 71 > group was statistically significant (1.83 vs. 1.32) 
P=O.O 1. There was no statistical significance for any of the other age groups (see table 
3.1. 15). 
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Gender 
aRobson Stage ( 44) Male %(n=32) Female %(n=12) 
1 (15) 37.5 (12) 25.0 (3) 
2 (12) 25.0 (8) 33.3 (4) 
3 (9) 21.9 (7) 16.7(2) 
4 (8) 15.6 (5) 25.0 (3) 
Table 3.1.16 Distribution of Robson stage with Gender for RCC patients 
This table shows the distribution ofRobson stage with respect to gender for HIF-
J a/GLUT -1. 3P= Male vs. female for all Robson stages, P=N/S. 
Robson stage 1 contained the most number of males followed by stages 2, 3, and 4. 
(frequencies of 37.5, 25.0, 21 .9, and 15.6 respectively). The distribution of Robson stage 
with respect to gender produced no significant differences between any of the Rob son 
stages. In the female population Robson stage 2 contained the most patients followed by 
stages 1 and 4 equally and then stage 3 (33.3, 25.0, and 16.7 respectively). Even though 
there were slight differences between the abundance ofRobson stage in male vs. females 
these were not significant (see table 3.1.16). 
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2 (12) 
3 (24) 
bMale %(n=25) 
16.0% (4) 
84.0 %(21) 
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Gender 
cFemale %(n=ll) 
72.7% (8) 
27.3% (3) 
Table 3.1.17 Distribution of Fuhrman grade with Gender for RCC patients 
This table shows the distribution ofFuhrrnan grade with respect to gender for HIF-
1 a /GLUT -1. a P= Male vs. female for all Fuhrrnan grades, P=0.003, bP= Male Fuhnnan 
grade 2 vs. 3, P=0.000006, cP= Female Fuhrman grade 2 vs. 3, P=0.003 
No Fuhm1an grades 1 or 4 were found for either male of female in the population. 
Fuhrman grade 3 was the most common in the male population (84.0) followed by 
Fuhrman grade 2 (16.0). Fuhrman grade 2 vs. 3 for the male population was statistically 
significant P=0.000006. Fuhnnan grade 2 was the most common in the female population 
(72.7) followed by Fuhrman grade 3 (27.3). Fuhrman grade 2 vs. 3 for the female 
population was significant P=003. Comparing Fuhrman grade 2 and 3 vs. gender produced 
significant differences ?=0.003 (see table 3.1.17). 
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Patients analysed for HIF-1a. GLUT-1 mRNA 
Age 
Robson stage <50 (4) 51-70 (24) 71> (16) 
1 (15) 50.0% (2) 20.8% (5) 50.0% (8) 
2 (12) 25.0% (1 ) 37.5% (9) 12.5% (2) 
3 (9) 25.0% (1 ) 20.8% (5) 18.7% (3) 
4 (8) 0.0% (0) 20.8% (5) 18.7% (3) 
Table 3.1.18 Distribution of Robson stage with age for RCC patients 
This table shows the distribution of Robson stage with respect to age for HJF-la./GLUT- 1 
in patients with RCC. The number of patients are shown in parenthesis. 3P=Age <50 vs. 
51-70 vs. 7 1 > for all Robson stages, P=NIS. 
The largest age group was the 51-70 years of age followed by the 71 > and <50 had the 
least number of patients (24 vs. 16 vs. 4 respectively). The distribution of Robson stage 
with respect to age was carried out and no significant differences were found . 
Robson stage 1 had the most patients for the <50 age group, followed by stages 2 and 3 
equally. Robson stage 2 had the most patients for the 51-70 age group followed by groups 
1, 3 and 4 equally. Age group 7 1 > had the most patients in Robson stage 1 followed by 3 
and 4 equally, with the least patients in stage 2. There were no significant differences 
between Robson stages vs. age P=N/S. There was no significant difference between 
Robson stage 1 to 4 in each age group (<50, 51-70, 71>) P=N/S (see table 3.1.18). 
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Fig 3.4 Regression analysis for IDF-la in relation to GLUT-1. 
This fig shows the relationship between HIF-Ia and GLUT-I in the normal (A) and 
tumour (B) tissue of patients with RCC. Fig A P=HIF-la normal vs. GLUT-I normal, 
P<O.OOOOI. Fig B P=HIF-la normal vs. GLUT-I normal, P=O.OOI. 
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HIF-1 alpha vs. VEGF Regression analysis 
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Fig 3.5 Regression analysis for HIF-la. in relation to VEGF 165 and VEGF 189 
This fig shows the relationship between HIF-1a. and VEGF 165 (A) and VEGF 189 (B) in 
the tumour tissue ofpatients with RCC. Fig A P=HIF- 1a. tumour vs. VEGF 165 tumour, 
P=0.004. Fig B P=HIF-1a. tumour vs. VEGF 189 tumour, P=0.01. 
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Regression analysis was used to look for any correlations between VEGF 165, YEGF 189 
and GLUT-I expression levels in relation to HIF-la. The value ofHlF-la increases in 
relation to an increase in the value (expression) of GLUT -I in both the tumour and nonnal 
tissue, fig 3.2 A and B. Indicating the HIF-1 a levels are correlated to increasing levels of 
GLUT-I at the mRNA level. VEGF 165 tumour vs. HIF-la tumour expression produced a 
significant relationship between the two species, P=0.004 shown in fig 3.3 A. This 
relationship was also seen for VEGF 189 tumour vs. HIF-1 a although it was not as strong, 
P=O.Ol fig 3.3 B. Showing that the value ofVEGF 165 and VEGF 189 mRNA in the 
tumour increases with HIF-1a. 
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3.2 VEGF promoter polymorphism 
The VEGF polymorphism studied was a C to A single nucleotide polymorphism (SNP) at 
position -2578 in the promoter region (identified by Brogan et a/, 1999). This 
polymorphism was of interest because the A allele also contains an insertion of 18 
nucleotides at position -2549, The control population was typed for this polymorphism 
with the results shown in table 3.2.1. 
With the polymorphism at -2578 either containing or not containing an 18-nucleotide 
insertion it was possible to separate the two alleles on a standard agarose gel. Figure 3.4 
shows the pattern produced by the different combination of alleles. 
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.___ 200bp 
.___ 500 bp 
Figure 3.6 Polymerase chain reaction for the 18-nucleotide insertion at -2578 into the 
VEGF promoter and a C to A single nucleotide polymorphism. 
Lanes l-3 and 5 show heterozygous CIA , with a homozygous NA in lane 4 and 
homozygous C/C in lane 6. Agarose gel showing the C ~ A polymorphism at - 2578 
relative to the translat ion start site. Two bands can be seen in the heterozygotes, while one 
band is present in the homozygotes. Lane 7 contains a 1 OObp ladder. 
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3.2.1 VEGF C-2578A polymorphism 
Variable Patients %(n =173) Controls (n =142) 
Age (years) 64.6 
Range 35-96 
Gender 
Male 71.1 (123) 45. 1 (64) 
Female 28.9 (50) 54.9 (78) 
Robson Stage 
I 32.9 (57) 
11 22.6 (39) 
Ill 32.9 (57) 
IV 11 .6 (20) 
Histology 
Clear Cell 90.2 (156) 
Papillary 5.2 (9) 
Chromophobe 2.3 (4) 
Others 2.3 (4) 
Fuhrman Grade 
GJ 1.9 (3) 
G2 34.4 (54) 
G3 56.7 (89) 
G4 7.0(11) 
Table 3.2.1 Characteristics of patients with renal ceU carcinoma and healthy controls 
for the 18 nucleotide insertion C-2578A polymorphism in the VEGF gene. 
This table shows the frequency of gender, Robson stage, Fuhrman grade, and histology of 
patient and control groups for the 18N insert C-2578A polymorphism. The actual number 
of subjects are shown in parenthesis. 
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The mean age of the patients was 64.6 years with a range from 35 to 96 years. The 
distribution of gender for the patients was 71.1 % male to 28.9% female, whilst the controls 
distribution was 45.1% male to 54.9% female. 
There were equal numbers of patients for both Robson stage I and Ill with 32.9% of 
patients falling into either of these categories. Robson stage 11 contained 22.6% of the 
patients and only 11.6% in Robson stage IV. 
The majority of patients were in the clear cell subgroup accounting for 90.2% of the total, 
followed by 5.2% for the papiJlary and the chromophobe and others making up the 
remaining 4.6%. 
Fuhnnan grade 3 was the most prevalent with 56.7% followed by 34.4% in grade 2, 7% in 
grade 4, and under 2% in grade l (see table 3.2.1 ). 
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RCC Normal controls 
C-2578A 
% (n=J73) % (n= l42) 
3 VEGF Genotype 
CA 66.5 (115) 62.0 (88) 
cc 22.0 (38) 2 1.1 (30) 
AA 11 .6 (20) 16.9 (24) 
b Allele 
c 55.2(191) 52.1 (148) 
A 44.8 (155) 47.9 ( 136) 
Table 3.2.2 VEGF 18 nucleotide insert C-2578A polymorphism genotype and allele 
frequencies. 
This table shows the frequency of the genotypes and alleles for the C-2578A 
polymorphism in RCC and control patients. The number of subjects is given in 
parentheses. 3P=VEGF genotypes patients vs. controls, P=N/S, bP=VEGF alleles patients 
vs. controls, P =N/S. 
The heterozygous CIA -2578 genotype was the most common in both the patient and 
control groups (66.5% vs. 62.0% respectively), followed by the CC genotype (22% vs. 
21 .1 %). The AA genotype was the least prevalent with only 11 .6% for the patients and 
16.9% for the controls. 
There were no significant di fferences between the patient and control groups for any of the 
genotypes. Although the AA genotype was slightly increased in the controls vs. patients 
( 16.9% vs. 11 .6%) this was not significant. The C allele was the most common for both 
patient and control groups with 55.2% and 52.1% respectively, although there was no 
significant difference between the patient and control groups for ei ther allele (see table 
3.2.2). 
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Fuhrman grade 
3 Genotype l (n=3) 2 (n=54) 3 (n=89) 4 (n=ll) 
cc 33.3 ( 1) 24.1 (13) 16.8 (l5) 27.3 (3) 
CA 66.7 (2) 61.1 (33) 74.2 (66) 63.6 (7) 
AA 0.0 (0) 14.8 (8) 9.0 (8) 9.1 (l) 
6 Alleles (n=6) (n=l08) (n=l78) (n=22) 
c 66.7 (4) 54.6 (59) 53.9 (96) 59.1 (13) 
A 33.3 (2) 45.4 (49) 46. 1 (82) 40.9 (9) 
Table 3.2.3 Distribution of the C-2578A alleles according to Fuhrman grade. 
This table shows the frequency of alleles (C-2578A) according to Fuhnnan grade. The 
number of subjects is given in parentheses. 3P =Genotype vs. Fuhnnan grade, P=N/S. 
b P=Alleles vs. Fuhrman grade, P=N/S. 
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Robson stage 
3 Genotype l (n=57) 2 (n=38) 3 (n=56) 4 (n=20) 
cc 29.8 (17) 18.4 (7) 17.9 (10) 20.0 (4) 
CA 57.9 (33) 63.2 (24) 73.2 (41) 75.0 (15) 
AA 12.3 (7) 18.4 (7) 8.9 (5) 5.0(1) 
6 Alleles (n= l14) (n=76) (n=l 12) (n=40) 
c 58.8 (67) 50.0 (38) 54.5(6 1) 57.5 (23) 
A 41.2 (47) 50.0 (38) 45.5 (5 1) 42.5 (17) 
Table 3.2.4 Distribution of the C-2578A alleles according to Robson stage. 
This table shows the frequency of alleles (C-2578A) according to Robson stage. The 
number of subjects is given in parentheses. 3P =Genotype vs. Robson stage, P=N/S. 
bP=Alleles vs. Robson stage, P =N/S. 
Fuhnnan grade 3 was the most common for the C-2578A genotype, followed by grade 2, 4 
and I. There were no significant differences between the Fuhrman grades for the three 
genotypes. The most common genotype in all Fuhrman grades was CA fo llowed by the CC 
with the AA genotype being the most rare. The C allele was the most common for all 
Fuhn11an grades. There were no significant differences between Fuhnnan grade and alleles 
(see table 3.2.3). 
Robson stage 1 was the most common with 57 patients followed by stage 3 (56), stage 2 
(3) and stage 4 (20). The CA genotype increased from Robson stage I to 4 (57.9, 63.2, 
73.2, and 75.0 for stages I, 2, 3, and 4 respectively), while the AA genotype decreased as 
the stage increased (12.3 to 5.0). The CC genotype was near 30% for Robson 1 and 20% 
for Robson stage 2 to 4. Although there were some trends they were not significant. The C 
allele was the most common for Robson stages 1, 3 and 4, with Robson stage 2 being equal 
between the C and A alleles. No significant differences were found between the alleles and 
Robson stage (see table 3.2.4). 
160 
Chapter 3: RESULTS 
Age (years at operation) 
3 VEGF C-2578A <50 % (n=18) 51-70 % (n=98) 71> % (n=57) 
cc 16.7(3) 23.5 (23) 2 1.1 ( 12) 
CA 6 1.1(11) 64.3 (63) 71.9(41) 
AA 22.2 (4) 12.2 (12) 7.0 (4) 
6 Alleles (n=36) (n=196) (n=l14) 
c 47.2 (17) 55.6 (109) 57.0 (65) 
A 52.8 (19) 44.4 (87) 43.0 (49) 
Table 3.2.5 Distribution of C-2578A alleles with age at operation. 
This table shows the frequencies ofthe C-2578A genoypes with respect to the age of 
patient at operation. The number of patients is shown in parenthesis. 3P =Genotype vs. age, 
P=N/S. bP=Alleles vs. age, P=N/S. 
Most of the population were in the 5 1-70 age group followed by the 71 > and then the <50. 
The frequency of the AA genotype decreased as the age increased, from 22.2 in the <50 
age group to 7.0% in 71 > age group. The frequency of the CA genotype increased slightly 
with age (6 1.1 vs. 64.3 vs. 71.9) although these increases were not statistically significant. 
The A allele was the most common in the <50 age group, with the C allele being the most 
prevalent in the other groups. These differences were not significant (see table 3.2.5). 
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VEGF isoform 
3 VEGF C-2578A VEGF 165 VEGF 189 
genotype (n~) 
CA (19) 2.9 ± 0.37 2.3 ± 0.38 
CC(7) b4.7 ± 0.45 c3.7 ± 1.03 
AA (8) 2.1 ± 0.58 1.4 ± 0.40 
Table 3.2.6 Expression of VEGF isoforms in comparison with the C-2578A 
polymorphism. 
This table shows the expression levels ofthe VEGF isoforms 165 and 189 and the VEGF 
polymorphism in the promoter region (C-2578A). Values are expressed as means± SE. 
8P=VEGF C-2578A CA vs. CC vs. AA, P=NIS, bP=VEGF165 C-2578A CC vs AA, 
P=N/S, CP=VEGF189 C-2578A cc vs. AA, ?=0.0515. 
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. VEGF 189 
Fig 3.7 Expression of VEGF isoforms 165 and 189 for the VEGF polymorphism C-
2578A. 
This fig shows the expression levels ofVEGF 165 and VEGF 189 according to VEGF C-
2578A genotype. 
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Expression of VEGF isoforrns with the VEGF polymorphism C-2578A shows that the CC 
genotype had the highest expression levels for both VEGF 165 and VEGF 189 ( 4. 7 and 3. 7 
respectively). The AA genotype had the lowest expression for VEGF 165 and VEGF 189 
(2.1 and 1.4 accordingly). The value of the CA genotype fell between these two values for 
both VEGF 165 and VEGF 189 (2.9 and 2.3 respectively). 
Although differences were seen for the three genotypes there was no significant differences 
for VEGF 165 CA vs. CC vs. AA, or VEGF 189 CA vs. CC vs. AA. Comparisons between 
CC vs. AA for VEGF 165 was also not significant, and although VEGF 189 CC vs. AA 
was not significant it was nearly significant P=0.05l5 (see table 3.2.6 and Fig 3.5). 
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Variable Patients %(n =156) Controls (n =142) 
Age (years) 64 
Range 35-96 
Gender 
Male 71.2(111) 45.1 (64) 
Female 28.8 (45) 54.9 (78) 
Robson Stage 
I 29.5 (46) 
IJ 22.4 (35) 
Ill 35.3 (55) 
IV 12.8 (20) 
Fuhrman Grade 
Gl 2.0 (3) 
G2 32.7 (49) 
G3 58.0 (87) 
G4 7.3 (11 ) 
Table 3.2.7 Characteristics of patients with clear ceiJ renal cell carcinoma and healthy 
controls for the 18 nucleotide insertion C-2578A polymorphism in the VEGF gene. 
This table shows the frequency of gender, Robson stage, Fuhrman grade, and histology of 
clear cell RCC patient and control groups for the 18N insert C-2578A polymorphism. The 
actual number of subjects are shown in parenthesis. 
The mean age of the patients was 64 years, with a range of35 to 96 years old. Of the 
patients with clear cell RCC 71.2% were male with 28.8% female (the controls were 45.1 
and 54.9 respectively). Robson stage 3 was the most common followed by stage 1, 2, and 
4. There was a significant difference between the amount of patients in each Robson stage 
P=0.00003 , and also in each Fuhrman grade P<O.OOOOOl (see table 3.2.7). 
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Clear ceiJ RCC Normal controls 
C-2578A 
% (n=l56) % (n=l42) 
aVEGF Genotype 
CA 69.2 ( 108) 62.0 (88) 
cc 20.5 (32) 2 1. 1 (30) 
AA 10.3 (16) 16.9 (24) 
b Allele 
c 55.1 (172) 52.1 ( 148) 
A 44.9 (140) 47.9(136) 
Table 3.2.8 VEGF 18 nucleotide insert C-2578A polymorphism genotype and allele 
frequencies for clear cell RRC patients. 
This table shows the distribution of the genotypes and alleles for the C-2578A 
polymorphism in clear cell RCC and control patients (the number of subjects is given in 
parentheses). 3P=VEGF genotypes patients vs. controls, P=N/S, bP=VEGF alleles patients 
vs. controls, P=N/S. 
The most common genotype was CA for both the patient and control groups (69.2% vs. 
62.0% respectively) followed by the CC genotype (20.5% vs. 21. 1 %) and the AA 
genotype was the least prevalent with only 10.3% for the patients and 16.9% for the 
controls. 
There were no significant differences between the patient and control groups for any of the 
genotypes. The C allele was the most common for both patient and control groups with 
55. 1% and 52.1% respectively, although there was no statistical difference between the 
patient and control groups for either allele (see table 3.2.8). 
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Fuhrman grade 
3 Genotype 1 (n=3) 2 (n=49) 3 (n=87) 4 (n=ll) 
cc 33.3 (1) 24.5 (12) 16.1(14) 27.3 (3) 
CA 66.7 (2) 65.3 (32) 74.7 (65) 63.6 (7) 
AA 0.0 (0) 10.2 (5) 9.2 (8) 9.1 (1) 
6 Alleles (n=6) (n=98) (n=174) (n=22) 
c 66.7 (4) 57.1 (56) 53.4 (93) 59.1(13) 
A 33.3 (2) 42.9 (42) 46.5 (81) 40.9 (9) 
Table 3.2.9 Distribution of the C-2578A alleles for clear cell RCC patients according 
to Fuhrman grade. 
This table shows the frequency of alle1es (C-2578A) according to Fuhrman grade for clear 
cell RCC patients. The number of subjects is given in parentheses. aP= Genotypes vs. 
Fuhrrnan grade, P=N/S. b P=AIIeles vs. Fuhrrnan grade, P=N/S. 
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Robson stage 
3 Genotype 1 (n=46) 2 (n=36) 3 (n=SS) 4 (n=20) 
cc 26.1 (12) 19.4 (7) 16.4 (9) 20.0 (4) 
CA 65.2 (30) 63.9 (23) 74.5 (41) 75.0 (15) 
AA 8.7 (4) 16.7(6) 9.1 (5) 5.0 (l) 
6 Alleles (n=92) (n=72) (n=llO) (n=40) 
c 58.7 (54) 51.4 (37) 53 .6 (59) 57.5 (23) 
A 41.3 (38) 48.6 (35) 46.4(5 1) 42.5 (17) 
Table 3.2.10 Distribution of the C-2578A alleles for clear cell RCC patients according 
to Robson stage. 
This table shows the frequency of alleles (C-2578A) according to Robson stage for clear 
cell RCC patients. The number of subjects is given in parentheses. 3P= Genotypes vs. 
Robson stage, P=N/S. bP=Alleles vs. Robson stage, P=N/S. 
Fuhrman grade 3 was the most common for the C-2578A genotype for clear cell RCC 
patients. The CA genotype was the most common for all Fuhnnan grades, followed by the 
CC genotype with the AA genotype being the most rare. There were no significant 
difference between the Fuhnnan grades and the three genotypes. The C allele was the most 
common for all the Fuhnnan grades, although this was not significant (see table 3.2.9). 
Robson stage 3 was the most common for the C-2578A genotype for clear cell RCC 
patients. The CA genotype was the most common for all Robson stages, followed by the 
CC genotype with the AA genotype being the most rare. There were no significant 
differences between the Robson stages and the three genotypes. The C allele was the most 
common for all the Robson stages, although this was not statistically significant (see table 
3.2.10). 
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VEGF C-2578A Age (years at operation) 
8 Genotypes <50 %(n=l5) 51-70 %(n=91) 71> %(n=50) 
cc 20.0 (3) 22.0 (20) 18.0 (9) 
CA 60.0 (9) 65.9 (60) 76.0 (38) 
AA 20.0 (3) 12.1(11) 6.0 (3) 
6 Alleles (n=30) (n=l82) (n=lOO) 
c 50.0 (15) 54.9 (lOO) 56.0 (56) 
A 50.0 (15) 45.1 (82) 44.0 (44) 
Table3.2.11 Distribution of C-2578A alleles with age at operation. 
This table shows the frequencies of the C-2578A genoypes with respect to the age of 
patient at operation. 3P= Genotypes vs. age, P=NIS. bP=AIIeles vs. age, P=NIS. 
Most of the population were in the 51-70 age group followed by the 71 > and then the <50. 
The frequency of the AA genotype decreased as the age increased, from 20.0% in the <50 
age group to 6.0% in 71> age group. The frequency ofthe CA genotype increased slightly 
with age (60.0 vs. 65.9 vs. 76.0) although these increases were not significant. The C allele 
was the most prevalent for the 51-70 and 7 1> age groups, while the <50 age group had an 
equal distribution of the alleles, these differences were not significant (see table 3.2.11 ). 
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VEGF isoform 
VE GF 189 
2.56 ± 0.42 
c3.60 ± 1.22 
1.3 1 ± 0.52 
Table 3.2.12 Expression of VEGF isoforms in comparison with the C-2578A 
polymorphism for clear cell RCC patients. 
This table shows the expression levels of the VEGF isoforms 165 and 189 and the VEGF 
polymorphism in the promoter region (C-2578A). Values are expressed as means± SE 
aP=VEGF C-2578A CA vs. CC vs. AA,P=N/S, bP=VEGF I65 C-2578A CC vs AA, 
P=NIS, CP=VEGF1 89 C-2578A cc vs. AA, P=N/S. 
6 ~ 
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CA cc AA 
Fig 3.8 Expression of VEGF isoforms 165 and 189 for the VEGF polymorphism C-
2578A. 
This fig shows the expression ofVEGF 165 and VEGF 189 according to VEGF C-2578A 
genotype in clear cell RCC patients. 
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Expression of YEGF isoforms with the YEGF polymorphism C-2578A shows that the CC 
genotype had the highest expression levels for both YEGF 165 and VEGF 189 (4.9 and 3.6 
respectively). The AA genotype had the lowest expression for VEGF 165 and VEGF 189 
( 1.78 and 1.31 accordingly). The value of the CA genotype fell between these two values 
for both YEGF I 65 and VEGF 189 (3.02 and 2.56 respectively). 
Although differences were seen for the three genotypes there was no significant differences 
for VEGF 165 CA vs. CC vs. AA, or VEGF 189 CA vs. CC vs. AA. Comparisons between 
CC vs. AA for VEGF 165 was not significant, along with VEGF 189 CC vs. AA (see table 
3.2.12 and Fig 3.6). 
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3.3 Polymorphisms in hypoxia-inducible factor-la. in patients with renal cell 
carcinoma and normal controls 
Genotyping for polymorpbisms in the HIF-la. gene began with aCto T single nucleotide 
polymorphism (SNP) at position Cl772T, the control population was typed for this 
polymorphism with the results shown in table 3.2.13. Genotyping for polymorphisms in 
the HIF-la. gene also included a G to A single nucleotide polymorphism (SNP) at position 
Gl790A. 
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Patients Controls 
Variable Gl790A Cl772T Gl790A C1772T 
Aci I %(n=l46) Hph I %(n=160) Aci I %(n=288) Hph I %(n=l62) 
Mean Age 64 64 
Range 35-96 29-89 
Gender 
Male 69.2 (1 01) 71.3 (114) 47.2 (136) 46.9 (76) 
Female 30.8 (45) 28.7 (46) 52.8 (152) 53.1 (86) 
Robson Stage 
31.7 (46) 34.4 (54) 
II 22.8 (33) 23.6 (37) 
IJI 33.8 (49) 30.6 (48) 
IV 11.7 ( 17) 11.4 ( 18) 
Histology 
C lear Cell 90.4 ( 132) 90.0 (144) 
Papillary 5.5 (8) 5.6 (9) 
Others 4. L (6) 4.4 (7) 
Fuhrman Grade 
Gl 1.5 (2) 2.1 (3) 
G2 35.3 (47) 33.8 (49) 
G3 57.9 (77) 56.5 (82) 
G4 5.3 (7) 7.6 (11) 
Table 3.2.13 Characteristics of patients with renal cell carcinoma and healthy 
controls for HIF-la. polymorphisms. 
This table shows the frequency of gender, Robson stage, Fuhrman grade, and histology of 
RCC patient and control groups for the HJF-1 a polymorph isms C 1772T (Hpb I) and 
G l790A (Aci I). The actual number of subjects are shown in parenthesis. 
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Subject characteristics 
The mean age of the patients for both the G 1790A and C 1772T polymorph isms was 64 
with a range of 35-96 and 29-89 years respectively. The G 1790A consisted of 69.2% male 
with 30.8% female (the controls were 47.2% male and 52.8% female). The distribution of 
gender for the C1772T was 71 .3% male and 28.7% female (controls being 46.9% male and 
53.1% female). 
The most common Robson stage for the G 1790A was stage 3 followed by stages 1, 2, and 
4 . The pattern for C 1772T was slightly different with Rob son stage 1 being the most 
common, followed by stages 3, 2, and 4. 
The clear cell histology was the highest for both G 1790A and C 1772T with 90.4% and 
90.0% of the patients. 
Fuhrman grade was the most abundant with 57.9% for G 1790A and 56.5% for C1772T, 
followed by grades 2, 4, and finally 1. 
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Fragment size 
11 8 bp __. 
229bp __. 
346 bp __. 
T CT T CT CT T CT 
Fig 3.9 HIF-la Cl772T polymorphism restriction endonuclease digest pattern 
This fig shows the alleles for the C 1772T HIF- 1 a polymorphism after digestion with tl1e 
restriction endonuclease Hph I 
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Fragment size 
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_____. 
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GG GG GA AA GGGA 
Fig 3.10 HIF-la. G1790A polymorphism restriction endonuclease digest pattern 
This fig shows the alleles for the G 1790A HIF-1 a. polymorphism after digestion with the 
restriction endonuclease Aci I 
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A RCC Controls 
C1772T % (n=160) % (n=162) 
HIF-la. (Hph I) Genotype 
aCT 33.8 (54) 55.5 (90) 
bee 10 (16) 0.7 (1) 
eT T 56.2 (90) 43.8{71) 
Allele 
c 26.9 (86) 28.4 (92) 
T 73.1 (234) 71.6 (232) 
B RCC Controls 
Gl790A % (n=l46) % (n=288) 
HIF-la. (Aci I) Genotype 
dGA 45.9 (67) 13.5 (39) 
eGG 44.5 (65) 83 (239) 
rAA 9.6 (14) 3.5 (10) 
&Allele 
G 67.5 (197) 89.8 (517) 
A 32.5 (95) 10.2 (59) 
Table 3.2.14 Frequency of HIF-la. polymorphisms in patients and controls 
This table shows the frequency of C l772T (A) and the frequency of G 1790A (B) alleles 
and genotypes in patients with renal cell carcinoma and normal healthy controls (The 
number of subjects is given in parentheses). 3P=HlF-1a. CT patients vs. controls, 
P=O.OOOl, bP=HIF-1a. CC patients vs. controls, P=0.0004, cP=HIF- l a. TT patients vs. 
controls P =0.03, dP=HIF-la. GA patients vs. controls, P <O.OOOOl , eP=HIF-la. GG 
patients vs. controls, P<O.OOOOl , rP=HIF-1 a. AA patients vs. controls, P=O.O l , gP=HlF-1 a. 
G and A alleles patient vs. controls, P<O.OOOO I . 
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HIF-la polymorphisms in RCC and control subjects 
Digestion of the amplification products with the restriction endonuclease Hph-1 yielded 
fragments of229 and 118 bp for the wild type C allele and 346 bp for the T allele. 
Digestion with the Aci I restriction endonuclease produced fragments of331 and 144 bp 
(wt) for the G allele and 475 bp for the A allele. The frequencies of the HIF-1 a C1772T 
and G l790A in the patients and conb·ol groups are shown in table 3.2.14. 
There was an increase in both the GA (45.9% vs. 13.5%, P<O.OOOOl) and CC (I 0% vs. 
0 .7%, P=0.00002) genotype in the patients with RCC, and a decrease in the GG (44.5% vs. 
83%, P <O.OOOOl) and CT (33.8% vs. 55.5%, P=0.00002) genotypes respectively. There 
was a slight increase in the TT genotype (56.2% vs. 43.8%, P =0.03) and AA genotype 
(9.6% vs. 3.5%, P =O.Ol). A significant difference between the G and A alleles was found 
with an increase in the A allele (32.5% vs. l 0.2%) in the patients and decrease in the G 
allele (67.5% vs. 89.8%, P <O.OOOOOl) no significant differences between the C and T 
alleles were found. 
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Haplotype Patients Control 
% (n=206) % (n=284) 
T-G 53.4( l10t 65.1 (185) 
T-A 22.8 (47) b 9.5 (27) 
C-G 18.9 (39) 24.3 (69) 
C-A 4.9(10)c 1.1 (3) 
Table 3.2.15 Haplotype analysis of HIF-la. polymorphisms. 
This table shows the frequency of haplotypes (Cl772T and G 1790A) in patients with renal 
cell carcinoma and nonnal healthy controls (The number of subjects is given in 
parentheses). Haplotypes were assigned in those subjects who were homozygous at one or 
both loci. 3P=HIF-1a T-G haplotype patients vs. controls, P=O.Ol , Pc=0.03. bP=HIF-la T-
A haplotype patients vs. controls, ? =0.00008, Pc=0.0002. cP =HIF- 1 a C-A haplotype 
patients vs. controls P=0.02, Pc=N/S. 
Haplotype analysis revea led there to be an increase in the T-A haplotype (22.8% vs. 9.5%, 
?=0.00008, corrected P value Pc=0.002), and a decrease in the T-G haplotype (53.4% vs. 
65.1 %, P=O.Ol, Pc=0.03), and a slight increase for the C-A haplotype (4.9% vs. 1.1 %, 
P=0.02, Pc=N/S). No differences were seen for the C-G haplotype (18.9% vs. 24.3%) 
respectively (see table 3.2.15). 
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Combined genotype Patients (N=l27) Controls (N=149) 
TT I GA 19.7 (25)3 5.4 (8) 
TT IGG 25.2 (32) 35.6 (53) 
TT / AA 7.1 (9) 4.0 (6) 
TC I GA 23.6 (30)b 12. 1 (1 8) 
TCIGG 1l.O(I4t 40.3 (60) 
TC I AA 3.1 (4) 2.0 (3) 
CCIGA 1.6 (2) 0 (0) 
CC I GG 7.9(10)d 0.6 (1) 
CC / AA 0.8(1) 0 (0) 
Table 3.2.16 Combined genotypes for HJF-la polymorphisms C1772T and Gl790A 
This table shows the combined genotypes for the IDF-1 a polymorph isms C 1772T and 
G 1790A. P= RCC patients vs. Controls. 3P=HIF- l a combined genotype TT/GA patients 
vs. controls, ? =0.0005, Pc=0.004. bP=HIF-1 a combined genotype TCIGA patients vs. 
controls, P=0.02, Pc=N/S. cP=HIF-1 a combined genotype TC/GG patients vs. controls, 
P =O.OOOOOOI , Pc=0.0000008. dP=HIF-la combined genotype GG/AA patients vs. controls 
P=0.006, Pc=0.05. 
For the combined genotype of the HIF- la G 1790A and C 1772T a number of statistically 
significant differences were found. The TTIGA combined genotype was increased in 
patients vs. controls (19.7 vs. 5.4% ? =0.0005, Pc=0.004), as was the TC/GA (23.6 vs. 
12.1% P=0.02, Pc=N/S). The TC/GG combined genotype was significantly decreased in 
the patients vs. controls (11 .0 vs. 40.3% P=O.OOOOOOl , P c=0.0000008). The CC/GG 
combined genotype was significantly increased in patients vs. controls (7.9 vs. 0.6% 
P=0.006, Pc=0.05) see table 3.2. 16. 
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Robson Stage 
Genotype 1 (n=54) 2 (n=37) 3 (n=49) 4 (n=l8) 
CT 33.3(18) 45.9 (17) 26.5 (13) 22.2 (4) 
cc 1.9 (1) 2.7 (1) 6.1 (3) 61.1(11t 
TT 64.8 (35) 51.4(19) 67.4 (33) 16.7 (3)b 
c Alleles (n= l 08) (n=74) (n=98) (n=36) 
c 18.5 (20) 25.7 ( 19) 19.4 (19) 72.2 (26) 
T 8 1.5 (88) 74.3 (55) 80.6 (79) 27.8 (10) 
Table 3.2.17 Distribution of the HlF -1 a polymorphism Cl772T alleles according to 
Robson stage. 
This table shows the frequency of C 1 772T alleles according to Robson stage. The number 
of subjects is given in parentheses. a P =HIF-1 a CC vs. Robs on stage, P<O.OOOOOOO 1, 
Pc=0.0000003. bP=HIF-la TT v. Robson stage, P=O.OOI , Pc=0.003. cP=HIF- la C and T 
alleles in Robson stage 4 vs. Robson stages I , 2, and 3, P<O.OOOOOO l , Pc=0.0000003. 
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Robson Stage 
3 Genotype 1 (n=46) 2 (n=33) 3 (n=49) 4 (n=17) 
GA 39.1 (18) 45.5 (15) 55.1 (27) 41.2 (7) 
GG 52.2 (24) 42.4 (14) 34.7 (17) 52.9 (9) 
AA 8.7 (4) 12.1 (4) 10.2 (5) 5.9 (1) 
6 Alleles (n=92) (n=66) (n=98) (n=34) 
G 71.7 (66) 65.2 (43) 62.2 (61) 73.5 (25) 
A 28.3 (26) 34.8 (23) 37.8 (37) 26.5 (9) 
Table 3.2.18 Distribution of the HlF -1 a. G 1790A alleles according to Robson stage. 
This table shows the frequency of G 1790A alleles according to Robson stage. The number 
of subjects is given in parentheses. 3P=Genotypes vs. Robson stage, P=N/S. bP=Allele vs. 
Robson stage, P=N/S. 
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HIF-la. polymorphism and tumour status 
The RCC group was classified into the Robson stages (1 , ll, 1IJ and IV) and the genotype 
frequencies of each polymorphism in groups were compared (see tables 3.2. 17 and 3.2. 18). 
Robson stage I was the most common for C l772T with 54 patients, followed by stages 3, 
2, and 4. 
There was a significant decrease in the TT genotype for C I772T (P=O. OO I , Pc=0.003) in 
Robson stage 4 in comparison with the other Robson stages. A highly significant increase 
was seen for the CC genotype for C 1772T also i11 the Robson stage 4 patients 
(P<0.000001 , Pc=0.000003) in comparison with the other stages. A statistically significant 
increase was seen for the C allele and a significant decrease for the T allele for Robson 
stage 4 vs. Robson stages I, 2 and 3, P<O.OOOOOO I , Pc=0.0000003 (see table 3.2. I7). 
The most common Robson stage for G I790A was stage 3 followed by stages I, 2, and 4 . 
No significant differences between the Gl790A polymorphism and Robson stage were 
found P=N/S. There were no significant differences for either the G or A allele in any of 
the Robson stages (see table 3.2. 18). 
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Fuhrman grade 
3 Genotype 1 (n=3) 2 (n=SO) 3 (n=81) 4 (n=ll) 
CT 0.0 (0) 46.0 (23) 29.6 (24) 36.4 (4) 
cc 0.0 (0) 4.0 (2) 11.1 (9) 18.2 (2) 
TT 100 (3) 50.0 (25) 59.3 (48) 45.4 (5) 
6 Alleles (n=6) (n=100) (n=J62) (n=22) 
c 0.0 (0) 27.0 (27) 25.9 (42) 36.4 (8) 
T 100 (6) 73.0 (73) 74. 1 (120) 63.6 (14) 
Table 3.2.19 Distribution of the HIF-la C1772T alleles according to Fuhrman grade. 
This table shows the frequency ofC1772T alleles according to Fuhnnan grade. The 
number of subjects is given in parentheses. aP=Genotypes vs. Fuhnnan grade, P=N/S. 
bP=Allele vs. Fuhnnan grade, P =N/S. 
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Fuhrman grade 
3 Genotype l (n=2) 2 (n=47) 3 (n=77) 4 (n=7) 
GA 0 (0) 51.0 (24) 48.0 (37) 57.1 (4) 
GG 50.0 {I) 44.7 (21) 39.0 (30) 14.3 (l) 
AA 50.0 (I) 4.3 (2) 13.0(10) 28.6 (2) 
Alleles (n=4) (n=94) (n=JS4) (n=l4) 
G 50.0 (2) 70.2 (66) 63.0 (97) 42.9 (6) 
A 50.0 (2) 29.8 (28) 37.0 (57) 57.1 (8) 
Table 3.2.20 Distribution of the HIF-la. Gl790A alleles according to Fuhrman grade. 
This table shows the frequency of G 1790A alleles according to Fuhrman grade (The 
number of subjects is given in parentheses). 3P=Genotypes vs. Fuhrman grade, P=N/S. 
bP=AIIele vs. Fuhrman grade, P=N/S. 
HIF-la. polymorphism and tumour grade 
Tumours were classified into Fuhrman grades and analysed respectively. No significant 
differences were seen between the four Fuhrman grades and distribution of the C 1772T 
and G 1790A genotypes respectively (see tables 3.2.19 and 3.2.20 respectively). 
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Age (years at operation) 
3 Genotype <50 %(n=16) 51-70 %(n=90) 71> %(n=52) 
CT 43.8 (7) 37.8 (34) 25.0 (13) 
cc 6.2 (1) 11.1 (10) 7.7 (4) 
TT 50.0 (8) 51.1 (46) 67.3 (35) 
6 Alleles (n=32) (n=l80) (n=104) 
c 28.1 (9) 30.0 (54) 20.2 (21) 
T 71.9 (23) 70.0 (126) 79.8 (83) 
Table 3.2.21 Distribution of Cl772T alleles with age at operation. 
This table shows the HIF-la polymorphism C1772T according to age. Patient numbers are 
shown in parenthesis. 3P=Genotypes vs. age, P=N/S. b ?=Allele vs. age, P=N/S. 
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Age (years at operation) 
aGenotype <50 %(n=15) 51-70 %(n=83) 71> %(n=46) 
GA 46.7 (7) 49.4 (41) 41.3 (19) 
GG 46.7 (7) 4 1.0 (34) 47.8 (22) 
AA 6.6 (1) 9.6 (8) 10.9 (5) 
Alleles (n=30) (n=l66) (n=92) 
G 70.0(21) 65.7 (109) 68.5 (63) 
A 30.0 (9) 34.3 (57) 3 1.5 (29) 
Table 3.2.22 Distribution of HJF-la polymorphism Gl790A alleles with age at 
operation. 
This table shows the distribution of the HIF-1 a polymorphism G l790A accord ing to age. 
Patient numbers are shown in parenthesis. 3P=Genotypes vs. age, P=N/S. bP=AIIele vs. 
age,P=N/S. 
Most of the patients for the C 1772T and G 1790A polymorph isms were in the 51-70 age 
group fo llowed by the 71> and then the <50 (see tables 3.2.21 and 3.2.22). The frequency 
of the CT genotype decreased as the age increased, from 43.8 in the <50 age group to 25.0 
in 71> age group. The frequency ofthe TT genotype increased slightly with age (50.0 vs. 
51.1 vs. 67 .3) although these increases were not significant. 
186 
Chapter 3: RESULTS 
Patients Controls 
Variable G1790A C1772T G1790A C1772T 
Aci I %(n=132) Hph I %(n=144) Aci I %(n=288) Hph I %(n=162) 
Age (years) 64 64 
Range 33-96 39-87 
Gender 
Male 65.9 (87) 71.5(103) 47.2 (136) 46.9 (76) 
Female 34.1 (45) 28.5 (41) 52.8 (152) 53.1 (86) 
Robson Stage 
I 28.8 (38) 30.6 (44) 
li 22.7 (30) 23.6 (34) 
Ill 35.6 (47) 33.3 (48) 
IV 12.8 (17) 12.5 (18) 
Fuhrman Grade 
Gl 1.6 (2) 2.2 (3) 
G2 33.8 (43) 33.1 (46) 
G3 59.1 (75) 56.8 (79) 
G4 5.5 (7) 7.9 (11) 
Table 3.2.23 Characteristics of patients with clear cell renal cell carcinoma and 
healthy controls for HIF-la. polymorphisms. 
This table shows the frequency of gender, Robson stage, and Fuhnnan grade for clear cell 
RCC patients and control groups for the HIF -1 a. polymorph isms C l772T and G 1790A. 
The actual number of subjects is shown in parenthesis. 
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Clear cell RCC patient characteristics 
The mean age of the clear cell RCC patients for both the G 1 790A and C 1772T 
polymorphisms was 64 with a range of 33-96 and 39-87 years respectively. The G 1790A 
consisted of 65.9% male with 34.1 % female (the controls were 47.2% male and 52.8% 
female). The distribution of gender for the Cl772T was 71.5% male and 28.5% female 
(controls being 46.9% male and 53 .I% female). 
The most common Rob son stage for the G 1790A and C 1772T was stage 3 followed by 
stages I, 2, and 4. Fuhrman grade I was the most abundant with 59. I% for. G l790A and 
56.8% for C 1772T, followed by grades 2, 4, and finally I (see table 3.2.23). 
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A RCC Controls 
C l 772T % (n=l44) % (n=162) 
H IF-l a (Hph I) Genotype 
3CT 34.0 (49) 55.5 (90) 
bee 9.7 (14) 0.7 (1) 
eT T 56.3(81) 43.8(7 1) 
Allele 
c 26.7 (77) 28.4 (92) 
T 73.3 (2 11) 71.6 (232) 
8 RCC Controls 
G l 790A % (n= l32) % (n=288) 
H IF-l a (Aci I) Genotyp e 
dGA 47.0 (62) 13.5 (39) 
eGG 42.4 (56) 83 (239) 
rAA 10.6(14) 3.5(10) 
gAIIele 
G 65.9 (174) 89.8 (5 17) 
A 34.1 (90) 10.2 (59) 
Table 3.2.24 Frequency of HIF-la. polymorphisms in clear cell RCC patients and 
controls 
This table shows the frequency of C 1772T (A) and G 1790A (B) alleles and genotypes in 
patients with clear cell RCC and normal healthy controls (The number of subjects is given 
in parentheses). 8P=HIF-la CT patients vs. controls, P=0.002, bP=HJF- 1 a CC patients vs. 
controls, P=0.0006, cP=HJF-la TT patients vs. controls P =0.04, dP=HIF- 1 a GA patients 
vs. controls, P<O.OOOO 1, cP=HlF- 1 a GG patients vs. controls, P<O.OOOO 1, rP=HlF-1 a AA 
patients vs. controls, P =0.007, gP=HlF-1a G and A alle1es patient vs. controls, P<O.OOOOl. 
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HIF-la polymorphisms in clear cell RCC and control subjects 
The frequencies of the HIF - I a C 1772T and G 1790A in the clear cell patients and control 
groups are shown in table 3.2.24. 
We found an increase in both the GA (47.0% vs. 13.5%, ? <0.00001) and CC (9.7% vs. 
0.7%, ?=0.0006) genotype in the patients with renal cell carcinoma, and a decrease in the 
GG (42.4% vs. 83%, ? <0.00001) and CT (34.0% vs. 55.5%, ?=0.002) genotypes 
respectively. There was a slight increase in the TT genotype (56.3% vs. 43 .8%, P=0.04) 
and AA genotype ( 10.6% vs. 3.5%, ?=0.007). A significant difference between the G and 
A alleles was found with an increase in the A allele (34.1 % vs. 1 0.2%) in the patients and 
decrease in the G allele (65.9% vs. 89.8%, ? <0.00001) no s ignificant differences between 
the C and T alleles were found . 
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Haplotype Patients Control 
% (n=l78) % (n=284) 
3T-G 52.8 (94) 65.1 (185) 
bT-A 25.3 (45) 9.5 (27) 
C-G 18.0 (32) 24.3 (69) 
C-A 3.9 (7) l.l (3) 
Table 3.2.25 Haplotype analysis of HJF-la polymorphisms. 
This table shows the frequency of haplotypes (G 1790A and CL 772T) in patients with clear 
cell renal cell carcinoma and normal healthy controls. The number of subjects is given in 
parentheses. Haplotypes were assigned in those subjects who were homozygous at one or 
both loci. 8 P=HTF- I a T-G haplotype patients vs. controls, P=O.Ol, Pc=0.03 . bP=HIF-1 aT-
A haplotype patients vs. controls, P=O.OOOO l , Pc=0.00003 . 
Haplotype analysis revealed there to be an increase in the T-A haplotype (25.3% vs. 9.5%, 
P=O.OOOOI , Pc=0.00003), and a decrease in the T-G haplotype (52.8% vs. 65.1%, P=O.Ol , 
Pc=0.03), and a slight increase for the C-A haplotype although it was not significant (3 .9% 
vs. 1.1 %, P=N/S). No differences were seen for the C-G haplotype (18.0% vs. 24.3%) 
respectively (see table 3.2.25). 
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Combined genotype Patients (N=ll9) Controls (N=l49) 
3TT /GA 19.3 (23) 5.4 (8) 
TT / GG 24.4 (29) 35.6 (53) 
TT / AA 7.6 (9) 4.0 (6) 
TC / GA 25.2 (30) 12.1 (18) 
bTC I GG 10.9(13) 40.3 (60) 
TC/AA 3.4 ( 4) 2.0 (3) 
CC/GA 0.8 (1) 0 (0) 
CC / GG 7.6 (9) 0.6 (1) 
CC / AA 0.8 (I) 0 (0) 
Table 3.2.26 Combined genotypes for HIF-la. polymorphisms Cl772T and G1790A 
This table shows the combined genotypes for HIF-1 a. polymorphisms C 1772T and 
G 1790A in clear cell RCC patients. a P= IDF -1 a. combined genotype TT /GA patients vs. 
controls, Pc=0.006. bP=HIF-la. combined genotype TC/GG patients vs. controls, 
P c=0.000002. 
For the clear cell RCC patients combined genotype of the HIF-1 a. G 1790A and C l772T a 
number of significant differences were found. The TT/GA combined genotype was 
increased in patients vs. controls (19.3% vs. 5.4%, Pc=0.006), as was the TC/GA (25.2% 
vs. 12.1 %, although not significant when corrected for the number of groups P c=N/S). The 
TCIGG combined genotype was significantly decreased in the patients vs. controls (I 0.9% 
vs. 40.3%, Pc=0.000002). The CC/GG combined genotype was increased in patients vs. 
controls (7 .6% vs. 0.6%, although not statistically significant when COITected for the 
number of groups P c=N/S) (see table 3.2.26). 
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Robson Stage 
Genotype J (n=44) 2 (n=34) 3 (n=48) 4 (n= l8) 
CT 36.4 (16) 47. 1 ( 16) 27. 1 (13) 22.2 (4) 
cc 0.0 (0) 0.0 (0) 6.2 (3) 361. 1 (11) 
TT 63.6 (28) 52.9( 18) 66.7 (32) b16.7 (3) 
c Alleles (n=88) (n=680 (n=96) (n=36) 
c 18.2 ( 16) 23.5 (1 6) 19.8 ( 19) 72.2 (26) 
T 8 1.8 (72) 76.5 (52) 80.2 (77) 27.8 (10) 
Table 3.2.27 Distribution of the Cl772T alleles according to Robson stage. 
This table shows the frequency of HIF-1 a. C 1772T alleles according to Robson stage. The 
number of subjects is given in parentheses. a P=HIF-1 a. CC vs. Robson stage, 
P<0.0000001 , P c=0.0000003 . bP =HIF- Ia. TT vs. Robson stage, P=0.002, Pc=0.02. 
cP =HlF- 1a. C and T alle les in Robson stage 4 vs. Robson stages 1, 2, and 3, P<O.OOOOOOl , 
Pc=0.0000003. 
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Robson Stage 
a Genotype 1 (n=38) 2 (n=30) 3 (n=47) 4 (n=l7) 
GA 42.1(16) 43.3 (13) 55.3 (26) 41.2 (7) 
GG 47.4 (18) 43 .3 (13) 34.1 (16) 52.9 (9) 
AA 10.5 (4) 13.4(4) 10.6 (5) 5.9 (1) 
6 Alleles (n=76) (n=60) (n=94) (n=34) 
G 47.4 (36) 65.0 (39) 61.7(58) 73.5 (25) 
A 31.6 (24) 35.0 (4) 38.3 (36) 26.5 (9) 
Table 3.2.28 Distribution of the G1790A alleles according to Robson stage. 
This table shows the frequency ofHIF-1 a G 1790A alleles according to Robson stage. The 
number of subjects is given in parentheses. 3P=Genotype vs. Robson stage, P=N/S. 
bP=Ailele vs. Robson stage, P=N/S. 
HIF-la polymorphism and tumour status 
The clear cell RCC group was classified into the Robson stages (1, II, Ill and IV) and the 
genotype frequencies of C 1772T and G 1790A were compared. 
There was a significant decrease in the TT genotype for C 1772T (?=0.002, Pc=0.02) in 
Robson stage 4 in comparison with the other Robson stages. A highly significant increase 
was seen for the CC genotype for C 1772T also in the Robson stage 4 patients 
(P<O.OOOOOO 1, Pc=0.0000003) in comparison with the other stages (see table 3.2.27). No 
significant differences between the G 1790A polymorphism and Robson stage were found 
(see table 3.2.28). 
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Fuhrman grade 
3 Genotype l (n=3) 2 (n=46) 3 (n=79) 4 (n=ll) 
CT 0.0 (0) 45.7 (21) 29.1 (23) 36.4 (4) 
cc 0.0 (0) 4.3 (2) 11.4 (9) 18.2 (2) 
TT 100 (3) 50.0 (23) 59.5 (47) 45.4 (5) 
6 Alleles (n=6) (n=92) (n=l58) (n=22) 
c 0.0 (0) 27.2 (25) 25.9 (41) 36.4 (8) 
T 100 (6) 72.8 (67) 74.1 (117) 63.8 (14) 
Table 3.2.29 Distribution of the Cl772T alleles according to Fuhrman grade. 
This table shows the frequency of HIF-1 a. C 1772T alleles according to Fuhrrnan grade. 
The number of subjects is given in parentheses. 3 P=Genotype vs. Fuhrman grade, P=N/S. 
bP=Allele vs. Fuhrman grade, P=N/S. 
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Fuhrman grade 
3 Genotype 1 (n=2) 2 (n=43) 3 (n=75) 4 (n=7) 
GA 50.0 (I) 51 .2 (22) 46.7 (35) 57.1 (4) 
GG 50.0 (l) 44.2 (19) 40.0 (30) 14.3 (l) 
AA 0.0 (0) 4.6 (2) 13.3(10) 28.6 (2) 
6 Alleles (n=4) (n=86) (n=lSO) (n=l4) 
G 75 .0 (3) 69.8 (60) 63.3 (95) 42.9 (6) 
A 25.0 (1) 30.2 (26) 36.7 (55) 57.1 (8) 
Table 3.2.30 Distribution of the Gl790A alleles according to Fuhrman grade. 
This table shows the frequency of HIF-1 a G l790A alleles according to Fuhnnan grade. 
The number of subjects is given in parentheses. 3P=Genotype vs. Fuhnnan grade, P=N/S. 
bP=Ailele vs. Fuhrman grade, P=N/S. 
HIF-la polymorphism and tumour grade 
The clear cell RCC group was classified into the Fuhnnan grades (1, 11, Ill and IV) and the 
genotype frequencies ofCl772T and G l790A were compared. No significant differences 
were seen between the four Fuhrman grades and distribution of the C l772T and G l790A 
genotypes respectively (see tables 3.2.29 and 3.2.30). 
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Age (years at operation) 
bGenotype <50 %(n=13) 51-70 %{n=84) 71> %(n=47) 
CT 46.2 (6) 36.9 (31) a23.4 (I 1) 
cc 7.6 (I) 9.5 (8) 10.6 (5) 
TT 46.2 (6) 53.6 (45) 66.0 (31) 
cAIIeles (n=26) (n=168) (n=94) 
c 30.8 (8) 28.0 (47) 22.3(21) 
T 69.2 (18) 72.0 (121) 77.7 (73) 
Table 3.2.31 Distribution of HJF-la. C1772T aUeles with age at operation. 
This table shows the distribution of HIF-1 a C 1772T polymorphism according to age. 
aP=HIF-la CT vs. age, ?=0.02, Pc=0.04. bP= Genotypes TT and CC vs. age, P=N/S. 
cP=Allele vs. age, P=N/S. 
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Age (years at operation) 
3 Genotype <50 %(n=l3) 51-70 %(n=77) 71> %(n=42) 
GA 53.8 (7) 49.3 (38) 40.5 (17) 
GG 38.5 (5) 40.3 (31) 47.6 (20) 
AA 7.7 (1) I 0.4 (8) 11.9 (5) 
Alleles (n=26) (n=154) (n=84) 
G 65.4 (17) 64.9 (lOO) 67.9 (57) 
A 34.6 (9) 35.1 (54) 32.1 (27) 
Table 3.2.32 Distribution of G1790A alleles with age at operation. 
This table shows the distribution of HIF-1 a G 1790A polymorphism according to age. 
3P=Genotype vs. age, P=N/S. bP=Allele vs. age, P=N/S. 
Most of the clear cell RCC patients for the C 1772T and G 1790A polymorphisms were in 
the 51-70 age group followed by the 71> and then the <50 (see tables 3.2.31 and 3.2.32). 
The frequency of the CT genotype decreased as the age increased, from 46.2 in the <50 age 
group to 23.4 in 71 > age group. The frequency of the TT genotype increased slightly with 
age (46.2 vs. 53.6 vs. 66.0) although these increases were not significant. 
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4.0 DISCUSSION 
4.1 RPA DATA DISCUSSION 
The expression of angiogenic factors has been poorly assessed in RC C. In this study the 
angiogenic factor VEGF, as well as its upstream transcription factor HIF- 1a. and the HIF-
1 a regulated glucose transporter gene GLUT -1 were investigated. 
The increase of highly angiogenic peptides and receptors in RCC has been analysed by a 
number of groups [Nicol et al 1997, Tomisawa et a/ 1999, Thelen et al 1999, Takahashi et 
a/ 1999], with only one so far using the quantitative method of ribonuclease protection 
assay (RP A) [Gunningham et a/200 I]. Increased expression of the angiogenic phenotype 
is now regarded as an accepted part of the tumour architecture. 
The findings of this thesis showed expression of VEGF throughout all pathological stages 
and no correlation between hjgber stage and level of expression was seen. The relationship 
between VEGF 165 and 189 did not change with respect to either the tumour or normal 
tissue, indicating a similar expression pattern in both the tumour tissue and surrounding 
non-neoplastic tissue. 
VEGF isoform expression was significantly increased for both VEGF 165 and VEGF 189 
in the tumour tissue of RCC patients in comparison with adjacent normal tissue. Increases 
ofVEGF 165 may be regarded as a replication of findings from other who have looked at 
mRNA expression ofVEGF isoforms groups [Tomisawa et a/1999, Nicol et a/1997]. The 
demonstration that VEGF 189 is also increased may be of importance in the phenotype of 
the disease. It has been hypothesised that matrix bound VEGF may be an important source 
ofVEGF after cleavage from the matrix [Park et al, 1993]. 
There was no significant difference between expression ofVEGF 165 and VEGF 189 in 
both tumour and normal tissue. When divided into histological subtypes it was only the 
clear cell population that showed a significant increase in the tumour vs. normal tissue for 
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VEGF 165 and VEGF 189. Increases were seen for the other subtypes but due to small 
numbers were not sign ificant. Increases in VEGF 165 and VEGF 189 were seen for the 
three Fuhnnan grades found, with significant increases seen for grades 2 and 3. Fuhnnan 
grade 4 was not significant, probab ly due to small group size yet showed increases for both 
isofom1s. The highest levels of expression were in the lower grade 2 for both isoforms, 
showing that increases in VEGF mRNA may correlate with the lower pathological grade. 
This data is in contrast to Tomisawa et a/ (1999) who have shown that pathological 
stage/grade correlates with increased VEGF expression. They analysed the expression of 
VEGF isofonns using RT-PCR and correlated the pattem of expression with clinical 
detai ls, finding that tumours with pathological stage pT3-4 showed expression of 
VEGF 12 1 + 165 + 189 at a s ignificantly higher incidence than those with pT0-2. Their 
observations may suggest that the YEGF 189 isoform is closely associated with 
angiogenesis and results in growth of RCC. No preferential expression of either VEGF 
isoform was seen for any stage or grade with the highest numbers being in Robson I and 4 
for the total population and clear cell (CCRCC) population. Mean ing that using YEGF 165 
or YEGF 189 mRNA expression levels alone does not provide any significantly useful 
prognosis information for RCC patients. Although circulating serum protein levels and 
levels measured by IHC have been used as a prognostic marker [Dosquet et a/1997, 
Paradis et a/2000, Jacobsen et a/2000, Jacobsen et a/2002]. There are a number of 
possible reasons for lack of correlation found between the RCC patients' expression of 
YEGF and tumour grade and stage. The techniques that have been employed were different 
from other studies who have demonstrated a positive correlation (RPA vs. RT-PCR) [Nicol 
et a/1997, The! en et a/ 1999]. Measurement of the VEGF protein in comparison with the 
mRNA levels may also produce differences in the results [Sato et a/ 1999, Jacobsen et a/ 
2000]. By measuring protein YEGF (by ELISA and immunohistochemical studies) a pan 
VEGF antibody has been used for the studies (Sato et a/ 1999, Jacobsen et a/2000, Paradis 
et a/ 2000, Lee et a/200 1 ]. This may have provided a correlation between increasing stage 
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and increasing expression but does not take into account differences between isofonn 
expression. 1t would therefore be important to distinguish between the expression ofthe 
various YEGF isoforms, and with the identification of a new inhibitory YEGF isoforms 
may complicate the picture further [Bates et a/2002]. Measurement of the VEGF protein 
may therefore also include the levels of these inhibitory isofonns, providing an inaccurate 
biological picture of true VEGF expression in the tumour and normal tissue. 
A number of these studies were in a Japanese population and there may be ethn ic 
differences in the expression of these factors in comparison with a Caucasian population 
[Tomisawa et a/ 1999, Takahashi et a/ 1999]. Significant increases for both male and 
female VEGF 165 and VEGF 189 tumour vs. normal were seen. 
Methods used to stage and grade RCC have been analysed in conjunction with the 
expression ofVEGF 165 and VEGF 189. Levels ofVEGF 165 and VEGF 189 in tumour 
vs. normal were significant for both Fuhrman grades 2 and 3, although there was no 
relationship between Fuhrman grade and these expression levels. Indicating that the 
expression of VEGF is not altered according to the higher grading of the tumour. The 
positive correlation between HIF- l a and VEGF 165 and VEGF 189 mRNA expression 
demonstrates that increasing levels ofHIF-la correlate with increasing levels ofYEGF. 
It has been shown in normal cells that HIF - la levels are regulated at the protein, not the 
mRNA level [Maxwell et al 1999]. The majority of clear cell carcinomas have mutations in 
the VHL gene, which in turn regulates the levels HIF-la protein by the attachment of 
ubiquitin molecules that direct it to the proteosome for destruction [Clifford et a/200 1 b]. 
Increases in HIF- la expression were seen in the tumour tissue in comparison with the 
normal tissue. After division into histological subtypes, the clear cell population was the 
only one with significant increases in mRNA expression of HIF-1 a . The expression of 
GLUT -I was also increased in the tumour tissue in comparison with the normal. It was 
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demonstrated that the expression of HIF-1 a. correlated with an increase in expression of 
GLUT-l in both tumour and normal tissue. 1t would be expected that increases in GLUT-I 
are seen in the tumour tissue in comparison with the normal tissue due to the increased 
metabolic activity of the tumour cells [Kunkel et a/ 2003]. Significant increases were only 
seen for GLUT-I in the Fuhnnan grade 3 patients and may relate to the more aggressive 
nature of the Fuhrman grade 3 tumours, due to their requirement for increased glucose and 
subsequently increased numbers of glucose transporters. In comparison Levels of HIF-I a. 
are regulated by hydroxylation of proline residues 402 and 564 and asparagine residue 803 
(under nonnoxic conditions) in the protein and therefore only slight increases were seen at 
the mRNA level in the tumour tissue. 
The pattern of expression of both HTF- 1 a. and GLUT-I for Robson stage was not 
conclusive of any relationship between either species. Significant increases were seen in 
the whole RCC population for Robson stage 3 HJF-1 a. tumour vs. nonnal. The CC RCC 
population had increases in Robson stage 3 HIF -1 a. tumour vs. normal and Robson stage I 
GLUT-I tumour vs. normal tissue, yet there was no particular trend in the data. There was 
no evidence that increased expression of HIF-1 a., and GLUT -1 may correlate with the 
Robson stage. The failure to find a correlation may be due to the small numbers in the 
study, heterogeneity of the tumour samples or the late stage of disease that the tumour was 
tn. 
HlF-1 a. and GLUT-I both showed significant increases in the male population, mirroring a 
similar pattern for the VEGF isoforms. With only HIF-la. and GLUT-I being significantly 
increased in the males this may point to another confounding factor as to why RCC in 
males is more prevalent. 
In RCC, mutation or hypermethylation of the VHL gene may disrupt the binding of HIF-
1 a. to p VHL, subsequently leading to increases in H1F -1 a. and the target genes of this 
transcription factor [Maxwell et a/ I999]. GLUT-I is one oftarget genes ofHIF- la., 
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consequently, if there is an unregulated increase in HJF- 1 a protein the knock on effect wi ll 
be increased expression of its targets including GLUT- I. 
Although increased expression ofHIF-la was shown in tumour tissue in comparison with 
the adjacent nonnal tissue it will not necessarily lead to increases in HIF-1 a protein. It has 
been shown that regulation of HJF-la occurs at the protein and not the RNA level 
[Maxwell et a/, 1999]. 
These differences between the studies could be accounted for by the technique employed, 
and differences in the ethnic makeup of the population, differences in genetics between the 
Caucasian and Japanese populations. In this study the highly sensitive and quantitative 
RPA was used, rather than relying on a DNA amplification technique such as RT-PCR 
[Nicol et a/1997, Tomisawa et al 1999]. 
Increasing the sample numbers may provide a statistical significance and wan·ants further 
study, as mRNA levels appeared to increase with increasing stage. It is possible therefore 
that ifpatients with a high baseline expression ofHIF-la and GLUT-I develop RCC, the 
tumours may be of a more aggressive nature. This may reflect the effect of different 
patients' expression pattem on the control of angiogenesis in renal cell carcinoma. 
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4.2 VEGF polymorphisms discussion 
The VEG F gene is highly polymorphic with a large number of genetic changes associated 
with the gene. More and more SNPs are being discovered and analysed in regard to disease 
and production of the protein. Polymorphisms in the VEGF gene have been shown to be 
implicated in diseases ranging from diabetic nephropathy/retinopathy to allograft rejection, 
skin and prostate cancer [Awata et a/ 2002, Shahbazi et a/2002, Howell et al 2002, Lin et 
a/2003, Yang et a/ 2003]. Given the importance of the role VEGF plays in angiogenesis, 
increases in expression or protein levels may play a significant role in the disease process, 
if the resulting fonnation of new blood vessels is a contributing factor to the disease. 
Susceptibility to diabetic nephropathy in association with the C-2578A allele may be 
explained by the enhanced rate of transcription in comparison with the A allele. Yang et a/ 
(2003) also showed significant interaction between VEGF and the ALR2 loci, and it has 
previously been shown that polymorphisms in the ALR2 loci are associated with 
susceptibility to diabetic microvascular complications [Demaine et a/ 2000, Heesom et a/ 
1997). 
VEGF polymorphisms have also been recently linked to calcium oxalate stone disease and 
steroid sensitive nephrotic syndrome [Chen et a/ 2003, Holt et a/2003]. It has also been 
shown the various polymorphisms have a direct effect on the levels of the VEGF protein 
[Renner et a/ 2000, Watson et a/ 2000] and therefore may implicate these polymorph isms 
in the disease process. 
Haplotypes of the VEGF gene containing the -460C/+405G were recently analysed and it 
was discovered that there were only two haplotypes containing these alleles [Stevens et a/ 
2003]. The only difference between them was one allele contained the -160C toT, and the 
other contained the - ll 6G to A. These two haplotypes were compared against the wild 
type (wt) promoter, and the haplotype containing the - 11 6A did not differ from the wt. The 
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haplotype containing the -160T showed increased VEGF promoter activity compared to 
the one containing- I 16A or wt. It is yet uncertain as to whether it is loss of the -1 16A or 
gain of the -160T polymorphism which is related to expression levels. 
YEGF polymorphisms C702T, C936T and G 1612A have recently been demonstrated that 
they are not linked to RCC within a Japanese population [Abe et a/2002], and may 
corroborate the findings of this thesis. Of these polymorph isms the C936T has been shown 
to be linked with VEGF plasma levels, yet is does not appear to be of importance in RCC 
[Renner et a/ 2000]. 
No significant differences between patients and controls were found for any of the VEGF 
C-2578A polymorphism in this cohort of Caucasian RCC patients. Although this 
polymorphism shows no relationship with the disease, and is not linked to the Robson or 
Fuhm1an stage/grade. It has been previously been shown to be associated with levels of 
mRNA expression and diabetic nephropathy [Yang et a/2003]. Although not significant, it 
was shown that alleles did appear to be related to levels ofmRNA expression ofYEGF 
165 and VEGF 189, this is consistent with the previously published data about this 
polymorphism [Sbahbazi et a/2002, Yang et a/2003]. The C allele was linked to higher 
production of VEGF mRNA and the A allele to lower mRNA levels. 
When segregated into just the clear cell population, no significant differences were found 
for age, gender, Robson stage, or Fuhrman grade. This may indicate that this particular 
polymorphism does not appear to play a role in the aetiology of RCC in a Caucasian 
population. 
Although the role of VEGF protein in the angiogenesis of RCC is not in any doubt the 
relationship between RCC and polymorphisms in the VEGF gene have yet to be confirmed 
and fully elucidated. The controlling factors surrounding the genetic analysis of the disease 
will require more comprehensive analysis before a complete picture of the role VEGF 
polymorph isms play in RCC progression, along with differing levels of the protein. 
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There are a number of other polymorphisms in the YEGF gene and many have been shown 
to be linked with protein production and serum levels [Renner et a/ 2000, Watson et a/ 
2000]. 
Changes in the promoter region ofthe VEGF gene caused by polymorphisms (in this case 
C-2578A and an 18 nucleotide insert) affect the levels of expression of the gene. Given the 
high ly polymorphic nature of the gene there may be SNP's that have yet to have been 
analysed in enough detail, which may be linked to RCC. The role in which this 
polymorphism plays in RCC maybe more subtle, and require elaborate measurement of 
patients YEGF levels to link the different genotype to a particular disease state. Even 
though no positive correlation between C-2578A and RCC could be found the trend 
between C-2578A and mRNA levels warrants furth er evaluation, in conjunction with 
polymorphisms that may also have a role in the susceptibility or onset of disease. Patients 
may therefore segregate into high or low expressers of the protein depending on their 
genotype. The impo1 ance ofVEGF polymorphisms in disease is an important area of 
research that requires more comprehensive analysis, and in conjunction with genomic and 
proteomic data correlation 's between these polymorphisms and disease may be elucidated. 
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4.3 HIF-la polymorphisms discussion 
The role of HIF- 1 a in RCC has increased recently by the elucidation of the structure 
function relationship between HIF- 1 a and VHL. Descti ption of the role of that PHDs play 
in the hypoxic regulation of the HIF-1 a has led to the importance of proline and asparagine 
residues in the HIF- 1 a molecule [Epstein et a/2001, I van et a! 200 I, Jaakkola et a! 200 I, 
McNeil et a/ 2002]. 
It has been demonstrated that proline 564 (P564) and proline 402 (P402) are key amino 
acids in the oxygen dependent destruction of the HIF- 1 a subunit by the 26S proteosome 
[Epstein et a/200 I, Elkins et a / 2003]. Amino acid changes within the ODD of the subunit 
(Proline to Serine at position 582 and Alanine to Threonine at position 588) have been 
described in relation to RCC and head and neck squamous cell carcinoma (HNSCC) 
[Ciifford et a! 200 I a, Tanimoto et a/ 2003]. The single nucleotide polymorph isms 
(C 1772T and G 1790A) studied resulted in the change from a proline to serine and alanine 
to threonine (at codons 582 and 588 respectively) within the ODD of the HIF-1 a protein 
[Ciifford et a / 200 I a]. 
Patients with HNSCC who had the rare alleles (T and G alleles) that encode the variant 
HIF- 1 a proteins had significantly increased numbers of microvessels compared to those 
with the wild type alleles [Tanimoto et a / 2003]. They also found the activity of the variant 
protein to be stronger than that of the wi ld type under hypoxic conditions. The proximity of 
these polymorph isms to the NT AD and ODD may mean that they affect the stability of the 
protein or its abil ity to bind to any accessory proteins involved in the response to hypoxia 
such as CBP/p300. Other residues in HIF- 1 a may also be subject to 0 2-dependent 
hydroxylation. The transactivation domain function is also 0 2-regulated by mechanisms 
that remain incompletely understood. Theoretical modell ing of the HIF - 1 a protein has 
shown that transactivation activity can be affected by changes in amino acids in the 
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T AD/ODD. Therefore these polymorphisms may provide important differences between a 
diseased population, or, they may just be markers of other changes in the HIF-1 a gene that 
are related to disease. 
These differences may be due to functional changes in the HIF- 1 a protein and therefore 
affect the properties of the protein giving it an increased or decreased ability to 
transactivate and cause transc1iption of its target genes. 
Although the polymorphisms studied have not been shown to be hydroxylated, we 
hypothesized that if it plays any part in the disease process then differences between the 
RCC and control populations will be found . 
Significant differences were found between the patient and control populations with 
increases in the GA and CC genotypes in the patients, along with a decrease in the GG and 
CT genotypes. Increases in the TT and AA genotypes (for C 1772T and G 1790A 
respectively) for the whole RCC population may indicate the importance of the variant 
alleles in RCC, and the clear cell RCC population who also showed a similar increase of 
the alleles. 
The T-A haplotype (mutant-mutant) was signjficantly increased in the patient population 
and could according to Tanimoto et a/ [2003] have the strongest transcriptional activation 
under both nonnoxic and hypoxic conditions. Demonstrating that these polymorphisms 
may have a role in the molecular genetic phenotype of RCC irrespective of the conditions 
that the cell is under. Increases were also seen for the C-A haplotype, and slight decrease in 
the T-G haplotype. The combined genotype TC/GG was decreased for both the whole and 
clear cell RCC populations and only contained one variant allele and three wt alleles 
indicating the importance of the variant alleles in RCC. The combined genotype TT/GA 
was increased in the patients and provides further evidence that the variant alleles (three 
variant and one wt in this genotype) may be increased in RCC, and cause some of the 
features oftbe disease via increased transcription of the genes targeted by 1-llf- l a . 
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Patients in Robson stage 4 (for the C 1772T) had significantly increased frequency of the 
CC genotype and a significantly decreased frequency of the TT genotype. There were only 
18 patients in the Robson stage 4 group, and therefore there is likelihood that these 
numbers may not be representative of the Robson stage 4 group. Robson stages 1, 2 and 3 
all have sim ilar patterns of C 1772T genotype frequencies and may provide a more accurate 
representation of the distribution of the Cl772T polymorphism in relation to Robson stage. 
These polymorphisms play an important role in not only the transactivational activity of 
the protein but ultimately may be involved in the RCC disease process. This is in 
accordance with the positive role that HlF- la has been shown to play in cancer [Zhong et 
a/ 1999, Bos et a/2001 , koukourakis et a/ 2001]. 
These changes may affect the function of the HIF-la protein, and we are currently 
investigating these changes to measure differences in the expression levels ofHlF- l a . 
If segregation into clear cell RCC does not provide any new differences between the 
patient and nonnal control groups could it be assumed that these polymorphisms may be 
involved in RCC but not exclusively to clear cell RCC and therefore have a wider role to 
play in the disease. It will be interesting to see if these polymorphisms are found in varying 
levels in other diseases that may be affected by aberrant 0 2 sensing given the ubiquitous 
role ofHlF-la in 0 2 sensing. 
The importance of these polymorph isms as markers of disease may in the future become 
more and more important as we enter the post-genomic era. A wide variety of SNP 
data bases are being developed and provide vast amounts of information for any researcher 
interested in the genetic basis of disease, and include the human SNP database at www-
genome.wi.mit.edu/snp/human/ and also the SNP consortium at snp.cshl.org/. 
Completion of the sequencing of the human genome has been described as great 
importance in the treatment and elucidation of disease. Currently the true promise of the 
data is yet to be fu lly realised and may take many years before its true worth can be 
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measured. There is also a genome browser which can be viewed at genome.ucsc.edu/ and 
provides useful information regarding the genome sequence so far. Susceptibility to cancer 
has more recently been linked to numerous low penetrance polymorphisms acting together 
to disrupt a cells regulatory controls. If this is the case then the differences between variant 
and wt polymorph isms in RCC may be just a part of these low penetrance polymorphisms 
in this disease, indicating their importance in the surveillance ofRCC. 
After diagnosis ofRCC it will be important to screen the patients using SNP's or 
expression and serum levels of proteins such as VEGF to determine whether they fall into 
any particular group of increased risk patients. If for instance a patient has a HIF -1 a 
genotype that suggests increased transcriptional activity of HIF -1 a, and also has a high 
level ofVEGF in their serum it may be linked to either having or the possibility to develop 
a more aggressive tumour. Treatment can then be tailored accordingly to suit the nature of 
the genetic phenotype of the patient. This would save time and money in the treatment of 
the patient and provide a customised approach to the diagnosis and treatment of disease. 
This approach may not be currently possible but as the data from the elucidation of the 
genome, proteome and transcriptome becomes available new possibilities like this will be 
ever more achievable. 
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4.4 Conclusions 
• In conclusion; 
• Increases in VEGF 165, VEGF 189, HlF- 1 a., and GLUT-I were seen in mRNA in 
the tumour tissue ofRCC patients in comparison with the nonnal tissue. 
• No relationship between tumour stage and grade for either VEGF or HJF-1 a. and 
GLUT - 1 was seen. 
• VEGF polymorphism in the 5' promoter region (C-2578A) was not associated with 
RCC or progression of the disease. 
• HIF- 1 a. C 1772T polymorphism showed decreased numbers of the CT genotype and 
increases in the CC and TT genotypes. 
• HIF-1 a. G 1790A polymorphism showed decreased numbers of the GG genotype 
and increases in the GA and AA genotypes. 
• The HIF-la. polymorphism (CJ772T) CC genotype was increased in patients at the 
higher Robson stage, whi le the TT genotype was decreased, with the C allele being 
increased and the T allele being decreased. 
• Combined genotype analysis demonstrated that TC/GG was decreased and may 
have a protective role by providing reduced transcriptional activity under normoxic 
and hypoxic conditions. 
• Haplotype analysis showed that T-A was increased and may be linked to increased 
transcriptional activity under hypoxia and normoxia. 
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4.5 Future work 
Given the importance of the various genes in the VEGF family, it is intended that the 
whole spectrum of these genes be analysed in both the tumour and normal tissue of RCC 
patients. This includes VEGF-B, C, and 0, along with their associated receptors VEGFR-
1, 2, and 3 
Expression of VEGF14s could be analysed in the RCC tumours and normal tissue by RT-
PCR, to confirm whether this isofonn is expressed in tumours as well as normal tissue. The 
predicted product of VEGF 148 is a truncated form of VEGF165 but may have no biological 
activity and thus act in an inhibitory fash ion. Although at present the complex nature of 
VEGF isofonn expression has yet to be fu lly elucidated. 
Expression of the HIF- la protein could be measured in the tumour and nonnal tissue by 
EMSA. Oligos designed to be able to bind to the protein and thus separate the transcription 
factor would be used in conjunction with antibodies to the HIF-a protein. Is there any 
correlation between the protein and downstream products of the transcription factor 
(VEGF, GLUT- I)? 
Other polymorphisms in the VEGF gene could be examined (including G-ll90A, G-
l154A, C-6340, C-460T, G+405C and C+936T) which have been linked to serum levels 
or promoter activity of VEGF, and will the higher expressing genotypes correlate with 
higher Robson stage or Fulmnan grade. Polymorphisms in the VEGF receptor have been 
identified. Will these changes lead to functional differences, or affect the ability of the 
receptor to bind its ligand? 
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Growing out the samples of tumour that have been collected from patients undergoing 
radical nephrectomy. Use these cells to determine their expression of various proteins and 
mRNA species that may be involved in the development of RCC under in vivo hypoxic 
conditions. 
Use of siRNA to block the expression of 1-IIF-la or YEGF in a RCC cell line or primary 
cell culture from cells grown from patients undergoing radical nephrectomy for RCC. Will 
the silenced HIF-1 a reduced the expression of its downstream genes, and could this 
provide a useful tool to treat RCC, by reducing the angiogenic potential of the tumour? It 
has been suggested that using siRNA to sequentially target the key proteins involved in 
cancer development it may be possible to arrest the tumour growth. 
213 
REFERENCES 
Adelman, D.M., Maltepe, E., Si m on, M.C. ( 1999). Multilineage embryonic 
hematopoiesis requires hypoxic ARNT activity. Genes Dev. 13. 2478-83. 
Agani, F., Kirsch, D.G., Friedman, S.L., Kastan, M.B., Semenza, G.L. (1997). p53 
does not repress hypoxia-induced transcription of the vascular endothelial growth factor 
gene. Cancer Res. 57.4474-7. 
Agani, F., Semenza, G.L. ( 1998). Mersayl is a novel inducer of vascular endothelial 
growth factor gene expression and hypoxic-inducible factor 1 activity. Mol Pharmacal. 54. 
749-54. 
Akiri, G., N ahari, D., Finkelstein, Y ., Le, S. Y ., Elroy-Stein, 0., Le vi, B.Z. ( 1998). 
Regulation of vascular endothelial growth factor (VEGF) expression is mediated by 
internal initiation of translation and alternative initiation of transcription. Oncogene. 17. 
227-36. 
Akiyama, T., Yamada, Y., Ogawara, H., Richert, N., Pastan, 1., Yamamoto, T., 
Kasuga, M. ( 1984). Site-specific antibodies to the erbB oncogene product 
immunoprecipitate epidermal growth factor receptor. Biochem Biophys Res Commun. 123. 
797-802. 
Antonia, S., Fish man, M., Seigne, J. (2001 ). Novel therapies for renal cell carcinoma. 
Expert Opin Investig Drugs. 10. 1033-44. 
Aprelikova, 0., Pajusola, K., Partanen, J., Armstrong, E., Alitalo, R., Bailey, S.K., 
McMahon, J., Wasmuth, J., Huebner, K., Alitalo, K. (1992). FLT4, a novel class Ill 
receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res. 52. 746-48 
Arany, Z., Huang, LE., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M.A., 
Bunn, H.F ., Livingston, D.M. ( 1996). An essential role for p300/CBP in the cellular 
response to hypoxia. Proc Natl Acad Sci USA 92.5510-14 
Arbiser, J.L., Larsson, H., Claesson-Welsh, L., Bai, X., LaMontagne, K., Weiss, S.W., 
Soler, S., Flynn, E., Brown, L.F. (2000). Over expression ofVEGF121 in immortalized 
endothelial cells causes conversion to slowly growing angiosarcoma, and high level 
expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol. 156. 
1469-76. 
Armitage, P., & Doll, R. ( 1957). A two-stage theory of carcinogenesis in relation to the 
age distribution of human cancer. Br J Cancer. 3. I 09. 
Asano, M., Yukita, A., Matsumoto, T., Matsuo, K., Kondo, S., Suzuki, H. (1995). 
Isolation and characterization of neutralizing monoclonal antibodies to human vascular 
endothelial growth factor I vascular permeability factor 121 (VEGF NPF 121 ). Hybridoma. 
14. 475-80. 
Atlas, I., Mendelsohn, J., Baselga, J., Fair, W.R., Masui, H., Kumar, R. (1992). 
Growth regulation of human renal carcinoma cells: role of transforming growth factor 
alpha. Cancer Res. 52. 3335-9. 
Auvinen, M., Laine, A., Paasinen-Sohns, A., Kangas, A., Kangas, L., Saksel, 0., 
Anderson, L.C., Holtta, E. (1997). Human ornithine decarboxylase-overproducing 
214 
NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer 
Res. 57. 3016-25. 
Awata, T., lnoue, K., Kurihara, S., Ohkubo, T., Watanabe, M., lnukai, K., lnoue, 1., 
Katayama, S. (2002). A common polymorphism in the 5'-untranslated region of the 
VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 51. 1635-
9. 
Baccala, A.A., Zhong, H., Clift, S.M., Nelson, W.G., Marshall, F.F., Passe, T.J., 
Gambill, N.B., Si mons, J.W. ( 1998). Serum vascular endothelial growth factor is a 
candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell 
cancer. Urology. 51. 327-32. 
Bacon, N.C., Wappner, P., O'Rourke, J.F., Bartlett, S.M., Shilo, B., Pugh, C.W., 
Ratcliffe, P.J. (1998). Regulation of the drosophila bHLH-PAS protein sima by hypoxia: 
functional evidence for homology with mammalian HIF-1 a. Biochem Biophys Res 
Commun. 249. 811-6. 
Baek, J.H., Jang, -E., Kang, C-M., Chung, H-Y., Kim, N.D., Kim, K-W. (2000). 
Hypoxia-induced VEGF enhances tumor survivability via suppression of serum 
deprivation-induced apoptosis. Oncogene. 19. 4621-31. 
Bailey, E., Bottomley, M.J., Westwell, S., Pringle, J.H., Furness, P.N., Feehally, J., 
Brenchley, P.E., Harper, S.J. (1999). Vascular endothelial growth factor mRNA 
expression in minimal change, membranous, and diabetic nephropathy demonstrated by 
non-isotopic in situ hybridisation. J Cl in Pathol. 52. 735-8. 
Baltaci, S., Orhan, D., Soyupek, S., Beduk, Y., Tulunay, 0., Gogus, 0. (2000). 
Influence of tumor stage, size, grade, vascular involvement, histological cell type, and 
histological pattern on multifocality of renal cell carcinoma. J. Urol. 164. 36-39. 
Barleon, B., Totzke, F., Herzog, C., Blanke, S., Kremmer, E., Siemeister, G., Marme, 
D., Martiny-Baron, G. ( 1997). Mapping of the sites of ligand hinging and receptor 
dimerization at the extracellular domain of the vascular endothelial growth factor receptor 
FLT-1. J Bioi Chem. 272. 10382-88. 
Barnabas, N., Amin, M.B., Pindolia, K., Nanavati, R., Amin, M.B., Worsham, M.J. 
(2002). Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic 
criteria in renal cell carcinoma. J. Surg. Oncol. 80. 52-60. 
Basaki, Y., Aoyagi, K. Chikahisa, L., Miyadera, K., Hashimoto, A., Yonekura, K., 
Okabe, S., Shibata, j., Wierzba, K., Yamada, Y. (2000). UFT and its metabolites inhibit 
cancer-induced angiogenesis via a VEGF-related pathway. Oncology. 14.68-71. 
Bates, D.O., Cui, T.G., Doughty, J.M., Winkler, M., Sugiono, M., Shields, J.D., Peat, 
D., Gillatt, D., Harper, S.J. (2002). VEGF165b, an inhibitory splice site variant of 
vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 
62. 4123-31. 
Bazan, N.G., Lukiw, W.J. ( 1999). Regulation of vascular endothelial growth factor 
(VEGF) gene transcription by insulin growth factor (IGF) and hypoxia inducible factor 
(HIF) in mouse retina undergoing neovascularization. Invest Opthalmol Vis Sci. 40. 5111 
215 
L 
Heckler, P.M., Alcasabas, A., Yu, A.Y., Semenza, G.L., Bunton, T.E. (2000). Oxygen-
independent upregulation of vascular endothelial growth factor and vascular barrier 
dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. Am J Respir 
Cell Mol Bioi. 22. 272-9. 
Bein, K., Ware, J.A., Simon, M. ( 1998). Myb-dependent regulation of thrombospondin 2 
expression. Role ofmRNA stability. J Bioi Chem. 273.21423-9. 
Bellomo, D., Haedrick, J.P., Silins, G.U., Paterson, C.A., Thomas, P.S., Gartside, M., 
Mould, A., Cahill, M.M., Tonks, I.D., Grimmond, S.M., Townson, S., Wells, C., Little, 
M., Cummings, M., Hayward, N.K., Kay, G.F. (2000). Mice lacking the vascular 
endothelial growth factor-B gene (Vegtb) have smaller hearts, dysfunctional coronary 
vasculature, and impaied recovery from cardiac ischemic. Cir Res. 86. E29-35. 
Bereblum, 1., & Shublik, P. (1949). Br J Cancer. 3. 109. 
Berger, D.P., Herbstritt, L., Dengler, W.A., Marme, d., Mertelsmann, R., Fiebig, H.H. 
( 1995). Vascular endothelial growth factor (VEGF) m RNA expression in human tumor 
models of different histologies. Ann Oncol. 6. 817-25. 
Bergerson, M., Yu, A.Y., Solway, K.E., Semenza, G.L., Sharp, F.R. (1999). Induction 
of hypoxia-inducible factor-! (HIF-1) and its target genes following focal ischemia in rat 
brain. EurJ Neurosci.ll. 4159-70. 
Blagosklonny, M. V., An, W.G., Romanova, L.Y., Trepel, S., Fojo, T., Neckers, L. 
(1998). p53 inhibits hypoxia-inducible factor-stimulated transcription. J Bioi Chem. 273. 
11995-8. 
Blancher, C., Moore, J.W., Robertson, N., Harris, A.L. (2001). Effects ofras and von 
Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF}- 1 alpha, HIF-
2alpha, and vascular endothelial growth factor expression and their regulation by the 
phosphatidylinositol3'-kinase/Akt signalling pathway. Cancer Res. 61.7349-55. 
Blancher, C., Moore, J.W., Talks, K.L., Houlbrook, S., Harris, A.L. (2000). 
Relationship of hypoxia-inducible factor (HIF)-Ia and HIF-2a expression to vascular 
endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. 
Cancer Res. 60.7106-13. 
Blankenship, C., Naglich, J.G., Whaley, J.M., Seizinger, B., Kley, N. (1999). Alternate 
choice of initiation codon produces a biologically active product of the von Hippei-Lindau 
gene with tumor suppressor activity. Oncogene. 18. 1529-35. 
Blomeke, B., Bennett, W.P., Harris, C.C,. Shields, P.G. (1997). Serum, plasma and 
paraffin-embedded tissues as sources of DNA for studying cancer susceptibility genes. 
Carcinogenesis. 18. 1271-5. 
Bolufer, Miralles, F., Rodriguez, A., Vazquez, C., Lluch, A., Garcia-Conde, J., Olmos, 
T. ( 1990). Epidermal growth factor receptor in human breast cancer: correlation with 
cytosolic and nuclear ER receptors and with biological and histological tumor 
characteristics. Eur J Cancer. 26. 283-90. 
Bonfanti, A., Lissoni, P., Rovelli, F., Brivio, F., Fumagalli, L. (2000). Changes in 
circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 
immunotherapy of metastatic renal cell carcinoma. lnt J Bioi Markers. 15. 161-4. 
216 
Bonicalzi, M.E., Groulx, I., de Paulson, N., Lee, S. (2001). Role ofexon 2-encoded beta-
domain of the von Hippel-Lindau tumor suppressor protein. J Bioi Chem. 276. 1407-16. 
Borg, J-P., deLapeyriere, 0., Noguchi, T., Rottapel, R., Dubreuil, P., Birnbaum, D. 
(1995). Biochemical characterization oftwo isoforms ofFLT4, a VEGF receptor-related 
tyrosine kinase. Oncogene. 10. 973-84. 
8os, R., Zhong, H., Hanrahan, C.F., Mommers, E.C., Semenza, G.L., Pinedo, H.M., 
Ableoff, M.D., Simons, J.W., van Diest, P.J., van der Wall, E. (2001). Levels of 
Hypoxia-inducible factor-! a during breast carcinogenesis. J Natl Cancer Inst. 93. 309-14. 
Botuyan, M. V., Koth, C.M., Mer, G., Chakrabartty, A., Conaway, J.W., Conaway, 
R.C., Edwards, A.M., Arrowsmith, C.H., Chazin, W. (1999). Binding of elongin A or a 
von Hippei-Lindau peptide stabilises the structure of yeast elongin C. Proc. Natl. Acad. 
Sci. 96. 9033-8. 
Brauch, H., Weirich, G., Brieger, J. Glavac, D., Rodl, H., Eichinger, M., Feurer, M., 
Weidt, E., Puranakanitstha, C., Neuhaus, C., Pomer, S., Brenner, W., Schirmacher, 
P., Storkel, S., Rotter, M., Masera, A., Gugeler, N., Decker, H-J. (2000). VHL 
alterations in human clear cell renal carcinoma: association with advanced tumor stage and 
a novel hot spot mutation. Cancer Res. 60. 1942-8. 
Braun, L., Kardon, T., Reisz-Porszasz, Z., Banhegyi, G., Mandl, S. (200 I). The 
regulation of the induction of vascular endothelial growth factor at the onset of diabetes in 
spontaneously diabetic rats. Life Sciences. 69. 2533-42. 
Braybrooke, J.P., O'Byrne, K.J., Propper, D.S., Blann, A., Saunders, M., Dobbs, N., 
Han, C., Woodhull, J., MitcheU, K., Crew, J., Smith, K., Stephens, R., Ganesan, T.S., 
Talbot, D.C., Harris, A.L. (2000). A phase II study ofrazoxane, an antiangiogenic 
topoisomerase 11 inhibitor, in renal cancer with assessment of potential surrogate markers 
of angiogenesis. Clin Cancer Res. 6. 4697-704. 
Brem, H., Folkman, J. ( 1975). Inhibition of tumor angiogenesis mediated by cartilage. J 
Exp Med. 141. 427-39. 
Bret, P., Streichenberger, N., Guyotat, J. (1999). Metastasis of renal carcinoma to a 
cerebellar hemangioblastoma in a patient with von Hippel-Lindau disease: a case report. Br 
J Neurosurgery. 13. 413-6. 
Brieger, J., Weidt, E.J., Schirmacher, P., Storkel, S., Huber, C., Decker, H.J. (1999). 
Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in 
sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 
tumors. J. Mol. Med. 77. 505-1 0. 
Brogan, I. J., Khan, N., Isaac, K., Hutchinson, J.A., Pravica, V., Hutchinson, I.V. 
(1999). Novel polymorphisms in the promoter and 5' UTR regions ofthe human vascular 
endothelial growth factor gene. Human Immunology. 60. 1245-9. 
Brogi, E., Schattenman, G., Wu, T., Kim, E.A., Varticovski, L., Keyt, 8., Isner, J.M. 
( 1996). Hypoxia-induced paracrine regulation of vascular endothelial growth factor 
receptor expression. J. Clin. Invest. 97. 469-76. 
217 
Brooks, P.C., Montgomery, A.M.P., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., 
Cheresh, D.A. ( 1994). lntegrin avJ33 antagonists promote tumor regression by inducing 
apoptosis of angiogenic blood vessels. Cell. 79. 1157-64. 
Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Manseau, E.J., Dvorak, H.F., 
Senger, D.R. (1993). Increased expression of vascular penneability factor (vascular 
endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J 
Pathol. 143. 1255-62. 
Bruick, R.K. (200). Expression of the gene encoding the proapoptotic Nip3 protein is 
induced by hypoxia. Proc Natl Acad Sci USA. 97.9082-7. 
Buchler, P., Hines, O.J., Hotz, H.G., Ryder, N., Friess, H., Reber, H.A. (1999). 
Hypoxia inducible factor (HIF-1) regulates VEGF production in pancreatic cancer. 
Gastroenterology. 116. 5020-24 
Caldwell, M.C., Hough, C., Furer, S., Linehan, W.M., Morin, P.J., Gorospe, M. 
(2002). Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent 
sensitivity to TNFa cytotoxicity. Oncogene. 21.929-36. 
Caniggia, 1., Mostachfi, H., Winter, J., Gassmann, M., Lye, S.J., Kuliszewski, M., 
Post, M. Hypoxia-inducible factor-! mediates the biological effects of oxygen on human 
trophoblast differentiation through TGFJ33. J. Clin. Invest. 105. 577-87. 
Cao, Y., Chen, H., Zhou, L., Chiang, M.K., Anand-Apte, B., Weatherbee, J.A., Wang, 
Y., Fang, F., Flanagan, J.G. Tsang, M.L. (1996). Heterodimers of placenta growth 
factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression and 
high affinity binding to Flk-1 /KDR. J Bioi Chem. 271. 3154-62. 
Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, 
M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C.J., Ratcliffe, P., 
Moons, L., Jain, R.K., Collen, D., Keshert, E., Keshet, E. ( 1998). Role of HIF-1 alpha in 
hypoxia-medaited apoptosis, cell proliferation and tumor angiogenesis. Nature. 394. 485-
90. 
Carmeliet, P., Ferreir, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., 
Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., 
Moons, L., Collen, D., Risau, W., Nagy, A. (1996). Abnormal blood vessel development 
and lethality in embryos lacking a single VEGF allele. Nature. 380. 435-9. 
Carmeliet, P., Lampugnani, M-G., Moons, L., Breviario, F., Compernolle, V., Bono, 
F., Balconi, G., Spagnuolo, R., Oothuye, B., Dewerchin, M., Zanetti, A., Angellilo, A., 
Mattot, V., Nuygens, D., Lutgens, E., Clotmam, F., de Ruiter, M.C., Gittenberger-de 
Groot, A., Poelmann, R., Lupu, F., Herbert, J-M., Collen, D., Dejana, E. (1999). 
Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs 
VEGF-mediated endothelial survival and angiogenesis. Cell. 98. 147-57. 
Carrero, P., Okamoto, K., Coumailleau, P., O'Brian, S., Tanaka, H., Poellinger, L. 
(2000). Redox-regulated recruitment of the transcriptional coactivators CREB-binding 
protein and SRC-I to hypoxia-inducible factor I a. Mol Cell Bioi. 20. 402-15. 
Caudill, M.M., Li, Z. (2001). HSPPC-96: a personalised cancer vaccine. Expert Opin Bioi 
Ther. 1. 539-47. 
218 
Chan, C-C., Vormeyer, A.O., Chew, E.Y., Green, W.R., Matteson, D.M., Shen, D.F., 
Linehan, W.M., Lubensky, I.A., Zhuang, Z. (1999). VHL gene deletion and enhanced 
VEGF gene expression detected in the stromal cells of retinal angioma. Arch Opt ha/mol. 
117.625-30. 
Chang, S.G., Jeon, S.H., Lee, S., Choi, J.M., Kim, Y.W. (2001). Clinical significance of 
urinary vascular endothelial growth factor and microvessel density in patients with renal 
cell carcinoma. Urology. 58. 904-8. 
Chen, F., Kishida, T., Duh, F-M., Renbaum, P., Orcutt, M., Schmidt, L., Zbar, B. 
(1995). Suppression of growth ofrenal carcinoma cells by the von Hippel-Lindau tumor 
suppressor gene. Cancer Res. 55.4804-7. 
Chen, W.C., Chen, H.Y., Wu, H.C., Hsu, C.D., Tsai, F.J. (2003). Vascular endothelial 
growth factor gene polymorphism is associated with calcium oxalate stone disease. Urol 
Res. 31.218-22. 
Cheng, S-Y., Nagane, M., Su Huang, H-J., Cavenee, W.K. (1997). Intracerebral tumor-
associated haemorrhage caused by over expression of the vascular endothelial growth 
factor isoforms VEGF121 and VEGF16s but not VEGF1s9. Proc. Natl. Acad. Sci. USA. 94. 
12081-7. 
Cheville, J.C., Lohse, C.M., Zincke, H., Weaver, A.L., Blute, M.L. (2003). 
Comparisons of outcome and prognostic features among histological sub types of renal cell 
carcinoma. Am J Surg Pathol. 27.612-24. 
Chilov, D., Kukk, E., Taira, S., Jeltsch, M., Kaukonen, J., Palotie, A., Joukov, V., 
Alitalo, K. ( 1997). Genomic organization of human and mouse genes for vascular 
endothelial growth factor C. J. Bioi. Chem. 272. 25176-83. 
Choi, K-S., Bae, M-K., Jeong, J-W., Moon, H-E., Kim, K-W. (2003). Hypoxia-induced 
angiogenesis during carcinogenesis. J Biochem Mol Bioi. 36. 120-7. 
Chomczynski, P. (1993). A reagent for the single-step simultaneous isolation ofRNA, 
DNA, and proteins from cell and tissue samples. Biotechniques. 15. 532-7. 
Chomczynski, P., Sacchi, N. (1987). Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162. 156-9. 
Cioffi, C.L., Qin Liu, X., Kosinski, P.A., Garay, M., Bowen, B.R. (2003). Differential 
regulation ofHIF-lalpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular 
cells. Biochem Biophys Res Commun. 303. 947-53. 
Claffey, K.P., Shih, S-C., Mullen, A., Dziennis, S., Cusick, J.L., Abrams, K.R., Lee, 
S.W., Detmar, M. (1998). Identification of a human VPFNEGF 3' untranslated region 
mediating hypoxia-induced mRNA stability. Mol Bioi Cell. 9. 469-81. 
Clifford, S.C., Astuti, D., Hooper, L., Maxwell, P.H., Ratcliffe, P.J., Maher, E.R. 
(2001a). The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis 
ofelongin Band C, RbX and HIF-Ia in renal cell carcinoma. Oncogene. 20.5067-71. 
Clifford, S.C., Cockman, M.E.,Smallwood, A.C., Mole, D.R., Woodward, E.R., 
Maxwell, P.H., Ratcliffe, P.J., M a her, E.R. (2001 b). Contrasting effects on HIF-1 alpha 
219 
regulation by disease-causing pVHL mutations correlate with patterns oftumourigenesis in 
von Hippel-Lindau disease. Hum Mol Gene/. 10. 1029-38. 
Clifford, S.C., Czapla, K., Richards, F.M., O'Donoghue, D.J., Maher, E.R. (1998). 
Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-
myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Br J Cancer. 
77. 1420-8. 
Clifford, S.C., Walsh, S., Hewson, K., Green, E.K., Brinke, A., Green, P.M., Gianelli, 
F., Eng, C., Maher, E.R. (1999). Genomic organization and chromosomal localization of 
the human CUL2 gene and the role ofvon Hippel-Lindau tumor suppressor-binding 
protein (CUL2 and VBPI) mutation and loss in renal-cell carcinoma development. Genes 
Chromosomes Cancer. 26. 20-8. 
Clifton, I.J., Hsueh, L.C., Baldwin, J.E., Harlos, K., Schofield, C.J. (2001). Structure of 
proline 3-hydroxylase. Evolution of the family of 2-oxoglutarate dependent oxygenases. 
Eur J Biochem. 268. 6625-36. 
Cockman, M.E., Masson, N., Mole, D.R., Jaakkola, P., Chang, G-W., Clifford, S.C., 
Maher, E.R., Pugh, C.W., Ratcliffe, P.J., Maxwell, P.H. (2000). Hypoxia inducible 
factor-a binding and ubiquitylation by the von Hippei-Lindau tumor suppressor protein. J 
Bioi Chem. 275. 25733-41. 
Cohen, A.J., Li, F.P., Berg, S., Marchetto, D.J., Tsai, S., Jacobs, S.C., Brown, R.S. 
( 1979). Hereditary renal-cell carcinoma associated with a chromosomal translocation. N 
Engl J Med. 301. 592-5. 
Cohen, H., Zhou, M., Welsh, A.M., Zarghamee, S., Scholz, H., Mukhopadhyay, D., 
Kihida, T., Zbar, B., Knebelmann, B., Sukhatme, V.P. (1999). An important von 
Hippel-Lindau tumor suppressor domain mediates Sp !-binding and self-association. 
Biochem Biophys Res Commun. 266. 43-50. 
Cohen, T., Gitay-Goren, H., Sharon, R., Shibuya, M., Halaban, R., Levi, B., Neufeld, 
G. (1995). VEGF 121 , a vascular endothelial growth factor (VEGF) isform lacking heparin 
binding ability, requires cell surface heparan sulfates for efficient binding to the VEGF 
receptors ofhuman melanoma cells. J Bioi Chem. 270. 11322-6. 
Collins, E. T. ( 1894). Intra-ocular growths (two cases, brother and sister, with peculiar 
vascular new growth, probably retinal, affecting both eyes). Trans Opthalmol Soc UK. 14. 
141-9 
Cooper, M.E., Vranes, D., Youssef, S., Stacker, S.A., Cox, A.J., Rizkalla, B., Casley, 
D.J., Bach, L. A., Kelly, D.J., Gilbert, R.E. (1999). Increased renal expression of 
vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental 
diabetes. Diabetes. 48. 2229-39. 
Crossey, P.A., Richards, F.M., Foster, K., Green, J.S., Prowse, A., Latif, F., Lerman, 
M. I., Zbar, B., Affara, N.A., Ferguson-Smith M.A., et a/ ( 1994). Identifiaction of 
intregenic mutations in the von Hippei-Lindau disease tumour suppressor gene and 
correlation with disease phenotype. Hum Mol Gene!. 3. 1303-8. 
Cybulski, C., Krzystolik, K., Maher, E.R., Richard, S., Kurzawski, G., Gronwald, J., 
Lubinski, J. ( 1999). Long polymerase chain reaction in detection of germline deletions in 
the exon Hippel-Lindau tumour suppressor gene. Hum Genet. 105. 333-6. 
220 
Dachs, G.U., Patterson, A. V., Firth, .D., Ratcliffe, P.J., Townsend, K.M., Stratford, 
I.J., Harris, A.L. ( 1997). Targeting gene expression to hypoxic tumor cells. Nat Med. 3. 
5 I 5-20. 
Daliani, D.D., Papandreou, C.N., Thall, P.F., Wang, X., Perez, C., Oliva, R., Pagliaro, 
L., Amato, R. (2002). A pilot study of thalidomide in patients with progressive metastatic 
cell carcinoma. Cancer. 95. 758-65. 
D' Amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J. (1994). Thalidomide I an 
inhibitor of angiogenesis. Proc Natl A cad Sci USA. 91. 4082-5. 
D' Angelo, G., Struman, 1., Marital, J., Weiner, R.I. ( 1995). Activation of mitogen-
activated protein kinases by vascular endothelial growth factor and basic fibroblast growth 
factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-
terminal fragment of prolactin. Proc Natl Acad Sci USA. 92.6374-8. 
Dameron, K.M., Volpert, O.V., Tainsky, M.A., Bouck, N. (1994). Control of 
angiogenesis in fibroblasts by p53 regulation of thrombopondin-1. Science. 265.1582-4. 
Damert, A., Machein, M., Breier, G., Fujita, M.Q., Hanahan, D., Risau, W. (1997). 
Up-regulation of vascular endothelial growth factor expression in rat glioma is conferred 
by two distinct hypoxia-driven mechanisms. Cancer Res. 57. 3860-4. 
Dames, S.A., Martinez-Yamout, M., De Guzman, R.N., Dyson, J., Wright, P.E. 
Structural basis for Hif-la/CBP recognition in the cellular hypoxic response. Proc. Natl. 
Acad. Sci.U.S.A. 99.5271-6. 
Danielsen, T., Rofstad, E.K. (2000). The constitutive level of vascular endothelial growth 
factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the 
angiogenesis of human melanoma xenografts. Br J Cancer. 82. 1528-34. 
Dann, C.E. 3•d., Bruick, R.K., Diesenhofer, J. (2002). Structure of factor-inhibiting 
hypoxia-inducible factor I: An asparaginyl hydroxylase involved in the hypoxic response. 
Proc Natl Acad Sci USA. 99. 15351-6. 
Davis-Smyth, T., Chen, H., Park, J., Presta, L.G., Ferrara, N. (1996). The second 
immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand 
binding and may initiate a signal transduction cascade. EMBO J. 15. 4919-27. 
Davis-Smyth, T., Presta, L.G., Ferrara, N. (1998). Mapping the charged residues in the 
second immunoglobulin-like domain of the vascular endothelial growth factor/placenta 
growth factor receptor Flt-1 required for binding and structural stability. J Bioi Chem. 273. 
3216-22, 
Demaine, A., Cross, D., Millward, A. (2000). Polymorphisms of the aldose reductase 
gene susceptibility to retinopathy in type 1 diabetes mellitus. Invest Opthalmol Vis Sci. 41. 
4064-8. 
De Paulson, N., Brychzy, A., Fournier, M-C., Klausner, R.D., Gnarra, J.R., Pause, A., 
Lee, S. (2001). Role of transforming growth factor-a. in von Hippei-Lindau (VHL) -/-clear 
cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor 
suppressor inactivation and tumorigenesis. Proc. Natl. Acad. Sci. USA. 98. 1387-92. 
221 
De Vries, C., Escobedo, J.A., Ueno, H., Houck, Ferrara, N., Williams, L.T. (1992). The 
fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255. 
989-91. 
Di Lorenzo, G., Tortora, G., D' Arminento, F.P., De Rosa, G., Staibano, S., Autorino, 
R., D' Armiento, M., De Laurentiis, M., De Placido, S., Catalano, G., Bianco, A.R., 
Cairdiello, F. (2002). Expression of epiderrnial growth factor receptor correlates with 
disase relapse and progression to androgen-independence in human prostate cancer. Clin 
Cancer Res. 8. 3438-44. 
Di Salvo, J., Bayne, M.L., Conn, G., Kwok, P.W., Trivedi, P.G., Soderman, D.D., 
Palisi, T.M., Sullivan, K.A., Thomas, K.A. ( 1995). Purification and characterization of a 
naturally occurring vascular endothelial growth factor: placenta growth factor heterodimer. 
J Bioi Chem. 270.7717-23. 
Distler, 0., Scheid, A., Kowalbielecka, 0., Schedel, J., Rethage, J., Carossino, A., 
Matuccjcerinic, M., Gay, R.E., Mullerlidner, U., Wenger, R.H., Gassmann, M., Gay, 
S. ( 1999). Expression and regulation of hypoxia-inducible factor I a (Hlf-l a) and vascular 
endothelial growth factor (VEGF) in systemic sclerosis. Arthritis Rheum. 42. 793-???? 
Dixon, E.P., Bales, K.R., Johnson, E.M., Santerre, R.F., Little, S.P. (1995). 
Ribonuclease protection assay on in situ hybridization tissue: An alternative to polymerase 
chain reaction. Anal. Biochem. 225. 353-6. 
Dosquet, C., Coudert, M.C., Lepage, E., Cabane, J., Richard, F. (1997). Are 
angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in 
patients with renal cell carcinoma? Clin Cancer Res. 3. 2451-8. 
Douglas, M.L., Reid, J.L., Hii, S.I., Jonsson, J.R., Nicol, D.L. (2002). Renal cell 
carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. BJU 
Int. 89.591-5. 
Drevs, J., Hofmann, 1., Hugenschmidt, H., Wittig, C., Madjar, H., Muller, M., Wood, 
J., Martiny-Baron, G., Unger, C., Marme, D. (2000). Effects ofPTK787/ZK 222584, a 
specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on 
primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma 
model. Cancer Res. 60.4819-24. 
Duan, D.R., Humphrey, J.S., Chen, D.Y.T., Weng, Y., Sukegawa, J., Lee, S., Gnarra, 
J.R., Linehan, W.M., Klausner, R.D. (1995). Characterization of the VHL tumor 
suppressor gene product: localization, complex formation, and effect of natural inactivating 
mutations. Proc Natl A cad Sci USA. 92. 6459-63. 
Duan, D.R., Pause, A., Burgess, W.H., Aso, T., Chen, D.Y., Garrett, K.P., Conaway, 
R.C., Conaway, J.W., Linehan, W.M., Klausner, R.D. (l995).lnhibition of 
transcriptional elongation by the VHL tumor suppressor protein. Science. 269. 1402-6. 
Duerr, E-M., Gimm, 0., Neuberg, D.S., Kum, J.B., Clifford, S.C., Toledo, S.P.A., 
Maher, E.R., Dahia, P.L.M., Eng, C. (1999). Differences in allelic distribution of two 
polymorphisms in the VHL-associated gene CIL2 in pheochromocytoma patients without 
somatic CUL2 mutations. J Clin Endocrinol Metab. 84. 3207-ll. 
222 
Dumont, D.J., Fong, G-H., Puri, M., Gradwohl, G., Alitalo, K., Breitman, M.L. 
(1995). Vascularization ofthe mouse embryo: a study of FLK-1, tek, tie and VEGF 
expression during development. Mech Dev. 203. 80-92. 
Dumont, D. Jussila, L., Taipale, J., Mustonen, T., Pajuola, K., Breitman, M., Alitalo, 
K. (1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. 
Science. 282. 946-9. 
Dvorak, H.F., Brown, L.F., Detmar, M., Dvorak, A.M. (1995). Vascular permeability 
factor I vascular endothelial growth factor, microvascular hyperperrneability, and 
angiogenesis. Am J Pathol. 146. 1029-39. 
Ebert, B.L., Firth, J.D., Ratcliffe, P.J. ( 1995). Hypoxia and mitochondrial inhibitors 
regulate expression of glucose transporter-) via distinct Cis-acting sequences. J Bioi Chem. 
270. 29083-9. 
Eckhart, A.D., Yang, N., Xin, X., Faber, J.E. (1997). Characterization of the alphaiB-
adrenergic receptor gene promoter region and hypoxia regulatory elements in vascular 
smooth muscle. Proc Natl A cad Sci USA. 94. 9487-92. 
Edgren, M., Lennernas, B., Larsson, A., Kalkner, K.M. (200 l ). Angiogenic factors: 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are 
not necessarily elevated in patients with advanced renal cell carcinoma. Anticancer Res. 
21. 1423-9. 
Edgren, M., Lennernas, B., Larsson, A., Nilsson, S. ( 1999). Serum concentrations of 
VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res. 
19. 869-73. 
Ema, M., Hirota, K., Mimura, J., Abe, H., Yodoi, J., Sogawa, K., Poellinger, L., Fujii-
Kuriyama, Y. (1999). Molecular mechanisms of transcription activation by HLF and 
HIF I a in response to hypoxia: their stabilization and redox signal-induced interaction with 
CBP/p300. EMBOJ.18. 1905-14. 
Enholm, B., Paavonen, K., Ristimakl, A., Kumar, V., Gunji, Y., Klefstrom, J., 
Kivinen, L., Laiho, M., Olofsson, B., Joukov, V., Eriksson, U., Alitalo, K. (1997). 
Comparison ofVEGF, VEGF-B, VEGF-C, and Ang-1 mRNA regulation by serum, growth 
factors, oncoproteins and hypoxia. Oncogene. 14. 2475-83. 
Epstein, A.C.R., Gleadle, J.M., McNeil, L.A., Hewitson, O'Rourke, J., Mole, D.R., 
Mukherji, M., Metzen, E., Wilson, M.I., Dhanda, A., Tian, Y-M., Masson, N., 
Hamilton, D.L., Jaakkola, P., Barstead, R., Hodgkln, J., MaxweU, P.H., Pugh, C.W., 
Schofield, C.J., Ratcliffe, P.J. (2001). C. elegans EGL-9 and mammalian homologs 
define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107. 43-
54. 
Eriksson, A., Cao, R., Pawliuk, R., Berg, S.M., Tsang, M., Zhou, D., Fleet, C., 
Tritsaris, K., Dissing, S., Leboulch, P., Cao, Y. (2002). Placenta growth factor- I 
antagonizes VEGF-induced angiogenesis and tumor growth by formation of functionally 
inactive PIGF-JNEGF heterodimers. Cancer Cell. 1. 99-108. 
Feil, G., Leipoldt, M., Nelde, H.J., Wunderer, A., Wechsel, H.W., Kaiser, P., Bickler, 
K.H. ( 1999). Loss of chromosomes in clear cell renal cell carcinoma and in corresponding 
renal parenchyma. Anticancer Res. 19. 1477-82. 
223 
Feldman, D.E., Thulasiraman, V., Ferreyra, R.G., Frydman, J. (I999). Formation of 
the VHL-elongin BC tumor suppressor complex is mediated by the chaperon in TriC. Mol 
Cell. 4. I 051-61. 
Feldser, D., Agani, F., Iyer, N. V., Pak, B., Ferreira, G., Semenza, G.L. (I999). 
Reciprocal positive regulation of hypoxia-inducible factor I a and insulin-like growth 
factor 2. Cancer Res. 59. 39I5-8. 
Fergany, A.F., Hafez, K.S., Novick, A.C. (2000). Long-term results of nephron sparing 
surgery for localized renal cell carcinoma: I 0-year follow up. J Urol. 163. 442-5. 
Fernandez, A., Udagawa, T., Schwesinger, C., Beecken, W., Achilles-Gert, E., 
McDonnell, T, D' Am a to, R. (200 I). Angiogenic potential of prostate carcinoma cells 
over expressing bcl-2. J Natl Cancer Inst. 93. 208-13. 
Ferrara, N. (1993). Vascular endothelial growth factor. TCM. 3. 244-50. 
Ferrara, N., and Henzel, W.J. ( I989). Pituitary follicular cells secrete a novel heparin-
binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. 
Commun. 161. 851-9. 
Finkenzeller, G., Technau, A., Marme, D. (1995). Hypoxia-induced transcription of the 
vascular endothelial growth factor gene is independent of functional AP-1 transcription 
factor. Biochem Biophys Res Commun. 208. 432-9. 
Firth, J.D., Ebert, B.L., Ratcliffe, P.J. ( I995). Hypoxic regulation of lactate 
dehydrogenase A. Interaction between hypoxia-inducible factor I and camp response 
elements. J Bioi Chem. 270. 2I02I-7. 
Fitz, L.S., Morris, J.C., Towler, P., Long, A., Burgess, P., Greco, R., Wang, J., 
Gassaway, R., Nickbarg, E., Kovacic, S., Ciarletta, A., Giannotti, J-A.,Finnerty, H., 
Zollner, R., Beier, D.R., leak, L.V., Turner, K.J., Wood, C.R. (1997). Characterization 
of murine Flt4ligandNEGF-C. Oncogene. 15.613-8. 
Flamme, L., Frohlich, T., von Reutern, M., Kappel, A., Damert, A., Risau, W. (1997). 
HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related 
to hypoxia-inducible factor-! a and developmentally expressed in blood vessels. Mech 
Dev. 63. 51-60. 
Flamme, L., Krieg, M., Plate, K.H. ( 1998). Up-regulation of vascular endothelial growth 
factor in stromal cells ofhemangioblastomas is correlated with up-regulation of the 
transcription factor HRF/HIF-2 alpha. Am J Pathol. 153. 25-9. 
Flemming, S. ( 1999). Renal cancer genetics: von Hippel-Lindau and other syndromes. Jnt 
J Dev Bioi. 43. 469-71. 
Folkman, J. ( 1971 ). Tumor angiogenesis: therapeutic implications. N Engl J Med. 285. 
Il82-6. 
Folkman, J. (1989). Successful treatment of an angiogenic disease. N Engl J Med. 320. 
1211-2. 
224 
---------
Folkman, J. ( 1991 ). What is the evidence that tumours are angiogenesis-dependent? J. 
Nail Cancer Inst. 82. 4-6. 
Folkman, J., Hochberg, M. ( 1973). Self-regulation of growth in three dimensions. J Exp 
Med. 138. 745-53. 
Folkman, J., Merler, E., Abernathy, C., Williams, G. (1971 ). Isolation of a tumor factor 
responsible for angiogenesis. J Exp Med. 133. 275-88. 
Fong, G.H., Rossant, J., Gertsenstein, M., Breitman, M.L., ( 1995). Role of the Flt-1 
receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376. 
66-70. 
Forsythe, J.A., Jiang, B.H., Iyner, N. V., Agani, F., Leung, S.W., Koos, R.D., Semenza, 
G.L. ( 1996). Activation of vascular endothelial growth factor gene transcription by 
hypoxia inducible factor I. Mol Cell Bioi. 16. 4604-13. 
Fossa, S.D. (2000). Interferon in metastatic renal cell carcinoma. Semin Oncol. 27. 187-93. 
Foster, K., Crossey, P.A., Cairns, P., Hetherington, J. W., Richards, F.M., Jones, 
M.H., Bentley, E., Affara, N.A., Ferguson-Smith, M.A., Maher, E.R. (1994). Molecular 
genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on 
chromosomes 3p, 5q, It p, 17 and 22. Br J Cancer. 69. 230-4. 
Foster, K., Prowse, A., van den Berg, A., Flemming, S., Hulsbeek, M.M., Crossey, 
P.A., Richards, F.M., Cairns, P., Affara, N.A., Ferguson-Smith. (1994b). Somatic 
mutations of the von Hippei-Lindau disease tumour suppressor gene in non-familial clear 
cell carcinoma. Hum Mol Gene/. 3. 2 I 69-73 
Fournier, E., Blaikie, P., Rosnet, 0., Margolis, B., Birnbaum, D., Borg, J-P. ( 1999). 
Role of tyrosine residues and protein interaction domains ofHC adaptor protein in VEGF 
receptor 3 signalling. Oncogene. 18.507-14. 
Foulds, L. (1957). Tumour progression. Cancer Res.11. 355-6. 
Fournier, E., Dubreuil, P., Birnbaum, D., Borg, J-P. (1995). Mutation at tyrosine 
residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor. 
Oncogene. 11. 921-31. 
Freedman, S.J., Sun, Z-Y.J., Poy, F., Kung, A.L., Livingston, D.M., Wagner, G., Eck, 
M.J. (2002). Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 a. 
Proc. Natl. A cad. Sci. U.S.A. 99. 5367-72. 
Fu, X., Roberts, W.G., Nobile, V., Shapiro, R., Kamps, M.P. (1999). mAngiogenin-3, a 
target of oncoprotein E2a-Pbx I, encodes a new angiogenic member of the angiogenin 
family. Growth Factors. 17. 125-37. 
Fuhrman, S.A., Lasky, L.C., Limas, C. ( 1982). Prognostic significance of morphologic 
parameters in renal cell carcinoma. Am J Surg Pathol. 6. 655-63. 
Funaki, H., Nishimura, G., Harada, S., Ninomiya, I., Terada, I., Fushida, S., Tani, T., 
Fujin, T., Kayahara, M., Shimizu, K., Ohta, T., Miwa, K. (2003). Expression of 
vascular endothelial growth factor D is associated with lymph node metastasis in human 
colorectal carcinoma. Oncology. 64. 416-22. 
225 
Gabler, C., Einspanner, A., Schams, D., Einspanner, R. (1999). Expression of vascular 
endothelial growth factor (VEGF) and its corresponding receptors (flt-1 and flk-1) in the 
bovine oviduct. Mol Reproduction Dev. 53. 376-83. 
Gallou, C., Joly, D., Mejean, A., Staroz, F., Martin, N., Tarlet, G., Orfanelli, M.T., 
Bouvier, R., Droz, D., Chretien, Y., Marechal, J.M., Richard, S., Junien, C., Beroud, 
C. ( 1999). Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk 
factor for VHL patients to develop an RCC. Hum 
Mutat. 13. 464-75. 
Garrett, K.P., Haque, D., Conaway, R.C., Conaway, J.W. (1994). A human cDNA 
encoding the small subunit of RNA polymerase 11 transcription factor Sill. Gene. 150.413-
4. 
Gerber, H.P., Condorelli, F., Park, J., Ferrara, N. (1997). Differential transcriptional 
regulation of the two vascular endothelial growth factor receptor gene&- Flt-1, but not Flk-
1/KDR, is up-regulated by hypoxia. J Bioi Chem. 272. 23659-67. 
Ghiso, N., Rohan, R.M., Amano, S., Garland, R., Adamis, A.P. (1999). Suppression of 
hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via 
cGMP. Invest Opthalmol Vis Sci. 40. 1033-9 
Gimbrone, M.A., Cotran, R.S., Lea pm an, S.B., Folkman, J. ( 1974). Tumor growth and 
neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Instil. 
52.413-27. 
Gimbrone, M.A., Leapman, S., Cotran, R.S., Folkman, J. {1972). Tumor donnancy in 
vivo by prevention ofneovascularization. J Exp Med. 136.261-76. 
Giordano, F.J., Johnson, R.S. (2001 ). Angiogenesis: the role of the microenvironment in 
flipping the switch. Curr. Opin, Genet. Dev. 11. 35-40. 
Gleadle, J.M., Ratcliffe, P.J. (1997). Induction of hypoxia-inducible factor- I, 
erythropoietin, vascular endothelial growth factor, and glucose transporter-! by hypoxia: 
evidence against a regulatory role for Scr kinase. Blood. 89. 503-9. 
Gomella, L.G., Sargent, E.R, Wade, T.P., Anglard, P., Linehan, W.M., Kasid, A. 
( 1989). Expression of transfonning growth factor alpha in nonnal human adult kidney and 
enhanced expression of transfonning growth factors alpha and beta 1 in renal cell 
carcinoma. Cancer Res. 49. 6972-5. 
Gorospe, M., Egan, J.M., Zbar, B., Lerman, M., Geil, L., Kuzmin, I., Holbrook, N.J. 
(1999). Protective function ofvon Hippei-Lindau protein against impaired protein 
processing in renal carcinoma cells. Mol Cell Bioi. 19. 1289-300. 
Gnarra, J.R., Zhou, S., Merrill, M.J., Wagner, J.R., Krumm, A., Papavassiliou, E., 
Oldfield, E.H., Klausner, R.D., Linehan, W.M. (1996). Post-transcriptional regulation of 
vascular endothelial growth factor mRNA by the VHL tumour suppressor gene product. 
Proc Nat. A cad Sci USA. 93. 10589-94. 
Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., 
Chen, F., Dub, F-M., Lubensky, 1., Duan, D.R., Florence, C., Pozzatti, R., Walther, 
M.M., Bander, N.H., Grossman, H.B., Branch, H., Pomer, S., Brooks, J.D., lssacs, 
226 
W.B., Lerman, M.l., Zbar, B., Linehan, W.M. (1994). Mutations ofthe VHL tumour 
suppressor gene in renal carcinoma. Nat Genet. 7. 85-90. 
Goldberg, M.A., and Schneider, T.J. ( 1994). Similarities between the oxygen-sensing 
mechanisms regulating the expression of vascular endothelial growth factor and 
erythropoietin. J. Bioi. Chem. 269. 4355-61. 
Goldberg-Cohen, I., Furneauxb, H., Levy, A.P. (2002). A 40-bp RNA element that 
mediates stabilization of vascular endothelial growth factor mRNA by HuR. J Bioi Chem. 
277. 13635-40. 
Goldman, E. ( 1907). The growth of malignant disease in man and the lower animals with 
special reference to the vascular system. Lancet. ii. 1236-40. 
Gomella, L.G., Sargent, E.R., Linehan, W.M., Kasid, A. (1989). Transfonned growth 
factor-beta inhibits the growth of renal cell carcinoma in vitro. J Urol. 141. 1240-4. 
Gothie, E., Richards, D.E., Berra, E., Pages, G., Pouyssegur, J. (2000). Identification of 
alternative spliced variants of human hypoxia-inducible factor-! a. J Bioi Chem. 275. 
6922-7. 
Grawitz, P. ( 1883). Die sogenanneten Lipoma der Niere. Virchows Arch Patlwl Anal. 93. 
39. 
Griffioen, A.W., Coenen, M.J., Damen, C.A., Hellwig, S.M., van Weering, D.H., 
Vooys, W., Blijham, G.H., Groenewegen, G. (1997). CD44 is involved in tumor 
angiogenesis; an activation antigen on human endothelial cells. Blood. 90. 1150-9. 
Griffith, E.C., Su, Z., Turk, B.E., Chen, S., Chang, Y.H., Wu, Z., Biemann, K., Liu, 
J.O. ( 1997). Methionine aminopeptidase (type 2) is the common target for angiogenesis 
inhibitors AGM-1470 and ovalicin. Chem Bioi. 4. 461-71. 
Grimmond, S., Lagercrantz, J., Drinkwater, C., Silins, G., Townson, S., Pollock, P., 
Gotley, D., Carcon, E., Rakar, S., Nordenskjold, M., Ward, L., Hayward, N., Weber, 
G. ( 1996). Cloning and characterization of a novel human gene related to vascular 
endothelial growth factor. Genome Res. 6. 124-31. 
Grone, H.J., Si m on, M., Grone, E.F. ( 1995). Expression of vascular endothelial growth 
factor in renal vascular disease and renal allografts. J Pathol. 177. 259-67. 
Groulx, I., Bonicalzi, M.E., Lee, S. (2000). Ran-mediated nuclear export of the von 
Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-
2. J Bioi Chem. 275. 8991-9000. 
Groulx, I., Lee, S. (2002). Oxygen-dependent ubiquitination and degradation of hypoxia-
inducible factor requires nuclear-cytoplasmic trafficking of the von Hippei-Lindau tumor 
suppressor protein. Mol Cell Bioi. 22. 5319-36. 
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., Marme, D. ( 1995). Both v-Ha-
ras and v-raf stimulate expression ofthe vascular endothelial growth factor in NIH 3T3 
cells. J Bioi Chem. 270. 25915-9. 
227 
Grunstein, J., Masbad, J.J., Hickey, R., Giordano, F., Johnson, R.S. (2000). Isofonns 
of vascular endothelial growth factor act in a coordinate fashion to recruit and expand 
tumor vasculature. Mol Cell Bioi. 20. 7282-91. 
Gu, Y-Z., Moran, S.M., Hogenesch, J.B., Wartman, L., Bradfield, C.A. (1998). 
Molecular characterization and chromosomal localization of a third a-class hypoxia 
inducible factor subunit, HIF3a. Gene Expr. 7. 205-13. 
Gunaratnam, L., Morley, M., Franovic, A., De Paulsen, N., Mekhail, K., Parolin, 
D.A., Nakamura, E., Lorimer, I.A., Lee, S. (2003). HIF activates the TGF-alpha /EGF-R 
growth stimulatory pathway in VHL-/- renal cell carcinoma cells. J Bioi Chem. In press. 
Gunningham, S.P., Currie, M.J., Han, C., Robinson B.A., Scott, P.A.E., Harris, A.L., 
Fox, S.B. (2000). The short fonn of the alternatively spliced flt-4 but not its ligand 
vascular endothelial growth factor C is related to lymph node metastasis in human breast 
cancers. Clin. Cancer. Res. 6. 4278-86. 
Gunningham, S.P., Currie, M.J., Han, C., Robinson B.A., Scott, P.A.E., Harris, A.L., 
Fox, S.B. (200 I). VEGF-B expression in human primary breast cancers is associated with 
lymph node metastasis but not angiogenesis. J. Pathol. 193. 325-32. 
Gunningham, S.P., Currie, M.J., Han, C., Turner, K., Scott., P.A.E., Robinson, B.A., 
Harris, A.L., Fox, S.B. (2001 b). Vascular endothelial growth factor-Band vascular 
endothelial growth factor-C expression in renal cell carcinomas: Regulation by the von 
Hippel-Lindau gene and hypoxia. Cancer Res. 61.3206-11. 
Guo, D., Jia, Q., Song, H.Y., Warren, R.S., Donner, D.B. (1995). Vascular endothelial 
growth factor promotes tyrosine phosphorylation of mediators of signal transduction that 
contain SH2 domains. Association with endothelial cell proliferation. J Bioi Chem. 270. 
6729-33. 
Guo, P., Xu, L., Pan, S., Brekken, R.A., Yang, S-T., Whitaker, B., Nagane, M., 
Thorpe, P.E., Rosenbaum, .S., Su Huang, H.-J., Cavenee, W.K., Cheng, S-Y. (2001). 
Vascular endothelial growth factor isofonns display distinct activities in promoting tumor 
angiogenesis at different anatomic sites. Cancer Res. 61. 8569-77. 
Haase, V.H., Glickman, N., Socolovsky, M., Jaenisch, R. (200 1). Vascular tumors in 
livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. 
Acad. Sci. USA. 98. 1583-158. 
Hamilton, W.J., Boyd, J.D., Mossman, H.W. (1962). Human embryology. Williams & 
Watkins, Baltimore. 
Hanahan, D., Weinberg, R. (2000). The hallmarks of cancer. Cell. 100. 57-70. 
Hanninen, E.L., Kirchner, H., Atzpodien, J. (1996). Interleukin-2 based home therapy 
of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution 
patients. J Urol. 155. 19-25. 
Hansen, W.J., Ohh, M., Moslehi, J., Kondo, K., Kaelin, W.G., Welch, W.J. (2002). 
Diverse effect of mutations in exon T1 of the von Hippei-Lindau (VHL) tumor suppressor 
gene on the interaction ofpVHL with the cytosolic chaperonin and pVHL-dependent 
ubiquitin ligase activity. Mol Cell Bioi. 22. 1947-60. 
228 
Hanrahan, V., Currie, M.J., Gunningham, S.P., Morrin, H.R., Scott, P.A., Robinson, 
B.A., Fox, S.B. (2003). The angiogenic switch for vascular endothelial growth factor 
(VEGF-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence) during 
colorectal cancer progression. J Pathol. 200. 183-94. 
Hara, S., Hamada, J., Kobayashi, C., Kondo, Y., lmura, N. (2001). Expression and 
characterization of hypoxia-inducible factor (HIF)-3a in human kidney: suppression of 
HIF-mediated gene expression by HIF-3a. Biochem Biophys Res Commun. 287.808-13. 
Hara, S., Kobayashi, C., Imura, N. (1999). Nuclear localization of hypoxia-inducible 
factor-2a in bovine arterial endothelial cells. Mol Cell Bioi Res Commun. 2. 119-23. 
Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R., Melmed, S. (1999). Early 
involvement of estrogen-inducing pituitary tumor transforming gene and fibroblast growth 
factor expression in prolactinoma pathogenesis. Nature Med. 5. 1317-21. 
Heesom, A.E., Hibberd, M.L., Millward, B.A., Demaine, A.G. (1997). A polymorphism 
at the 5' end of the aldose reductase gene is strongly associated with the development of 
diabetic nephropathy in type I diabetes. Diabetes. 46. 287-91. 
Hegele, A., Varga, Z., von Knobloch, R., Heidenreich, A., Kropf, J., Hofmann, R. 
(2002). TGF-beta I ion patient with renal cell carcinoma. Urol Res. 30. 126-9. 
Hegg, E.L., Que, L. ( 1997). The 2-His-1-carboxylate facial triad, an emerging structural 
motif in mononuclear non-heme iron(Il) enzymes. Eur J Biochem. 250. 625-9. 
Heidbreder, M., Frohlich, F., Johren, 0., Dendorfer, A., Quadri, F., Dominiak, P. 
(2003). Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J. 17. 1541-3. 
Hellwig, S.M., Damen, C.A., van Adrichem, N.P., Blijham, G.H., Groenewegen, G., 
Griffioen, A.W. (1997). Endothelial CD34 is suppressed in human malignancies: role of 
angiogenic factors. Cancer Lett. 120. 203-11. 
Hellwigburgel, T., Rutkowski, K,. Metzen, E., Fandrey, J., Jelkmann, W. (1999). 
lnterleukin-1 beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-
inducible factor-1. Blood. 94. 1561-7. 
Hemmerlein, B., Kugler, A., Ozisik, R., Ringert, R.H., Radzun, H.J., Thelen, P. 
(2001). Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal 
cell carcinoma. Virchows Arch. 439. 645-52. 
Herman, J. G., Latif, F., Weng, Y., Lerman, M.I., Zbar, B., Liu, S., Samid, D., Duan, 
D-S.R., Gnarra, J.R., Linehan, W.M., Baylin, S.B. (1994). Silencing of the VHL tu m or-
suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. 91. 9700-
4. 
Hes, F., Zewald, R., Peeters, T., Sijmons, R. Links, T., Verheij, J., Matthijs, G., 
Leguis, E., Mortier, G., van der Torren, K., Rosman, M., Lips, C., Pearson, P., van 
der Luijt, R. (2000). Genotype-phenotype correlations in families with deletions in the 
von Hippei-Lindau (VHL) gene. Hum Genet. 106.425-31. 
Hewitson, K.S., McNeill, L.A., Riordan, M. V., Tian, Y-M., Bullock, A.N., Welford, 
R.W., Elkins, J.M., Oldbam, N.J., Bhattacharya, S., Gleadle, J.M., Ratcliffe, P.J., 
Pugh, C.W., Schofield, C.J. (2002). Hypoxia inducible factor (HIF) asparagines 
229 
hydroxylase is identical to factor inhibiting T-TIF (FIH) and is related to the cupin structural 
family. J. Bioi. Chem. 277. 26351-5. 
Hiratsuka, S., Minowa, 0., Kuno, J., Nod a, T., Shibuya, M. (I 998). Flt-1 lacking the 
tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. 
Proc Natl A cad Sci USA. 4. 9349-54. 
Hise, M.K., Jacobs, S.C., Papadimitriou, J.C., Drachenberg, C.l. (I 996). Transfonning 
growth factor-alpha expression in human renal cell carcinoma: TGF-alpha expression in 
renal cell carcinoma. Urology. 47. 29-33. 
Holt, R.C., Ralph, S.A., Webb, N.J., Watson, C.J., Clark, A.G., Mathieson, P.W., 
Brenchley, P.E. (2003). Steroid-sensitive nephrotic syndrome and vascular endothelial 
growth factor gene polymorphisms. EurJ Immunogenet. 30. 1-3. 
Hon, W-C., Wilson, M.l., Harlos, K., Claridge, T.D.W., Schofield, C.J., Pugh, C.W., 
Maxwell, P.H., Ratcliffe, P.J., Stuart, D.l., Jones, E.Y. (2002). Structural basis for the 
recognition of hydroxyproline in HIF-Ia by pVHL. Nature. 417. 975-8. 
Houck, K.A., Ferrara, N., Winer, J., Cachianes, G., Li, B., Leung, D.W. (1991). The 
vascular endothelial growth factor family: identification of a fourth molecular species and 
characterization of alternative splicing of RNA. Mol Endocrinol. 5. 1806- I 4. 
Hovind, P., Tarnow, L., Oestergaard, P.B., Parving, H.H. (2000). Elevated vascular 
endothelial growth factor in type I diabetic patients with diabetic nephropathy. Kidney Int. 
57. 56-61. 
Hu, J., Discher, D.J., Bishopric, N.H., Webster, K.A. (1998). Hypoxia regulates 
expression of the endothelin-1 gene through a proximal hypoxia-indicible factor-1 binding 
site on the antisense strand. Biochem Biophys Res Commun. 245. 894-9. 
Huez, I., Bornes, S., Bresson, D., Creancier, L., Prats, H. (200 I). New vascular 
endothelial growth factor isoform generated by internal ribosome entry site-driven CUG 
translation initiation. Mol Endocrino/.15. 2197-210. 
Hunter, J. ( 1787). Lectures on the principles of surgery. In The works of John Hunter 
Volume I (ed. J. Palmer), p. 368. London. 
lgarashi, H., Esumi, M., lshida, H., Okada, K. (2002). Vascular endothelial growth 
factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene 
inactivation in patients with sporadic renal cell carcinoma. Cancer. 95. 47-53. 
lgarahi, K., Shigeta, K., lsohara, T., Yamano, T., Uno, I. (1998). Sck interacts with 
KDR and Fit- I via its SH2 domain. Biochem Biophys Res Commun. 251. 77-82. 
lkeda, R., Furukawa, T., Kitazono, M., lshitsuka, K., Okumura, H., Tani, 
A.,Sumizawa, T., Haraguchi, M., Komatsu, M., Uchimiya, H., Ren, X-Q., Motoya, T., 
Yamada, K., Akiyama, S-1. (2002). Molecular basis for the inhibition of hypoxia-induced 
apoptosis by 2-deoxy-D-ribose. Biochem Biophys Res Commun. 291. 806-12. 
lkeda, T., Wakiya, K., Shibuya, M. (I 996). Characterization of the promoter region for 
the tlt-1 tyrosine kinase gene, a reporter for vascular endothelial growth factor. Growth 
Factors. 13. 151-62. 
230 
Iliopoulos, 0., Kibel, A., Gray, S., Kaelin, W.G. {1995). Tumor suppression by the 
human von Hippel-Lindau gene product. Nat. Med. 1. 822-6. 
Iliopoulos, 0., Levy, A.P., Jiang, C., Kaelin, W.G. Jr., Goldberg, M.A. (1996). 
Negative regulation of hypoxia-inducible genes by the von Hippei-Lindau protein. Proc 
Natl Acad Sci USA. 93. 10595-9. 
lliopoulos, 0., Ohh, M., Kaelin, W.G. (1998). pVHL 19 is a biologically active product of 
the von Hippei-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. 
Sci.U.S.A. 95. 11661-6. 
Ingber, D., Fujita, T., Kihimoto, S., Sudo, K., Kanamara, T., Brem, H., Folkman, J. 
( 1990). Synthetic analogs of Fumagillin that inhibit angiogenesis and suppress tumour 
growth. Nature. 348.555-7. 
Ishikawa, M., Kitayama, J., Kazama, S., Nagawa, H. (2003). Expression of vascular 
endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for 
lymphatic metastasis in undifferentiated early gastric cancer. Jpn J Cl in Oncol. 33. 21-7. 
Ishizuka, T., Hayashi, T., Nakazawa, H., Ito, F., Nitta, K., Horita, S., Uchida, K., 
Nihei, H., Toma, H. (2000). Serum vascular endothelial growth factor is a candidate 
biomarker of renal cell carcinoma in hemodialysis patients. Nephron. 84. 83-4. 
Issacs, J.S., Jung, Y.J., Mimnaugh, E.G., Martinez, A., Cuttitta, F., Neckers, L.M. 
(2002). Hsp90 regulates a VHL-independent HIF-1 a degradative pathway. J. Bioi. 
Chem.277. 29936-44. 
lvan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Asara, J.H., Lane, 
W.S., Kaelin, W.G. Jr. (2001). HIFa targeted for VHL-mediated destruction by proline 
hydroxylation: Implications for 0 2 sensing. Science. 292. 464-8. 
Ivanov, S.V., Kuzmin, I., Wei, M-H., Pack, S., Geil, L., Johnson, B.E., Stanbridge, 
E.J., Lerman, M .I. ( 1998). Down-regulation of transmembrane carbonic anhydrases in 
renal cell carcinoma cell lines by wild-type von Hippei-Lindau transgenes. Proc. Natl. 
Acad. Sci. USA. 95. 12596-601. 
lwai, K., Yamanaka, K., Kamura, T., Minato, N., Conaway, R.C., Conaway, J.W., 
Klausner, R.D., Pause, A. (1999). Identification of the von Hippel-Lindau tumor-
suppressor protein as part of an active E3 Ubiquitin ligase complex. Proc. Natl. A cad. Sci. 
USA. 96. 12436-41. 
lyer, N. V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H., 
Gassmann, M., Gearhart, J.D., Lawler, A.M., Yu, A.Y., Semenza, G.L. (1998a). 
Cellular and developmental control of02 homeostasis by hypoxia-inducible factor la. 
Genes Dev. 12. 149-62. 
Iyer, N. V., Leung, S.W., Semenza, G.L. {l998b). The human hypoxia-inducible factor 
I a gene: HJF 1 a structure and evolutionary conservation. Genomics. 52. 159-65. 
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., Jain, R.K. (2002). Tumor biology: 
Herceptin acts as an antiangiogenic cocktail. Nature. 416. 279-80. 
Jaakkola, P., Mole, D.R., Tian, Y-M., Wilson, M.I., Gielbert, J., Gaskell, S.J., von 
Kriegsheim, A., Hebestreit, H.F., Mukherji, M., Schofield, C.J., Maxwell, P.H., Pugh, 
231 
C.W., Ratcliffe, P.J. Targeting of HIF-1 a to the von Hippel-Lindau ubiquitylation 
complex by 0 2- regulated prolyl hydroxylation. Science. 292. 468-72. 
Jackson, T., Kwon, E., Chachuska, A.M., Hyman, L.E. (2000). Novel roles for elongin 
C in yeast. Biochim Biophys Acta. 1491. 161-76. 
Jacobsen, J., Grankvist, K., Rasmuson, T., Bergh, A., Landberg, G., Ljungberg, B. 
(2004). Expression of vascular endothelial growth factor protein in human renal cell 
carcinoma. BJU 1nl. 93. 297-302. 
Jacobsen, J., Grankvist, K., Rasmuson, T., Ljunberg, B. (2002). Prognostic importance 
of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in 
human renal cell carcinoma. Eur J Cancer Prev. 11. 245-52. 
Jacobsen, J., Rasmuson, T., Grankvist, K., Ljunberg, B. (2000). Vascular endothelial 
growth factor as prognostic factor in renal cell carcinoma. J Urol. 163.343-7. 
Jakeman, L.B., Winer, J., Bennett, G.L., Altar, C.A., Ferrara, N. (1992). Binding sites 
for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. 
J Clin Invest. 89. 244-53. 
Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M., 
Fukumura, D., Jain, R.K., Alitalo, K. ( 1997). Hyperplasia of lymphatic vessels in 
VEGF-C transgenic mice. Science. 276. 1423-5. 
Jiang, B-H., Agani, F., Passaniti, A., Semenza, G.L. ( 1997). V -SRC induces expression 
of hypoxia-inducible factor l(HIF-1) and transcription of genes encoding vascular 
endothelial growth factor and eN OS I : involvement of HIF -1 in tu m or progression. Cancer 
Res. 57. 5328-35. 
Jiang, B.H., Rue, E., Wang, G.L., Roe, R., Semenza, G.L. (1996a). Dimerization, DNA 
binding, and transactivation properties of hypoxia-inducible factor I. J Bioi Chem. 271. 
17771-8. 
Jiang, B.H., Semenza, G.L., Bauer, C., Marti, H.H. (l996b). Hypoxia-inducible factor l 
levels vary exponentially over a physiological relevant range of02 tension. Am J Physiol. 
271. 1172-80. 
Jiang, B.H., Zheng, J.Z., Aoki, M., Vogt, P.K. (2000). Phosphatidylinositol 3-kinase 
signalling mediates angiogenesis and expression of vascular endothelial growth factor in 
endothelial cells. Proc Nail Acad Sci USA. 91. 1749-53. 
Jiang, B.H., Zheng, J.Z., Leung, S.W., Roe, R., Semenza, G.L. (1997). Transactivation 
and inhibitory domains of hypoxia-inducible factor 1 a. J Bioi Chem. 272. 19253-60. 
Jiang, H., Guo, R., PoweU-Coffman, J.P. (2001). The Caenorhabditis elegans HJF-1 
gene encodes a bHLH-PAS protein that is required for adaptation to hypoxia. Proc Natl 
AcadSci USA. 98.7916-21. 
Jingjing, L., Xue, Y., Agarwal, N., Roque, R. S. ( 1999). Human m tiller cells express 
VEGFI83, a novel spliced variant of vascular endothelial growth factor. Invest Opthalmo/ 
Vis Sci. 40. No 3, 752-9. 
232 
Jones, A., Fujiyama, C., Turner, K., Fuggle, S., Cranston, D., Bicknell, R., Harris, 
A.L. (2000). Elevated serum vascular endothelial growth factor in patients with honnone-
escaped prostate cancer. BJU 1nl. 85. 276-80. 
Joukov, V., Kaipainen, A., Jeltsch, M., Pajusola, K., Olofsson, B., Kumar, V., 
Eriksson, U., Alitalo, K. ( 1997). Vascular endothelial growth factors VEGF-B and 
VEGF-C. J Cell Physiol. 173. 211-5. 
Joukov, V., Kumar, V., Sorsa, T., Arighi, E., Weich, H., Saksela, 0., Alitalo, K. 
( 1998). A recombinant mutant vascular endothelial growth factor-C that has lost vascular 
endothelial growth factor receptor-2 binding, activation and vascular penneability 
activities. J Bioi Chem. 273. 6599-602. 
Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, 1., Kukk, E., Saksela, 
0., Kalkkinen, N., Alitalo, K. (1996). A novel vascular endothelial growth factor, VEGF-
C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. 
EMBO, IS. 290-8. 
Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksela, 
0., Kalkkinen, N., Alitalo, K. (1997). Proteolytic processing regulated receptor 
specificity and activity ofVEGF-C. EMBO. 16. 3898-911. 
Junker, U., Knoefel, B., Nuske, K., Rebstock, K., Steiner, T., Wunderlich, H., Junker, 
K., Reinhold, D. ( 1996). Transfonning growth factor beta I is significantly elevated in 
plasma of patients suffering from renal cell carcinoma. Cytokine. 8. 794-8. 
Kaelin. W. G. Jr. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nat 
Rev Cancer. 2. 673-82 
Kaelin, W. G. Jr., and Maher, E. R. (1998). The VHL tumour-suppressor gene 
paradigm. Trends in Genetics. 14. 423-6. 
Kaipainen, A., Korhonen, J., Mustonen, T., van Hinsbergh., Fang, G-H., Dumont, D., 
Breitman, M., Alitalo, K. (1995). Expression offms-like tyrosine kinase gene becomes 
restricted to lymphatic endothelium during development. Proc Nail Acad Sci USA. 92. 
3566-70. 
Kallio, P.J., Wilson, W.J., O'Brien, S., Makino, Y., Poellinger, L. (1999). Regulation of 
the hypoxia-inducible transcription factor la by the ubiquitin-proteosome pathway. J Bioi 
Chem. 274.6519-25. 
Kamura, T., Koepp, D.M., Conrad, M.N., Skowyra, D., Moreland, R.J., lliopoulos, 
0., Lane, W.S., Kaelin, W.G. Jr., Elledge, S.J., Conaway, R.C., Harper, J.W., 
Conaway, J.W. (1999). Rbxl, a component of the VHL tumor suppressor complex and 
SCF ubiquitin ligase. Science. 284. 657-61. 
Kamura, T., Sto, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R.C., Conaway, J.W. 
(2000). Activation of HIF-la ubiquitination by a reconstituted von Hippei-Lindau (VHL) 
tumor suppressor complex. Proc Nail Acad Sci USA. 97. 10430-5. 
Kanayama, H., Yano, S., Kim, S.J., Ozawa, L.M., Fidler, I.J. (1999). Expression of 
vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of 
primary tumors and production of ascites but not metastasis to the lungs in nude mice. C/in 
Exp Metastasis. 17. 831-40. 
233 
Kankuri, M., Pelliniemi, T.T., Pyrhonen, S., Nikkanen, V., Helenius, H., Salminen, E. 
(200 I). Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a 
phase ll study. Cancer. 92.761-7. 
Kappel, A., Volker, R., Damert, A., Flamme, I., Risau, W., Breier, G. (1999). 
Identification of vascular endothelial growth factor (VEGF) receptor-2 (Fik- 1) 
promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific 
transcription in transgenic mice. Blood. 93. 4284-92. 
Kawakami, M., Furuhata, T., Kimura, Y., Yamaguchi, K., Hata, F., Sasaki, K., 
Hirata, K. (2003). Expression analysis of vascular endothelial growth factors and their 
relationships to lymph node metastasis in human colorectal cancer. J Exp Cl in Cancer Res. 
22. 229-37. 
Keck, P.J., Hauser, S.D., Krivi, G., Sanzo, K., Warren, T., Feder, J., Connolly, D.T. 
( 1989). Human vascular permeability factor, an endothelial cell mitogen related to platelet 
derived growth factor. Science. 246. 1309-12. 
Kedar, E., Gur, H., Babai, I., Samira, S., Even-Chen, S., Barebholz, Y. (2000). 
Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of 
interleukin-2 encapsulated in conventionalliposomes and in long-circulating liposomes. J 
Immunother. 23. 131-45. 
Kenck, C., Bugert, P., Wihelm, M., Kovacs, G. (1997). Duplication of an approximately 
1.5 Mb DNA segment at chromosome 5q22 indicates the locus of a new tumour gene in 
non-papillary renal cell carcinoma. Oncogene. 14. I 093-8. 
Kendall, R.L., Thomas, K.A. (1993). Inhibition of vascular endothelial cell growth factor 
activity by an endogenously encoded soluble receptor. Proc Natl A cad Sci USA. 90. I 0705-
9. 
Kerbal, R., Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. Nat Rev 
Cancer. 2. 727-39 
Keyt, B.A., Berleau, L.T., Nguyen, H. V., Chen, H., Heinsohn, H., Vandlen, R., 
Ferrara, N. (1996). The carboxyl-terminal domain (111-165) of vascular endothelial 
growth factor is critical for its mitogenic potency. J Bioi Chem. 271. 7788-95. 
Khatua, S., Peterson, K.M., Brown, K.M., Lawlor, C., Santi, M.R., LaFieur, B., 
Dressman, D., Stephan, D.A., MacDonald, T.J. (2003). Overexpression of the 
EGFRIFK.BP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis 
gene profiling. Cancer Res. 63. 1865-70. 
Kibel, A., lliopoulos, 0., DeCaprio, J.A., Kaelin, W.G. Jr. (1995). Binding of the von 
Hippei-Lindau tumor suppressor protein to Elongin Band C. Science. 269. 1444-6. 
Kietzmann, T., Roth, U., Jungermann, K. (1999). Induction of the plasminogen activator 
inhibitor-! gene expression by mild hypoxia via a hypoxia response element binding the 
hypoxia-inducible factor-) in rat hepatocytes. Blood. 94. 4177-85. 
Kim, S., Bell, K., Mousa, S.A., Varner, J.A. (2000). Regulation of angiogenesis in vivo 
by ligation of integrin alpha5betal with the central cell-binding domain of fibronectin. Am 
J Pathol. 156. 1345-62. 
234 
Kim, K.J., Li, 8., Houck, K., Winer, J., Ferrara, N. (1992). The vascular endothelial 
growth factor proteins: identification of biologically relevant regions by neutralizing 
monoclonal antibodies. Growth Factors. 1. 53-64. 
Kisker, 0., Becker, C.M., Prox, D., Fannon, M., D' Amato, R., Flynn, E., Fogle, W.E., 
Sim, B.K., All red, E.N., Pirie-Shepherd, S.R., Folkman, J. (200 I). Continuous 
administration ofEndostatin by intraperitoneally implanted osmotic pump improves the 
efficacy and potency of therapy in a mouse xenograft tumour model. Cancer Res. 61. 
7669-74. 
Kivirikko, K.l., Pihlajaniemi. T. Collagen hydroxylases and the protein disulfide 
isomerase subunit ofprolyl4-hydroxylases. (1998). Adv Enzymol Re/at Areas Mol Bioi. 
72.325-98. 
Klade, C.S., Dohnal, A., Furst, W., Sommergruber, W., Heider, K-H., Gharwan, H., 
Ratschek, M., Adolf, G.R. (2002). Identification and characterization of9D7, a novel 
human protein over expressed in renal cell carcinoma./nt J Cancer. 91. 217-24. 
Knebelmann, B., Ananth, S., Cohen, H.T., Sukhatme, V.P. (1998). Transforming 
growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 
58. 226-31. 
Knudson, A.G. Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc 
Natl Acad Sci USA. 68. 820-3. 
Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H.D., Mayer, T.U., Jentsch, S. (1999). A 
novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell. 96. 635-
44. 
Kondo, K., Kico, J., Nakamura, E., Lechpammer, M., Kaelin, W.G Jr. (2002). 
Inhibition ofHIF is necessary for tumor suppression by the von Hippei-Lindau protein. 
Cancer Cell. 1. 237-46. 
Kondo,Y., Arii, S., Furutani, M., Isigmi, S.I., Mori, A., Onodera, H. Chiba, T., 
Imamura, M. (2000). Implication of vascular endothelial growth factor and p53 status for 
angiogenesis in non-invasive colorectal carcinoma. Cancer. 88. 1820-7. 
Konig, B., Steinbach, F., anocha, B., Drynda, A., Stumm, M., Philipp, C., Allhoff, 
E.P., Konig, W. (1999). The differential expression ofproinflammatory cytokines IL-6, 
IL-8, and TNF-a in renal cell carcinoma. Anticancer Res. 19. 1519-24. 
Konishi, T., Huang, C-L., Adachi, M., Taki, T., lnufusa, H., Kodama, K., Kohno, N., 
Miyake, M. (2000). The K-ras gene regulates vascular endothelial growth factor gene 
expression in non-small cell lung cancers. lnt J Oncol. 16. 501-11. 
Koochekpour, S., Jeffers, M., Wang, P.H., Gong, C., Taylor, G.A., Roessler, L.M., 
Stearman, R., Vasselli, J.R., Stetler-Stevenson, W.G., Kaelin, W.G. Jr., Linehan, 
W.M., Klausner, R.D., Gnarra, J.R., Vande Woude, G.F. (1999). The von Hippel-
Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced 
invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Bioi. 19. 5902-
12. 
235 
Korpelainen, E. I., Klirkkliinen, M., Gunji, Y., Vikkula, M., Alitalo, K. ( 1999). 
Endothelial receptor tyrosine kinases activate the STAT signalling pathway: mutant Tie-2 
causing venous malformations signals a distinct ST AT activation response. Oncogene. 18. 
1-8. 
Kotch, L.E., ltner, N.V., Laughner, E., Semenza, G.L. (1999). Defective vascularization 
ofHIF-Ia-null embryos is not associated with VEGF deficiency but with mesenchymal 
cell death. Dev Bioi. 209. 254-67. 
Koukourakis, M.I., Glatromanolaki, A., Skarlatos, J., Corti, L., Blandamura, S., 
Piazza, M., Gatter, K.C., Harris, A.L. (200 I). Hypoxia inducible factor (HIF-1 a and 
HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and 
radiotherapy. Cancer Res. 61. 1830-2. 
Koury, S.T., Bondurant, M.C., Koury, M.J., Semenza, G.L. ( 1991). Localization of 
cells producing erythropoietin in murine liver by in situ hybridization. Blood. 71. 2497-
503. 
Kovacs, G., Emanuel, A., Neumann, H.P., Kong, H.F. (1991 ). Cytogenetics of renal cell 
carcinomas associated with von Hippel-Lindau disease. Genes Chromosomes Cancer. 3. 
256-62. 
Kovacs, G., Frisch, S. ( 1989). Clonal chromosome abnormalities in tumor cell from 
patients with sporadic renal cell carcinoma. Cancer Res. 49. 651-9. 
Krieg, M., Haas, R., Branch, H., Acker, T., Flamme, 1., Plate, K.H. (2000). Up-
regulation of hypoxia-inducible factors HlF-Ia and HIF-2a under normoxic conditions in 
renal cell carcinoma cells by von Hippei-Lindau tumor suppressor gene loss of function. 
Oncogene. 19. 5435-43. 
Kuenen, B.C., Levi, M., Meijers, J.C., Kakkar, A.K., van Hinsberg, V.W., Kostense, 
P.J., Pinedo, H.M., Hoekman, K. (2002). Analysis of coagulation cascade and 
endothelial cell activation during inhibition of vascular endothelial growth factor/vascular 
endothelial growth factor receptor pathway in cancer patients. Artherioscler Thromb Vase 
Bioi. 22. 1500-5. 
Kong, A.L., Wang, S., Klco, J.M., Kaelin, W.G. Jr., Livingston, D.M. (2000). 
Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat 
Med. 6. 1335-40. 
Kunkel, M., Reichert, T.E., Benz, P., Lehr, H.A., Jeong, J.H., Wieand, S., Bartenstein, 
P., Wagner, W., Wbiteside, T.L. (2003). Overexpression ofGiut-1 and increased glucose 
metabolism in tumors are associated with a poor prognosis in patients with oral squamous 
cell carcinoma. Cancer. 91. 1015-24. 
Kuzmin, 1., Dub, F-M., Latif, F., Geil, L., Zbar, B., Lerman, M.l. (1995).ldentification 
of the promoter of the human von Hippei-Lindau disease tumor suppressor gene. 
Oncogene. 10.2185-94. 
Kuzmin, I., Geil, L., Ge, H., Bangtsson, U., Dub, F.M., Stanbridge, E .. , Lerman, M.I. 
( 1999). Analysis of aberrant methylation of the VHL gene by transgenes, 
monochromosome transfer, and cell fusion. Oncogene. 18. 5672-9. 
236 
Kvietikova, l.,Wenger, R.H., Marti, H.H., Gassmann, M. ( 1995). The transcription 
factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor -I (HIF-1) 
DNA recognition site. Nucleic Acids Res. 23. 4542-50. 
Laderoute, K.R., Grant, T.D., Murphy, B.J., Sutherland, R.M. ( 1992). Enhanced 
epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to 
low levels ofoxygen./nt J Cancer. 52.428-32. 
Ladoux, A., Frelin, C. (1997). Cardiac expressions ofHIF-Ia and HLF/EPAS, two basic 
helix loop helix/PAS domain transcription factors involved in adaptive responses to 
hypoxic stresses. Biochem Biophys Res Commun. 240. 552-6. 
Lager, D.J., Slagel, D.D., Palechek, P.L. (1994). The expression of epidermal growth 
factor receptor and receptor and transforming growth factor alpha in renal cell carcinoma. 
Mod Pathol. 1. 544-8. 
Landis, S.H., Murray, T., Holden, S., Wingo, P.A. (1998). Cancer statistics. CA Cancer 
J Clin. 48. 6-30. 
Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw, M.L., Bruick, R.K. 
(2002). FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional 
activity of hypoxia-inducible factor. Genes Dev. 16. 1466-71. 
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F-M., Orcutt, M.L., Stackhouse, T., 
Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F., Li, H., Wei, M.H., Chen, F., 
Glenn, G., Choyke, P., Walther, M.M., Weng, Y., Duan, D-S.R., Dean, M., Glavac, D., 
Richards, F.M., Crossey, P.A., Ferguson-Smith, M.A., Le Pastier, D., Chumakov, 1., 
Cohen, D., Chinault, A.C., Maher, E.R., Linehan, W.M., Zbar, B., Lerman, M.I. 
(1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 
260. 1317-20. 
Lavaissiere, L., Jia, S., Nihiyama, M., de la Monde, S., Stern, A.M., Wands, J.R., 
Friedman, P.A. (1996). Overexpression of human aspartyl (asparaginyl) ~-hydroxylase in 
hepatocellular carcinoma and cholangiocarcinoma. J Cl in Invest. 98. 1313-23. 
La Vecchia, C., Negri, E., D' Avanzo, B., Franceschi, S. (I 990). Smoking and renal cell 
carcinoma. Cancer Res. 50. 5231-3. 
Le Buanec, H., D' Anna, R., Lachgar, A., Zagury, J.F., Bernard, J., Ittele, D., 
d' Alessio, P., Hallez, S., Giannouli, C., Burny, A., Bizzini, B., Gallo, R.C., Zagury, D. 
( 1999). HPV -16 E7 but not E6 oncogenic protein trigger both cellular immunosuppression 
and angiogenic processes. Biomed Pharmacother. 53. 424-31. 
LeCouter, J., Kowalski, J., Foster, J., Ha ss, P., Zhang, Z., Dillard-Telm, L., Frantz, 
G., Rangell, L., DeGuzman, L., Keller, G-A., Peale, F., Gurney, A., Hillan, K.J., 
Ferrara, N. (200 I). Identification of an angiogenic mitogen selective for endocrine gland 
endothelium. Nature, 412. 877-84. 
Lee, J., Gray, A., Yuan, J., Luoh, S-M., Avarham, H., Wood, W.I. (1996). Vascular 
endothelial growth factor-related protein: A ligand and specific activator of the tyrosine 
kinase receptor Flt-4. Proc Natl Acad Sci USA. 93. 1988-92. 
237 
Lee, J.S., Kim, H.S., Jung, J.J,. Park, C.S., Lee, M,C. (200 I). Expression of vascular 
endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 
protein expression. J Surg Oncol. 77. 55-60. 
Lee, C., Kim, S.J., Jeong, D.G., Lee, S.M., Ryu, S.E. (2003). Structure of human FIH-1 
reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J 
Bioi Chem. 278. 7558-63. 
Lee, P.J., Jiang, B.H., Chin, B.Y., Iyner, N.V., Alam, J., Semenza, G.L., Choi, A.M. 
(1997). Hypoxia-inducible factor-! mediates transcriptional activation of the heme 
oxygenase-! gene in response to hypoxia. J Bioi Chem. 272. 5375-81. 
Lee, S., Chen, D.Y.T., Humphrey, J.S., Gnarra, J.R., Linehan, W.M., Klausner, R.D. 
( 1996). Nuclear I cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene 
product is determined by cell density. Proc. Natl. Acad. Sci. USA. 93. 1770-5. 
Leek, R.D., Talks, K.L., Pezzella, F., Turley, H., Campo, L., Brown, N.S., Bicknell, R., 
Taylor, M., Gatter, K.C., Harris, A.L. (2002). Relation of hypoxia-inducible factor-2 
alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis 
and the oxidative thymidine phosphorylase pathway in Human breast cancer. CancerRes. 
62. 1326-9. 
Le Jan, S., Amy, C., Cazes, A., Monnot, C., Lamande, N., Favier, J., Philippe, J., 
Sibony, M., Gasc, J.M., Corvol, P., Germain, S. (2003). Angiopoietin-like 4 is a 
proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. 
Am J Pathol. 162. 1521-8. 
Leung, D.W., Cachianes, G. Kuang, W.J., Goeddel, D. V., Ferrara, N. {1989). Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science. 246. 1306-9. 
Leung, S. Y., Chan, A.S.Y., Wong, M.P., Yuen, S.T., Fan, Y.W., Chung, L.P. (1998). 
Expression of vascular endothelial growth factor in von Hippel-Lindau syndrome 
associated papillary cystadenoma of the epididymis. Human Pathology. 29. 1322-4. 
Levy, N.S., Chung, S., Furneaux, H., Levy, A.P. (1998). Hypoxic stabilization of 
vascular endothelial growth factor mRNA by the RN A-binding protein HuR. J. Bioi. 
Chem. 273.6417-23. 
Li, W., Keller, .G. (2000). VEGF nuclear accumulation correlates with phenotypical 
changes in endothelial cells. J Cell Sci. 113. 1525-34. 
Li, X., Aase, K., Li, H., von Euler, G., Eriksson, U. (2001). Isoform-specific expression 
ofVEGF-B in normal tissues and tumors. Growth Factors. 19. 49-59. 
Li, X., Liu, X., Wang, J., Wang, Z., Jiang, W., Reed, E., Zhang, Y., Liu, Y, Li, Q.Q. 
(2003). Effects of thalidomide on the expression of angiogenesis growth factors in human 
A549 lung adenocarcinoma cells. Int J Mol Med. 11. 785-90. 
Lia, T., Collins, C.M.P., Hall, P., Morgan, A.P., Smith, P.J.B., Stonebridge, B.R., 
Symes, M.O. (1993). Verapamil enhances doxorubicin activity in cultured human renal 
carcinoma cells. Eur. J. Cancer. 29A. 378-83. 
238 
Liakopoulos, D., Doenges, G., Matuschewski, K., Jentsch, S. ( 1998). A novel protein 
modification pathway related to the ubiquitin system. EMBO. 17. 2208-14. 
Lindau, A. (1927). Zur Frage der Angiomatosis Retinae und Ihrer Himcomplikation. Acta 
Ophthalmol. 4. 193-226. 
Lindblad, P., Mellemgaard, A., Schlehofer, B., Adami, H.O., McCredie, M., 
McLaughlin, J.K., Mandel, J.S. (1995). International renal cell cancer study: V. 
Reproductive factors gynaecological operations and exogenous hormones. lnt J Cancer. 
61. 192-8. 
Lissoni, P., Fumagalli, L,. Giani, L., RoveUi, F., Confalonieri, G., Pescia, S. (1998). 
Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy 
with IL-2: preliminary considerations. Int J Bioi Markers. 13. 98-10 I. 
Lissoni, P., Rovelli, F., Baiocco, N., Tangini, G., Fumagalli, L. (2001). A phase Il study 
of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell 
carcinoma progressing on interleukin-2 alone. Anticancer Res. 21. 777-9. 
Lissoni, P., Rovelli, F., Malugani, F., Bucovec, Conti, A., Maestroni, G.J. (2001). Anti-
angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett. 22. 
45-7. 
Lisztwan, J., lmbert, G., Wirbelauer, C., Gstaiger, M., Krek, W. (1999). The von 
Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase 
activity. Genes and Development. 13. No 14, 1822-33. 
Liu, L.X., Lu, H., Luo, Y., Date, T., Belanger, A.J., Vincent, K.A., Akita, G.Y., 
Goldberg, M., Cheng, S.H., Gregory, R.J., Jiang, C. (2002). Stabilization of vascular 
endothelial growth factor mRNA by hypoxia-inducible factor I. Biochem Biophys Res 
Commun. 291.908-14. 
Liu, Y., Christou, H., Morita, T., Laughner, E., Semenza, G.L., Kourembanas, S. 
( 1998). Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular 
endothelial growth factor gene via the 5' enhancer. J Bioi Chem. 273. 15257-62. 
Liu, Y., Cox, S.R., Morita, T., Kourembanas, S. (1995). Hypoxia regulates vascular 
endothelial growth factor gene expression in endothelial cells. CircRes. 77. 638-43. 
Ljungberg, B., Jacobsen, J., Haggstrom-Rudolfssson, S., Rasmuson, T., Lindh, G., 
Grankvist, K. (2003). Tumour vascular endothelial growth factor (VEGF) mRNA in 
relation to serum VEGF protein levels and tumour progression in human renal cell 
carcinoma. 31. 335-40. 
Lonergan, K.M., lliopoulos, 0., Ohh, M., Kamura, T., Conaway, R.C., Conaway, 
J.W., Kaelin, W.G. Jr. (1998). Regulation of hypoxia-inducible mRNA by the von 
Hippei-Lindau tumor suppressor protein requires binding to complexes containing elongins 
B/C and Cul2. Mol Cell Bioi. 18. 732-41. 
239 
Lummen, G., Blass-Kampmann, S., Rubben, H., Suhr, J., Otto, T. (2000). Tumor-
infiltrating lymphocytes express vascular endothelial growth factor in renal cell 
carcinomas. Onkologie. 23. 458-62. 
Lundstam, S., Jonsson, 0., Lyrdal, D., Peeker, R., Pettersson, S. (2003). Nephron-
sparing surgery for renal cell carcinoma. Scand J Urol Nephrol. 37. 299-304. 
Maclure, M. (1987). Asbestos and renal adenocarcinoma: A case-control study. Environ 
Res. 42. 353-61. 
Maemura, K., Hsieh, C.M., Jain, M.K., Fukumoto, S., Layne, M.D., Liu, Y.X., 
Kourembanas, S., Yet, S.F., Perrella, M.A., Lee, M.E. (1999). Generation of a 
dominant-negative mutant of endothelial PAS domain protein I by deletion of a potent C-
terminal. J Bioi Chem. 274. 31565-70. 
Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P., Persico, M.G. (1991 ). 
Isolation of a human placenta cDNA coding for a protein related to the vascular 
permeability factor. Proc Natl A cad Sci USA. 88. 9267-71. 
Maglione, D., Guerriero, V., Viglietto, G., Ferraro, M.G., Aprelikova, 0., Alitalo, K., 
Del Vecchio, S., Lei, K-J., Chou, J.Y., Persico, M.G. (1993). Two alternative mRNAs 
coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a 
single gene of chromosome 14. Oncogene. 8. 925-31. 
Maher, E., Kaelin, W.G. (1997). V on Hippei-Lindau disease. Medicine. 76.381-91. 
Maher, E.R., Webster, A.R., Richards, F.M., Green, J.S., Crossey, P.A., Payne, S.J., 
Moo re, A. ( 1996). Phenotypic expression in von Hippei-Lindau disease: correlations with 
germline VHL gene mutations. J Med Genet. 33. 328-32. 
Mahon, P.C., Hirota, K., Semenza, G.L. (200 I). FIH-1: a novel protein that interacts 
with HIF-1 a and VHL to mediate repression of HlF-1 transcriptional activity. Genes Dev. 
15. 2675-86. 
Makinen, T., Olofsson, B., Karpanen, T., Hellman, U., Soker, S., Kiagsbrun, M., 
Eriksson, U., Alitalo, K. (1999). Differential binding of vascular endothelial growth factor 
B splice and Proteolytic isoforms to neuropillin-1. J Bioi Chem. 274. 21217-22. 
Mandel, J.S., McLaughlin, J.K., Schlehofer, B., Mellemgaard, A., Helmert, U., 
Lindblad, P., McCredie, M., Adami, H.O. ( 1995). International renal cell cancer study: 
IV. Occupation. Int J Cancer. 61. 601-5. 
Mandriota, S., Montesano, R., Orci, L., Seghezzi, G., Vassalli, J-D., Ferrara. (1995). 
Vascular endothelial growth factor increases urokinase receptor expression in vascular 
endothelial cells. J. Bioi. Chem. 270. 9709-16. 
Maranchie, J.K., Vasselli, J.R., Riss, J., Bonifacino, J.S., Linehan, W.M., Kiausner, 
R.D. (2002). The contribution ofthe VHL substrate binding and HIF-la to the phenotype 
ofVHL loss in renal cell carcinoma. Cancer Cell. 1. 247-55. 
Martin, C., Yu, A.Y., Jiang, B.H>, Davis, L., Kimberly, D., Hohimer, A.R., Semenza, 
G.L. (1998). Cardiac hypertrophy in chronically anaemic fetal sheep: increased 
vascularization is associated with increased myocardial expression of vascular endothelial 
growth factor and hypoxia-inducible factor 1. Am J Obstet Gynecol. 178. 527-34. 
240 
Martinez, A., Fullwood, P., Kondo, K., Kishida, T., Yao, M., Maher, E.R., Latif, F. 
(2000). Role of chromosome 3p 12-p21 tumour suppressor genes in clear cell renal cell 
carcinoma: analysis ofVHL dependent and VHL independent pathways of tumorigenesis. 
Mol Pathol. 53. 137-44. 
Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, 
J.J., Hankinson, 0., Pugh, C.W., Ratcliffe, P.J. (1997). Hypoxia-inducible factor- I 
modulates gene expression in solid tumors and influences both angiogenesis and tumor 
growth. Proc Natl A cad Sci USA. 94. 8104-9. 
Maxwell, P. H., Wiesener, M.S., Chang, G-W., Clifford, S.C., Vaux, E.C., Cockman, 
M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., Ratcliffe, P.J. (1999). The tumour 
suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent 
proteolysis. Nature. 399. 371-5. 
Mazure, N.M., Brahimi-Horn, M.C., Pouyssegur, J. (2003). Protein kinases and the 
hypoxia-inducible factor- I, two switches in angiogenesis. Curr Pharm Des. 9. 531-41. 
Mazure, N.M., Chen, E. Y., Laderoute, K.R., Giaccia, A.J. ( 1997). Induction of vascular 
endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase Akt 
signalling pathway in Ha-ras-transfonned cells through a hypoxia inducible factor- I 
transcriptional element. Blood. 90. 3322-31. 
McCarron, S.L., Edwards, S., Evans, P.R., Gibbs, R., Dearnaley, D.P., Dowe, A., 
Southgate, C., Easton, D. F., Eeles, R.A., Howell, W.M. (2002). Influence of cytokine 
gene polymorphims on the development of prostate cancer. Cancer Res. 62. 3369-72. 
McCredie, M., Pommer, W., McLaughlin, J.K., Stewart, J.H., Lindblad, P., Mandel, 
J.S., MeUemgaard, A., Schlehofer, B., Niwa, S. ( 1995). International renal cell cancer 
study 11: Analgesics./nt J Cancer. 60. 345-9. 
McGregor, L.M., McCune, B.K., Graff, J.R., McDowell, P.R., Romans, K.E., 
Yancopoulos, G.D., Ball, D.W., Baylin, S.B., Nelkin, B.O. (1999). Roles oftrk family 
neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc 
Natl A cad Sci USA. 96. 4540-5. 
McLaughin, J.K., Blot, W.J., Mehl, E.S., Stewart, P.A., V enable, F.S., Fraumeni, J.F. 
Jr. ( 1985). Petroleum-related employment and renal cell cancer. J Occup Med. 27. 672-4. 
McLaughlin, J.K., Mandel, J.S., Blot, W.J., Schuman, L.M., Mehl, E.S., Fraumeni, 
J.F. Jr ( 1984). A population-based case-control study of renal cell carcinoma. J Natl 
Cancer Inst. 72. 275-84. 
McNeil, L.A., Hewitson, K.S., Claridge, T.D., Seibel, J.F., Horsfall, L.E., Schofield, 
C.J. (2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses 
hydroxylation at the beta-carbon of asparagine-803. Biochem J. 367. 571-5. 
Meitar, D., Crawford, S.E., Rademaker, A.W., Cohn, S.L. (1995). Tumor angiogenesis 
correlates with metastatic disease, N-myc amplification, and poor outcome in human 
neuroblastoma. J Clin Oncol. 14. 405-14. 
Menetrier-Caux, C., Montmain, G., Dieu, M.C., Bain, C.,Favrot, M.C., Caux, C., Blay 
J. Y. ( 1998). Inhibition of the differentiation of dendritic cells from CD34( +) progenitors 
241 
by tumor cells: role ofinterleukin-6 and macrophage colony-stimulating factor. Blood. 92. 
4778-91. 
Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J.H., Stolze, 1., Klinger, 
M., Huang, W.Q., Wotzlaw, C., Hellwig-Burgel, T., Jelkmann, W., Acker, H., 
Fandrey, J. (2003). Intracellular localisation of human HIF-1 alpha hydroxylases: 
implications for oxygen sensing. J Cell Sci. 116. 1319-26. 
Michel, G., Minet, E., Ern est, L., Du rant, F., Remacle, J., Michiels, C. ( 1999). 
Molecular modelling of the hypoxia-inducible factor-! (HIF-1 ). Theor Chem Accounts. 
101. 51-56. 
Michel, G., Minet, E., Ernest, 1., Roland, I., Du rant, F., Remacle, J., Michiels, C. 
(2000). A model for the complex between the hypoxia-inducible factor-! (HIF-1) and its 
consensus DNA sequence. J Biomol Stmc Dynamics. 18. 169-79. 
Migdal, M., Huppertz, B., Tessler, S., Comforti. A., Shibuya, M., Reich, R., Baumann, 
H., Neufeld, G. ( 1998). Neuropilin-1 is a placenta growth factor-2 receptor. J Bioi Chem. 
273. 22272-8. 
Minchenko, A., Bauer. T., Salceda, S., Caro, J. (1994). Hypoxic stimulation of vascular 
endothelial growth factor expression In vitro and In vivo. Lab Invest. 71. No 3, 374-9. 
Minchenko, A., Salceda, S., Bauer, T., Caro, J. ( 1994b). Hypoxia regulatory elements of 
the human vascular endothelial growth factor gene. Cell Mol Bioi Res. 40. 35-9. 
Minchenko, A., Leshchinsky, 1., Opentanova, 1., Sang, N., Srinivas, V., Armstead, V., 
Caro, J. (2002). Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-
2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg 
effect. J Bioi Chem. 277.6183-7. 
Miyajima, A., Asano, T., Seta, K., Asano, T., Kakoi, N., Hayakawa, M. (2003). Loss of 
expression of transforming growth factor-beta receptor a prognostic factor in patients with 
renal cell carcinoma. Urology. 61. I 072-7. 
Miyamoto, K., Khosrof, S., Bursell, S-E., Moromizato, Y., Aiello, L.P., Ogura, Y., 
Adamis, A.P. (2000). Vascular endothelial growth factor (VEGF)-induced retinal vascular 
permeability is mediated by intercellular adhesion molecule- I {I CAM-I). Am J Pathol. 
156. 1733-39. 
Moll, V., Becht, E., Ziegler, M. ( 1993). Kidney preserving surgery in renal cell tumors: 
Indications, techniques, and results in 152 patients. J Urol. 41. 9. 
Morita, R,. Ishikawa, J., Tutsumi, M., Hikiji, K., Tsukada, Y., Kamidono, S., Maeda, 
S., Nakamura, Y. (1991). Allelotype of renal cell carcinoma. Cancer Res. 51.820-3. 
Morita, R., Saito, S., lhikawa, J., Ogawa, 0., Yoshida, 0, Yamakawa, K., Nakamura, 
Y. ( 1991 ). Common regions of deletion on chromosomes 5q, 6q, and I Oq in renal cell 
carcinoma. Cancer Res. 51.5817-20. 
Morohashi, k., Takada, T., Omori, K., Suzuki, E., Gejyo, F. (2003). Vascular 
endothelial growth factor gene polymorphisms in Japanese patient with sarcoidosis. Chest. 
123. 1520-6. 
242 
Motzer, R.J., Bander, N.H., Nanus, D.M. (1996). Renal-cell carcinoma. Mass Med Soc. 
335. 865-75. 
Motzer, R.J., Rakhit, A., Ginsberg, M., Rittweger, K., Vuky, J., Yu, R., Fettner, S., 
Hooftman, L. (2001). Phase I trial of 40-kd branched pegylated interferon alpha-2a for 
patients with advanced renal cell carcinoma. J Cl in Oncol. 19. 1312-9. 
Motzer, R.J., Rakhit, A., Thompson, J., Gurney, H., Selby, P., Figlin, R., Negrier, S., 
Ernst, S., Siebels, M., Ginsberg, M., Rittweger, K., Hooftman, L. (2002). Phase II trial 
of branched peginterferon-alpha 2a (40kDa) for patient with advanced renal cell 
carcinoma. Ann Oncol. 13. 1799-805. 
Mukhopadhyay, D., Knebelmann, B., Cohen, H.T., Ananth, S., Sukhatme, V.P. 
(1997). The von Hippel-Lindau tumor suppressor gene product interacts with Sp I to 
repress vascular endothelial growth factor promoter activity. Mol Cell Bioi. 17. 5629-39. 
Muller, Y.A., Li, B., Christinger, H.W., Wells, J.A., Cunningham, B.C., de V os, A.M. 
(1997). Vascular endothelial growth factor: crystal structure and functional mapping of the 
kinase domain receptor binding site. Proc Natl A cad Sci USA. 94. 7192-7 
Mydlo, J.H., Michaeli, J., Cordon-Cardo, C., Goldenberg, A.S., Heston, W.D., Fair, 
W.R. (1989). Expression of transforming growth factor alpha and epidennal growth factor 
receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer 
Res. 49. 3407-ll. 
Nabors, L.B., Gillespie, G.Y., Harkins, L., King, P.H. (2001). HuR, a RNA stability 
factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich 
elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. 
Cancer Res. 61.2154-61. 
Nagao, K., Yoshihiro, S., Matsuyama, H., Yamaguchi, S., Oba, K., Naito, K. (2002). 
Clinical significance of allelic loss of chromosome region 5q22.3 approximately q23.2 in 
nonpapillary renal cell carcinoma. Cancer Gene/ Cytogenet. 136. 23-30. 
Nakagawa, M., Emoto, A, Hanada, T., Nasu, N., Nomura, Y. (1997). Tubulogenesis by 
microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) 
in renal cell carcinoma. Br J Urol. 19. 681-7. 
Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yang, Q., lmabun, S., Nakahara, M., 
Nakao, K., Nakamura, M., Mori, 1., Kakudo, K. (2003). Prognostic significance of 
vascular endothelial growth factor D in breast carcinoma with long-term follow up. Clin 
Cancer Res. 9. 716-21. 
Nawroth, P., and Stern, D. ( 1988). Modulation of endothelial cell hemostatic properties 
by tumor necrosis factor. J. Exp. Med. 164. 470-8. 
Neckers, L. M. ( 1999). aHIF: The missing link between HIF-1 and VHL. J Natl Cancer 
Inst. 91. No 2, I 06-7. 
Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. (1999). Vascular endothelial 
growth factor (VEGF) and its receptors. F ASEB J. 13. 9-22. 
243 
Neumann, H.P.H., Bender, B.U. ( 1998). Genotype-phenotype correlations in von Hippel-
Lindau disease. J Intern Med. 243. 541-5. 
Nicol, D., Hii, S.l .. , Walsh, M., Teh, B., Thompson, L., Ken nett, C., Gotley, D. ( 1997). 
Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol. 
157. No 4, 1482-6. 
Nowell, P.C. (1976). The clonal evolution oftumor cell population. Science. 194. 23-8. 
O'Byrne, K.J., Dobbs, N., Harris, A.L. (2000). Serum vascular endothelial growth factor 
load and interleukin-6 in cancer patients. Br J Cancer. 82. 1895-6. 
Ogawa, S., Oku, A., Sawano, A., Yamaguchi, S., Yazaki, Y., Shibuya, M. (1998). A 
novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially 
utilizes KDR/Fik-1 receptor and carries a potent mitotic activity without heparin-binding 
domain. J Bioi Chem. 273. 31273-82. 
Ohh, M., and Kaelin, W. G. (1999). The von Hippei-Lindau tumour suppressor protein: 
new perspectives. Molecular Medicine Today. 5. 257-63. 
Ohh, M., Yauch, R.L., Lonergan, K.M., Whaley, J.M., Stemmer-Rachamimov, A.O., 
Louis, D.N., Gavin, B.J., Kley, N., Kaelin, W.G. Jr., Iliopoulos, 0. (1998). The von 
Hippei-Lindau tumor suppressor protein is required for proper assembly of an extracellular 
fibronectin matrix. Mol Cell. 1. 959-68. 
Oikawa, M., Abe, M., Kurosawa, H., Hida, W., Shirato, K., Sato, Y. (2001). Hypoxia 
induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-!. Biochem 
Biophys Res Commun. 289. 39-43. 
Okajima, E., Thorgeirsson, U.P. (2000). Different regulation of vascular endothelial 
growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc 
transformed cells. Biochem Biophys Res Commun. 270. 108-11. 
Oku, T., Tjuvajev, J.G., Miyagawa, T., Sasajima, T., Joshi, A., oshi, R., Finn, R., 
Claffey, K.P., Blasberg, R.G. (1998). Tumor growth modulation by sense and antisense 
vascular endothelial growth factor gene expression: effects on angiogenesis, vascular 
penneability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of 
human melanoma intracerebral xenografts. Cancer Res. 58. 4185-92. 
Ollerenshaw, M., Page, T., Hammonds, J.C., Demaine, A.G. (2004). Hypoxia-inducible 
factor 1 alpha (HIF-1a) polymorphisms are associated with the renal cell carcinoma 
phenotype. Cancer Genetics and Cytogenetics. In Press. 
Olofsson, B., Korpelainen, E., Pepper, M.S., Mandriota, S.J., Aase, K., Kumar, V., 
Gunji, Y., Jeltsch, M.M., Shibuya, M., Alitalo, K., Eriksson, U. (1998). Vascular 
endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates 
plasminogen activator activity in endothelial cells. Proc. Natl. A cad. Sci. US. A. 95. 11709-
14. 
Olofsson, B., Pajusola, K., Kaipainen, A., V on Euler, G., Joukov, V., Saksela, 0., 
Orpana, A., Pettersson, R.F., Alitalo, K., Eriksson, U. (1996a). Vascular endothelial 
growth factor B, a novel growth factor for endothelial cells. Proc. Natl. A cad. Sci. U.S.A. 
93. 2576-81. 
244 
-- - -- - - -----------------------------
Olofsson, B., Pajusola, K., von Euler, G., Chilov, D., Alitalo, K., Eriksson, U. (1996b). 
Genomic organization of the mouse and human genes for vascular endothelial growth 
factor B (VEGF-B) and characterization of a second splice isoform. J Bioi Chem. 271. 
19310-7. 
Olschwang, S., Richard, S., Boisson, C., Giraud, S., Laurent-Puig, P., Resche, F., 
Thomas, G. (1998). Germline mutation profile of the VHL gene in von Hippel-Lindau 
disease and in sporadic hemangioblastoma. Hum Mutat. 12. 424-30. 
Onita, T., Ji, P.G., Xuan, J.W., Sakai, H., Kanetake, H., Maxwell, P.H., Fong, G.H., 
Gabril, M.Y., Moussa, M., Chin, J.L. (2002). Hypoxia-induced, perinecrotic expression 
of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates 
with tumor progression, vascularization, and focal macrophage infiltration in bladder 
cancer. C/in Cancer Res. 8. 471-80. 
Orlandini, M., Marconcini, L., Ferruzi, R., Oliviero, S. ( 1996). Identification of a c-fos-
induced gene that is related to the platelet-derived growth factor/vascular endothelial 
growth factor family. Proc Natl Acad Sci USA. 93. 11675-80. 
Or1andini, M., Oliviero, S. (2001). In fibroblasts Vegf-D expression is induced by cell-
cell contacet mediated by cadherin-11. J Bioi Chem. 276. 6576-81. 
Orlandini, M., Semboloni, S., Oliviero, S. (2003). {beta}-catenin inversely regulates 
VEGF-D mRNA stability. J Bioi Chem. In Press. 
Orlidge, A., D' A more, P.A. ( 1987). Inhibition of capillary endothelial cells by pericytes 
and smooth muscle cells. J Cell Bioi. 105. 1455-62. 
Ornstein, D.K., Lubensky, I.A., Venzon, D., Zbar, B., Linehan, W.M., Walther, M.M. 
(2000). Prevalence of microscopic tumors in normal appearing renal parenchyma of 
patients with hereditary papillary renal cancer. J Urol. 163. 431-3. 
O'Rourke, J.F., Pugh, C.W., Bartlett, S.M., Ratcliffe, P.J. (1996). Identification of 
hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of 
hypoxia-inducible factor-1. Eur J Biochem. 241. 403-10. 
O'Rourke, J.F., Tian, Y -M., Ratcliffe, P.J., Pugh, C.W. (1999). Oxygen-regulated and 
transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible 
factor-! a. J Bioi Chem. 274. 2060-71. 
Ozaki, H., Yu, A.Y., Della, N., Ozaki, K., Luna, J.D., Yamada, H., Hackett, S.F., 
Okamoto, N., Zack, D.J., Semenza, G.L., Campochiaro, P.A. (1999). Hypoxia inducible 
factor 1 a is increased in ischemic retina: temporary spatial correlation with VEGF 
expression. Invest Opthalmol Vis Sci. 40. 182-9. 
Ozawa, K., Kondo, T., Hori, 0., Kitao, Y., Stern, D.M., Eisenmenger, W., Ogawa, S., 
Ohshima, T. (2001). Expression of the oxygen-regulated protein ORP150 accelerates 
wound healing by modulating intracellular VEGF transport. J. C/in.Jnvest. 108. 41-50. 
Paavonen, K., Horelli-Kuitunen, N., Chilov, D., Kukk, E., Pennanen, S., Kallioniemi, 
0-P., Pajusola, K., Olofsson, B., Eriksson, U., Joukov, V., Palotie, A., Alitalo, K. 
(1996). Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C 
localize to chromosomes 11ql3 and 4q34, respectively. Circulation. 93. 1079-82. 
245 
Pajusola, K., Aprelikova, 0., Armstrong, E., Morris, S., Alitalo, K. (1993). Two human 
FL T4 receptor kinase isoforms with distinct carboxyterminal tails are produced by 
alternative processing of primary transcripts. Oncogene. 8. 2931-7. 
Pajusola, K., Aprelikova, 0., Pelicci, G., Weich, H., Claesson-Welsh, L., Alitalo, K. 
( 1994). Signalling properties of FL T4, a proteolytically processed receptor tyrosine kinase 
related to two VEGF receptors. Oncogene. 9. 3545-55. 
Pal, S., Claffey, K.P., Cohen, H.T., Mukhopadhyay, D. (1998). Activation of Sp1-
mediated vascular permeability factor/vascular endothelial growth factor transcription 
requires specific interaction with protein kinase C zeta. J Bioi Chem. 273. 26277-80. 
Pal, S., Claffey, K.P., Dvorak, H.F., Mukhopadhyay, D. (1997). The von Hippel-Lindau 
gene product inhibits vascular permeability factor/vascular endothelial growth factor 
expression in renal cell carcinoma by blocking protein kinase C pathways. J. Bioi. Chem. 
272. 27509-12. 
Palmer, L.A., Semenza, G.L., Stoler, M.H., Johns, R.A. (1998). Hypoxia induces type 11 
NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol. 274. 
212-9. 
Paradis, V., Lagha, N.B., Zeimoura, L., Blanchet, P., Eschwege, P., Ba, N., Benoit, G., 
Jardin, A., Bedossa, P. (2000). Expression of vascular endothelial growth factor in renal 
cell carcinomas. Virchows Arch. 436. 351-6. 
Park, J.E., Chen, H.H., Win er, J., Houck, K.A., Ferrara, N. ( 1994). Placenta growth 
factor. Potentiation of vascular endothelial growth factor bioactivity in vitro and in vivo 
and high affinity binding to Flt-1 but not to Flk-1/KDR. J Bioi Chem. 269. 25646-54. 
Park, J.E., Keller, G.A., Ferrara, N. (1993). The vascular endothelial growth factor 
(VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and 
bioactivity of extracellular matrix-bound VEGF. Molecular Biology of the Cell. 4. 1317-
26. 
Parkin, D.M., Pisani, P., Ferlay, J. ( 1993). Estimates of the worldwide incidence of 
eighteen major cancers in 1985. lnt J Cancer. 54. 594-606. 
Pause, A., Lee, S., Lonergan, K.M., Klausner, R.D. (1998). The von Hippel-Lindau 
tumor suppressor gene is required for ce"ll cycle exit upon serum withdrawal. Proc. Natl. 
Acad. Sci. 95. 993-8. 
Pause, A., Lee, S., Worrell, R.A., Chen, D.Y.T., Burgess, W.H., Linehan, W.M., 
Klausner, R.D. (1997). The von Hippel-Lindau tumor-suppressor gene product forms a 
stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. 
Acad. Sci. 94. 2156-61. 
Pavlovich, C.P., Padilla-Nah, H., Wangsa, D., Nickerson, M.L., Matrosova, V., 
Linehan, W.M., Ried, T., Phillip, J.L. (2003). Pattern of aneuploidy in stage IV clear cell 
renal cell carcinoma revealed by comparative genomic hybridization and spectral 
karyotyping. Genes Chromosomes Cancer. 37. 252-60. 
Pekala, P., Mar low, M., Heuvelman, D., Connolly, D. ( 1990). Regulation of hexose 
transport in aortic endothelial cells by vascular permeability factor and tumor necrosis 
factor-alpha, but not by insulin. J. Bioi. Chem. 265. 18051-4. 
246 
Pelengaris, S., Littlewood, T., Khan, M., Elia, G., Evan, G. ( 1999). Reversible 
activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single 
oncogenic lesion. Mol Cell. 3. 565-77. 
Peng, J., Zhang, L., Drysdale, L., Fong, G-H. (2000). The transcription factor EPAS-1 I 
hypoxia-inducible factor 2a plays an important role in vascular remodelling. Proc Natl 
Acad Sci USA. 97. 8386-91. 
Perera, A.D., K.leymenova, E. V., Walker, C.L. (2000). Requirement for the von Hippei-
Lindau tumor suppressor gene for functional epidennal growth factor receptor blockade by 
monoclonal antibody C225 in renal cell carcinoma. Cl in Cancer Res. 6. 1518-23. 
Perrotte, P., Matsumoto, T., lnoue, K., Kuniyau, H., Eve, B.Y., Hicklin, D.J., 
Radinsky, R., Dinney, C.P. (1999). Anti-epidennal growth factor receptor C225 inhibits 
angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. 
Clin Cancer Res. 5. 257-65. 
Petit, A.M, Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B., Kerbel, R.S. 
(1997). Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases 
down-regulate VEGF production by tumour cells in vitro and in vivo: angiogenic 
implications for signal transduction therapy of solid tumours. Am J Pathol. 151. 1523-30. 
Pioli, P.A., Rigby, W.F.C. (2001). The von Hippei-Lindau protein interacts with 
heteronuclear ribonucleoprotein A2 and regulates its expression. J Bioi Chem. 276. 40346-
52. 
Pisani, P., Parkin, D.M., Ferlay, J. (1993). Estimates of the worldwide mortality from 
eighteen major cancers in 1985: Implications for prevention and projections of future 
burden. In J Cancer. 55. 891-903. 
Plate, K.H., Breier, G., Weich, H.A., Risau, W. (1992). Vascular endothelial growth is a 
potential tumour angiogenesis factor in vivo. Nature. 359. 845-7. 
Plouet, J., Moro, F., Bertagnolli, S., Coldboeuf, N., Mazarguil, H., Clamens, S., 
Bayard, F. (1997). Extracellular cleavage of the vascular endothelial growth factor 189-
amino acid fonn by urokinase is required for its mitogenic effect. J Bioi Chem. 272. 
13390-6. 
P1ouet, J., Schilling, J ., Gospodarowicz, D. ( 1989). I solation and characterization of a 
newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO. 8. 3801-6. 
Poltorak, z., Cohen, T., Sivan, R., Kandelis, Y., Spira, G., Vlodavsky, 1., Keshet, E., 
Neufeld. ( 1997). VEGF 145, a secreted vascular endothelial growth factor isofonn that binds 
to extracellular matrix. J. Bioi. Chem. 272. 7151-8. 
Post, D.E., Van Meir, E.G. (2001). Generation of bi-directional hypoxia/HIF-responsive 
expression vectors to target gene expression to hypoxic cells. Gene Therapy. 8. 1801-7. 
Potgens, A.J., Lubsen, N.H., van Altena, M.C., Vermeulen, R., Bakker, A., 
Schoenmakers, J.G., Ruiter, D.J., de Waal, R.M. (1994). Covalent dimerization of 
vascular penneability factor/vascular endothelial growth factor is essential for its 
biological activity. Evidence from Cys to Ser mutations. J Bioi Chem. 269. 32879-85. 
247 
Presti, J.C., Jr, Rao, P.H., Chen, Q., Reuter, V.E., Li, F.P., Fair, W.R., Jhanwar, S.C. 
(1991). Histopathological, cytogenic, and molecular characterization of renal cortical 
tumors. Cancer Res. 51. 1544-52. 
Pugh, C.W., O'Rourke, J.F., Nagao, M., Gleadle, J.M., Ratcliffe, P.J. (1997). 
Activation of hypoxia-inducible factor-1: definition of regulatory domain within the alpha 
subunit. J Bioi Chem. 272. 11205-14. 
Pulkkanen, K.J., Parkkinen, J.J., Kettunen, M.I., Kauppinen, R.A., Lappalainen, M., 
Ala-Opas, M. Y., Yla-Herttuala, S. (2000). Characterization of a new animal model for 
human renal cell carcinoma. In Vivo. 14. 393-400. 
Punglia, R.S., Lu, M., Hso, J., Kuroki, M., Tolentino, M.J., Keough, K., Levy, A.P., 
Levy, N.S., Goldberg, M.A., D' Amato, J., Adamis, A.P. ( 1997). Regulation of vascular 
endothelial growth factor expression by insulin-like growth factor I. Diabetes. 46. 1619-26. 
Pyrhonen, S., Sa.lminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., 
Juuela, H., Rintala. E., Hietanen, P., Kellokumpu-Lehtinen, P.L. (1999). Prospective 
randomised trial of interferon alpha-2a plus vinblastine versus vinblastine alone in patients 
with advanced renal cell carcinoma. JC/in Onco/.11. 2859-67. 
Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shiraawa, S., Sasazuki, T., Kerbel, R.S. 
(1995). Mutant ras oncogenes upregulate VEGFNPF expression: implications for 
induction and inhibition oftumor angiogenesis. Cancer Res. 55. 4575-80. 
Rak, J., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria-Petit, A., Filmus, J., 
Mansour, S.J., Ahn, N.G. Kerbel, R.S. (2000a). Oncogenes and tumor angiogenesis: 
differential modes of vascular endothelial growth factor up-regulation in ras-transformed 
epithelial cells and fibroblasts. Cancer Res. 60. 490-8. 
Rak, J., Yu, J.L., Klement, G., Kerbel, R.S. (2000b). Oncogenes and angiogenesis: 
signalling three-dimensional tumor growth. J Invest Dermatol Symp Proc. 5. 24-33. 
Ramp, U., Reinbeck, P., Gabbert, H.E., Gerharz, C.D. (2000). Differential response to 
transforming growth factor (TGF) alpha and fibroblast growth factor (FGF) in human renal 
cell carcinomas of clear cell and papillary types. Eur J Cancer. 36. 932-41. 
Ratcliffe, P. J., O'Rourke, J.F., Maxwell, P.H., Pugh, C.W. (1998). Oxygen sensing, 
hypoxia-inducible factor- I and the regulation of mammalian gene expression. Journal of 
Experimental biology. 201. 1153-62. 
Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., 
Dillehay, L.E., Madan, A., Semenza, G.L., Dedi, A. (2000). Regulation oftumor 
angiogenesis by p53-induced degradation of hypoxia-inducible factor la.. Genes Dev. 14. 
34-44. 
Relf, M., LeJeune, S., Scott, P.A.E., Fox, S., Smith, K., Leek, R., Moghaddam, A., 
Whitehouse, R., Bicknell, R., Harris, A.L. ( 1997). Expression of the angiogenic factors 
vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor 
growth factor 13-I, platelet-derived endothelial growth factor, placenta growth factor, and 
pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 
57.963-9. 
248 
Renner, W., Kotchan, S., Hoffmann, C., Obermayer-Pietsch, B., Pilger, E. (2000). A 
common 936 C/T mutation in the gene for vascular endothelial growth factor is associated 
with vascular endothelial growth factor plasma levels. J Vase Res. 37. 443-8. 
Richard, D.E., Berra, E., Gothie, E., Roux, D., Pouyssegur, J. (1999). p42/p44 mitogen-
activated protein kinases phosphorylate hypoxia-inducible factor la (HIF-la) and enhance 
the transcriptional activity of HIF-1. J Bioi Chem. 274. 32631-7. 
Rioux-Leclercq, N., Epstein, J.I., Bansard, J.Y., Turlin, B., Patard, J.J., Manunta, A., 
Chan, T., Ramee, M.P., Lobel, B., Moulinoux, J.P. (2001 ). Clinical significance of cell 
proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell 
carcinoma. Hum. Pathol. 32. I 009-1 5. 
Rivard, A., Berthou-Soulie, L., Principe, N., Kearney, M., Curry, C., Branellec, D., 
Semenza, G.L., lsner, J.M. (2000). Age-dependent defect in vascular endothelial growth 
factor expression is associated with reduced hypoxia-inducible factor I activity. J. Bioi. 
Chem. 275.29643-7. 
Roach, P.L., Clifton, I.J., Fulop, V., Harlos, K., Barton, G.J., Hajdu, J., Andersson, I., 
Schofield, C.J., Baldwin, J.E. (1995). Structure of isopenicillin N synthase is the first 
from a new structural family of enzymes. Nature. 375. 700-4. 
Robert, B., St John, P.L., Abrahamson, D.R. ( 1998). Direct visualization of renal 
vascular morphogenesis in Flkl mutant mice. Am J Physiol. 275. 164-72. 
Robson, C.J. (1963). Radical nephrectomy for renal cell carcinoma. J Urol. 89. 37. 
Rolfs, A., Kvietikova, I., Gassmann, M., Wenger, R.H. ( 1997). Oxygen-regulated 
transferrin expression is mediated by hypoxia-inducible factor-1. J Bioi Chem. 272. 20055-
62. 
Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, 
S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T., Seipp, C.A., Simpson, C., 
Reichert, C.M. (1985). Observations on the systemic administration of autologous 
lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic 
cancer. N Engl J Med. 313. 1485-92. 
Rousseau, S., Houle, F., Landry, J., Huot, J. ( 1997). P38 Map kinase activation by 
vascular endothelial growth factor mediates actin reorganization and cell migration in 
human endothelial cells. J Bioi Chem. 15. 2169-77. 
Ryan, H.E., Lo, J., Johnson, R.S. (1998). H1F-1 a is required for solid tumor formation 
and embryonic vascularization. EMBO. 11. 3005-15. 
Ryan, H.E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J.M., 
Johnson, R.S. (2000). Hypoxia-inducible factor-1 a is a positive factor in solid tumor 
growth. Cancer Res. 60. 40 I 0-5. 
Saez, E., Rutberg, S.E., Mueller, E., Oppenheim, H., Smoluk, J., Yupa, S.H., 
Spiegelman, B.M. (1995). c-Fos is required for malignant progression for kin tumors. 
Cell. 82. 721-32. 
249 
Sakashita, N., takeya, M., Kishida, T., Stackhouse, T.M., Zbar, B., Takahashi, K. 
( 1999). Expression of von Hippei-Lindau protein in nonnal and pathological human 
tissues. The Histochem J. 31. 133-44. 
Salceda. S., Caro, J. ( 1997). Hypoxia-inducible factor I a (HIF-1 a) protein is rapidly 
degraded by the ubiquitin-protcosome system under normoxic conditions. J Bioi Chem. 
272.22642-7. 
Salome, F. Colombeau, P., Fermeaux, V., Cazaux, P., Dumas, J.P., Pfeifer, P., 
Moreau, J.S., Richard, S., Labrousse, F. ( 1998). Renal lesions in von Hippel-Lindau 
disease: the benign, the malignant, the unknown. Eur Urol. 34. 383-92. 
Sargent, E.R., Gomella, L.G., Belldegrun, A., Linehan, W.M., Kasid, A. (1989). 
Epidermal growth factor receptor gene expression in nonnal human kidney and renal cell 
carcinoma. J Vrol. 142. 1364-8. 
Sasamura, H., Takahashi A., Miyao, n., Yanase, M., Masumori, N., Kitamura, H., 
Itoh, N., Tsukamoto, T. (2002). Inhibitory effect on expression of angiogenic factors by 
antiangiogenic agents in renal cell carcinoma. Br. J. Cancer. 86. 768-73. 
Sato, K., Terada, K., Sugiyama, T., Takahashi, S., Saito, M., Moriyama, M., 
Kakinuma, H. Suzuki, Y., Kato, M., Kato, T. (1994). Frequent over expression of 
vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J Exp Med. 
173. 355-60. 
Sato, K., Tsuchiya, N., Sasaki, R., Shimoda, N., Satoh, S., Ogawa, 0., Kato, T. (1999). 
Increased serum levels of vascular endothelial growth factor in patients with renal cell 
carcinoma. Jpn J Cancer Res. 90. 874-9. 
Scatena, M., Almeida, M., Chaisson, M.L., Fausto, N., Nicosia, R.F., Giachelli, C.M. 
(1998). NF-KB mediates av~J integrin-induced endothelial cell survival. J Cell Bioi. 141. 
1083-93. 
Scheel, J., Hussong, R., Schrenk, D., Schmitz, H-J. (2002). Variability o fthc human 
aryl hydrocarbon receptor nuclear translocator (ARNT) gene. J Hum Genet. 47. 217-24. 
Schoenfeld, A., Davidowitz, E.J., Burk, R.D. ( 1998). A second major native von 1-Iippei-
Lindau gene product, initiated from an internal translation start site, functions as a tumor 
suppressor. Proc. Natl. Acad. Sci. U.S.A. 95. 8817-22. 
Schoenfeld, A., Davidowitz, E.J, Burk, R.D. (2000). Elongin BC complex prevents 
degradation ofvon 1-Iippei-Lindau tumor suppressor gene products. Proc. Natl. Acad. Sci. 
V.S.A. 97.8507-12. 
Schoenfeld, A., Davidowitz, E.J., Burk, R.D. (200 I). Endoplasmic reticulum/cytosolic 
localization ofvon Hippei-Lindau gene products is mediated by a 64 amino acid region. Jnt 
J Cancer. 91.457-67. 
Schmidinger, M., Steger, G., Wenzel, C., Locker, G.J., Budinsky, A.C., Brodowicz, T., 
Kramer, G., Marberger, M., Zielinski, C. C. (200 I). Sequential administration of 
interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell 
carcinoma: results of a phase 11 trial. J Jmmunother. 24. 257-62. 
250 
Schmidinger, M., Steger, G.G., Wenzel, C., Locker, G.J., Brodowicz, T., Budinky, 
A.C., Wiltschke, C., Kramer, G., Marberger, M., Zielinski, C.C. (2000). Sequential 
administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: 
results of a phase Il triaL Austrian renal cell carcinoma study group. Cancer Jmmunol 
Jmmunother. 49. 395-400. 
Schraml, P., Hergovitz, A., Hatz, F., Amin, M.B., Lim, S.D., Krek, W., Mihatsch, 
M.J., Moch, H. (2003). Relevance of nuclear and cytoplasmic von Hippel-Lindau protein 
expression for renal carcinoma progression. Am J Pathol. 163. I 013-20. 
Schultz, A., Lavie, L., Hochberg, 1., Beyar, R., Stone, T., Skorecki, K., Lavie, P., 
Roguin, A., Levy, A.P. (1999). lnterindividual heterogeneity in the hypoxic regulation of 
VEGF: significance for the development of the coronary artery collateral circulation. 
Circulation. 100. 547-52. 
Schumacher, B., Pecher, P., von Specht, B.U., Stegmann, T. (1998). Induction of 
neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of 
a new treatment of coronary heart disease. Circulation. 91. 645-50. 
Scott, P .A.E., Gleadle, J.M., Bicknell, R., Harris, A.L. ( 1998). Role of the hypoxia 
sensing system, acidity and reproductive hormones in the variability of vascular 
endothelial growth factor induction in human breast carcinoma cell lines. Jnt J Cancer. 75. 
706-12. 
Scott, P.A.E., Smith, K., Bicknell, R., Harris, A.L. ( 1997). A reliable external control for 
ribonuclease protection assays. Nucleic Acids Res. 25. 1305-6. 
Seetharam, L., Gotoh, N., Maru, Y., Neufeld, G., Yamaguchi, S., Shibuya, M. ( 1995). 
A unique signal transduction from FL T tyrosine kinase, a receptor for vascular endothelial 
growth factor VEGF. Oncogene. 10. 135-47. 
Seizinger, B.R., Rouleau, G.A., Ozelius, L.J., Lane, A.H., Farmer, G.E., Lamiell, J.M., 
Haines, J., Yuen, J.W.M., Collins, D., Majoor-Krakauer, D., Bonner, T., Mathew, C., 
Rubenstein, A., Halperin, S., McConkie-Rosell, A., Green, J.S., Trofatter, J.A., 
Ponder, B.A., Eierman, L., Bowmer, M.I., Schimke, R., Oostra, B., Aronin, N., Smith, 
D.l., Drabkin, H., Waziri, M.H., Hobbs, W.J., Martuza, R.L., Conneally, P.M., Hsia, 
Y.E., Gusella, J.F. (1988). von Hippei-Lindau disease maps to the region of chromosome 
3 associated with renal cell carcinoma. Nature. 332. 1599-604. 
Semenza, G. L. ( 1996). Transcriptional regulation by hypoxia-inducible factor I: 
molecular mechanisms of oxygen homeostasis. TCM6. No 5, 151-7. 
Semenza, G.L., Agani, F., Feldser, D., Iyer, N., Kotch, L., Laughner, E., Yu, A. (2000). 
Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Bioi. 
475.123-30. 
Semenza, G.L., Agani, F., Iyer, N., Kotch, L., Laughner, E., Leung, S., Yu, A.M. 
(1999). Regulation of cardiovascular development and physiology by hypoxia-inducible 
factor 1. Annals NY Acad Sci. 874. 262-8. 
Semenza, G.L., Dureza, R.C., Traystman, M.D., Gearhart, J.D., Antonarakis, S.E. 
(1990). Human erythropoietin gene expression in transgenic mice: multiple transcription 
initiation sites and cis-acting regulatory elements. Mol Cell Bioi. 10. 930-8. 
251 
Semenza, G.L., Jiang, B-H., Leung, S.W., Passantino, R., Concordet, -P., Maire, P., 
Giallongo, A. (1996). Hypoxia response elements in the alsolase A, Endolase I, and 
lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-
inducible factor I. J Bioi Chem. 271. 32529-37. 
Semenza, G.L., Koury, S.T., Nejfelt, M.K., Gearhart, J.D., Antonarakis, S.E. (1991). 
Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in 
transgenic mice. Proc Natl Acad Sci USA. 88. 8725-9. 
Semenza, G.L., Nefelt, M.K., Chi, S.M., Antonarakis, S.E. ( 1991 ). Hypoxia-inducible 
nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. 
Proc Natl Acad Sci USA. 88. 5680-4. 
Semenza, G.L., Roth, P.H., Fang, H.M., Wang, G.L. (1994). Transcriptional regulation 
of genes encoding glycolytic enzymes by hypoxia inducible factor I. J Bioi Chem. 269. 
23757-63. 
Semenza, G.L., Rue, E.A., Iyer, N. V., Pang, M.G., Kearns, W.G. (1996). Assignment of 
the hypoxia-inducible factor I a gene to a region of conserved synteny on mouse 
chromosome 12 and human chromosome I. Genomics. 34.437-9. 
Semenza, G.L., Traystman, M.D., Gearhart, J.D., Antonarakis, S.E. (1989). 
Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc Natl 
AcadSci USA. 86.2301-5. 
Semenza, G.L., Wang, G.L. ( 1992). A nuclear factor induced by hypoxia via de novo 
protein synthesis binds to the human erythropoietin gene enhancer at a site required for 
transcription activation. Mol Cell Bioi. 12. 5447-54. 
Semenza, G.L., Wang, G.L., Kundu, R. (1995). DNA binding and transcriptional 
properties of wild-type and mutant fonns of the homeodomain protein Msx2. Biochem 
Biophys Res Commun. 209. 257-62. 
Semenza, J.C., Ziogas, A., Largent, J., Peel, D., Anton-Culver, H. (2001). Gene-
environment interactions in renal cell carcinoma. Am J Epidemiol. 153. 851-9. 
Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. 
( 1983). Tumor cells secrete a vascular penneability factor that promotes accumulation of 
ascites fluid. Science. 219. 983-5. 
Senger, D.R., Van de Water, L., Brown, L.F., Nagy, J.A., Yeo, K.T., Yeo, T.K., Berse, 
B., Jackman, R.W., Dvorak, A.M., Dvorak, H.F. (1993). Vascular penneability factor 
(VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12. 303-24. 
Sergeant, A., Saute, S., Leprince, D., Begue, A., Rommens, C., Stehelin, D. ( 1982). 
Molecular cloning and characterization of the chicken DNA locus related to the oncogene 
erbB of avian erythroblastosis virus. EMBOJ. 1. 237-42. 
Shahbazi, M., Fryer, A.A., Pravica, V., Brogan, I.J., Ramay, H.M., Hutchinson, I. V., 
Harden, P.N. (2002). Vascular endothelial growth factor gene polymorphisms are 
associated with acute renal allograft rejection. JAm Soc Nephrol. 13. 260-4. 
252 
Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertentein, M., Wu, X.F., Breitman, M.L., 
Schuh, A.C. ( 1995). Failure of blood island formation and vasculogenesis in Flk-1-
deficient mice. Nature. 376. 62-6. 
Sheibani, N., Frazier, W.A. (1996). Repression ofthrombospondin-1 expression, a 
natural inhibitor of angiogenesis, in polyoma middle T transformed NIH 3T3 cells. Cancer 
Lett. 107. 45-52. 
Shi, Q, Le, X., Abbruzzese, J.L., Peng, Z., Qian, C-N., Tang, H., Xiong, Q., Wang, B., 
Li, X-C., Xie, K. (200 I). Constitutive Sp I activity is essential for differential constitutive 
expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. 
Cancer Res. 61.4143-54. 
Shi, W., Siemann, D.W. (2002). Inhibition of renal cell carcinoma angiogenesis and 
growth by anti sense oligonucleotides targeting vascular endothelial growth factor. Br J 
Cancer. 87. 119-26. 
Shibata, T., Giaccia, A.J., Brown, J.M. (2000). Development of a hypoxic-responsive 
vector for tumor-specific gene therapy. Gene Ther. 7. 493-8. 
Shibuya, M., Yamaguchi, S., Yamane, A., lkeda, T., Tojo, A., Matsushime, H., Sato, 
M. ( 1990). Nucleotide sequence and expression of a novel human receptor type tyrosine 
kinase gene (jlt) closely related to thefms family. Oncogene. 5. 519-24. 
Shibuya, M., Ito, N., Claesson-Welsh, L. ( 1999). Structure and function of vascular 
endothelial growth factor receptor-1 and -2. Curr Top Microbial Jmmunol. 237. 59-83 
Shih, S-C., Claffey, K.P. ( 1999). Regulation of human vascular endothelial growth factor 
mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Bioi Chem. 
274. 1359-65. 
Shimazui, T., Giroldi, L.A., Bringuier, P.P., Oosterwijk, E., Schalken, J.A. ( 1996). 
Complex cadherin expression in renal cell carcinoma. Cancer Res.56. 3234-7. 
Shing, Y., Folkman, ., Sullivan, R., Butterfield, C., Murray, J., Klagsbrun, M. (1984). 
Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. 
Science. 223. 1296-9. 
Shweiki, D., ltin, A., Soffer, D., Keshet, E. (1992). Vascular endothelial growth factor 
induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359. 843-5. 
Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G., Marme, D. 
( 1996). Reversion of deregulated expression of vascular endothelial growth factor in 
human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 
56. 2299-301. 
Silvestre, J.S., Tamarat, R., Ebrahimian, T.G., Le-Roux, A., Clergue, M., Emmanuel, 
F., Duriez. M., Schwartz, B., Branellec, D., Levy, B.I. (2003). Vascular endothelial 
growth factor-B promotes in vivo angiogenesis. Cir Res. 93. 114-23. 
Sin, N., Meng, L., Wang, W.Q., Wen, J.J., Bornmann, W.G., Crews, C.M. (1997). The 
anti-angiogenic agent Fumagillin covalently binds and inhibits the methionine 
aminopeptidase, MetAP-2. Proc Natl A cad Sci USA. 94. 6099-l 03. 
253 
Singh, R.K., et a/ ( 1995). lnterferons a and ~ down-regulate the expression of basic 
fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 92. 4562-6. 
Slaton, J.W., lnoue, K., Perrrotte, P., EI-Naggar, A.K., Swanson, D.A., Fidler, I.J., 
Dinney, C.P. (200 I). Expression levels of genes that regulate metastasis and angiogenesis 
correlate with advanced pathological stage of renal cell carcinoma. Am Pathol. 158. 735-
43. 
Smith, L.E.H., Shen, W., Perruzzi, C., Soker, S., Finose, F., Xu, X., Robinson, G., 
Driver, S., Bischoff, J., Zhang, B., Schaeffer, J.M., Senger, D.R. (1999). Regulation of 
vascular endothelial growth factor-dependent retinal neovascularization by insulin-like 
growth factor-! receptor. Nat Med. 5. 1390-5. 
Soker, S., Takashima, S., Miao, H., Neufeld, G., Klagsbrun, M. (1998). Neuropilin-1 is 
expressed by endothelial and tumor cells as an isoform-specific receptor for vascular 
endothelial growth factor. Cell. 92. 735-45. 
Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G., Bussolino, F. (1999). Role of 
av~3 in the activation ofvacular endothelial growth factor receptor-2. EMBO J. 18. 882-92. 
Sondergaard, K.L., Hilton, D.A., Penney, M., OUerenshaw, M., Demaine, A.G. (2002). 
Expression of hypoxia-inducible factor I alpha in tumours of patients with glioblastoma. 
Neuropathol. Appl. Neurobiol. 3. 210-7. 
Song, K.H., Song,., Jeong, G.B., Kim, J.M., Jung, S.H., Song, J. (2001). Vascular 
endothelial growth factor- its relation to neovascularization and their significance as 
prognostic factors in renal cell carcinoma. Yonsei Med J. 42. 539-46. 
Srinivas, V., Zhu, X., Salceda, S., Nakamura, R., Caro, J. (1998). Hypoxia-inducible 
factor la {HIF-Ia) is a non-heme iron protein. J Bioi Chem. 273. 18019-22. 
Stacker, S.A., Vitali, A., Caesar, C., Domagala, T., Groenen, L.C., Nice, E., Achen, 
M.G., Wilks, A.F. (1999). A mutant fonn ofvacular endothelial growth factor (VEGF) 
that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J 
Bioi Chem. 274. 34884-92. 
Stadler. W.M., et al (1999). Multi-institutional study of the angiogenesis inhibitor TNP-
470 in metastatic renal carcinoma. J Cl in Onco/. 17. 2541-5. 
Stalmans, 1., Ng., Y-S., Rohan, R., Fruttiger, M., Bouche, A., Yuce, A., Fujisawa, H., 
Hermans, B., Shani, M., Jansen, S., Hicklin, D., Anderson, D.J., Gardiner, T., 
Hammes, H-P., Moons, L., Dewerchin, M., Collen, D., Carmeliet, P., D' Amore, P. 
(2002). Arteriolar and venular patteming in retinas of mice selectively expressing VEGF 
isoforms. J. C/in. Invest. 109. 327-36. 
Stebbing, J., Benson, C., Eisen, T., Pyle, L., Smalley, K., Bridle, H., Mak, 1., Sapunar, 
F., Ahern, R., Gore, M.E. (200 I). The treatment of advanced renal cell cancer with high-
dose oral thalidomide. Br J Cancer. 85. 953-8. 
Stebbins, C. E., Kaelin, W.G. Jr., Pavletich, N.P. (1999). Structure of the VHL-Eiongin 
C-Elongin B complex: Implications for VHL tumor suppressor function. Science. 284. 
455-61. 
254 
Stein, 1., Neeman, M., Shweiki, D., Itin, A., Keshet, E. ( 1995). Stabilization of vascular 
endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with 
other ischemia-induced genes. Mol Cell Bioi. 15. 5363-8. 
Steiner, T.H., Junker, U., Wunderlich, H., Schubert, J. (1999). Are renal cell carcinoma 
cells able to modulate the cytotoxic effect oftumor infiltrating lymphocytes by secretion of 
interleukin-6? Anticancer Res. 19. 1533-6. 
Stenflo, J., Holme, E., Lindstedt, S., Chandramouli, N., Huang, L.H.T., Tarn, J.P., 
Merrifield, R.B. ( 1989). Hydroxylation of aspartic acid in domains homologous to the 
epidennal growth-factor precursor is catalysed by a 2-oxoglutarate-dependent 
dioxygenase. Proc Natl Acad Sci USA. 86.444-7. 
Stevens, A., Soden, J., Brenchley, P.E., Ralph, S., Ray, D.W. (2003). Haplotype analysis 
of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 
63. 812-6. 
Storkel, S., & van den Berg. ( 1995). Morphological cl as si fication of renal cancer. World 
J Urol. 13. 153-8. 
Stratmann, R., Krieg, M., Ha as, R., Plate, K.H. ( 1997). Putative control of angiogenesis 
in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropathol 
Exp Neural. 56. 1242-52. 
Sutter, C.H., Laughner, E., Semenza, G.L. (2000). Hypoxia-inducible factor la protein 
expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions 
and missense mutations. Proc Natl Acad Sci USA. 97. 4748-53. 
Takagi, Y., Pause, A., Conaway, R.C., Conaway, J.W. (1997). Identification of elongin 
C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein. 
J. Bioi. Chem. 272. 27444-49. 
Takahama, M., Tsutsumi, M., Tsujiuchi, T., Nezu, K., Kushibe, K., Taniguchi, S., 
Kotake, Y ., Konishi, Y. ( 1999). Enhanced expression of Tie2, its ligand angiopoietin-1, 
vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. 
Clin. Cancer. Res. 5. 2506-10. 
Takahashi, A., Sasaki, H., Kim, S.J., Kakizoe, T., Miyao, N., Sugimura, T., Terada, 
M., Tsukamoto, T. ( 1999). Identification of receptor genes in renal cell carcinoma 
associated with angiogenesis by differential hybridisation technique. Biochem. Biophy. Res 
Commun. 257. 855-9. 
Takahashi, A., Sasaki, H., Kim, S.J., Tobisu, K., Kakizoe, T., Tsukamoto, T., 
Kumamoto, Y., Sugimura, T., Terada, M. (1994). Markedly increased amounts of 
messenger RN As for vascular endothelial growth factor and placenta growth factor in renal 
cell carcinoma associated with angiogenesis. Cancer Res. 54. 4233-7. 
Takahashi, T., Shibuya, M. (1997). The 230 kDa mature fonn ofKDR/Fik-1 (VEGFR-2) 
activates the PLC-y pathway and partially induces mitotic signals in NIH3T3 fibroblasts. 
Oncogene. 14. 2079-89. 
Takahashi, Y., Takahashi, S., Shiga, Y., Yoshimi, T., Miura, T. (2000). Hypoxic-
induction ofprolyl-4-hydroxylase alpha (I) in cultured cells. J Bioi Chem. 275. 14139-46. 
255 
Talks, K.L., Turley, H., Gatter, K.C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., 
Harris, A.L. (2000). The expression and distribution of the hypoxia-inducible factors HIF-
1 a and HIF-2a in normal human tissues, cancers, and tumor-associated macrophages. Am 
J Pathol. 157.411-21. 
Tanimoto, K., Makino, Y., Pereira, T., Poellinger L. (2000).Mechanism of regulation of 
the hypoxia-inducible factor- I alpha by the von Hippei-Lindau tumor suppressor protein. 
EMBO. 19.4298-309. 
Tanimoto, K., Yoshiga, K., Eguchi, H., Kaneyasu, M., Ukon, K., Kumazaki, T., Oue, 
N., Yasui, W., Imai, K., Nakachi, K., Poellinger, L., Nishiyama, M. (2003). Hypoxia-
inducible factor- I alpha polymorphisms associated with enhanced transactivation capacity, 
implying clinical significance. Carcinogenesis. 24. 1779-83. 
Tate, J., Olencki, T., Finke, J., Kottke-Marchant, K., Rybicki, L.A., Bukowski, R.M. 
(2001). Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with 
renal-cell carcinoma: clinical and laboratory effects. Ann Oncol. 12. 655-9. 
Thelen, P., Hemmerlein, B., Kugler, A., Seiler, T., Ozisik, R., Kallerhoff, M., Ringert, 
R-H. (1999). Quantification by competitive quantitative RT-PCR ofVEGF121 and 
VEGF165 in renal cell carcinoma. Anticancer Res. 19. 1563-6. 
Thrash-Bingham, C.A., Greenberg, R.E., Howard, S., Bruzel, A., Bremer, M., Goll, 
A. Salazar, H., Freed, J.J., Tartof, K.D. (1995). Comprehensive allelotyping of human 
renal cell carcinomas using microsatellite DNA probe. Proc Natl A cad Sci USA. 92. 2854-
8. 
Thrash-Bingham, C.A., Salazar, H., Freed, J.J., Greenberg, R.E., Tartof, K.D. (1995). 
Genomic alterations and instabilities in renal cell carcinomas and their relationship to 
tumor pathology. Cancer Res. SS. 6189-95. 
Thrash-Bingham, C. A., and Tartof, K. D. ( 1999). aHIF: a natural anti sense transcript 
overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst. 91. 143-51. 
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J., 
Abraham, J.A. ( 1991 ). The human gene for vascular endothelial growth factor: Multiple 
forms are encoded through alternative exon splicing. J. Bioi. Chem. 266. 11947-54. 
Tomisawa, M., Tokunaga, T., Oshika, Y., Tsuchida, T., Fukushima, Y., Satp, H., 
Kijima, H., Yamazaki, H., Ueyama, Y., Tamaoki, N., Nakamura, M. (1999). 
Expression pattern of vascular endothelial growth factor isoform is closely correlated with 
tumour stage and vascularization in renal cell carcinoma. Eur J Cancer. 35. 133-7. 
Tricarico, C., Salvadori, B., Villari, D., Nicita, G., Della Meelina, A., Pinzani, P., 
Ziche, M., Pazzagli, M. (1999). Quantative RT-PCR assay for VEGF mRNA in human 
tumors of the kidney. Jnt J Bioi Markers. 14. 247-50. 
Troaneck, B., Niemitz, S., Micka, B., Lefterova, P., Blasczyk, R., Scheffold, C., Huhn, 
D., Schmidt-Wolf, I.G.H. (2000). Establishment and characterization of colon carcinoma 
and renal cell carcinoma primary cultures. Cancer Biotherapy Radiopharma. IS. 169-74. 
Tsuchida, K., Makita, Z., Yamagishi, S., Atsumi, T., Miyoshi, H., Obara, S., Ishida, 
M., Ishikawa, S., Yasumura, K., Koike, T. (1999). Suppression of transforming growth 
256 
factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a 
novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 42. 579-88. 
Tsuchiya, N., Sato, K., Akao, T., Kakinuma, H., Sasaki, R., Shimoda, N., Satoh, S., 
Habuchi, T., Ogawa, 0., Kato, T. (200 I). Quantitative analysis of gene expressions of 
vascular endothelial growth factor-related factors and their receptors in renal cell 
carcinoma. Tohoku J Exp Med. 195. 101-13. 
Tsui, K-H., Shvarts, 0., Smith, R.B., Figlin, R., DeKernion, J.B., Belldegrun, A. 
(2000). Renal cell carcinoma: prognostic significance of incidentally detecting tumors. J 
Urol. 163.426-30. 
Tsurusaki, T., Kanda, S., Sakai, H,. Kanetake, H., Saito, Alitalo, K., Koji, T. (1999). 
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its 
relationship to lymph node metastasis.Br J Cancer. 80. 309-13. 
Tsutsui, S., Ohno, S., Murakami, S., Kataoka, A., Kinoshita, J., Hachitanda, Y. 
(2003). Prognostic value of the combination of epidermal growth factor receptor and c-
erbB-2 in breast cancer. Surgery. 133. 219-21. 
Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., Jain, R.K. (2000). 
Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible 
factor-! a ~ hypoxia response element ~ VEGF cascade differentially regulates vascular 
response and growth rate. Cancer Res. 60. 6248-52. 
Turner, D.M., Williams, D.M., Sankaran, D., Lazarus, M., Sinnnott, P .. , Hutchinson, 
I.V. (1997). An investigation ofpolymorphism in the interleukin-10 gene promoter. EurJ 
lmmunogenet. 24. 1-8. 
Turner, K.J., Moore, J.W., Jones, A., Taylor, C.F., Cuthbert-Heavens, D., Han, C., 
Leek, R.D., Gatter, K.C., Maxwell, P.H., Ratcliffe, P.J., Cranston, D., Harris, A.L. 
(2002). Expression of hypoxia-inducible factors in human renal cancer: Relationship to 
angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 62. 2957-61. 
Uhlman, D.L., Nguyen, P., Manivel, J.C., Zhang, G., Hagen, K., Fraley, E., Aeppli, 
Niehans, G.A. ( 1995). Epidermal growth factor receptor and transforming growth factor 
alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with 
metastatic behaviour and prognosis. Clin Cancer Res. 1. 913-20. 
U nemori, E., Ferrara, N., Orci, L., Montesano, R. ( 1992). Vascular endothelial growth 
factor induces interstitial collagenase expression in human endothelial cells. J. Cell. 
Physiol. 153. 557-62. 
Uwatoko, N., Tokunaga, T., Hatanaka, H., Osada, H., Kawakami, T., Yamazaki, H., 
A be, Y., kijima, H., Ueyama, Y., Nakamura, M. (2002). Expression of interleukin-1 0 is 
inversely correlated with distant metastasis of renal cell carcinoma. Jnt. J. Oncol. 20. 729-
33. 
Uzzo, R.G., Rayman, P., Kolenko, V., Clark, P.E., Cathcart, M.K., Bloom, T., Novick, 
A.C., Bukowski, R.M., Hamilton, T., Finke, J.H. (1999). Renal cell carcinoma-derived 
gangliosides suppress nuclear factor-KB activation in T cells. J Cl in Invest. 104. 769-76. 
257 
Vajkoczy, P., Farhadi, M., Gaumann, A., Heidenreich, R., Erber R., Wunder, A., 
Tonn, J.C., Menger, M.D., Breier, G. (2002). Microtumor growth initiates angiogenic 
sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. 
JCJ. 109. 777-85. 
Valtola, R., Salven, P., Heikkila, P., Taipale, J., Joensuu, H., Rehn, M., Pihajaniemi, 
T., Weich, H., deWaal, R., Alitalo, K. (1999). VEGFR-3 and its ligand VEGF-C are 
association with angiogenesis in breast cancer. Am J Patho/. 154. 1381-90. 
Vermeulen, P.B., Dirix, L.Y., Martin, M., Lemmens, J., Van Oosterom, A.T. (1997). 
Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic 
renal cell carcinoma treated with interferon alfa-2b. Nat/ Cancer Inst. 89. 1316-7. 
Vincenti, V., Cassano, C., Rocchi, M., Persico, G. ( 1996). Assignment of the vascular 
endothelial growth factor gene to human chromosome 6p21.3. Circulation. 93. 1493-5. 
von Hippel, E. ( 1904). Ueber eine sehr seltene Erkrankung der Nethaut. Graefe Arch 
Optha/mol. 59. 83-106. 
von Marschell, Z., Cramer, T., Hocker, M., Finkenzeller, G., Wiedenmann, B., 
Rosewicz, S. (200 I). Dual mechanism of vascular endothelial growth factor upregulation 
by hypoxia in human hepatocellular carcinoma. Gut. 48. 87-96 
Wada, H., Yeh, E.T.H., Kamitani, T. (1999). The von Hippei-Lindau tumor suppressor 
gene product promotes, but is not essential for, NEDD8 conjugation to cullin-2. J Bioi 
Chem. 274. 36025-9. 
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., Heldin, C-H. 
( 1994). Different signal transduction properties of KDR and Flt-1, two receptors for 
vascular endothelial growth factors. J Bioi Chem. 269. 26988-95. 
Wang, G.L., Jiang, B.H., Rue, E.A., Semenza, G.L. ( 1995). Hypoxia-inducible factor I 
is a basic helix-loop-helix-PAS heterodimer regulated by cellular 0 2 tension. Proc Natl 
AcadSci USA. 92.5510-4. 
Wang, G.L., Jiang, B.H., Semenza, G.L. (1995a). Effect of altered redox states on 
expression and DNA-binding activity of hypoxia-inducible factor I. Biochem Biophys Res 
Commun. 212. 550-6. 
Wang, G.L., Jiang, B.H., Semenza, G.L. (1995b). Effect of protein kinase and 
phosphatase inhibitors on expression of hypoxia inducible factor I. Biochem Biophys Res 
Commun. 216.669-75. 
Wang, G.L., Semenza, G.L. ( 1993). General involvement of hypoxia-inducible factor 1 in 
transcriptional response to hypoxia. Proc Natl Acad Sci USA. 90. 4304-8. 
Wang, G.L., Semenza, G.L. ( 1993). Characterization of hypoxia-inducible factor and 
regulation of DNA binding activity by hypoxia. J Bioi Chem. 268. 21513-18. 
Wang, G.L., Semenza, G.L. ( 1993). Desferrioxamine induces erythropoietin gene 
expression and hypoxia-inducible factor I DNA-binding activity: implications for models 
of hypoxic signal transduction. Blood. 82. 3610-5. 
258 
Wang, G.L., Semenza, G.L. (1995). Purification and characterization of hypoxia-
inducible factor I. J Bioi Chem. 270. 1230-7. 
Watson, C.J., Webb, N.J., Bottomley, M.J., Brenchley, P.E. (2000). Identification of 
polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation 
with variation in VEGF protein production. Cytokine. 12. 1232-5. 
Webster, K.A., Gunning, P., Hardeman, E., Wallace, D.C., Kedes, L. (1990). 
Coordinate reciprocal trends in glycolytic and mitochondrial transcript accumulations 
during the in vitro differentiation of human myoblasts. J Cell Physiol. 142. 566-73. 
Wechsel, H.W., Bichler, K.H., Feil, G., Loeser, W., Lahme, S., Petri, E. ( 1999). Renal 
cell carcinoma: relevance of angiogenic factors. Anticancer Res. 19. 1537-40. 
Wechsel, H.W., Feil, G., Bichler, K.H., Beiter, T., Gleichmann, R. (2000). Serologic 
angiogenesis factors and microvascular density in renal cell carcinoma: two independent 
parameters. Anticancer Res. 20. 5117-20. 
Wenger, R.H., Kvietikova, I., Rolfs, A., Gassmann, M., Marti, H.H. (1997). Hypoxia-
inducible factor-la is regulated at the post-mRNA level. Kidney Int. 51. 560-3. 
Werner, N.S., Siprashvili, Z., Fong, L.Y., Marquitan, G., Schroder, .K., 
Bardenheuser, W., Seeber, S., Huebner, K., Schutte, J., Opalka, B. (2000). Differential 
susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit 
expression. Cancer Res. 60. 2780-5. 
Whaley, J.M., Naglich, J., Gelbert, L., Hsia, E., Lamiell, J.M., Green, J.S., Collins, D., 
Neumann, P.H., Laidlaw, J., Li, F.P., Klein-Szanto, A.J.P., Seizinger, B.R., Kley, N. 
(1994). Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar 
to somatic von Hippei-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum 
Gene/. SS. 1092-102. 
White, C.W., Sondheimer, H.M., Crouch, E.C., Wilson, H., Fan, L.L. (1989). 
Treatment of pulmonary hemangiomatosis with recombinant interferon a-2a. N Engl J 
Med. 320. 1197-200. 
Whittle, C., Gillespie, K., Harrison, R., Mathieson, P.W., Harper, S. (1999). 
Heterogeneous vascular endothelial growth factor (VEGF) isoforrn mRNA and receptor 
mRNA expression in human glomeruli, and the identification ofVEGF 148 mRNA, a novel 
truncated splice variant. C/in Sci. 97. 303-12. 
Wiener, C.M., Booth, G., Semenza, G.L. (1996).Jn vivo expression ofmRNAs encoding 
hypoxia-inducible factor 1. Biochem Biophys Res Commun. 225. 485-8. 
Wiesener, M.S., Munchenhagen, P.M., Berger, I., Morgan, N.V., Roigas, J., 
Schwiertz, A., Jurgensen, J.S., Gruber, G., Maxwell, P.H., Loning, S.A., Frei, U., 
Maher, E.R., Grone, H.S., Eckardk, K.U. (2001). Constitutive activation of hypoxia-
inducible genes related to overexpression of hypoxia-inducible factor-1 a in clear cell renal 
carcinomas. Cancer Res. 61. 5215-22. 
Wiesener, M.S., Turley, H., Alien, W.E., Willam, C., Eckardt, K.U., Talks, K.L., 
Wood, S.M., Gatter, K.C., Harris, A.L., Pugh, C.W., Ratcliffe, P.J., Maxwell, P.H. 
( 1998). Induction of endothelial PAS domain protein- I by hypoxia: characterization and 
comparison with hypoxia-inducible factor-la. Blood. 92. 2260-8. 
259 
Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, .A., de V os, A.M. 
{1997). Crystal structure at 1.7 A resolution ofVEGF in complex with domain 2 of the Flt-
1 receptor. Cell. 91. 695-704. 
Witzenbichler, B., Asahara, T., Murohara, T., Silver, M., Spyridopoulos, I., Magner, 
M., Principle, N., Kearney, M., Hu, J-S., Jsner, J.M. (1998). Vascular endothelial 
growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue 
ischemia. Am J Pathol. 153. 381-94. 
Wizigmann-Voos, S., Breier, G., Risau, W., Plate, K.H. (1995). Up-regulation of 
Vascular endothelial growth factors and its receptors in von Hippel-Lindau disease-
associated with sporadic hemangioblastomas. Cancer Research. 55. 1358-64. 
Wolk, A., Grindley, G., Niwa, S., Lindblad, P., McCredie, M., Mellemgaard, A., 
Man del, J.S., Wahrendorf, J., McLaughlin, J.K., Adami, H.O. ( 1996). International 
renal. cell cancer study: VII. Role of diet. Jnt J Cancer. 65. 67-73. 
Wood, S.M., Gleadle, J.M., Pugh, C.W., Hankinson, 0., Ratcliffe, P.J. (1996). The role 
of the aryl hydrocarbon receptor nuclear translocator (ARNT): hypoxic induction of gene 
expression . Studies in ARNT-deficient cells. J Bioi Chem. 271. 15117-23. 
Wood, S.M., Wiesener, M.S., Yeates, K.M., Okada, N., Pugh, C.W., Maxwell, P.H., 
Ratcliffe, P.J. ( I998). Selection and analysis of a mutant cell line defective in the hypoxia-
inducible factor-1 a-subunit (HIF-1 a): characterization of HIF-1 a-dependent and-
independent hypoxia-inducible gene expression. J Bioi Chem. 273. 8360-8. 
Woodward, E.R., Clifford, S.C., Astuti, D., Affara, N.A., Maher, E.R. (2000). Familial 
clear cell renal cell carcinoma(FCRC): clinical features and mutation analysis of the VHL, 
MET, and CUL2 candidate genes. J Med Genet. 37. 348-53. 
Wright, G., Higgin, J.J., Raines, R.T., Steenbergen, C., Murphy, E. (2003). Activation 
of the prolyl hydroxylase oxygen-sensor results in induction of GLUT I, HO-I, NOS-2 
proteins, and confers protection from metabolic inhibition to cardiomyocytes. J Bioi Chem. 
278. 20235-9. 
Wunderlich, H., Steiner, T., Kosmehl, H., Junker, U., Reinhold, D., Reichel, 0., 
Zermann, D.H., Schubert, J. (1998). Increased transforming growth factor beta I plasma 
level in patients with renal cell carcinoma: a tumor-specific marker? Urol Jnt. 60. 205-7. 
Wykoff, C.C., Beasley, N.J., Watson, P.H., Turner, K.J., Pastorek, J., Sibtain, A., 
Wilson, G.D., Turley, H., Talks, K.L., MaxweU, P.H., Pugh, C.W., Ratcliffe, P.J., 
Harris, A.L. (2000a). Hypoxia-inducible expression of tumor-associated carbonic 
anhydrases. Cancer Res. 60. 7075-83. 
Wykoff, C.C., Pugh, C.W., Maxwell, P.H., Harris, A.L., Ratcliffe, P.J. (2000b). 
Identification of novel independent target genes of the von Hippei-Lindau (VHL) tumor 
suppressor by mRNA differential expression profiling. Oncogene. 19. 6297-305. 
Xia, G., Kageyama, Y., Kawakami, S., Yoshida, M., Kihara, K. (2001). Regulation of 
vascular endothelial growth factor transcription by endothelial PAS domain protein I 
(EP AS I) and possible involvement of EP AS I in the angiogenesis of renal cell carcinoma. 
Cancer. 91. I429-36. 
260 
Xia, P., Aiello, L.P., Jshii, H., Jiang, Z.Y., Park, D.J., Robinson, G.S., Takagi, H., 
Newsome, W.P., Jirousek, M.R., King, G.L. ( 1996). Characterization of vascular 
endothelial growth factor's effect on the activation of protein kinase C, and its isoforms, 
and endothelial cell growth. J Cl in Invest. 98. 2018-26. 
Yagasaki, H., Kawata, N., Takimoto, Y., Nemoto, N. (2003). Histopathological analysis 
of angiogenic factors in renal cell carcinoma. Jnt J Urol. 10. 220-7. 
Yamada, Y., Nezu, J., Shimane, M., Hirata, Y. (1997). Molecular cloning of a novel 
vascular endothelial growth factor. Genomics. 42. 483-8. 
Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, 1., 
Lowik, C., Timp1, R., Olsen, B.R. (l999). Endostatin inhibits VEGF-induced endothelial 
cell migration and tumor growth independently of zinc binding. EMBO. 18.4414-23. 
Yamakawa, K., Morita, R., Takahahi, E., Hori, T., Jshikawa, J., Nakamur, Y. (1991). 
A detailed deletion mapping of the short arm of chromosome 3p in sporadic renal cell 
carcinoma. Cancer Res. 51. 4707-ll. 
Yang, B., Cross, D.F., Ollerenhaw, M., Millward, B.A., Demaine, A.G. (2003). 
Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic 
microvascular complications in patients with type I diabetes mellitus. J Diabetes 
Complications. 17. 1-6. 
Yang, C.C., Chu, K.C., Yeh, W.M. (2003b). Expression of vascular endothelial growth 
factor in renal cell carcinoma is correlated with cancer advancement. J C/in Lab Anal. 11. 
85-9. 
Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Parkinson, D.R., Marincola, 
F.M., Weber, J.S., Seipp, C. A., White, D.E., Rosenberg, S.A. ( 1995). The use of 
polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with 
metastatic renal cell carcinoma and melanoma. A phase I study and a randomised 
prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer. 76. 
687-94. 
Yang, R., Thomas, G.R., Bunting, S., Ko, A., Keyt, B., Ferrara, N. ( 1996). Effects of 
VEGF on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacal. 27. 838-41. 
Yao, M., Latif, F., Orcutt, M.L., Kuzmin, 1., Stackhouse, T., Zhou, F.W., Tory, K., 
Duh, F.M., Richards, F., Maher, E. (1993). von Hippei-Lindau disease: identification of 
deletion mutations by pulsed-field gel electrophoresis. Hum Genet. 92. 605-14. 
Yin, J-H., Yang, D-1., Ku, G., Hsu, C.Y. (2000). INos expression inhibits hypoxia-
inducible factor- I activity. Biochem Biophys Res Commun. 279. 30-4. 
Yokoyama, Y., Charnock-Jones, D.S., Licence, D., Yanaihara, A., Hastings, J.M., 
Holland, C.M., Emoto, M., Sakamoto, A., Sakamoto, T., Maruyama, H., Sato, S., 
Mizunuma, H., Small, S.K. (2003). Expression of vascular endothelial growth factor 
(VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial 
carcinoma. C/in Cancer Res. 9. 1361-9. 
Yonemura, Y., Endo, Y., Fujita, H., Fushida, S., Ninomiya, I., Bandou, E., Taniguchi, 
K., Miwa, K., Ohoyama, S., Sugiyama, K., Sasaki, T. (1999). Role of vascular 
261 
endothelial growth factor C expression in the development of lymph node metastasis in 
gastric cancer. C/in Cancer Res. 5. 1823-9. 
Yu, A.Y., Frid, M.G., Shimoda, L.A., Wiener, C.M., Stenmark, K., Semenza, G.L. 
(1998). Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 
in the lung. AmJ Physio/. 275.818-26. 
Yu, M.C., Mack, T .M., Hanish, R., Cicioni, C., Henderson, B.E. ( 1986). Cigarette 
smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell 
carcinoma. J Nat/ Cancer inst. 77. 351-6. 
Zagzag, D., Zhong, H., Scalzitti, J.M., Laughner, E., Simons, J.W., Semenza, G.L. 
(2000). Expression of hypoxia-inducible factor 1 a in brain tumors: association with 
angiogenesis, invasion, and progression. Cancer. 88. 2606-18. 
Zaman, K., Ryu, H., Hall, D., O'Donovan, K., Lin, K.I., Miller, M.P., Marquis, J.C., 
Baraban, J.M., Semenza, G.L., Ratan, R.R. (1999). Protection from oxidative stress-
induced apoptosis in cortical neuronal cultures by iron chelators is associated with 
enhanced DNA binding of hypoxia-inducible factor- I and ATF-1/CREB and increased 
expression of glycolytic enzymes, p21 (wafl/cipl), and erythropoietin. J Neurosci. 19. 
9821-30. 
Zang, T., Zhuang, L., Zhang, Z., Xin, D., Guo, Y. (2001). Expression ofbeta-catenin in 
renal cell carcinoma. Chin Med J (Eng/). 114. 152-4. 
Zbar, B., Kihida, T., Chen, F., Schmidt, L., Maher, E.R., Richards, F.M., Crossey, 
P.A., Webster, A.R., Affara, N.A., Ferguson-Smith, M.A., Brauch, B., Glavac, D., 
Neumann, H.P., Tiherman, S., Mulvihill, J.J., Gross, D.J., Shuin, T., Whaley, J., 
Seizinger, B., Kley, N., Olchwang, S., Boisson, C., Richard, S., Lips, C.H., Lerman, 
M., et al ( 1996). Gennline mutations in the von Hippei-Lindau (VHL) gene in families 
from North America, Europe, and Japan. Hum Mutat. 8. 348-57. 
Zelzer, E., Levy, Y., Kahana, C., Shilo, B.Z., Rubinstein, M., Cohen, B. (1998).1nsulin 
induces transcription of target genes through the hypoxia-inducible factor HIF-
lalpha/ARNT. EMBO. 17. 5085-94. 
Zhang, X., Yamashita, M., Uetsuki, H., Kakehi, Y. (2002). Angiogenesis in renal cell 
carcinoma: Evaluation ofmicrovessel density, vascular endothelial growth factor and 
matrix metalloproteinases. lnt J Uro/. 9. 509-14. 
Zhong, H., Agani, F., Baccala, A.A., Laughner, E., Rioseco-Camacho, N., Isaacs, 
W.B., Si mons, J.W., Semenza, G.L. {1998). Increased expression of hypoxia inducible 
factor-la in rat and human prostate cancer. Cancer Res. 58. 5280-4. 
Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M.M., 
Simons, J.W., Semenza, G.L. (2000). Modulation of hypoxia-inducible factor la 
expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/ PTEN/ AKT/ 
FRAP/ pathway in human prostate cancer cells: implications for tumor angiogenesis and 
therapeutics. Cancer Res. 60. 1541-5. 
Zhong, H., De Marzo, A.M., Laughner, E., Lim, M., Hilton, D.A., Zagzag, D., 
Buechler, P., lsaacs, W.B., Semenza, G.L., Simons, J.W. {1999). Overexpression of 
262 
hypoxia-inducible factor I a in common human cancers and their metastases. Cancer Res. 
59.5830-5. 
Zhong, H., Si mons, J. W. ( 1999). Direct comparison of GAPDH, ~-actin, cyclophilin, and 
28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem. 
Biophys. Res. Commun. 259. 523-6. 
Zhu, Z., Hattori, K., Zhang, H., Jimenez, X., Ludwig, D.L., Dias, S., Kussie, P., Koo, 
H., Kim, H.J., Lu, D., Liu, M., Tejada, R., Friedrich, M., Bohlen, P., Witte, L., Rafii, 
S. (2003). Inhibition of human leukaemia in an animal model with human antibodies 
directed against vascular endothelial growth factor receptor 2. Correlation between 
antibody affinity and biological activity. Leukemia. 17. 604-11. 
Zhuang, L., Guo, H., Xin, D., Zhang, Z., Li, H., Yuan, X., Tang, D. ding, Y., Liu, L., 
Guo, Y. (2000). Different Wnt-5A gene expressions in renal cell carcinoma GRC-1 cell 
line during the cell cycle. Chin Med J (Engl). 113. 306-9. 
Ziche, M., Maglione, D., Ribatti, D., Morbidelli, L., Lago, C.T., Battiti, M., Paoletti, 
1., Barra, A., Tucci, M., Parise, G., Vincenti, V., Granger, H.J., Vigle, G., Persico, 
M.G. (1997). Placenta growth factor-] is chemotatic, mitogenic, and angiogenic. Lab 
Invest. 16. 517-31. 
263 
